{
  "fdff8f59aa063fea": [
    {
      "text": "High blood sugar (hyperglycemia), exceeding 180 mg/dL or your target range, is dangerous, especially readings of 300 mg/dL or higher (requiring immediate medical attention if repeated).  Causes include improper medication, illness, stress, missed doses, reduced exercise, increased carbohydrate intake, or unknown reasons potentially indicating infection or illness. High blood sugar (hyperglycemia), exceeding 180 mg/dL or your target range, is dangerous, especially readings of 300 mg/dL or more (consult a doctor if this occurs twice).  Causes include insufficient medication, illness, stress, missed doses, reduced exercise, or excess carbohydrate intake.  High levels may also signal infection or illness.",
      "metadata": {
        "producer": "Adobe PDF Library 19.12.66",
        "creator": "Acrobat PDFMaker 19 for Word",
        "creationdate": "2019-07-17T15:58:40-04:00",
        "author": "University of Michigan",
        "comments": "",
        "company": "University of Michigan Medical Center",
        "keywords": "",
        "moddate": "2019-07-19T15:58:28-04:00",
        "sourcemodified": "D:20190717194814",
        "subject": "",
        "title": "",
        "source": "data-1\\Diabetes-Hyperglycemia.pdf",
        "total_pages": 3,
        "page": 0,
        "page_label": "1",
        "source_file": "Diabetes-Hyperglycemia.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\Diabetes-Hyperglycemia.pdf",
        "summary_en": "High blood sugar (hyperglycemia), exceeding 180 mg/dL or your target range, is dangerous, especially readings of 300 mg/dL or higher (requiring immediate medical attention if repeated).  Causes include improper medication, illness, stress, missed doses, reduced exercise, increased carbohydrate intake, or unknown reasons potentially indicating infection or illness.",
        "summary_ur": "High blood sugar (hyperglycemia), exceeding 180 mg/dL or your target range, is dangerous, especially readings of 300 mg/dL or more (consult a doctor if this occurs twice).  Causes include insufficient medication, illness, stress, missed doses, reduced exercise, or excess carbohydrate intake.  High levels may also signal infection or illness."
      }
    },
    {
      "text": "High blood sugar, sometimes a symptom of illness or stress, can cause weakness, fatigue, blurred vision, frequent urination, dry mouth, thirst, nausea, and vomiting.  A \"sick day plan\" with your healthcare team is recommended for managing diabetes during illness.  Symptoms may be absent at times. High blood sugar, sometimes a symptom of illness or stress, can cause weakness, blurred vision, frequent urination, dry mouth, thirst, nausea, and vomiting.  A \"sick day plan\" with your healthcare team is crucial for managing diabetes during illness.  Sometimes, high blood sugar shows no symptoms.",
      "metadata": {
        "producer": "Adobe PDF Library 19.12.66",
        "creator": "Acrobat PDFMaker 19 for Word",
        "creationdate": "2019-07-17T15:58:40-04:00",
        "author": "University of Michigan",
        "comments": "",
        "company": "University of Michigan Medical Center",
        "keywords": "",
        "moddate": "2019-07-19T15:58:28-04:00",
        "sourcemodified": "D:20190717194814",
        "subject": "",
        "title": "",
        "source": "data-1\\Diabetes-Hyperglycemia.pdf",
        "total_pages": 3,
        "page": 0,
        "page_label": "1",
        "source_file": "Diabetes-Hyperglycemia.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\Diabetes-Hyperglycemia.pdf",
        "summary_en": "High blood sugar, sometimes a symptom of illness or stress, can cause weakness, fatigue, blurred vision, frequent urination, dry mouth, thirst, nausea, and vomiting.  A \"sick day plan\" with your healthcare team is recommended for managing diabetes during illness.  Symptoms may be absent at times.",
        "summary_ur": "High blood sugar, sometimes a symptom of illness or stress, can cause weakness, blurred vision, frequent urination, dry mouth, thirst, nausea, and vomiting.  A \"sick day plan\" with your healthcare team is crucial for managing diabetes during illness.  Sometimes, high blood sugar shows no symptoms."
      }
    },
    {
      "text": "This text describes hyperglycemia symptoms (high blood sugar), including nausea, dizziness, confusion, and potential coma.  Treatment involves hydration and identifying the cause (illness, stress, missed medication, etc.).  If lifestyle adjustments don't resolve high blood sugar, immediate medical attention is needed. High blood sugar (hyperglycemia) symptoms include dizziness, nausea, confusion.  Prolonged high blood sugar is an emergency requiring immediate hospital treatment to prevent coma. Treatment involves hydration and identifying the cause (illness, stress, missed medication, diet).  If lifestyle is the issue, normalization should follow routine resumption.",
      "metadata": {
        "producer": "Adobe PDF Library 19.12.66",
        "creator": "Acrobat PDFMaker 19 for Word",
        "creationdate": "2019-07-17T15:58:40-04:00",
        "author": "University of Michigan",
        "comments": "",
        "company": "University of Michigan Medical Center",
        "keywords": "",
        "moddate": "2019-07-19T15:58:28-04:00",
        "sourcemodified": "D:20190717194814",
        "subject": "",
        "title": "",
        "source": "data-1\\Diabetes-Hyperglycemia.pdf",
        "total_pages": 3,
        "page": 1,
        "page_label": "2",
        "source_file": "Diabetes-Hyperglycemia.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\Diabetes-Hyperglycemia.pdf",
        "summary_en": "This text describes hyperglycemia symptoms (high blood sugar), including nausea, dizziness, confusion, and potential coma.  Treatment involves hydration and identifying the cause (illness, stress, missed medication, etc.).  If lifestyle adjustments don't resolve high blood sugar, immediate medical attention is needed.",
        "summary_ur": "High blood sugar (hyperglycemia) symptoms include dizziness, nausea, confusion.  Prolonged high blood sugar is an emergency requiring immediate hospital treatment to prevent coma. Treatment involves hydration and identifying the cause (illness, stress, missed medication, diet).  If lifestyle is the issue, normalization should follow routine resumption."
      }
    },
    {
      "text": "This text provides advice for managing high blood sugar.  Temporary high readings may result from routine changes, but persistent high readings (over 300 mg/dL twice or above target range for over a week), or illness, necessitate contacting a doctor.  Patients should discuss target blood sugar ranges, management strategies, and sick-day plans with their healthcare provider. High blood sugar?  Normal routine changes may cause temporary spikes.  Persistently high readings (over 300 mg/dL twice or above target for >1 week), or illness, warrants immediate doctor contact.  Discuss target ranges, high-sugar management, sick-day plans with your healthcare team.",
      "metadata": {
        "producer": "Adobe PDF Library 19.12.66",
        "creator": "Acrobat PDFMaker 19 for Word",
        "creationdate": "2019-07-17T15:58:40-04:00",
        "author": "University of Michigan",
        "comments": "",
        "company": "University of Michigan Medical Center",
        "keywords": "",
        "moddate": "2019-07-19T15:58:28-04:00",
        "sourcemodified": "D:20190717194814",
        "subject": "",
        "title": "",
        "source": "data-1\\Diabetes-Hyperglycemia.pdf",
        "total_pages": 3,
        "page": 1,
        "page_label": "2",
        "source_file": "Diabetes-Hyperglycemia.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\Diabetes-Hyperglycemia.pdf",
        "summary_en": "This text provides advice for managing high blood sugar.  Temporary high readings may result from routine changes, but persistent high readings (over 300 mg/dL twice or above target range for over a week), or illness, necessitate contacting a doctor.  Patients should discuss target blood sugar ranges, management strategies, and sick-day plans with their healthcare provider.",
        "summary_ur": "High blood sugar?  Normal routine changes may cause temporary spikes.  Persistently high readings (over 300 mg/dL twice or above target for >1 week), or illness, warrants immediate doctor contact.  Discuss target ranges, high-sugar management, sick-day plans with your healthcare team."
      }
    },
    {
      "text": "This Michigan Medicine document provides patient education on high blood sugar, noting that it's for general information only and doesn't replace individual medical advice.  The content is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License. This Michigan Medicine document provides diabetes education, specifically addressing hyperglycemia.  It's for informational purposes only and shouldn't replace advice from a healthcare provider.  The content is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License.",
      "metadata": {
        "producer": "Adobe PDF Library 19.12.66",
        "creator": "Acrobat PDFMaker 19 for Word",
        "creationdate": "2019-07-17T15:58:40-04:00",
        "author": "University of Michigan",
        "comments": "",
        "company": "University of Michigan Medical Center",
        "keywords": "",
        "moddate": "2019-07-19T15:58:28-04:00",
        "sourcemodified": "D:20190717194814",
        "subject": "",
        "title": "",
        "source": "data-1\\Diabetes-Hyperglycemia.pdf",
        "total_pages": 3,
        "page": 2,
        "page_label": "3",
        "source_file": "Diabetes-Hyperglycemia.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\Diabetes-Hyperglycemia.pdf",
        "summary_en": "This Michigan Medicine document provides patient education on high blood sugar, noting that it's for general information only and doesn't replace individual medical advice.  The content is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License.",
        "summary_ur": "This Michigan Medicine document provides diabetes education, specifically addressing hyperglycemia.  It's for informational purposes only and shouldn't replace advice from a healthcare provider.  The content is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License."
      }
    }
  ],
  "71cada5afac053ad": [
    {
      "text": "Diabetes mellitus is a chronic disease affecting millions, characterized by high blood sugar (hyperglycemia).  This occurs because the pancreas doesn't produce enough insulin, or the body's cells don't respond properly to insulin, preventing glucose from being used as fuel.  This leads to elevated blood sugar levels. The text describes diabetes mellitus, a chronic disease affecting millions.  High blood sugar (hyperglycemia) results from insufficient insulin production or cellular insulin resistance, preventing glucose uptake from the bloodstream.  This leads to various health complications and is a significant cause of death.  The text mentions different types of diabetes will be discussed later.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 0,
        "page_label": "1",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Diabetes mellitus is a chronic disease affecting millions, characterized by high blood sugar (hyperglycemia).  This occurs because the pancreas doesn't produce enough insulin, or the body's cells don't respond properly to insulin, preventing glucose from being used as fuel.  This leads to elevated blood sugar levels.",
        "summary_ur": "The text describes diabetes mellitus, a chronic disease affecting millions.  High blood sugar (hyperglycemia) results from insufficient insulin production or cellular insulin resistance, preventing glucose uptake from the bloodstream.  This leads to various health complications and is a significant cause of death.  The text mentions different types of diabetes will be discussed later."
      }
    },
    {
      "text": "Diabetes is characterized by high blood sugar due to insulin resistance (inability of cells to respond to insulin).  Type 1 diabetes results from the pancreas's inability to produce insulin, requiring daily injections. Type 2 diabetes, the most common type, often develops in adulthood and involves insulin resistance. Diabetes mellitus has two main types. Type 1 (T1D) results from the pancreas's inability to produce insulin, requiring daily injections. Type 2 (T2D) involves insulin resistance, where cells don't respond normally to insulin.  Both types lead to high blood sugar.  T2D, the most common, is often linked to obesity.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 0,
        "page_label": "1",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Diabetes is characterized by high blood sugar due to insulin resistance (inability of cells to respond to insulin).  Type 1 diabetes results from the pancreas's inability to produce insulin, requiring daily injections. Type 2 diabetes, the most common type, often develops in adulthood and involves insulin resistance.",
        "summary_ur": "Diabetes mellitus has two main types. Type 1 (T1D) results from the pancreas's inability to produce insulin, requiring daily injections. Type 2 (T2D) involves insulin resistance, where cells don't respond normally to insulin.  Both types lead to high blood sugar.  T2D, the most common, is often linked to obesity."
      }
    },
    {
      "text": "Type 2 diabetes (T2D), typically an adult-onset disease, is increasingly affecting teens and young adults due to rising obesity and inactivity.  The text mentions a precursor to T2D, but doesn't specify what it is. Type 2 diabetes (T2D), primarily an adult disease, is increasingly affecting teens and young adults due to rising obesity and inactivity.  Pre-diabetes often precedes T2D.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 0,
        "page_label": "1",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Type 2 diabetes (T2D), typically an adult-onset disease, is increasingly affecting teens and young adults due to rising obesity and inactivity.  The text mentions a precursor to T2D, but doesn't specify what it is.",
        "summary_ur": "Type 2 diabetes (T2D), primarily an adult disease, is increasingly affecting teens and young adults due to rising obesity and inactivity.  Pre-diabetes often precedes T2D."
      }
    },
    {
      "text": "The text describes three types of diabetes: Type 1 (autoimmune destruction of insulin-producing cells), Type 2 (insulin resistance), and gestational diabetes (pregnancy-related insulin impairment).  Risk factors for Type 1 include family history, pancreatic disease, and infections affecting the pancreas.  Gestational diabetes often resolves after pregnancy but increases the risk of developing Type 2 diabetes later. Type 1 diabetes is an autoimmune disease where the pancreas doesn't produce insulin. Type 2 diabetes involves insulin resistance, where cells don't respond properly to insulin. Gestational diabetes develops during pregnancy, often resolving afterward but increasing the risk of later type 2.  Risk factors include family history and pancreatic issues.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 1,
        "page_label": "2",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "The text describes three types of diabetes: Type 1 (autoimmune destruction of insulin-producing cells), Type 2 (insulin resistance), and gestational diabetes (pregnancy-related insulin impairment).  Risk factors for Type 1 include family history, pancreatic disease, and infections affecting the pancreas.  Gestational diabetes often resolves after pregnancy but increases the risk of developing Type 2 diabetes later.",
        "summary_ur": "Type 1 diabetes is an autoimmune disease where the pancreas doesn't produce insulin. Type 2 diabetes involves insulin resistance, where cells don't respond properly to insulin. Gestational diabetes develops during pregnancy, often resolving afterward but increasing the risk of later type 2.  Risk factors include family history and pancreatic issues."
      }
    },
    {
      "text": "The text outlines risk factors and symptoms for Type 1, Type 2, and gestational diabetes.  Type 1 is linked to pancreatic issues and family history, while Type 2 involves obesity, family history, ethnicity, age, and hypertension. Gestational diabetes shares some risk factors with Type 2, adding pregnancy-related factors.  Type 1 symptoms include rapid weight loss, urination, thirst, hunger, weakness, nausea, and vomiting. Type 1 diabetes stems from pancreatic issues (genetic, disease, infection), causing rapid onset symptoms like weight loss, thirst, and fatigue.  Type 2 diabetes develops more slowly, linked to obesity, family history, ethnicity, age, and hypertension. Gestational diabetes affects pregnant women, often with similar risk factors as type 2.  Shared risk factors include family history and ethnicity.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 1,
        "page_label": "2",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "The text outlines risk factors and symptoms for Type 1, Type 2, and gestational diabetes.  Type 1 is linked to pancreatic issues and family history, while Type 2 involves obesity, family history, ethnicity, age, and hypertension. Gestational diabetes shares some risk factors with Type 2, adding pregnancy-related factors.  Type 1 symptoms include rapid weight loss, urination, thirst, hunger, weakness, nausea, and vomiting.",
        "summary_ur": "Type 1 diabetes stems from pancreatic issues (genetic, disease, infection), causing rapid onset symptoms like weight loss, thirst, and fatigue.  Type 2 diabetes develops more slowly, linked to obesity, family history, ethnicity, age, and hypertension. Gestational diabetes affects pregnant women, often with similar risk factors as type 2.  Shared risk factors include family history and ethnicity."
      }
    },
    {
      "text": "Type 1 diabetes symptoms appear suddenly and include weight loss, frequent urination, thirst, hunger, weakness, nausea, and vomiting.  Type 2 diabetes symptoms develop gradually or may be absent, but can include any of the type 1 symptoms, plus blurred vision, slow-healing sores, infections, and tingling/numbness. Type 1 diabetes shows rapid onset with symptoms like weight loss, frequent urination, thirst, hunger, weakness, nausea, and vomiting.  Type 2 develops slowly, sometimes silently, but may include similar symptoms plus blurred vision, slow-healing sores, infections, and numbness.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 1,
        "page_label": "2",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Type 1 diabetes symptoms appear suddenly and include weight loss, frequent urination, thirst, hunger, weakness, nausea, and vomiting.  Type 2 diabetes symptoms develop gradually or may be absent, but can include any of the type 1 symptoms, plus blurred vision, slow-healing sores, infections, and tingling/numbness.",
        "summary_ur": "Type 1 diabetes shows rapid onset with symptoms like weight loss, frequent urination, thirst, hunger, weakness, nausea, and vomiting.  Type 2 develops slowly, sometimes silently, but may include similar symptoms plus blurred vision, slow-healing sores, infections, and numbness."
      }
    },
    {
      "text": "Gestational diabetes, with symptoms similar to type 2, requires testing during pregnancy.  Untreated diabetes leads to serious complications including kidney disease, blindness, heart disease, nerve damage, foot sores, and diabetic coma. Louisiana has a high diabetes prevalence and mortality rate, ranking 11th nationally in diagnosed cases and 2nd in mortality. Gestational diabetes, sharing symptoms with type 2, requires testing during pregnancy.  Untreated diabetes risks kidney disease, blindness, heart issues, nerve damage, foot sores, and coma.  Louisiana has high diabetes rates and mortality, ranking 11th nationally and second highest in mortality.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 2,
        "page_label": "3",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Gestational diabetes, with symptoms similar to type 2, requires testing during pregnancy.  Untreated diabetes leads to serious complications including kidney disease, blindness, heart disease, nerve damage, foot sores, and diabetic coma. Louisiana has a high diabetes prevalence and mortality rate, ranking 11th nationally in diagnosed cases and 2nd in mortality.",
        "summary_ur": "Gestational diabetes, sharing symptoms with type 2, requires testing during pregnancy.  Untreated diabetes risks kidney disease, blindness, heart issues, nerve damage, foot sores, and coma.  Louisiana has high diabetes rates and mortality, ranking 11th nationally and second highest in mortality."
      }
    },
    {
      "text": "Between 2000 and 2010, diabetes was the fifth leading cause of death in Louisiana.  African Americans, comprising 32% of the population, had the highest diabetes prevalence (12.9%), exceeding that of Hispanics (8.1%) and Caucasians (9.2%), according to the 2010 BRFSS. Between 2000 and 2010, diabetes was a significant cause of death in Louisiana, disproportionately affecting African Americans.  This group, comprising 32% of the population, experienced a diabetes diagnosis rate of 12.9%, exceeding that of Hispanics (8.1%) and Caucasians (9.2%).  (Source: BRFSS, 2010).",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 2,
        "page_label": "3",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Between 2000 and 2010, diabetes was the fifth leading cause of death in Louisiana.  African Americans, comprising 32% of the population, had the highest diabetes prevalence (12.9%), exceeding that of Hispanics (8.1%) and Caucasians (9.2%), according to the 2010 BRFSS.",
        "summary_ur": "Between 2000 and 2010, diabetes was a significant cause of death in Louisiana, disproportionately affecting African Americans.  This group, comprising 32% of the population, experienced a diabetes diagnosis rate of 12.9%, exceeding that of Hispanics (8.1%) and Caucasians (9.2%).  (Source: BRFSS, 2010)."
      }
    },
    {
      "text": "In 2010, Louisiana spent approximately $231 million on hospitalizations for diabetes.  The state is in the CDC's \"Diabetes Belt,\" an area with high obesity and inactivity rates, increasing type 2 diabetes risk.  Diabetes is diagnosed via fasting blood glucose levels;  levels \u2265126 mg/dL indicate diabetes, while 100-126 mg/dL suggests prediabetes, a risk factor for type 2. In 2010, Louisiana spent roughly $231,000,000 on hospitalizations for diabetes.  The state is part of the CDC's \"Diabetes Belt,\"  characterized by high obesity and inactivity rates, increasing type 2 diabetes risk.  Diabetes is diagnosed via fasting blood glucose level;  \u2265126 mg/dL indicates diabetes, 100-126 mg/dL prediabetes.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 3,
        "page_label": "4",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "In 2010, Louisiana spent approximately $231 million on hospitalizations for diabetes.  The state is in the CDC's \"Diabetes Belt,\" an area with high obesity and inactivity rates, increasing type 2 diabetes risk.  Diabetes is diagnosed via fasting blood glucose levels;  levels \u2265126 mg/dL indicate diabetes, while 100-126 mg/dL suggests prediabetes, a risk factor for type 2.",
        "summary_ur": "In 2010, Louisiana spent roughly $231,000,000 on hospitalizations for diabetes.  The state is part of the CDC's \"Diabetes Belt,\"  characterized by high obesity and inactivity rates, increasing type 2 diabetes risk.  Diabetes is diagnosed via fasting blood glucose level;  \u2265126 mg/dL indicates diabetes, 100-126 mg/dL prediabetes."
      }
    },
    {
      "text": "Prediabetes, characterized by higher-than-normal blood sugar, significantly increases the risk of type 2 diabetes (T2D).  Diagnosis of T2D involves blood tests:  Hemoglobin A1c measures average blood glucose over three months, while the oral glucose tolerance test (OGTT) assesses glucose breakdown after a sugary drink; a reading of 200 mg/dL or higher after OGTT indicates diabetes. Prediabetes signifies higher-than-normal blood sugar, increasing type 2 diabetes risk.  Diagnosis involves A1c tests (measuring average blood glucose over three months) and oral glucose tolerance tests (OGTT), with a blood glucose level of 200 mg/dL or higher after a glucose drink indicating diabetes.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 3,
        "page_label": "4",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Prediabetes, characterized by higher-than-normal blood sugar, significantly increases the risk of type 2 diabetes (T2D).  Diagnosis of T2D involves blood tests:  Hemoglobin A1c measures average blood glucose over three months, while the oral glucose tolerance test (OGTT) assesses glucose breakdown after a sugary drink; a reading of 200 mg/dL or higher after OGTT indicates diabetes.",
        "summary_ur": "Prediabetes signifies higher-than-normal blood sugar, increasing type 2 diabetes risk.  Diagnosis involves A1c tests (measuring average blood glucose over three months) and oral glucose tolerance tests (OGTT), with a blood glucose level of 200 mg/dL or higher after a glucose drink indicating diabetes."
      }
    },
    {
      "text": "Gestational diabetes is diagnosed via oral glucose tolerance tests (OGTT).  Type 2 diabetes screening is recommended for overweight individuals with risk factors or over 45.  Diabetes management involves insulin, weight loss, blood glucose monitoring, oral medication (if prescribed), a healthy diet, and exercise.  There's no cure. Diabetes, diagnosed via blood glucose tests, lacks a cure.  Management focuses on insulin, weight loss, consistent blood glucose monitoring (glucometers), oral medication (doctor-prescribed), balanced diet (low-calorie, controlled carbs, healthy fats), and exercise.  Screening is recommended for at-risk groups.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 4,
        "page_label": "5",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "Gestational diabetes is diagnosed via oral glucose tolerance tests (OGTT).  Type 2 diabetes screening is recommended for overweight individuals with risk factors or over 45.  Diabetes management involves insulin, weight loss, blood glucose monitoring, oral medication (if prescribed), a healthy diet, and exercise.  There's no cure.",
        "summary_ur": "Diabetes, diagnosed via blood glucose tests, lacks a cure.  Management focuses on insulin, weight loss, consistent blood glucose monitoring (glucometers), oral medication (doctor-prescribed), balanced diet (low-calorie, controlled carbs, healthy fats), and exercise.  Screening is recommended for at-risk groups."
      }
    },
    {
      "text": "This text outlines diabetes management, emphasizing lifestyle changes as foundational.  It recommends a balanced diet (including monounsaturated fats), regular exercise, and potentially insulin or oral medication to maintain healthy blood glucose levels.  Resources from the NDIC, American Diabetes Association, and CDC are provided. This text discusses diabetes management.  It emphasizes a healthy lifestyle including diet (reduced saturated and trans fats, increased monounsaturated fats), exercise, and medication (insulin or oral).  It provides links to further information from reputable health organizations.",
      "metadata": {
        "producer": "Microsoft\u00ae Office Word 2007",
        "creator": "Microsoft\u00ae Office Word 2007",
        "creationdate": "D:20121023153348",
        "author": "Jyothi",
        "moddate": "D:20121023153348",
        "source": "data-1\\DIABETES.pdf",
        "total_pages": 5,
        "page": 4,
        "page_label": "5",
        "source_file": "DIABETES.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\DIABETES.pdf",
        "summary_en": "This text outlines diabetes management, emphasizing lifestyle changes as foundational.  It recommends a balanced diet (including monounsaturated fats), regular exercise, and potentially insulin or oral medication to maintain healthy blood glucose levels.  Resources from the NDIC, American Diabetes Association, and CDC are provided.",
        "summary_ur": "This text discusses diabetes management.  It emphasizes a healthy lifestyle including diet (reduced saturated and trans fats, increased monounsaturated fats), exercise, and medication (insulin or oral).  It provides links to further information from reputable health organizations."
      }
    }
  ],
  "50f769db781bdbc2": [
    {
      "text": "The 2025 11th edition of the Diabetes Atlas reports that 589 million people worldwide have diabetes. The 2025 Diabetes Atlas reports 589 million individuals globally have diabetes.  This is a significant public health concern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 0,
        "page_label": "1",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2025 11th edition of the Diabetes Atlas reports that 589 million people worldwide have diabetes.",
        "summary_ur": "The 2025 Diabetes Atlas reports 589 million individuals globally have diabetes.  This is a significant public health concern."
      }
    },
    {
      "text": "The IDF Diabetes Atlas, 11th edition (2025), is a comprehensive report on the global prevalence and impact of diabetes.  It provides updated statistics on the number of people with diabetes, projections for the future, and information on diabetes-related complications and healthcare needs. The provided text is not legal text; it's a reference to a publication.  Therefore, there's no legal summary to provide.  The IDF Diabetes Atlas, 11th edition (2025), is a report on diabetes prevalence and statistics.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 1,
        "page_label": "2",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas, 11th edition (2025), is a comprehensive report on the global prevalence and impact of diabetes.  It provides updated statistics on the number of people with diabetes, projections for the future, and information on diabetes-related complications and healthcare needs.",
        "summary_ur": "The provided text is not legal text; it's a reference to a publication.  Therefore, there's no legal summary to provide.  The IDF Diabetes Atlas, 11th edition (2025), is a report on diabetes prevalence and statistics."
      }
    },
    {
      "text": "This document details methods for estimating diabetes prevalence and its impact.  It covers various diabetes types (Type 1, Type 2, gestational), diagnostic criteria, data collection and analysis techniques (including extrapolation and confidence interval estimation), and methods for projecting future prevalence and associated economic costs. This document details diabetes prevalence and future projections.  It includes definitions of diabetes types (Chapters 1),  methodologies for data gathering, analysis (Chapter 2), including prevalence estimation,  confidence intervals, and economic impact assessment.  References are provided.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 2,
        "page_label": "IV",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This document details methods for estimating diabetes prevalence and its impact.  It covers various diabetes types (Type 1, Type 2, gestational), diagnostic criteria, data collection and analysis techniques (including extrapolation and confidence interval estimation), and methods for projecting future prevalence and associated economic costs.",
        "summary_ur": "This document details diabetes prevalence and future projections.  It includes definitions of diabetes types (Chapters 1),  methodologies for data gathering, analysis (Chapter 2), including prevalence estimation,  confidence intervals, and economic impact assessment.  References are provided."
      }
    },
    {
      "text": "This document, part of the IDF Diabetes Atlas 11th Edition, details methods for estimating diabetes prevalence and impact.  Chapters 2 and 3 present global prevalence data (2024-2050 projections), focusing on various subgroups (older adults, pregnant women, children),  undiagnosed cases,  mortality rates, and economic consequences, specifically addressing type 1 and overall diabetes. This document, a section from the IDF Diabetes Atlas 11th Edition, presents global diabetes data.  It details prevalence estimations for various diabetes types (including gestational), mortality rates, economic impacts, and projections to 2050, across different age groups.  Specific estimations are provided for both diagnosed and undiagnosed cases.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 2,
        "page_label": "IV",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This document, part of the IDF Diabetes Atlas 11th Edition, details methods for estimating diabetes prevalence and impact.  Chapters 2 and 3 present global prevalence data (2024-2050 projections), focusing on various subgroups (older adults, pregnant women, children),  undiagnosed cases,  mortality rates, and economic consequences, specifically addressing type 1 and overall diabetes.",
        "summary_ur": "This document, a section from the IDF Diabetes Atlas 11th Edition, presents global diabetes data.  It details prevalence estimations for various diabetes types (including gestational), mortality rates, economic impacts, and projections to 2050, across different age groups.  Specific estimations are provided for both diagnosed and undiagnosed cases."
      }
    },
    {
      "text": "This is a table of contents for the 11th edition (2025) of the IDF Diabetes Atlas.  It covers diabetes prevalence by region (Africa, Europe, etc.) and then details complications such as cardiovascular disease, dementia, and eye disease.  Appendices include a country summary table, abbreviations, a glossary, and a list of figures. This is a table of contents, not legal text.  The document is the 11th edition of the IDF Diabetes Atlas (2025), covering diabetes prevalence by region (Africa, Europe, etc.),  and its complications (cardiovascular disease, dementia, eye disease),  plus supporting data and a glossary.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 3,
        "page_label": "V",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This is a table of contents for the 11th edition (2025) of the IDF Diabetes Atlas.  It covers diabetes prevalence by region (Africa, Europe, etc.) and then details complications such as cardiovascular disease, dementia, and eye disease.  Appendices include a country summary table, abbreviations, a glossary, and a list of figures.",
        "summary_ur": "This is a table of contents, not legal text.  The document is the 11th edition of the IDF Diabetes Atlas (2025), covering diabetes prevalence by region (Africa, Europe, etc.),  and its complications (cardiovascular disease, dementia, eye disease),  plus supporting data and a glossary."
      }
    },
    {
      "text": "This is the tenth edition (2021) of the International Diabetes Federation's Diabetes Atlas, copyrighted and published with previous editions dating back to 2000.  All rights reserved; reproduction requires prior written permission (details at diabetesatlas.org/copyright-requests/).  The online version and data sources are also available at diabetesatlas.org. This is the 2025 International Diabetes Federation (IDF) Diabetes Atlas.  Copyright belongs to IDF; reproduction requires prior written permission (diabetesatlas.org/copyright-requests/).  The Atlas, in its tenth edition, contains data from various studies (listed on the website).  Optima handled design and editing.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 4,
        "page_label": "VI",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This is the tenth edition (2021) of the International Diabetes Federation's Diabetes Atlas, copyrighted and published with previous editions dating back to 2000.  All rights reserved; reproduction requires prior written permission (details at diabetesatlas.org/copyright-requests/).  The online version and data sources are also available at diabetesatlas.org.",
        "summary_ur": "This is the 2025 International Diabetes Federation (IDF) Diabetes Atlas.  Copyright belongs to IDF; reproduction requires prior written permission (diabetesatlas.org/copyright-requests/).  The Atlas, in its tenth edition, contains data from various studies (listed on the website).  Optima handled design and editing."
      }
    },
    {
      "text": "This is the 11th edition (2025) of the IDF Diabetes Atlas, property of the International Diabetes Federation.  The publication's map and country designations do not reflect any political opinions, instead using UN official names.  It's dedicated to the late Professor Akhtar Hussain, IDF President (2022-2024). The International Diabetes Federation (IDF) holds copyright to the 11th edition of the IDF Diabetes Atlas.  The map's depiction of boundaries doesn't reflect IDF's opinion on any country's legal status.  The Atlas uses UN-listed country names and is dedicated to the late Professor Akhtar Hussain.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 4,
        "page_label": "VI",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This is the 11th edition (2025) of the IDF Diabetes Atlas, property of the International Diabetes Federation.  The publication's map and country designations do not reflect any political opinions, instead using UN official names.  It's dedicated to the late Professor Akhtar Hussain, IDF President (2022-2024).",
        "summary_ur": "The International Diabetes Federation (IDF) holds copyright to the 11th edition of the IDF Diabetes Atlas.  The map's depiction of boundaries doesn't reflect IDF's opinion on any country's legal status.  The Atlas uses UN-listed country names and is dedicated to the late Professor Akhtar Hussain."
      }
    },
    {
      "text": "This document acknowledges the IDF Diabetes Atlas 11th Edition Committee, including co-chairs Dianna Magliano and Edward Boyko.  It lists numerous Special Interest Group (SIG) leads and members who contributed to the project. The IDF Diabetes Atlas 11th Edition was prepared by a large committee, co-chaired by Magliano and Boyko.  Numerous SIG leads and members contributed expertise across various specialties.  This collaborative effort reflects a broad range of diabetic research and clinical practice.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 5,
        "page_label": "1",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This document acknowledges the IDF Diabetes Atlas 11th Edition Committee, including co-chairs Dianna Magliano and Edward Boyko.  It lists numerous Special Interest Group (SIG) leads and members who contributed to the project.",
        "summary_ur": "The IDF Diabetes Atlas 11th Edition was prepared by a large committee, co-chaired by Magliano and Boyko.  Numerous SIG leads and members contributed expertise across various specialties.  This collaborative effort reflects a broad range of diabetic research and clinical practice."
      }
    },
    {
      "text": "This text is a list of names, seemingly of individuals involved in a legal matter or project.  No legal text or context is provided. The text lists a sizable group of names, appearing to be a roster of individuals.  No legal context or summary is provided within the names themselves.  Further information is needed for a legal summary.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 5,
        "page_label": "1",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text is a list of names, seemingly of individuals involved in a legal matter or project.  No legal text or context is provided.",
        "summary_ur": "The text lists a sizable group of names, appearing to be a roster of individuals.  No legal context or summary is provided within the names themselves.  Further information is needed for a legal summary."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th edition was created by a large editorial and support team,  funded by unrestricted educational grants from unnamed sources.  The text lists numerous contributors including editors, team members, and grant providers. The International Diabetes Federation's 11th Diabetes Atlas was created by a large team (Naumovski et al.),  with editorial support (Magliano et al.) and funding from unspecified educational grantors.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 5,
        "page_label": "1",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th edition was created by a large editorial and support team,  funded by unrestricted educational grants from unnamed sources.  The text lists numerous contributors including editors, team members, and grant providers.",
        "summary_ur": "The International Diabetes Federation's 11th Diabetes Atlas was created by a large team (Naumovski et al.),  with editorial support (Magliano et al.) and funding from unspecified educational grantors."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th edition (2025) acknowledges unrestricted educational grants from unnamed supporters Lorenzo Piemonte, Phil Riley, and Paraskevi Salpea.  Further details are available at diabetesatlas.org. This text simply lists the names of three individuals (Lorenzo Piemonte, Phil Riley, Paraskevi Salpea) as supporters of the IDF Diabetes Atlas 11th edition, funded by unrestricted educational grants.  No legal content is present.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 5,
        "page_label": "1",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th edition (2025) acknowledges unrestricted educational grants from unnamed supporters Lorenzo Piemonte, Phil Riley, and Paraskevi Salpea.  Further details are available at diabetesatlas.org.",
        "summary_ur": "This text simply lists the names of three individuals (Lorenzo Piemonte, Phil Riley, Paraskevi Salpea) as supporters of the IDF Diabetes Atlas 11th edition, funded by unrestricted educational grants.  No legal content is present."
      }
    },
    {
      "text": "The IDF Diabetes Atlas, launched at the 2025 World Diabetes Congress, marks the IDF's 75th anniversary and 25 years of Atlas publication.  The IDF, initially a 16-country collaboration, now unites over 240 organizations across 161 countries to address the growing global diabetes challenge. The IDF Diabetes Atlas, launched at the 2025 World Diabetes Congress, marks the IDF's 75th anniversary and 25 years of Atlas publication.  Initially uniting 16 countries, the IDF now comprises over 240 organizations across 161 countries, encompassing researchers, healthcare professionals, and people with diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 6,
        "page_label": "2",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas, launched at the 2025 World Diabetes Congress, marks the IDF's 75th anniversary and 25 years of Atlas publication.  The IDF, initially a 16-country collaboration, now unites over 240 organizations across 161 countries to address the growing global diabetes challenge.",
        "summary_ur": "The IDF Diabetes Atlas, launched at the 2025 World Diabetes Congress, marks the IDF's 75th anniversary and 25 years of Atlas publication.  Initially uniting 16 countries, the IDF now comprises over 240 organizations across 161 countries, encompassing researchers, healthcare professionals, and people with diabetes."
      }
    },
    {
      "text": "This text describes an organization dedicated to improving global diabetes care, founded in 1950 by Dr. R.D. Lawrence, a researcher and person with type 1 diabetes.  The organization prioritizes listening to the community and addressing health inequities, particularly in resource-limited countries.  Its mission is to advance diabetes care through scientific progress and advocacy. This text describes an organization dedicated to improving global diabetes care since 1950.  Founded by leading diabetologists, including a person with type 1 diabetes, it prioritizes patient voices and addresses health inequities, focusing on resource-limited countries.  The organization's work builds upon advancements in insulin treatment and continues to push the boundaries of diabetes research and care.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 6,
        "page_label": "2",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes an organization dedicated to improving global diabetes care, founded in 1950 by Dr. R.D. Lawrence, a researcher and person with type 1 diabetes.  The organization prioritizes listening to the community and addressing health inequities, particularly in resource-limited countries.  Its mission is to advance diabetes care through scientific progress and advocacy.",
        "summary_ur": "This text describes an organization dedicated to improving global diabetes care since 1950.  Founded by leading diabetologists, including a person with type 1 diabetes, it prioritizes patient voices and addresses health inequities, focusing on resource-limited countries.  The organization's work builds upon advancements in insulin treatment and continues to push the boundaries of diabetes research and care."
      }
    },
    {
      "text": "The text highlights the historical inequities in diabetes care, contrasting the life-saving insulin treatment received by early patients with the persistent global disparities in access to diagnosis, treatment, and management.  Despite progress, diabetes care remains a privilege for many, not a right. Early insulin recipient Lawrence's story highlights persistent inequities in diabetes care.  Despite advancements, access remains unequal globally, with diagnosis, treatment, and management privileged for many, not a universal right.  This disparity persists despite diabetes being a global health crisis.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 6,
        "page_label": "2",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text highlights the historical inequities in diabetes care, contrasting the life-saving insulin treatment received by early patients with the persistent global disparities in access to diagnosis, treatment, and management.  Despite progress, diabetes care remains a privilege for many, not a right.",
        "summary_ur": "Early insulin recipient Lawrence's story highlights persistent inequities in diabetes care.  Despite advancements, access remains unequal globally, with diagnosis, treatment, and management privileged for many, not a universal right.  This disparity persists despite diabetes being a global health crisis."
      }
    },
    {
      "text": "Despite progress, diabetes care remains inaccessible to many.  The International Diabetes Federation (IDF) emphasizes the need for global action to improve access and raise awareness.  The IDF Diabetes Atlas provides resources to advocate for policy changes and address systemic inequities hindering equitable diabetes care worldwide. 75 years on, diabetes care remains unequal.  The IDF urges global unity to improve access and raise awareness using the Diabetes Atlas (diabetesatlas.org) as a tool for advocacy and policy change.  Much progress has been made, but systemic inequities persist, demanding continued effort.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 6,
        "page_label": "2",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Despite progress, diabetes care remains inaccessible to many.  The International Diabetes Federation (IDF) emphasizes the need for global action to improve access and raise awareness.  The IDF Diabetes Atlas provides resources to advocate for policy changes and address systemic inequities hindering equitable diabetes care worldwide.",
        "summary_ur": "75 years on, diabetes care remains unequal.  The IDF urges global unity to improve access and raise awareness using the Diabetes Atlas (diabetesatlas.org) as a tool for advocacy and policy change.  Much progress has been made, but systemic inequities persist, demanding continued effort."
      }
    },
    {
      "text": "The text describes a mission to improve the lives of people with diabetes and prevent the disease, particularly addressing systemic inequities affecting vulnerable communities.  It highlights the \"defining decade\" for diabetes, marked by the launch of the WHO's Global Diabetes Compact aiming for equitable access to care and prevention efforts. The text describes a mission to improve diabetic lives and prevent the disease, acknowledging systemic inequities impacting various communities.  The Diabetes Atlas provides data to drive change.  A defining decade for diabetes includes the WHO's Global Diabetes Compact aiming for equitable, affordable care and type 2 diabetes prevention.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 6,
        "page_label": "2",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text describes a mission to improve the lives of people with diabetes and prevent the disease, particularly addressing systemic inequities affecting vulnerable communities.  It highlights the \"defining decade\" for diabetes, marked by the launch of the WHO's Global Diabetes Compact aiming for equitable access to care and prevention efforts.",
        "summary_ur": "The text describes a mission to improve diabetic lives and prevent the disease, acknowledging systemic inequities impacting various communities.  The Diabetes Atlas provides data to drive change.  A defining decade for diabetes includes the WHO's Global Diabetes Compact aiming for equitable, affordable care and type 2 diabetes prevention."
      }
    },
    {
      "text": "This text mentions a resolution aimed at strengthening diabetes prevention and control,  a key part of a broader non-communicable disease (NCD) response.  Member states have agreed on targets to reduce diabetes risk and improve care for those diagnosed. This text mentions a resolution to strengthen diabetes prevention and control,  a key part of non-communicable disease (NCD) efforts.  Member states set targets to reduce diabetes risk and improve care for those diagnosed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 6,
        "page_label": "2",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text mentions a resolution aimed at strengthening diabetes prevention and control,  a key part of a broader non-communicable disease (NCD) response.  Member states have agreed on targets to reduce diabetes risk and improve care for those diagnosed.",
        "summary_ur": "This text mentions a resolution to strengthen diabetes prevention and control,  a key part of non-communicable disease (NCD) efforts.  Member states set targets to reduce diabetes risk and improve care for those diagnosed."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th edition highlights the world's insufficient progress toward 2030 diabetes targets.  It emphasizes the urgent need for increased governmental investment in prevention and care to improve early diagnosis, access to quality treatment, and ultimately reduce diabetes complications and prevalence.  The Atlas's improved data offers a more precise global picture of the diabetes crisis. The IDF Diabetes Atlas (11th edition) reveals a critical shortfall in meeting 2030 diabetes care targets.  Urgent action is needed: governments must fulfill commitments to invest in prevention and improved care access, ensuring early diagnosis and complication management for all.  Increased data highlights the growing global diabetes crisis.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 7,
        "page_label": "3",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th edition highlights the world's insufficient progress toward 2030 diabetes targets.  It emphasizes the urgent need for increased governmental investment in prevention and care to improve early diagnosis, access to quality treatment, and ultimately reduce diabetes complications and prevalence.  The Atlas's improved data offers a more precise global picture of the diabetes crisis.",
        "summary_ur": "The IDF Diabetes Atlas (11th edition) reveals a critical shortfall in meeting 2030 diabetes care targets.  Urgent action is needed: governments must fulfill commitments to invest in prevention and improved care access, ensuring early diagnosis and complication management for all.  Increased data highlights the growing global diabetes crisis."
      }
    },
    {
      "text": "Professor Peter Schwarz dedicates the 11th edition of the IDF Diabetes Atlas to the late Professor Aktar Hussain, whose untimely death prevented him from writing the foreword.  The Atlas, a product of international expert collaboration, provides an updated global overview of the diabetes landscape. The 11th edition of the IDF Diabetes Atlas provides an updated global diabetes overview.  Professor Peter Schwarz dedicates this edition to the late Professor Aktar Hussain, whose advocacy for diabetes patients, especially in low- and middle-income countries, is remembered and honored.  The Atlas aims to inspire positive change.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 7,
        "page_label": "3",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Professor Peter Schwarz dedicates the 11th edition of the IDF Diabetes Atlas to the late Professor Aktar Hussain, whose untimely death prevented him from writing the foreword.  The Atlas, a product of international expert collaboration, provides an updated global overview of the diabetes landscape.",
        "summary_ur": "The 11th edition of the IDF Diabetes Atlas provides an updated global diabetes overview.  Professor Peter Schwarz dedicates this edition to the late Professor Aktar Hussain, whose advocacy for diabetes patients, especially in low- and middle-income countries, is remembered and honored.  The Atlas aims to inspire positive change."
      }
    },
    {
      "text": "The 11th edition of the IDF Diabetes Atlas provides updated global diabetes prevalence data.  Showing a continued rise in cases, the Atlas serves as both a data resource and advocacy tool, urging action to improve the lives of those affected by diabetes.  The co-chairs highlight the challenges in accurately estimating diabetes impact across diverse populations. The 11th edition of the IDF Diabetes Atlas provides updated global diabetes prevalence data.  Showing a continued rise in cases, this resource\u2014used for national and international health advocacy\u2014urges action to improve the lives of those affected by diabetes.  The data's estimation, while utilizing available resources, faces inherent challenges.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 8,
        "page_label": "4",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition of the IDF Diabetes Atlas provides updated global diabetes prevalence data.  Showing a continued rise in cases, the Atlas serves as both a data resource and advocacy tool, urging action to improve the lives of those affected by diabetes.  The co-chairs highlight the challenges in accurately estimating diabetes impact across diverse populations.",
        "summary_ur": "The 11th edition of the IDF Diabetes Atlas provides updated global diabetes prevalence data.  Showing a continued rise in cases, this resource\u2014used for national and international health advocacy\u2014urges action to improve the lives of those affected by diabetes.  The data's estimation, while utilizing available resources, faces inherent challenges."
      }
    },
    {
      "text": "This text discusses the methodological challenges in estimating the global impact of diabetes.  It highlights the need to select data types (clinic vs. population-based), define the time period, determine data quality inclusion criteria, and standardize diabetes definitions (self-reported vs. lab tests, specific tests used).  These choices significantly impact prevalence estimates. The text discusses methodological challenges in estimating global diabetes prevalence.  Researchers must choose between data types (clinic vs. population-based), timeframes, data quality levels, and diabetes definitions (self-reported vs. lab tests, and which specific tests to use).  These choices significantly impact prevalence estimates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 8,
        "page_label": "4",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text discusses the methodological challenges in estimating the global impact of diabetes.  It highlights the need to select data types (clinic vs. population-based), define the time period, determine data quality inclusion criteria, and standardize diabetes definitions (self-reported vs. lab tests, specific tests used).  These choices significantly impact prevalence estimates.",
        "summary_ur": "The text discusses methodological challenges in estimating global diabetes prevalence.  Researchers must choose between data types (clinic vs. population-based), timeframes, data quality levels, and diabetes definitions (self-reported vs. lab tests, and which specific tests to use).  These choices significantly impact prevalence estimates."
      }
    },
    {
      "text": "Global diabetes prevalence estimates vary widely (500-800 million in 2021-2024) due to differing methodologies used by various groups (IDF, GBD, NCD-RisC).  A critical examination of these methods is needed for accurate healthcare planning.  Data gaps, particularly in Africa, remain a significant concern. Different studies estimate global diabetes prevalence between 500 and 800 million (2021-2024), varying due to methodological differences.  Data from 29% of countries (62/215) is missing, particularly from Africa, hindering accurate healthcare planning.  Improved data collection is crucial.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 8,
        "page_label": "4",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Global diabetes prevalence estimates vary widely (500-800 million in 2021-2024) due to differing methodologies used by various groups (IDF, GBD, NCD-RisC).  A critical examination of these methods is needed for accurate healthcare planning.  Data gaps, particularly in Africa, remain a significant concern.",
        "summary_ur": "Different studies estimate global diabetes prevalence between 500 and 800 million (2021-2024), varying due to methodological differences.  Data from 29% of countries (62/215) is missing, particularly from Africa, hindering accurate healthcare planning.  Improved data collection is crucial."
      }
    },
    {
      "text": "Due to outdated and insufficient data, particularly from Africa, the study excludes research before 2005.  It prioritizes recent national surveys (like NHANES and KHANES) and leverages national registries and health insurance data for more accurate diabetes prevalence estimations. This text discusses limitations in using older studies to predict current diabetes prevalence, especially in Africa.  Data is sparse and older research underestimates the rising epidemic. The authors chose to use only post-2005 data from reliable national surveys and registries for more accurate estimations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 8,
        "page_label": "4",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Due to outdated and insufficient data, particularly from Africa, the study excludes research before 2005.  It prioritizes recent national surveys (like NHANES and KHANES) and leverages national registries and health insurance data for more accurate diabetes prevalence estimations.",
        "summary_ur": "This text discusses limitations in using older studies to predict current diabetes prevalence, especially in Africa.  Data is sparse and older research underestimates the rising epidemic. The authors chose to use only post-2005 data from reliable national surveys and registries for more accurate estimations."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th Edition uses national registries, administrative sources, and health insurance data to estimate diabetes prevalence.  These sources capture known cases, adjusted for undiagnosed diabetes.  WHO STEPS surveys supplement this data, providing a comprehensive, albeit still evolving, global picture. The IDF Diabetes Atlas uses national registries, health insurance data, and WHO STEPS surveys to estimate diabetes prevalence.  While these primarily capture diagnosed cases, adjustments for undiagnosed diabetes provide a more complete picture.  Future registry expansion will improve accuracy.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 8,
        "page_label": "4",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th Edition uses national registries, administrative sources, and health insurance data to estimate diabetes prevalence.  These sources capture known cases, adjusted for undiagnosed diabetes.  WHO STEPS surveys supplement this data, providing a comprehensive, albeit still evolving, global picture.",
        "summary_ur": "The IDF Diabetes Atlas uses national registries, health insurance data, and WHO STEPS surveys to estimate diabetes prevalence.  While these primarily capture diagnosed cases, adjustments for undiagnosed diabetes provide a more complete picture.  Future registry expansion will improve accuracy."
      }
    },
    {
      "text": "The Atlas team improved its methodology for estimating deaths attributed to diabetes, using statistical expert review and new data to achieve greater accuracy.  Comparisons to previous editions should account for these methodological changes, as differences may reflect actual changes or improved estimation techniques.  A key improvement involves separating mortality rates for diagnosed and undiagnosed diabetes. Atlas methodology improved for greater precision and reduced bias.  Statistical experts reviewed methods.  New data allowed more accurate diabetes death estimation, accounting for undiagnosed cases.  Comparisons to older editions should consider methodological changes.  Updated urbanization ratios from WHO were also used.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 9,
        "page_label": "5",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The Atlas team improved its methodology for estimating deaths attributed to diabetes, using statistical expert review and new data to achieve greater accuracy.  Comparisons to previous editions should account for these methodological changes, as differences may reflect actual changes or improved estimation techniques.  A key improvement involves separating mortality rates for diagnosed and undiagnosed diabetes.",
        "summary_ur": "Atlas methodology improved for greater precision and reduced bias.  Statistical experts reviewed methods.  New data allowed more accurate diabetes death estimation, accounting for undiagnosed cases.  Comparisons to older editions should consider methodological changes.  Updated urbanization ratios from WHO were also used."
      }
    },
    {
      "text": "This report updates diabetes prevalence forecasts to 2050, using improved methodology and data (WHO urbanization ratios).  Forecasts only consider age, sex, and urban/rural distribution changes,  excluding other potentially influential factors to avoid inaccurate speculation.  The report emphasizes the need for continued diabetes surveillance and robust national studies. This report presents updated diabetes prevalence forecasts to 2050, using improved methodologies and data (WHO urbanization ratios).  Forecasts only account for age, sex, and urban/rural distribution changes, omitting other potentially influential factors to avoid inaccurate speculation.  Continued diabetes surveillance and robust national studies are urged.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 9,
        "page_label": "5",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This report updates diabetes prevalence forecasts to 2050, using improved methodology and data (WHO urbanization ratios).  Forecasts only consider age, sex, and urban/rural distribution changes,  excluding other potentially influential factors to avoid inaccurate speculation.  The report emphasizes the need for continued diabetes surveillance and robust national studies.",
        "summary_ur": "This report presents updated diabetes prevalence forecasts to 2050, using improved methodologies and data (WHO urbanization ratios).  Forecasts only account for age, sex, and urban/rural distribution changes, omitting other potentially influential factors to avoid inaccurate speculation.  Continued diabetes surveillance and robust national studies are urged."
      }
    },
    {
      "text": "The 11th edition of the IDF Diabetes Atlas (2025) emphasizes the need for improved national diabetes prevalence studies to monitor the disease's impact and inform future predictions.  It stresses a collaborative effort\u2014involving individuals, governments, NGOs, and the medical community\u2014for effective diabetes prevention and control. The IDF Diabetes Atlas (11th Edition, 2025) stresses the need for improved national diabetes prevalence studies to monitor impact and forecast trends.  Continued awareness, prevention efforts, and collaborative action from individuals, governments, NGOs, and healthcare professionals are crucial to combatting the rising tide of diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 9,
        "page_label": "5",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition of the IDF Diabetes Atlas (2025) emphasizes the need for improved national diabetes prevalence studies to monitor the disease's impact and inform future predictions.  It stresses a collaborative effort\u2014involving individuals, governments, NGOs, and the medical community\u2014for effective diabetes prevention and control.",
        "summary_ur": "The IDF Diabetes Atlas (11th Edition, 2025) stresses the need for improved national diabetes prevalence studies to monitor impact and forecast trends.  Continued awareness, prevention efforts, and collaborative action from individuals, governments, NGOs, and healthcare professionals are crucial to combatting the rising tide of diabetes."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th Edition (2025) projects a significant global increase in diabetes cases from 588.7 million in 2024 to 852.5 million in 2050.  Regional increases vary widely, with Africa experiencing the most dramatic rise (142%). The global diabetes population is projected to rise from 588.7 million in 2024 to 852.5 million in 2050, a 45% increase.  Significant regional variations exist, with Africa experiencing the most dramatic rise (142%).  Other regions also show substantial increases, highlighting a growing global diabetes crisis.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 10,
        "page_label": "6",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th Edition (2025) projects a significant global increase in diabetes cases from 588.7 million in 2024 to 852.5 million in 2050.  Regional increases vary widely, with Africa experiencing the most dramatic rise (142%).",
        "summary_ur": "The global diabetes population is projected to rise from 588.7 million in 2024 to 852.5 million in 2050, a 45% increase.  Significant regional variations exist, with Africa experiencing the most dramatic rise (142%).  Other regions also show substantial increases, highlighting a growing global diabetes crisis."
      }
    },
    {
      "text": "The IDF Diabetes Atlas is a comprehensive resource providing global, regional, and national data on diabetes prevalence, morbidity, mortality, and healthcare costs.  It details diabetes pathophysiology, classification, diagnosis, and management, offering evidence-based prevention and treatment strategies.  Its credibility stems from rigorous data selection and analysis by expert committees. The IDF Diabetes Atlas is a key resource providing global diabetes prevalence data, related health issues, and costs.  It details diabetes types, diagnosis, and management, offering evidence-based prevention and treatment strategies.  Its credibility stems from rigorous data analysis and expert review.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 11,
        "page_label": "7",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas is a comprehensive resource providing global, regional, and national data on diabetes prevalence, morbidity, mortality, and healthcare costs.  It details diabetes pathophysiology, classification, diagnosis, and management, offering evidence-based prevention and treatment strategies.  Its credibility stems from rigorous data selection and analysis by expert committees.",
        "summary_ur": "The IDF Diabetes Atlas is a key resource providing global diabetes prevalence data, related health issues, and costs.  It details diabetes types, diagnosis, and management, offering evidence-based prevention and treatment strategies.  Its credibility stems from rigorous data analysis and expert review."
      }
    },
    {
      "text": "The IDF Diabetes Atlas Committee, using data from peer-reviewed studies and national registries,  updates its estimates of global diabetes prevalence.  The 11th edition confirms diabetes' rapid global growth,  with future editions expected to incorporate more electronic health record data. The IDF Diabetes Atlas, updated to its 11th edition, uses data from peer-reviewed studies and national registries to estimate diabetes prevalence.  Its methodology, detailed by Guariguata et al., confirms diabetes' rapid global increase.  Future editions will incorporate more electronic records and national registry data.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 11,
        "page_label": "7",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas Committee, using data from peer-reviewed studies and national registries,  updates its estimates of global diabetes prevalence.  The 11th edition confirms diabetes' rapid global growth,  with future editions expected to incorporate more electronic health record data.",
        "summary_ur": "The IDF Diabetes Atlas, updated to its 11th edition, uses data from peer-reviewed studies and national registries to estimate diabetes prevalence.  Its methodology, detailed by Guariguata et al., confirms diabetes' rapid global increase.  Future editions will incorporate more electronic records and national registry data."
      }
    },
    {
      "text": "The 11th edition's findings show diabetes as a rapidly expanding global health crisis.  In 2024, 589 million adults (20-79) had diabetes,  with projections reaching 853 million by 2050.  Over 3.4 million diabetes-related deaths occurred in 2024, and direct healthcare costs exceeded one trillion USD.  Millions more have impaired glucose tolerance, highlighting a substantial at-risk population. The 11th edition's findings reveal a rapidly escalating global diabetes crisis.  In 2024, 589 million adults (20-79) had diabetes,  projected to reach 853 million by 2050.  Over 3.4 million died from related causes, with healthcare costs exceeding one trillion USD.  Millions more have impaired glucose tolerance, highlighting a vast at-risk population.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 11,
        "page_label": "7",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition's findings show diabetes as a rapidly expanding global health crisis.  In 2024, 589 million adults (20-79) had diabetes,  with projections reaching 853 million by 2050.  Over 3.4 million diabetes-related deaths occurred in 2024, and direct healthcare costs exceeded one trillion USD.  Millions more have impaired glucose tolerance, highlighting a substantial at-risk population.",
        "summary_ur": "The 11th edition's findings reveal a rapidly escalating global diabetes crisis.  In 2024, 589 million adults (20-79) had diabetes,  projected to reach 853 million by 2050.  Over 3.4 million died from related causes, with healthcare costs exceeding one trillion USD.  Millions more have impaired glucose tolerance, highlighting a vast at-risk population."
      }
    },
    {
      "text": "The 11th edition of the IDF Diabetes Atlas reveals a global diabetes crisis.  Direct healthcare costs exceeded $1 trillion in 2024, and  hyperglycemia in pregnancy affects 20% of pregnancies.  A concerning 43% of people with diabetes remain undiagnosed, primarily type 2, highlighting the urgent need for improved diagnosis and early intervention. The 2025 IDF Diabetes Atlas reveals a global diabetes crisis.  Direct costs exceeded $1 trillion in 2024, and cases continue to rise rapidly.  A concerning 43% of those with diabetes remain undiagnosed, mostly type 2, highlighting the urgent need for improved diagnosis and early care.  Hyperglycaemia in pregnancy also affects a significant portion of pregnancies.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 11,
        "page_label": "7",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition of the IDF Diabetes Atlas reveals a global diabetes crisis.  Direct healthcare costs exceeded $1 trillion in 2024, and  hyperglycemia in pregnancy affects 20% of pregnancies.  A concerning 43% of people with diabetes remain undiagnosed, primarily type 2, highlighting the urgent need for improved diagnosis and early intervention.",
        "summary_ur": "The 2025 IDF Diabetes Atlas reveals a global diabetes crisis.  Direct costs exceeded $1 trillion in 2024, and cases continue to rise rapidly.  A concerning 43% of those with diabetes remain undiagnosed, mostly type 2, highlighting the urgent need for improved diagnosis and early care.  Hyperglycaemia in pregnancy also affects a significant portion of pregnancies."
      }
    },
    {
      "text": "The IDF Diabetes Atlas, first published in 2000, estimates global diabetes prevalence.  While its 2015 estimate (415 million) was close to the WHO's (422 million),  the WHO's 2022 estimate (828 million) significantly exceeds the Atlas's 2024 projection (589 million).  The Atlas serves as an advocacy tool to quantify and reduce the impact of diabetes worldwide. The IDF Diabetes Atlas, first published in 2000, estimates global diabetes prevalence.  Its projections, close to WHO estimates in the past, now show a discrepancy.  The Atlas serves to quantify diabetes' impact and advocate for preventative measures and improved long-term care.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 12,
        "page_label": "8",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas, first published in 2000, estimates global diabetes prevalence.  While its 2015 estimate (415 million) was close to the WHO's (422 million),  the WHO's 2022 estimate (828 million) significantly exceeds the Atlas's 2024 projection (589 million).  The Atlas serves as an advocacy tool to quantify and reduce the impact of diabetes worldwide.",
        "summary_ur": "The IDF Diabetes Atlas, first published in 2000, estimates global diabetes prevalence.  Its projections, close to WHO estimates in the past, now show a discrepancy.  The Atlas serves to quantify diabetes' impact and advocate for preventative measures and improved long-term care."
      }
    },
    {
      "text": "The WHO/NCD-RisC 2022 diabetes estimate (far exceeding IDF and GBD figures) may be inflated due to its inclusion of HbA1c levels (limited global availability and prone to inaccuracies with iron deficiency) and its broad diabetes definition (including medication use).  Different methodologies and data selections significantly impact global prevalence estimations. The 2022 WHO/NCD-RisC estimate of diabetes cases (far exceeding 2021 and 2024 projections) is likely inflated.  This is due to their diabetes definition (including HbA1c, unreliable in many areas) and estimation methodology.  The IDF's approach differs, leading to discrepancies.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 12,
        "page_label": "8",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The WHO/NCD-RisC 2022 diabetes estimate (far exceeding IDF and GBD figures) may be inflated due to its inclusion of HbA1c levels (limited global availability and prone to inaccuracies with iron deficiency) and its broad diabetes definition (including medication use).  Different methodologies and data selections significantly impact global prevalence estimations.",
        "summary_ur": "The 2022 WHO/NCD-RisC estimate of diabetes cases (far exceeding 2021 and 2024 projections) is likely inflated.  This is due to their diabetes definition (including HbA1c, unreliable in many areas) and estimation methodology.  The IDF's approach differs, leading to discrepancies."
      }
    },
    {
      "text": "The International Diabetes Federation (IDF) Atlas reveals a sharply increasing global diabetes prevalence.  High readings may be spurious due to factors like iron deficiency, and estimation methods may inflate numbers in data-scarce regions.  Despite these limitations, the Atlas uses the best available data to highlight the growing diabetes burden and inform advocacy efforts. The IDF Diabetes Atlas reports a rising global diabetes prevalence, noting potential inaccuracies due to data limitations in lower-income countries.  These estimates, while based on best available data, may be inflated by methodological issues affecting blood glucose readings.  The Atlas serves as a crucial research and advocacy tool highlighting this growing health crisis.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 12,
        "page_label": "8",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The International Diabetes Federation (IDF) Atlas reveals a sharply increasing global diabetes prevalence.  High readings may be spurious due to factors like iron deficiency, and estimation methods may inflate numbers in data-scarce regions.  Despite these limitations, the Atlas uses the best available data to highlight the growing diabetes burden and inform advocacy efforts.",
        "summary_ur": "The IDF Diabetes Atlas reports a rising global diabetes prevalence, noting potential inaccuracies due to data limitations in lower-income countries.  These estimates, while based on best available data, may be inflated by methodological issues affecting blood glucose readings.  The Atlas serves as a crucial research and advocacy tool highlighting this growing health crisis."
      }
    },
    {
      "text": "The IDF Diabetes Atlas's 11th edition (2025) provides estimates of diabetes impact globally, using the highest-quality data available.  The report's key messages are not detailed in the provided text. Please provide the legal text you wish me to summarize.  The provided text is not legal text; it's a description of data from the IDF Diabetes Atlas.  I cannot summarize it in Ur (Urdu) without the actual legal text.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 12,
        "page_label": "8",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas's 11th edition (2025) provides estimates of diabetes impact globally, using the highest-quality data available.  The report's key messages are not detailed in the provided text.",
        "summary_ur": "Please provide the legal text you wish me to summarize.  The provided text is not legal text; it's a description of data from the IDF Diabetes Atlas.  I cannot summarize it in Ur (Urdu) without the actual legal text."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th edition aims to describe the current diabetes landscape, advocate for improved lives for those affected, and discuss updated monitoring methodologies.  While incorporating new data and topics, it maintains methodological continuity with previous editions, allowing for trend analysis.  Chapter 2 details the methodological changes. The IDF Diabetes Atlas's 11th edition updates global diabetes data, advocates for improved lives of those affected, and discusses new monitoring methodologies.  While employing refined epidemiological methods and new data, it maintains continuity with previous editions' estimation bases.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 13,
        "page_label": "9",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th edition aims to describe the current diabetes landscape, advocate for improved lives for those affected, and discuss updated monitoring methodologies.  While incorporating new data and topics, it maintains methodological continuity with previous editions, allowing for trend analysis.  Chapter 2 details the methodological changes.",
        "summary_ur": "The IDF Diabetes Atlas's 11th edition updates global diabetes data, advocates for improved lives of those affected, and discusses new monitoring methodologies.  While employing refined epidemiological methods and new data, it maintains continuity with previous editions' estimation bases."
      }
    },
    {
      "text": "The 11th edition of the Diabetes Atlas maintains continuity with previous editions while adding a chapter on diabetes complications, expanding coverage of diabetes in older adults,  projecting data to 2050, and differentiating mortality data for diagnosed and undiagnosed diabetes.  The inclusion of prediabetes data is also highlighted. The 11th edition maintains continuity with previous editions, focusing on global diabetes trends.  New features include a dedicated chapter on diabetes complications, analysis of diabetes in older adults, updated projections to 2050, and a breakdown of mortality data by diagnosed/undiagnosed status.  Prediabetes is also given increased attention.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 13,
        "page_label": "9",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition of the Diabetes Atlas maintains continuity with previous editions while adding a chapter on diabetes complications, expanding coverage of diabetes in older adults,  projecting data to 2050, and differentiating mortality data for diagnosed and undiagnosed diabetes.  The inclusion of prediabetes data is also highlighted.",
        "summary_ur": "The 11th edition maintains continuity with previous editions, focusing on global diabetes trends.  New features include a dedicated chapter on diabetes complications, analysis of diabetes in older adults, updated projections to 2050, and a breakdown of mortality data by diagnosed/undiagnosed status.  Prediabetes is also given increased attention."
      }
    },
    {
      "text": "This text describes updates to a diabetes report.  It now separates mortality data for diagnosed and undiagnosed diabetes, includes prediabetes prevalence data using HbA1c criteria, and features a new, user-friendly online data portal allowing for easy access and stratification of data by indicator, region, and country. This report innovatively separates diabetes mortality data by diagnosed and undiagnosed cases.  It also includes new data on prediabetes prevalence, using HbA1c criteria,  for a more comprehensive view of hyperglycemia's impact.  A new user-friendly data portal offers easy access to this information, stratified by region and country.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 13,
        "page_label": "9",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes updates to a diabetes report.  It now separates mortality data for diagnosed and undiagnosed diabetes, includes prediabetes prevalence data using HbA1c criteria, and features a new, user-friendly online data portal allowing for easy access and stratification of data by indicator, region, and country.",
        "summary_ur": "This report innovatively separates diabetes mortality data by diagnosed and undiagnosed cases.  It also includes new data on prediabetes prevalence, using HbA1c criteria,  for a more comprehensive view of hyperglycemia's impact.  A new user-friendly data portal offers easy access to this information, stratified by region and country."
      }
    },
    {
      "text": "The text describes an accessible website with downloadable data and resources from the IDF Diabetes Atlas.  The website offers stratified data by indicator, region, and country, along with fact sheets and presentations.  A figure displays estimates and projections of global diabetes prevalence (20\u201379 year olds) from 2000 to 2050. The text describes a website offering easy access to downloadable data from the IDF Diabetes Atlas.  This includes global and regional data on diabetes prevalence, stratified by indicator, region, and country, alongside supplementary resources like fact sheets and presentations.  A figure shows diabetes prevalence estimates and projections from 2000 to 2050.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 13,
        "page_label": "9",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text describes an accessible website with downloadable data and resources from the IDF Diabetes Atlas.  The website offers stratified data by indicator, region, and country, along with fact sheets and presentations.  A figure displays estimates and projections of global diabetes prevalence (20\u201379 year olds) from 2000 to 2050.",
        "summary_ur": "The text describes a website offering easy access to downloadable data from the IDF Diabetes Atlas.  This includes global and regional data on diabetes prevalence, stratified by indicator, region, and country, alongside supplementary resources like fact sheets and presentations.  A figure shows diabetes prevalence estimates and projections from 2000 to 2050."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th edition (2024) differs from the 10th due to updated data sources.  Changes include incorporating new studies and national registries (adjusting for diagnosed and undiagnosed cases), and excluding some surveys deemed invalid.  Consider these factors when interpreting the data. The IDF Diabetes Atlas (11th edition, 2024) differs from the 10th due to updated data sources.  New studies, national registry data (adjusted to include diagnosed and undiagnosed cases), and exclusions of invalid surveys account for variations.  Consider these factors when comparing figures across editions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 14,
        "page_label": "10",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th edition (2024) differs from the 10th due to updated data sources.  Changes include incorporating new studies and national registries (adjusting for diagnosed and undiagnosed cases), and excluding some surveys deemed invalid.  Consider these factors when interpreting the data.",
        "summary_ur": "The IDF Diabetes Atlas (11th edition, 2024) differs from the 10th due to updated data sources.  New studies, national registry data (adjusted to include diagnosed and undiagnosed cases), and exclusions of invalid surveys account for variations.  Consider these factors when comparing figures across editions."
      }
    },
    {
      "text": "This text discusses limitations in a diabetes prevalence study.  Older studies were excluded, potentially inflating prevalence estimates.  Using more recent, higher-quality data might lower estimates.  The study's epidemiological definition of diabetes (one abnormal test) differs from clinical diagnosis, impacting accuracy. The IDF Diabetes Atlas uses updated data, excluding studies before 2005, potentially overestimating prevalence.  Only the latest surveys per country were included.  Methodological improvements and a broader epidemiological definition of diabetes compared to clinical diagnosis may also influence prevalence figures.  Previous Atlas versions may show lower prevalence due to these factors.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 14,
        "page_label": "10",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text discusses limitations in a diabetes prevalence study.  Older studies were excluded, potentially inflating prevalence estimates.  Using more recent, higher-quality data might lower estimates.  The study's epidemiological definition of diabetes (one abnormal test) differs from clinical diagnosis, impacting accuracy.",
        "summary_ur": "The IDF Diabetes Atlas uses updated data, excluding studies before 2005, potentially overestimating prevalence.  Only the latest surveys per country were included.  Methodological improvements and a broader epidemiological definition of diabetes compared to clinical diagnosis may also influence prevalence figures.  Previous Atlas versions may show lower prevalence due to these factors."
      }
    },
    {
      "text": "The Diabetes Atlas uses a less stringent definition of diabetes than clinical diagnosis, requiring only one abnormal blood glucose test.  Data limitations exist; some prevalence estimates are adjusted using national registers, while others rely on extrapolation from similar countries, introducing potential errors. The Diabetes Atlas uses a less stringent definition of diabetes than clinical diagnosis, relying on a single abnormal blood glucose test.  Data limitations exist; some prevalence estimates are adjusted for undiagnosed cases or extrapolated from similar countries, introducing potential inaccuracies.  Careful interpretation is needed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 14,
        "page_label": "10",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The Diabetes Atlas uses a less stringent definition of diabetes than clinical diagnosis, requiring only one abnormal blood glucose test.  Data limitations exist; some prevalence estimates are adjusted using national registers, while others rely on extrapolation from similar countries, introducing potential errors.",
        "summary_ur": "The Diabetes Atlas uses a less stringent definition of diabetes than clinical diagnosis, relying on a single abnormal blood glucose test.  Data limitations exist; some prevalence estimates are adjusted for undiagnosed cases or extrapolated from similar countries, introducing potential inaccuracies.  Careful interpretation is needed."
      }
    },
    {
      "text": "The prevalence of diabetes was estimated using data from a demographically similar country, introducing potential error.  Urban/rural classifications relied on existing data sources, not a uniform IDF definition. The diabetes prevalence data uses estimations from a comparable country, introducing potential inaccuracy.  Urban/rural classifications follow the original data sources, not a uniform IDF standard.  This may affect the study's reliability.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 14,
        "page_label": "10",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The prevalence of diabetes was estimated using data from a demographically similar country, introducing potential error.  Urban/rural classifications relied on existing data sources, not a uniform IDF definition.",
        "summary_ur": "The diabetes prevalence data uses estimations from a comparable country, introducing potential inaccuracy.  Urban/rural classifications follow the original data sources, not a uniform IDF standard.  This may affect the study's reliability."
      }
    },
    {
      "text": "These references cite several studies on global diabetes prevalence.  They detail methodologies for estimating diabetes prevalence (Guariguata et al., 2011),  present findings from large-scale pooled analyses of population-based studies (NCD-RisC, 2016, 2024), and offer global prevalence estimates for 2015 and projections to 2040 (Ogurtsova et al., 2017).  The studies highlight the increasing global burden of diabetes. These references detail studies on global diabetes prevalence.  Studies from the International Diabetes Federation (IDF) and the NCD Risk Factor Collaboration (NCD-RisC) show increasing diabetes rates worldwide from 1980 to 2022, with projections extending to 2040.  The papers offer methodologies and data on prevalence estimations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 15,
        "page_label": "11",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These references cite several studies on global diabetes prevalence.  They detail methodologies for estimating diabetes prevalence (Guariguata et al., 2011),  present findings from large-scale pooled analyses of population-based studies (NCD-RisC, 2016, 2024), and offer global prevalence estimates for 2015 and projections to 2040 (Ogurtsova et al., 2017).  The studies highlight the increasing global burden of diabetes.",
        "summary_ur": "These references detail studies on global diabetes prevalence.  Studies from the International Diabetes Federation (IDF) and the NCD Risk Factor Collaboration (NCD-RisC) show increasing diabetes rates worldwide from 1980 to 2022, with projections extending to 2040.  The papers offer methodologies and data on prevalence estimations."
      }
    },
    {
      "text": "These citations detail studies on the global rise of diabetes from 1990-2022, projecting prevalence to 2050.  Research includes large-scale analyses of diabetes prevalence, treatment, and associated factors like iron deficiency anemia, particularly focusing on the Indian population.  The IDF Diabetes Atlas is also referenced. These sources detail the global rise in diabetes from 1990-2022, citing numerous studies and a large participant pool.  They analyze prevalence, treatment trends, and project future increases, also noting the impact of factors like iron deficiency anemia, particularly in India.  The data highlights a significant and growing global health crisis.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 15,
        "page_label": "11",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations detail studies on the global rise of diabetes from 1990-2022, projecting prevalence to 2050.  Research includes large-scale analyses of diabetes prevalence, treatment, and associated factors like iron deficiency anemia, particularly focusing on the Indian population.  The IDF Diabetes Atlas is also referenced.",
        "summary_ur": "These sources detail the global rise in diabetes from 1990-2022, citing numerous studies and a large participant pool.  They analyze prevalence, treatment trends, and project future increases, also noting the impact of factors like iron deficiency anemia, particularly in India.  The data highlights a significant and growing global health crisis."
      }
    },
    {
      "text": "This text excerpt is from the IDF Diabetes Atlas,  briefly outlining different types of diabetes (Type 1, Type 2, gestational, and others), diagnostic criteria, and impaired glucose tolerance.  It's not legal text. This text is not a legal text; it's an outline of a section on diabetes from a medical publication (likely the IDF Diabetes Atlas).  It covers type 1 and 2 diabetes, impaired glucose tolerance, diagnostic criteria, gestational diabetes, other diabetes types, and references.  It's not summarizing a legal case or statute.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 16,
        "page_label": "12",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text excerpt is from the IDF Diabetes Atlas,  briefly outlining different types of diabetes (Type 1, Type 2, gestational, and others), diagnostic criteria, and impaired glucose tolerance.  It's not legal text.",
        "summary_ur": "This text is not a legal text; it's an outline of a section on diabetes from a medical publication (likely the IDF Diabetes Atlas).  It covers type 1 and 2 diabetes, impaired glucose tolerance, diagnostic criteria, gestational diabetes, other diabetes types, and references.  It's not summarizing a legal case or statute."
      }
    },
    {
      "text": "Diabetes, a chronic condition causing high blood glucose, comes in several types.  Type 1 requires insulin for survival, while Type 2, the most common, is often preventable or even reversible in early stages. Prediabetes increases the risk of Type 2 diabetes and cardiovascular issues. Gestational diabetes in pregnant women elevates birth complication risks. DIABETES:  A serious illness where the body doesn't make enough insulin or use it properly, causing high blood sugar.  Type 1 requires insulin for survival; Type 2, the most common, is often preventable or even reversible early on.  Prediabetes increases risk of Type 2 and heart problems. Gestational diabetes affects pregnant women and increases birth complications.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 17,
        "page_label": "13",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes, a chronic condition causing high blood glucose, comes in several types.  Type 1 requires insulin for survival, while Type 2, the most common, is often preventable or even reversible in early stages. Prediabetes increases the risk of Type 2 diabetes and cardiovascular issues. Gestational diabetes in pregnant women elevates birth complication risks.",
        "summary_ur": "DIABETES:  A serious illness where the body doesn't make enough insulin or use it properly, causing high blood sugar.  Type 1 requires insulin for survival; Type 2, the most common, is often preventable or even reversible early on.  Prediabetes increases risk of Type 2 and heart problems. Gestational diabetes affects pregnant women and increases birth complications."
      }
    },
    {
      "text": "Prediabetes significantly raises the risk of type 2 diabetes, cardiovascular issues, and stroke.  Gestational diabetes (GDM) increases the risk of birth complications, highlighting the importance of regular prenatal care for early intervention. Prediabetes significantly raises the risk of type 2 diabetes, heart issues, and stroke.  Gestational diabetes increases birth complications.  Regular prenatal care is crucial for timely management.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 17,
        "page_label": "13",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Prediabetes significantly raises the risk of type 2 diabetes, cardiovascular issues, and stroke.  Gestational diabetes (GDM) increases the risk of birth complications, highlighting the importance of regular prenatal care for early intervention.",
        "summary_ur": "Prediabetes significantly raises the risk of type 2 diabetes, heart issues, and stroke.  Gestational diabetes increases birth complications.  Regular prenatal care is crucial for timely management."
      }
    },
    {
      "text": "Diabetes is a chronic condition caused by insufficient insulin production or ineffective insulin use.  This leads to high blood glucose (hyperglycemia), diagnosed by measuring blood glucose levels or HbA1c, reflecting glucose levels over the past 90 days.  Insufficient insulin prevents glucose from entering cells for energy, impacting metabolism. Diabetes is a chronic illness where the body doesn't produce enough insulin or can't use it properly.  Insulin helps glucose enter cells for energy.  Lack of insulin causes high blood glucose (hyperglycaemia), diagnosed by measuring glucose levels or HbA1c, reflecting glucose levels over the past 90 days.  High levels indicate diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 18,
        "page_label": "14",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes is a chronic condition caused by insufficient insulin production or ineffective insulin use.  This leads to high blood glucose (hyperglycemia), diagnosed by measuring blood glucose levels or HbA1c, reflecting glucose levels over the past 90 days.  Insufficient insulin prevents glucose from entering cells for energy, impacting metabolism.",
        "summary_ur": "Diabetes is a chronic illness where the body doesn't produce enough insulin or can't use it properly.  Insulin helps glucose enter cells for energy.  Lack of insulin causes high blood glucose (hyperglycaemia), diagnosed by measuring glucose levels or HbA1c, reflecting glucose levels over the past 90 days.  High levels indicate diabetes."
      }
    },
    {
      "text": "High blood glucose, diagnosed via plasma concentration or HbA1c levels (Figure 1.1), causes long-term damage to organs.  Untreated, it leads to serious complications like cardiovascular disease, nerve damage, kidney failure, limb amputation, eye disease, and cognitive decline.  Maintaining near-normal blood glucose levels delays or prevents these complications. High blood sugar, diagnosed via plasma or HbA1c levels (see Figure 1.1), causes long-term organ damage.  Untreated, it leads to serious complications like cardiovascular disease, nerve damage, kidney failure, blindness, and cognitive decline.  Maintaining near-normal blood glucose levels can prevent or delay these issues.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 18,
        "page_label": "14",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "High blood glucose, diagnosed via plasma concentration or HbA1c levels (Figure 1.1), causes long-term damage to organs.  Untreated, it leads to serious complications like cardiovascular disease, nerve damage, kidney failure, limb amputation, eye disease, and cognitive decline.  Maintaining near-normal blood glucose levels delays or prevents these complications.",
        "summary_ur": "High blood sugar, diagnosed via plasma or HbA1c levels (see Figure 1.1), causes long-term organ damage.  Untreated, it leads to serious complications like cardiovascular disease, nerve damage, kidney failure, blindness, and cognitive decline.  Maintaining near-normal blood glucose levels can prevent or delay these issues."
      }
    },
    {
      "text": "Diabetes is diagnosed if fasting plasma glucose is \u2265 126 mg/dL, or two-hour plasma glucose during an oral glucose tolerance test is \u2265200 mg/dL, or random plasma glucose is \u2265200 mg/dL with hyperglycemia symptoms, or HbA1c is \u22656.5%.  Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are diagnosed based on intermediate glucose levels, as specified in the table. This text outlines diagnostic criteria for diabetes and impaired glucose tolerance.  Diabetes is diagnosed if fasting plasma glucose, two-hour plasma glucose after a glucose load, or random plasma glucose exceeds specified thresholds, or HbA1c is \u22656.5%. Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) have their own, less severe, criteria.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 19,
        "page_label": "15",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes is diagnosed if fasting plasma glucose is \u2265 126 mg/dL, or two-hour plasma glucose during an oral glucose tolerance test is \u2265200 mg/dL, or random plasma glucose is \u2265200 mg/dL with hyperglycemia symptoms, or HbA1c is \u22656.5%.  Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are diagnosed based on intermediate glucose levels, as specified in the table.",
        "summary_ur": "This text outlines diagnostic criteria for diabetes and impaired glucose tolerance.  Diabetes is diagnosed if fasting plasma glucose, two-hour plasma glucose after a glucose load, or random plasma glucose exceeds specified thresholds, or HbA1c is \u22656.5%. Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) have their own, less severe, criteria."
      }
    },
    {
      "text": "Diabetes diagnosis requires two abnormal tests (fasting plasma glucose, two-hour postprandial plasma glucose, or HbA1c)  unless hyperglycemia symptoms are present.  Prediabetes is diagnosed with impaired fasting glucose (5.6-6.9 mmol/L), impaired glucose tolerance (7.8-11.1 mmol/L 2-hour postprandial), or HbA1c (39-47 mmol/mol).  Fasting is defined as at least eight hours without caloric intake.  HbA1c testing must be NGSP-certified. To diagnose diabetes, at least two abnormal tests are needed (unless hyperglycemia symptoms exist).  These tests include fasting plasma glucose (\u22657.0 mmol/L), a two-hour postprandial plasma glucose test (\u226511.1 mmol/L), and HbA1c (\u226548 mmol/mol).  \"Prediabetes\" is diagnosed with intermediate values.  Fasting means at least eight hours without caloric intake.  Testing must use NGSP-certified methods.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 19,
        "page_label": "15",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes diagnosis requires two abnormal tests (fasting plasma glucose, two-hour postprandial plasma glucose, or HbA1c)  unless hyperglycemia symptoms are present.  Prediabetes is diagnosed with impaired fasting glucose (5.6-6.9 mmol/L), impaired glucose tolerance (7.8-11.1 mmol/L 2-hour postprandial), or HbA1c (39-47 mmol/mol).  Fasting is defined as at least eight hours without caloric intake.  HbA1c testing must be NGSP-certified.",
        "summary_ur": "To diagnose diabetes, at least two abnormal tests are needed (unless hyperglycemia symptoms exist).  These tests include fasting plasma glucose (\u22657.0 mmol/L), a two-hour postprandial plasma glucose test (\u226511.1 mmol/L), and HbA1c (\u226548 mmol/mol).  \"Prediabetes\" is diagnosed with intermediate values.  Fasting means at least eight hours without caloric intake.  Testing must use NGSP-certified methods."
      }
    },
    {
      "text": "Type 1 diabetes is an autoimmune disease where the body attacks insulin-producing pancreatic cells, causing insulin deficiency.  Its cause is unknown but involves genetic and environmental factors.  Onset occurs in stages, from autoimmunity to overt disease requiring insulin treatment, and can happen at any age, though most frequently in children and young adults.  Global incidence varies significantly. Type 1 diabetes is an autoimmune disease where the body attacks insulin-producing cells, causing insulin deficiency.  Its cause is unknown but involves genetic and environmental factors.  Onset occurs in stages, from autoimmunity to overt disease requiring insulin treatment, and can happen at any age, though most common in children and young adults. Global incidence varies significantly.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 20,
        "page_label": "16",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 1 diabetes is an autoimmune disease where the body attacks insulin-producing pancreatic cells, causing insulin deficiency.  Its cause is unknown but involves genetic and environmental factors.  Onset occurs in stages, from autoimmunity to overt disease requiring insulin treatment, and can happen at any age, though most frequently in children and young adults.  Global incidence varies significantly.",
        "summary_ur": "Type 1 diabetes is an autoimmune disease where the body attacks insulin-producing cells, causing insulin deficiency.  Its cause is unknown but involves genetic and environmental factors.  Onset occurs in stages, from autoimmunity to overt disease requiring insulin treatment, and can happen at any age, though most common in children and young adults. Global incidence varies significantly."
      }
    },
    {
      "text": "Type 1 diabetes, diagnosed by high blood glucose and symptoms like excessive thirst and urination,  can develop at any age.  Its incidence varies globally, increasing in many regions, though the rate of increase may be stabilizing in some high-income countries.  The reasons for this global trend are not fully understood, but environmental factors are suspected.  Diagnosis can be challenging, requiring further testing to differentiate it from type 2 or other rarer forms. Type 1 diabetes, diagnosed by high blood glucose and symptoms like excessive thirst and urination,  affects people of all ages, with varying global incidence.  While increasing in many areas, the rise is stabilizing in some high-income countries, due to unknown environmental factors.  Diagnosis can be complex, requiring tests to differentiate it from type 2 and other rarer forms.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 20,
        "page_label": "16",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 1 diabetes, diagnosed by high blood glucose and symptoms like excessive thirst and urination,  can develop at any age.  Its incidence varies globally, increasing in many regions, though the rate of increase may be stabilizing in some high-income countries.  The reasons for this global trend are not fully understood, but environmental factors are suspected.  Diagnosis can be challenging, requiring further testing to differentiate it from type 2 or other rarer forms.",
        "summary_ur": "Type 1 diabetes, diagnosed by high blood glucose and symptoms like excessive thirst and urination,  affects people of all ages, with varying global incidence.  While increasing in many areas, the rise is stabilizing in some high-income countries, due to unknown environmental factors.  Diagnosis can be complex, requiring tests to differentiate it from type 2 and other rarer forms."
      }
    },
    {
      "text": "Type 1 diabetes symptoms (excessive thirst, urination, weight loss) can be absent, leading to delayed or missed diagnoses, even in countries with universal healthcare.  A significant percentage (29.9%) of type 1 diabetes diagnoses involve diabetic ketoacidosis (DKA), sometimes fatally.  Awareness campaigns targeting parents, teachers, and healthcare professionals, including immediate blood glucose testing for unwell children, are needed. Type 1 diabetes symptoms (excessive thirst, urination, weight loss) aren't always obvious, leading to delayed diagnosis, sometimes only upon diabetic ketoacidosis (DKA) hospitalization, even in countries with universal healthcare.  A study showed a concerningly high DKA rate (29.9%) at diagnosis.  Awareness campaigns targeting parents, teachers, and healthcare professionals, including immediate blood glucose testing for unwell children, are crucial.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 20,
        "page_label": "16",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 1 diabetes symptoms (excessive thirst, urination, weight loss) can be absent, leading to delayed or missed diagnoses, even in countries with universal healthcare.  A significant percentage (29.9%) of type 1 diabetes diagnoses involve diabetic ketoacidosis (DKA), sometimes fatally.  Awareness campaigns targeting parents, teachers, and healthcare professionals, including immediate blood glucose testing for unwell children, are needed.",
        "summary_ur": "Type 1 diabetes symptoms (excessive thirst, urination, weight loss) aren't always obvious, leading to delayed diagnosis, sometimes only upon diabetic ketoacidosis (DKA) hospitalization, even in countries with universal healthcare.  A study showed a concerningly high DKA rate (29.9%) at diagnosis.  Awareness campaigns targeting parents, teachers, and healthcare professionals, including immediate blood glucose testing for unwell children, are crucial."
      }
    },
    {
      "text": "Type 1 diabetes, often misdiagnosed, especially in low-resource settings, requires daily insulin injections for survival.  Symptoms include excessive thirst, weight loss, frequent urination, fatigue, hunger, and blurred vision.  With proper treatment (insulin, monitoring, education), individuals can lead healthy lives and mitigate complications. Type 1 diabetes, often misdiagnosed, especially in low-resource areas, requires daily insulin injections for survival.  Early symptoms include excessive thirst, weight loss, frequent urination, fatigue, hunger, and blurred vision.  With proper treatment (insulin, monitoring, education), individuals can live healthy lives and mitigate complications.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 20,
        "page_label": "16",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 1 diabetes, often misdiagnosed, especially in low-resource settings, requires daily insulin injections for survival.  Symptoms include excessive thirst, weight loss, frequent urination, fatigue, hunger, and blurred vision.  With proper treatment (insulin, monitoring, education), individuals can lead healthy lives and mitigate complications.",
        "summary_ur": "Type 1 diabetes, often misdiagnosed, especially in low-resource areas, requires daily insulin injections for survival.  Early symptoms include excessive thirst, weight loss, frequent urination, fatigue, hunger, and blurred vision.  With proper treatment (insulin, monitoring, education), individuals can live healthy lives and mitigate complications."
      }
    },
    {
      "text": "That's not legal text; it's a list of common type 1 diabetes symptoms.  These include excessive thirst, weight loss, frequent urination, fatigue, hunger, blurred vision, and potentially diabetic ketoacidosis. This text isn't legal text; it's a medical list.  It describes common type 1 diabetes symptoms:  extreme thirst, weight loss, frequent urination, fatigue, hunger, blurred vision, and ketoacidosis.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 20,
        "page_label": "16",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "That's not legal text; it's a list of common type 1 diabetes symptoms.  These include excessive thirst, weight loss, frequent urination, fatigue, hunger, blurred vision, and potentially diabetic ketoacidosis.",
        "summary_ur": "This text isn't legal text; it's a medical list.  It describes common type 1 diabetes symptoms:  extreme thirst, weight loss, frequent urination, fatigue, hunger, blurred vision, and ketoacidosis."
      }
    },
    {
      "text": "Type 2 diabetes is the most prevalent form of diabetes globally.  Managing type 1 diabetes, even with advanced treatments like insulin pumps and glucose monitors, presents significant challenges, particularly in resource-limited settings.  Optimal care, including automated insulin delivery systems, is expensive and inaccessible to many.  Suboptimal glycemic control leads to complications like poor growth and cardiovascular issues. Type 2 diabetes is the most prevalent form of diabetes globally.  Managing type 1 diabetes, even with advanced technology and care, presents significant challenges, especially in resource-limited settings.  Optimal care (automated insulin delivery systems) is expensive and not widely accessible.  Suboptimal control leads to complications like poor growth and vascular issues.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 21,
        "page_label": "17",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes is the most prevalent form of diabetes globally.  Managing type 1 diabetes, even with advanced treatments like insulin pumps and glucose monitors, presents significant challenges, particularly in resource-limited settings.  Optimal care, including automated insulin delivery systems, is expensive and inaccessible to many.  Suboptimal glycemic control leads to complications like poor growth and cardiovascular issues.",
        "summary_ur": "Type 2 diabetes is the most prevalent form of diabetes globally.  Managing type 1 diabetes, even with advanced technology and care, presents significant challenges, especially in resource-limited settings.  Optimal care (automated insulin delivery systems) is expensive and not widely accessible.  Suboptimal control leads to complications like poor growth and vascular issues."
      }
    },
    {
      "text": "High-income countries have better access to expensive diabetes treatments than low-income ones.  Type 2 diabetes, the most prevalent form, is a growing global health crisis, projected to become the second leading cause of disease burden by 2050.  Limited access to insulin and education in low-income areas leads to serious complications and premature death. High-income countries predominantly access expensive diabetes treatments.  Many, especially low-income families, lack access to insulin and education, leading to severe complications and premature death. Type 2 diabetes, the most common form, is a growing global health crisis, projected to become the second leading cause of disease burden by 2050 due to insulin resistance and eventual pancreatic beta-cell failure.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 21,
        "page_label": "17",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "High-income countries have better access to expensive diabetes treatments than low-income ones.  Type 2 diabetes, the most prevalent form, is a growing global health crisis, projected to become the second leading cause of disease burden by 2050.  Limited access to insulin and education in low-income areas leads to serious complications and premature death.",
        "summary_ur": "High-income countries predominantly access expensive diabetes treatments.  Many, especially low-income families, lack access to insulin and education, leading to severe complications and premature death. Type 2 diabetes, the most common form, is a growing global health crisis, projected to become the second leading cause of disease burden by 2050 due to insulin resistance and eventual pancreatic beta-cell failure."
      }
    },
    {
      "text": "Type 2 diabetes, often asymptomatic, develops gradually due to the pancreas's inability to meet insulin demands, frequently linked to increased insulin production initially.  Diagnosis is often delayed, leading to complications. Risk factors include obesity, age, ethnicity, and family history, with causes still not fully understood.  A significant portion of those with type 2 diabetes remain undiagnosed. Type 2 diabetes, often asymptomatic, develops gradually, causing eventual insulin deficiency.  Delayed diagnosis, common due to subtle onset, leads to complications.  Risk factors include obesity, age, ethnicity, and family history; its precise causes remain unclear.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 21,
        "page_label": "17",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes, often asymptomatic, develops gradually due to the pancreas's inability to meet insulin demands, frequently linked to increased insulin production initially.  Diagnosis is often delayed, leading to complications. Risk factors include obesity, age, ethnicity, and family history, with causes still not fully understood.  A significant portion of those with type 2 diabetes remain undiagnosed.",
        "summary_ur": "Type 2 diabetes, often asymptomatic, develops gradually, causing eventual insulin deficiency.  Delayed diagnosis, common due to subtle onset, leads to complications.  Risk factors include obesity, age, ethnicity, and family history; its precise causes remain unclear."
      }
    },
    {
      "text": "Type 2 diabetes, linked to weight, age, ethnicity, and family history, is managed primarily through lifestyle changes (diet, exercise, smoking cessation).  If lifestyle changes are insufficient, metformin is the first-line medication, with combination therapies available if needed. Type 2 diabetes, linked to weight, age, ethnicity, and family history, is managed primarily through lifestyle changes (diet, exercise, smoking cessation).  If lifestyle changes fail, metformin is the first-line medication, with combination therapies available if needed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 21,
        "page_label": "17",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes, linked to weight, age, ethnicity, and family history, is managed primarily through lifestyle changes (diet, exercise, smoking cessation).  If lifestyle changes are insufficient, metformin is the first-line medication, with combination therapies available if needed.",
        "summary_ur": "Type 2 diabetes, linked to weight, age, ethnicity, and family history, is managed primarily through lifestyle changes (diet, exercise, smoking cessation).  If lifestyle changes fail, metformin is the first-line medication, with combination therapies available if needed."
      }
    },
    {
      "text": "This text lists several classes of drugs used to treat type 2 diabetes: glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1R agonists, GIP agonists, and SGLT2 inhibitors.  The source cites the IDF Diabetes Atlas. This text lists several drug classes used to treat type 2 diabetes: glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1R agonists, GIP agonists, and SGLT2 inhibitors.  The source cites Heather Koga from Zimbabwe and the IDF Diabetes Atlas.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 21,
        "page_label": "17",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text lists several classes of drugs used to treat type 2 diabetes: glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1R agonists, GIP agonists, and SGLT2 inhibitors.  The source cites the IDF Diabetes Atlas.",
        "summary_ur": "This text lists several drug classes used to treat type 2 diabetes: glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1R agonists, GIP agonists, and SGLT2 inhibitors.  The source cites Heather Koga from Zimbabwe and the IDF Diabetes Atlas."
      }
    },
    {
      "text": "Type 2 diabetes management involves achieving glycemic control through medication (including insulin if necessary), alongside blood pressure and cholesterol management.  Regular screenings for complications (kidney disease, retinopathy, etc.) are crucial.  With proper care and lifestyle changes, individuals can live long and healthy lives, despite the rising global prevalence of the disease. Type 2 diabetes requires careful management.  If blood sugar isn't controlled with non-insulin medications, insulin may be needed.  Regular monitoring of blood pressure, cholesterol, and early complications (kidney disease, eye problems, nerve damage, etc.) is crucial.  With proper lifestyle, medication, and education, people with type 2 diabetes can live long and healthy lives.  The global prevalence of this disease is unfortunately increasing.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 22,
        "page_label": "18",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes management involves achieving glycemic control through medication (including insulin if necessary), alongside blood pressure and cholesterol management.  Regular screenings for complications (kidney disease, retinopathy, etc.) are crucial.  With proper care and lifestyle changes, individuals can live long and healthy lives, despite the rising global prevalence of the disease.",
        "summary_ur": "Type 2 diabetes requires careful management.  If blood sugar isn't controlled with non-insulin medications, insulin may be needed.  Regular monitoring of blood pressure, cholesterol, and early complications (kidney disease, eye problems, nerve damage, etc.) is crucial.  With proper lifestyle, medication, and education, people with type 2 diabetes can live long and healthy lives.  The global prevalence of this disease is unfortunately increasing."
      }
    },
    {
      "text": "Type 2 diabetes prevalence is globally increasing due to aging populations, economic development, and urbanization.  These factors promote sedentary lifestyles and unhealthy diets, leading to obesity and increased risk.  Early detection and treatment are improving lifespans, contributing to higher prevalence, particularly among younger adults and children.  Prevalence also varies by race. Type 2 diabetes is increasingly prevalent globally due to aging populations, economic shifts, and unhealthy lifestyles.  While early detection and treatment extend lifespans,  the rise also reflects increased obesity, particularly among younger people and specific racial groups.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 22,
        "page_label": "18",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes prevalence is globally increasing due to aging populations, economic development, and urbanization.  These factors promote sedentary lifestyles and unhealthy diets, leading to obesity and increased risk.  Early detection and treatment are improving lifespans, contributing to higher prevalence, particularly among younger adults and children.  Prevalence also varies by race.",
        "summary_ur": "Type 2 diabetes is increasingly prevalent globally due to aging populations, economic shifts, and unhealthy lifestyles.  While early detection and treatment extend lifespans,  the rise also reflects increased obesity, particularly among younger people and specific racial groups."
      }
    },
    {
      "text": "Childhood obesity contributes to rising type 2 diabetes rates, varying across racial and ethnic groups.  Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), also called prediabetes,  represent elevated blood glucose levels, increasing the risk of developing type 2 diabetes and cardiovascular disease.  Early detection through IGT/IFG screening allows for preventative interventions. This text discusses the rising prevalence of childhood obesity and type 2 diabetes, noting variations across racial and ethnic groups.  It highlights impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) \u2013 conditions increasing the risk of type 2 diabetes and cardiovascular disease.  Early detection of IGT/IFG allows for preventative interventions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 22,
        "page_label": "18",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Childhood obesity contributes to rising type 2 diabetes rates, varying across racial and ethnic groups.  Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), also called prediabetes,  represent elevated blood glucose levels, increasing the risk of developing type 2 diabetes and cardiovascular disease.  Early detection through IGT/IFG screening allows for preventative interventions.",
        "summary_ur": "This text discusses the rising prevalence of childhood obesity and type 2 diabetes, noting variations across racial and ethnic groups.  It highlights impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) \u2013 conditions increasing the risk of type 2 diabetes and cardiovascular disease.  Early detection of IGT/IFG allows for preventative interventions."
      }
    },
    {
      "text": "The text discusses diagnostic criteria for diabetes, focusing on the IDF and WHO guidelines which utilize fasting plasma glucose and oral glucose tolerance test results.  It notes the ADA's inclusion of HbA1c, though WHO's global application is limited by quality assurance concerns.  Progression from impaired glucose tolerance/impaired fasting glucose to type 2 diabetes depends on hyperglycemia severity and risk factors like age and BMI. This text discusses diagnosing diabetes and prediabetes.  It highlights the progression from intermediate hyperglycemia (IGT/IFG) to type 2 diabetes, influenced by factors like age and weight.  Diagnostic criteria, using fasting plasma glucose, OGTT, and HbA1c (with caveats regarding global access to quality HbA1c testing), are detailed, referencing IDF, WHO, and ADA guidelines.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 22,
        "page_label": "18",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text discusses diagnostic criteria for diabetes, focusing on the IDF and WHO guidelines which utilize fasting plasma glucose and oral glucose tolerance test results.  It notes the ADA's inclusion of HbA1c, though WHO's global application is limited by quality assurance concerns.  Progression from impaired glucose tolerance/impaired fasting glucose to type 2 diabetes depends on hyperglycemia severity and risk factors like age and BMI.",
        "summary_ur": "This text discusses diagnosing diabetes and prediabetes.  It highlights the progression from intermediate hyperglycemia (IGT/IFG) to type 2 diabetes, influenced by factors like age and weight.  Diagnostic criteria, using fasting plasma glucose, OGTT, and HbA1c (with caveats regarding global access to quality HbA1c testing), are detailed, referencing IDF, WHO, and ADA guidelines."
      }
    },
    {
      "text": "Globally, consistent HbA1c measurements for diabetes diagnosis are lacking.  The IDF and WHO recommend a 75-gram oral glucose tolerance test (OGTT), though a one-hour OGTT might be more sensitive.  A single random plasma glucose \u226511.1 mmol/l with symptoms (polyuria, polydipsia, weight loss) can also diagnose type 2 diabetes. The text discusses diagnosing diabetes and impaired glucose tolerance.  Globally, HbA1c isn't consistently available, so the 75-gram oral glucose tolerance test (OGTT) is recommended by IDF and WHO.  A one-hour OGTT might be more sensitive.  A single random plasma glucose \u226511.1 mmol/l with symptoms also confirms type 2 diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 22,
        "page_label": "18",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Globally, consistent HbA1c measurements for diabetes diagnosis are lacking.  The IDF and WHO recommend a 75-gram oral glucose tolerance test (OGTT), though a one-hour OGTT might be more sensitive.  A single random plasma glucose \u226511.1 mmol/l with symptoms (polyuria, polydipsia, weight loss) can also diagnose type 2 diabetes.",
        "summary_ur": "The text discusses diagnosing diabetes and impaired glucose tolerance.  Globally, HbA1c isn't consistently available, so the 75-gram oral glucose tolerance test (OGTT) is recommended by IDF and WHO.  A one-hour OGTT might be more sensitive.  A single random plasma glucose \u226511.1 mmol/l with symptoms also confirms type 2 diabetes."
      }
    },
    {
      "text": "The text classifies hyperglycaemia in pregnancy (HIP) into pre-gestational diabetes (existing before pregnancy), gestational diabetes (GDM, developing during pregnancy and resolving postpartum), and diabetes in pregnancy (DIP, diagnosed during pregnancy meeting non-pregnant diabetes criteria).  Early detection, particularly of DIP, is emphasized, with evidence suggesting benefits from intervention even in cases of milder hyperglycemia. The World Health Organization (WHO) and the International Federation of Gynecology and Obstetrics (FIGO) classify hyperglycaemia in pregnancy as pre-gestational diabetes, gestational diabetes (GDM), or diabetes in pregnancy (DIP).  Pre-gestational diabetes exists before pregnancy; GDM appears during pregnancy and resolves postpartum; DIP is diagnosed during pregnancy and meets WHO criteria for non-pregnant individuals.  Early detection, particularly of DIP in the first trimester, is crucial.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 23,
        "page_label": "19",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text classifies hyperglycaemia in pregnancy (HIP) into pre-gestational diabetes (existing before pregnancy), gestational diabetes (GDM, developing during pregnancy and resolving postpartum), and diabetes in pregnancy (DIP, diagnosed during pregnancy meeting non-pregnant diabetes criteria).  Early detection, particularly of DIP, is emphasized, with evidence suggesting benefits from intervention even in cases of milder hyperglycemia.",
        "summary_ur": "The World Health Organization (WHO) and the International Federation of Gynecology and Obstetrics (FIGO) classify hyperglycaemia in pregnancy as pre-gestational diabetes, gestational diabetes (GDM), or diabetes in pregnancy (DIP).  Pre-gestational diabetes exists before pregnancy; GDM appears during pregnancy and resolves postpartum; DIP is diagnosed during pregnancy and meets WHO criteria for non-pregnant individuals.  Early detection, particularly of DIP in the first trimester, is crucial."
      }
    },
    {
      "text": "Early detection and treatment of hyperglycemia during pregnancy, including gestational diabetes mellitus (GDM), benefit both mother and baby.  While overt symptoms are rare, screening via oral glucose tolerance tests (OGTT) between weeks 24-28 (earlier for high-risk individuals) is recommended.  Diagnostic criteria for GDM vary, hindering research comparisons. Early detection of hyperglycemia in pregnancy, often gestational diabetes mellitus (GDM), benefits mothers and babies.  Screening via oral glucose tolerance tests (OGTT) between weeks 24-28 (earlier for high-risk individuals) is recommended.  Diagnostic criteria for GDM vary, hindering research comparisons.  Managing pre-existing diabetes and GDM in pregnancy utilizes new technologies.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 23,
        "page_label": "19",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Early detection and treatment of hyperglycemia during pregnancy, including gestational diabetes mellitus (GDM), benefit both mother and baby.  While overt symptoms are rare, screening via oral glucose tolerance tests (OGTT) between weeks 24-28 (earlier for high-risk individuals) is recommended.  Diagnostic criteria for GDM vary, hindering research comparisons.",
        "summary_ur": "Early detection of hyperglycemia in pregnancy, often gestational diabetes mellitus (GDM), benefits mothers and babies.  Screening via oral glucose tolerance tests (OGTT) between weeks 24-28 (earlier for high-risk individuals) is recommended.  Diagnostic criteria for GDM vary, hindering research comparisons.  Managing pre-existing diabetes and GDM in pregnancy utilizes new technologies."
      }
    },
    {
      "text": "Diagnostic criteria for gestational diabetes mellitus (GDM) vary internationally, impacting research comparisons.  The International Association of Diabetes and Pregnancy Study Groups (IADPSG)/WHO criteria have increased GDM prevalence.  Diagnosis typically involves an oral glucose tolerance test (OGTT), though alternative methods like HbA1c are being explored.  Current diagnostic criteria are under review, with some countries adopting the Canadian Diabetes Association (CDA) criteria and earlier screening. Gestational diabetes (GDM) diagnosis varies internationally, impacting research comparisons.  The IADPSG/WHO criteria increased GDM prevalence.  Diagnosis typically involves an oral glucose tolerance test (OGTT).  Current criteria (Table 1.1) are under review, with some nations adopting the CDA criteria and early screening/HbA1c testing.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 23,
        "page_label": "19",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diagnostic criteria for gestational diabetes mellitus (GDM) vary internationally, impacting research comparisons.  The International Association of Diabetes and Pregnancy Study Groups (IADPSG)/WHO criteria have increased GDM prevalence.  Diagnosis typically involves an oral glucose tolerance test (OGTT), though alternative methods like HbA1c are being explored.  Current diagnostic criteria are under review, with some countries adopting the Canadian Diabetes Association (CDA) criteria and earlier screening.",
        "summary_ur": "Gestational diabetes (GDM) diagnosis varies internationally, impacting research comparisons.  The IADPSG/WHO criteria increased GDM prevalence.  Diagnosis typically involves an oral glucose tolerance test (OGTT).  Current criteria (Table 1.1) are under review, with some nations adopting the CDA criteria and early screening/HbA1c testing."
      }
    },
    {
      "text": "The text discusses diagnostic criteria for hyperglycemia in pregnancy from various organizations (ADA, NDDG, ADIPS, CDA, DIPSI, WHO, IADPSG, NICE).  Different criteria are presented, using fasting and post-glucose-load blood glucose levels (mg/dL and mmol/L) to define gestational diabetes mellitus (GDM).  Early HbA1c testing for GDM is also mentioned as an area of ongoing research. The text discusses varying diagnostic criteria for hyperglycemia in pregnancy across different organizations (ADA, NDDG, ADIPS, CDA, DIPSI, WHO, IADPSG, NICE).  These criteria utilize fasting and post-glucose load blood glucose levels (mg/dL and mmol/L) to define gestational diabetes mellitus (GDM).  Further research on early HbA1c testing for GDM is noted.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 23,
        "page_label": "19",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text discusses diagnostic criteria for hyperglycemia in pregnancy from various organizations (ADA, NDDG, ADIPS, CDA, DIPSI, WHO, IADPSG, NICE).  Different criteria are presented, using fasting and post-glucose-load blood glucose levels (mg/dL and mmol/L) to define gestational diabetes mellitus (GDM).  Early HbA1c testing for GDM is also mentioned as an area of ongoing research.",
        "summary_ur": "The text discusses varying diagnostic criteria for hyperglycemia in pregnancy across different organizations (ADA, NDDG, ADIPS, CDA, DIPSI, WHO, IADPSG, NICE).  These criteria utilize fasting and post-glucose load blood glucose levels (mg/dL and mmol/L) to define gestational diabetes mellitus (GDM).  Further research on early HbA1c testing for GDM is noted."
      }
    },
    {
      "text": "This table presents diagnostic criteria for gestational diabetes from various sources (Carpenter Coustan, CDA, WHO, IADPSG/ADA WHO/FIGO, NICE, IDF).  It shows differing glucose threshold values (mg/dL) for diagnosis using different tests and at various times.  The lack of uniformity highlights the evolution and variation in diagnostic standards. The table presents diagnostic criteria for diabetes from various sources (Carpenter Coustan, CDA, WHO, IADPSG/ADA, NICE, IDF).  It shows differing glucose thresholds (mg/dL) for fasting and non-fasting plasma glucose, reflecting evolving diagnostic standards over time.  Notably, there is inconsistency in the criteria used.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 23,
        "page_label": "19",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents diagnostic criteria for gestational diabetes from various sources (Carpenter Coustan, CDA, WHO, IADPSG/ADA WHO/FIGO, NICE, IDF).  It shows differing glucose threshold values (mg/dL) for diagnosis using different tests and at various times.  The lack of uniformity highlights the evolution and variation in diagnostic standards.",
        "summary_ur": "The table presents diagnostic criteria for diabetes from various sources (Carpenter Coustan, CDA, WHO, IADPSG/ADA, NICE, IDF).  It shows differing glucose thresholds (mg/dL) for fasting and non-fasting plasma glucose, reflecting evolving diagnostic standards over time.  Notably, there is inconsistency in the criteria used."
      }
    },
    {
      "text": "Gestational diabetes mellitus (GDM) occurs in women with insufficient insulin to counter pregnancy-induced insulin resistance.  Risk factors include older age, obesity, family history of diabetes, and certain ethnicities.  GDM is linked to an increased risk of type 2 diabetes and cardiovascular disease later in life. Gestational diabetes (GDM) affects women with inadequate insulin, often linked to placental hormones.  Risk factors include age, weight, family history, and ethnicity.  GDM signals underlying metabolic issues, increasing the risk of future type 2 diabetes and cardiovascular disease.  Prior GDM significantly raises the risk of recurrence in subsequent pregnancies.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 24,
        "page_label": "20",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Gestational diabetes mellitus (GDM) occurs in women with insufficient insulin to counter pregnancy-induced insulin resistance.  Risk factors include older age, obesity, family history of diabetes, and certain ethnicities.  GDM is linked to an increased risk of type 2 diabetes and cardiovascular disease later in life.",
        "summary_ur": "Gestational diabetes (GDM) affects women with inadequate insulin, often linked to placental hormones.  Risk factors include age, weight, family history, and ethnicity.  GDM signals underlying metabolic issues, increasing the risk of future type 2 diabetes and cardiovascular disease.  Prior GDM significantly raises the risk of recurrence in subsequent pregnancies."
      }
    },
    {
      "text": "Women with gestational diabetes (GDM) face a heightened risk of developing type 2 diabetes within 3-6 years postpartum, and this risk remains elevated.  Their babies also have increased lifetime risks of obesity and type 2 diabetes.  Lifestyle interventions initiated within three years post-pregnancy are recommended to mitigate these risks. Pregnant women with hyperglycemia face increased GDM risk in future pregnancies and heightened type 2 diabetes risk (3-6 years postpartum).  Early lifestyle intervention (within 3 years post-pregnancy) is crucial to prevent diabetes and CVD.  Babies of mothers with GDM also have a higher risk of obesity and type 2 diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 24,
        "page_label": "20",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Women with gestational diabetes (GDM) face a heightened risk of developing type 2 diabetes within 3-6 years postpartum, and this risk remains elevated.  Their babies also have increased lifetime risks of obesity and type 2 diabetes.  Lifestyle interventions initiated within three years post-pregnancy are recommended to mitigate these risks.",
        "summary_ur": "Pregnant women with hyperglycemia face increased GDM risk in future pregnancies and heightened type 2 diabetes risk (3-6 years postpartum).  Early lifestyle intervention (within 3 years post-pregnancy) is crucial to prevent diabetes and CVD.  Babies of mothers with GDM also have a higher risk of obesity and type 2 diabetes."
      }
    },
    {
      "text": "The WHO classifies diabetes into several categories beyond types 1 and 2.  \"Other specific types\" include monogenic diabetes (caused by a single gene defect, comprising 1.5-2% of cases and often misdiagnosed), encompassing neonatal diabetes, maturity-onset diabetes of the young (MODY), and rare syndromic forms.  These rarer forms offer valuable insights into diabetes development. The WHO identifies \"other specific types\" of diabetes beyond types 1 and 2.  Monogenic diabetes, caused by a single gene defect, accounts for a small percentage of cases, often misdiagnosed.  These include neonatal diabetes, MODY, and rare syndromic forms, offering valuable insights into diabetes development.  Precise diagnosis is clinically important.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 25,
        "page_label": "21",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The WHO classifies diabetes into several categories beyond types 1 and 2.  \"Other specific types\" include monogenic diabetes (caused by a single gene defect, comprising 1.5-2% of cases and often misdiagnosed), encompassing neonatal diabetes, maturity-onset diabetes of the young (MODY), and rare syndromic forms.  These rarer forms offer valuable insights into diabetes development.",
        "summary_ur": "The WHO identifies \"other specific types\" of diabetes beyond types 1 and 2.  Monogenic diabetes, caused by a single gene defect, accounts for a small percentage of cases, often misdiagnosed.  These include neonatal diabetes, MODY, and rare syndromic forms, offering valuable insights into diabetes development.  Precise diagnosis is clinically important."
      }
    },
    {
      "text": "Monogenic diabetes, including Maturity Onset Diabetes of the Young (MODY), comprises rare subtypes impacting diagnosis and treatment.  Precise genetic identification allows for tailored therapies and better prediction of complications.  Genome-wide association studies are revealing more monogenic forms, suggesting current prevalence underestimation.  Diabetes also results from other specific conditions, as categorized by the WHO. The text discusses rare, monogenic forms of diabetes, including Maturity Onset Diabetes of the Young (MODY) and syndromic diseases.  Precise diagnosis is crucial for tailored treatment and risk assessment, varying across MODY subtypes.  Genome-wide association studies reveal increasing numbers of these monogenic forms, suggesting underestimated prevalence.  The text also notes diabetes resulting from other specific conditions (a list is omitted from this summary).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 25,
        "page_label": "21",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Monogenic diabetes, including Maturity Onset Diabetes of the Young (MODY), comprises rare subtypes impacting diagnosis and treatment.  Precise genetic identification allows for tailored therapies and better prediction of complications.  Genome-wide association studies are revealing more monogenic forms, suggesting current prevalence underestimation.  Diabetes also results from other specific conditions, as categorized by the WHO.",
        "summary_ur": "The text discusses rare, monogenic forms of diabetes, including Maturity Onset Diabetes of the Young (MODY) and syndromic diseases.  Precise diagnosis is crucial for tailored treatment and risk assessment, varying across MODY subtypes.  Genome-wide association studies reveal increasing numbers of these monogenic forms, suggesting underestimated prevalence.  The text also notes diabetes resulting from other specific conditions (a list is omitted from this summary)."
      }
    },
    {
      "text": "The text describes various types of diabetes beyond the common type 1 and type 2 classifications.  These include diabetes resulting from pancreatic diseases, endocrine disorders, drug interactions, infections,  rare immune disorders, and genetic syndromes.  It also mentions managing hyperglycemia during pregnancy. The text details various diabetes types beyond the common Type 1 and Type 2, as classified by the WHO.  These include diabetes stemming from pancreatic diseases, endocrine disorders, drug interactions, infections,  rare immune issues, and genetic syndromes.  It also mentions managing high blood sugar during pregnancy.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 25,
        "page_label": "21",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text describes various types of diabetes beyond the common type 1 and type 2 classifications.  These include diabetes resulting from pancreatic diseases, endocrine disorders, drug interactions, infections,  rare immune disorders, and genetic syndromes.  It also mentions managing hyperglycemia during pregnancy.",
        "summary_ur": "The text details various diabetes types beyond the common Type 1 and Type 2, as classified by the WHO.  These include diabetes stemming from pancreatic diseases, endocrine disorders, drug interactions, infections,  rare immune issues, and genetic syndromes.  It also mentions managing high blood sugar during pregnancy."
      }
    },
    {
      "text": "The text discusses managing hyperglycemia during pregnancy.  Pregnant women with hyperglycemia face increased risks of complications like high blood pressure and macrosomia.  Early detection and management, including optimal blood glucose control and antenatal care, reduce these risks.  Women with pre-existing diabetes need pre-conception counseling and intensive management. This text discusses managing hyperglycemia during pregnancy.  Pregnant women with hyperglycemia face risks like high blood pressure and macrosomia, increasing birth complications.  Early detection and optimal glucose management are crucial.  Women with pre-existing diabetes need pre-conception counseling, including medication review and intensive diabetes management to minimize risks.  All women with hyperglycemia in pregnancy require close antenatal care.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 25,
        "page_label": "21",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text discusses managing hyperglycemia during pregnancy.  Pregnant women with hyperglycemia face increased risks of complications like high blood pressure and macrosomia.  Early detection and management, including optimal blood glucose control and antenatal care, reduce these risks.  Women with pre-existing diabetes need pre-conception counseling and intensive management.",
        "summary_ur": "This text discusses managing hyperglycemia during pregnancy.  Pregnant women with hyperglycemia face risks like high blood pressure and macrosomia, increasing birth complications.  Early detection and optimal glucose management are crucial.  Women with pre-existing diabetes need pre-conception counseling, including medication review and intensive diabetes management to minimize risks.  All women with hyperglycemia in pregnancy require close antenatal care."
      }
    },
    {
      "text": "Women with hyperglycaemia in pregnancy (HIP), including gestational diabetes (GDM) and pre-existing diabetes, need optimal antenatal and postnatal care.  Management often involves lifestyle changes (diet, exercise), blood glucose monitoring, and may require medication or obstetric intervention as needed.  Healthcare professional support is crucial. Pregnant women with hyperglycemia (GDM, DIP, or existing diabetes) need thorough prenatal and postnatal care.  Lifestyle changes (diet, exercise) are often effective, but medical intervention (insulin, medication) may be necessary.  Healthcare professional guidance is crucial for blood glucose management and appropriate care.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 25,
        "page_label": "21",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Women with hyperglycaemia in pregnancy (HIP), including gestational diabetes (GDM) and pre-existing diabetes, need optimal antenatal and postnatal care.  Management often involves lifestyle changes (diet, exercise), blood glucose monitoring, and may require medication or obstetric intervention as needed.  Healthcare professional support is crucial.",
        "summary_ur": "Pregnant women with hyperglycemia (GDM, DIP, or existing diabetes) need thorough prenatal and postnatal care.  Lifestyle changes (diet, exercise) are often effective, but medical intervention (insulin, medication) may be necessary.  Healthcare professional guidance is crucial for blood glucose management and appropriate care."
      }
    },
    {
      "text": "This text lists several references related to diabetes management and classification.  Sources include IDF clinical practice recommendations, American Diabetes Association standards of care, and research articles on type 1 and type 2 diabetes incidence, diagnosis, and staging.  The references cover both adult and youth populations. These documents detail clinical practice recommendations for managing type 1 and type 2 diabetes.  They cover diagnosis, classification, incidence trends, and treatment guidelines from organizations like the IDF and ADA.  Specific areas addressed include primary care management and presymptomatic staging of type 1 diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 26,
        "page_label": "22",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text lists several references related to diabetes management and classification.  Sources include IDF clinical practice recommendations, American Diabetes Association standards of care, and research articles on type 1 and type 2 diabetes incidence, diagnosis, and staging.  The references cover both adult and youth populations.",
        "summary_ur": "These documents detail clinical practice recommendations for managing type 1 and type 2 diabetes.  They cover diagnosis, classification, incidence trends, and treatment guidelines from organizations like the IDF and ADA.  Specific areas addressed include primary care management and presymptomatic staging of type 1 diabetes."
      }
    },
    {
      "text": "This text cites several research articles (2002-2022) on the epidemiology, classification, diagnosis, and management of type 1 and type 2 diabetes in children and adolescents.  The studies cover global incidence rates, clinical practice guidelines, and  focus on both common and monogenic forms of the disease. Several studies (2002-2022) cited here detail the global rise in type 1 and type 2 diabetes among young people.  These works cover epidemiology, classification, diagnosis, and management of these conditions, including monogenic forms.  The research highlights the increasing prevalence and international scope of childhood diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 26,
        "page_label": "22",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text cites several research articles (2002-2022) on the epidemiology, classification, diagnosis, and management of type 1 and type 2 diabetes in children and adolescents.  The studies cover global incidence rates, clinical practice guidelines, and  focus on both common and monogenic forms of the disease.",
        "summary_ur": "Several studies (2002-2022) cited here detail the global rise in type 1 and type 2 diabetes among young people.  These works cover epidemiology, classification, diagnosis, and management of these conditions, including monogenic forms.  The research highlights the increasing prevalence and international scope of childhood diabetes."
      }
    },
    {
      "text": "These citations cover various aspects of pediatric diabetes management.  They address monogenic diabetes management, the spectrum of diabetes subtypes, trends in diabetic ketoacidosis at diagnosis, interventions to promote early diagnosis, and indices for assessing diabetes care in children and youth. These citations cover pediatric diabetes research.  Studies address monogenic diabetes management, the spectrum of diabetes subtypes, trends in diabetic ketoacidosis at diagnosis, interventions to promote early diagnosis, and indices of diabetes care for children and youth.  The research spans multiple countries and continents.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 26,
        "page_label": "22",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations cover various aspects of pediatric diabetes management.  They address monogenic diabetes management, the spectrum of diabetes subtypes, trends in diabetic ketoacidosis at diagnosis, interventions to promote early diagnosis, and indices for assessing diabetes care in children and youth.",
        "summary_ur": "These citations cover pediatric diabetes research.  Studies address monogenic diabetes management, the spectrum of diabetes subtypes, trends in diabetic ketoacidosis at diagnosis, interventions to promote early diagnosis, and indices of diabetes care for children and youth.  The research spans multiple countries and continents."
      }
    },
    {
      "text": "These citations reference several studies on diabetes in children and youth.  They cover topics including indices of diabetes care, changes in diabetes-related complications over time, global prevalence and mortality of type 1 diabetes, and projections for future incidence.  Data sources include the Institute for Health Metrics and Evaluation (IHME). These citations detail research on childhood diabetes.  Studies cover the IDF Life for a Child Program, diabetes complications in the US (1990-2010), global type 1 diabetes care levels, global incidence/prevalence/mortality (2021-2040 projections), and data visualizations from the Institute for Health Metrics and Evaluation (IHME).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 26,
        "page_label": "22",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations reference several studies on diabetes in children and youth.  They cover topics including indices of diabetes care, changes in diabetes-related complications over time, global prevalence and mortality of type 1 diabetes, and projections for future incidence.  Data sources include the Institute for Health Metrics and Evaluation (IHME).",
        "summary_ur": "These citations detail research on childhood diabetes.  Studies cover the IDF Life for a Child Program, diabetes complications in the US (1990-2010), global type 1 diabetes care levels, global incidence/prevalence/mortality (2021-2040 projections), and data visualizations from the Institute for Health Metrics and Evaluation (IHME)."
      }
    },
    {
      "text": "This bibliography cites several sources on diabetes, including visualizations from the Institute for Health Metrics and Evaluation (IHME),  studies on diabetes complications in the US (Gregg et al., 2014), the UK Prospective Diabetes Study (King et al., 1999), risk factors (Bellou et al., 2018), and the implications of young-onset type 2 diabetes (Magliano et al., 2020). This text cites several sources regarding diabetes.  References 18 and 19 concern visualizations and changes in diabetes complications in the US.  References 19-22 discuss UKPDS, risk factors for type 2 diabetes, and the implications of young-onset type 2 diabetes.  The sources provide data and research on various aspects of diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 26,
        "page_label": "22",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This bibliography cites several sources on diabetes, including visualizations from the Institute for Health Metrics and Evaluation (IHME),  studies on diabetes complications in the US (Gregg et al., 2014), the UK Prospective Diabetes Study (King et al., 1999), risk factors (Bellou et al., 2018), and the implications of young-onset type 2 diabetes (Magliano et al., 2020).",
        "summary_ur": "This text cites several sources regarding diabetes.  References 18 and 19 concern visualizations and changes in diabetes complications in the US.  References 19-22 discuss UKPDS, risk factors for type 2 diabetes, and the implications of young-onset type 2 diabetes.  The sources provide data and research on various aspects of diabetes."
      }
    },
    {
      "text": "This text cites two scientific publications: one from *PLoS One* (2018) and another from *Nature Reviews Endocrinology* (2020),  both concerning young-onset type 2 diabetes and its health consequences.  It also references the 11th edition of the IDF Diabetes Atlas (2025). This text cites three sources: a 2018 PLoS One article (e0194127), a 2020 Nature Reviews Endocrinology article on young-onset type 2 diabetes (Magliano et al.), and the 11th edition (2025) of the IDF Diabetes Atlas.  The sources likely pertain to research on diabetes, specifically its impact on morbidity and mortality, particularly in younger populations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 26,
        "page_label": "22",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text cites two scientific publications: one from *PLoS One* (2018) and another from *Nature Reviews Endocrinology* (2020),  both concerning young-onset type 2 diabetes and its health consequences.  It also references the 11th edition of the IDF Diabetes Atlas (2025).",
        "summary_ur": "This text cites three sources: a 2018 PLoS One article (e0194127), a 2020 Nature Reviews Endocrinology article on young-onset type 2 diabetes (Magliano et al.), and the 11th edition (2025) of the IDF Diabetes Atlas.  The sources likely pertain to research on diabetes, specifically its impact on morbidity and mortality, particularly in younger populations."
      }
    },
    {
      "text": "Several studies (Wu et al., 2022; Mayer-Davis et al., 2017; Urakami et al., 2018) report rising childhood and adolescent type 2 diabetes incidence globally.  The IDF Atlas (2022) highlights the disproportionate impact on Indigenous populations.  These findings utilize WHO/IDF diagnostic criteria (2006) and consider the progression from intermediate hyperglycemia (Richter et al.,  [year missing]). Several studies (Wu et al., 2022; Mayer-Davis et al., 2017; Urakami et al., 2018; IDF Atlas Report 2022) reveal a concerning rise in childhood/adolescent type 2 diabetes globally.  The WHO/IDF (2006) defines and diagnoses diabetes, while further research (Richter et al.) explores the progression from intermediate hyperglycemia to type 2 diabetes.  These sources highlight the increasing prevalence and importance of this health issue.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 27,
        "page_label": "23",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies (Wu et al., 2022; Mayer-Davis et al., 2017; Urakami et al., 2018) report rising childhood and adolescent type 2 diabetes incidence globally.  The IDF Atlas (2022) highlights the disproportionate impact on Indigenous populations.  These findings utilize WHO/IDF diagnostic criteria (2006) and consider the progression from intermediate hyperglycemia (Richter et al.,  [year missing]).",
        "summary_ur": "Several studies (Wu et al., 2022; Mayer-Davis et al., 2017; Urakami et al., 2018; IDF Atlas Report 2022) reveal a concerning rise in childhood/adolescent type 2 diabetes globally.  The WHO/IDF (2006) defines and diagnoses diabetes, while further research (Richter et al.) explores the progression from intermediate hyperglycemia to type 2 diabetes.  These sources highlight the increasing prevalence and importance of this health issue."
      }
    },
    {
      "text": "Several studies (Richter et al., 2018; Tab\u00e1k et al., 2012; Twigg et al., 2007; Schmidt et al., 2019; Huang et al., 2016) show a strong link between intermediate hyperglycemia (prediabetes) and the development of type 2 diabetes, as well as increased risks of cardiovascular disease and mortality.  These studies highlight prediabetes as a significant health concern requiring preventative strategies. Several studies (Richter et al., 2018; Tab\u00e1k et al., 2012; Twigg et al., 2007; Schmidt et al., 2019; Huang et al., 2016) confirm that intermediate hyperglycaemia (prediabetes) significantly increases the risk of developing type 2 diabetes and cardiovascular disease,  leading to higher mortality.  These findings highlight prediabetes as a crucial risk factor requiring preventative measures.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 27,
        "page_label": "23",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies (Richter et al., 2018; Tab\u00e1k et al., 2012; Twigg et al., 2007; Schmidt et al., 2019; Huang et al., 2016) show a strong link between intermediate hyperglycemia (prediabetes) and the development of type 2 diabetes, as well as increased risks of cardiovascular disease and mortality.  These studies highlight prediabetes as a significant health concern requiring preventative strategies.",
        "summary_ur": "Several studies (Richter et al., 2018; Tab\u00e1k et al., 2012; Twigg et al., 2007; Schmidt et al., 2019; Huang et al., 2016) confirm that intermediate hyperglycaemia (prediabetes) significantly increases the risk of developing type 2 diabetes and cardiovascular disease,  leading to higher mortality.  These findings highlight prediabetes as a crucial risk factor requiring preventative measures."
      }
    },
    {
      "text": "These studies show a strong link between prediabetes and increased risks of cardiovascular disease and all-cause mortality.  Meta-analyses confirm this association, highlighting the importance of prediabetes diagnosis and management through lifestyle interventions or medication like metformin to mitigate these risks. These studies show a strong link between prediabetes and increased risk of cardiovascular disease and death.  Meta-analyses confirm this association, highlighting the importance of prediabetes diagnosis and management through lifestyle changes or medication to mitigate these risks.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 27,
        "page_label": "23",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These studies show a strong link between prediabetes and increased risks of cardiovascular disease and all-cause mortality.  Meta-analyses confirm this association, highlighting the importance of prediabetes diagnosis and management through lifestyle interventions or medication like metformin to mitigate these risks.",
        "summary_ur": "These studies show a strong link between prediabetes and increased risk of cardiovascular disease and death.  Meta-analyses confirm this association, highlighting the importance of prediabetes diagnosis and management through lifestyle changes or medication to mitigate these risks."
      }
    },
    {
      "text": "These studies examine the long-term effects of lifestyle interventions and metformin on diabetes prevention and complications.  Research shows that lifestyle changes and medication can significantly impact diabetes development and microvascular complications over 15 years.  Further studies analyze weight loss mechanisms and the clinical impact of interventions, along with updated diagnostic criteria. These studies examine long-term impacts of lifestyle changes and metformin on diabetes prevention and complications.  Findings show that interventions significantly reduce diabetes risk and microvascular issues over 15 years.  Further research explores weight loss mechanisms and the clinical effectiveness of lifestyle interventions.  Diagnostic criteria for diabetes are also discussed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 27,
        "page_label": "23",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These studies examine the long-term effects of lifestyle interventions and metformin on diabetes prevention and complications.  Research shows that lifestyle changes and medication can significantly impact diabetes development and microvascular complications over 15 years.  Further studies analyze weight loss mechanisms and the clinical impact of interventions, along with updated diagnostic criteria.",
        "summary_ur": "These studies examine long-term impacts of lifestyle changes and metformin on diabetes prevention and complications.  Findings show that interventions significantly reduce diabetes risk and microvascular issues over 15 years.  Further research explores weight loss mechanisms and the clinical effectiveness of lifestyle interventions.  Diagnostic criteria for diabetes are also discussed."
      }
    },
    {
      "text": "These citations discuss diagnostic criteria and prevalence for hyperglycemia, specifically focusing on gestational diabetes.  They reference the WHO, FIGO guidelines, and various studies on  plasma glucose levels and diagnostic methods for intermediate hyperglycemia and type 2 diabetes, both during and outside pregnancy. These sources discuss diagnostic criteria and prevalence of hyperglycemia, including gestational diabetes.  Studies cover post-load plasma glucose tests for type 2 diabetes and intermediate hyperglycemia diagnosis, along with WHO and FIGO guidelines for gestational diabetes management and screening.  Global prevalence estimates are also included.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 27,
        "page_label": "23",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations discuss diagnostic criteria and prevalence for hyperglycemia, specifically focusing on gestational diabetes.  They reference the WHO, FIGO guidelines, and various studies on  plasma glucose levels and diagnostic methods for intermediate hyperglycemia and type 2 diabetes, both during and outside pregnancy.",
        "summary_ur": "These sources discuss diagnostic criteria and prevalence of hyperglycemia, including gestational diabetes.  Studies cover post-load plasma glucose tests for type 2 diabetes and intermediate hyperglycemia diagnosis, along with WHO and FIGO guidelines for gestational diabetes management and screening.  Global prevalence estimates are also included."
      }
    },
    {
      "text": "Guariguata et al. (2014) published global estimates of hyperglycemia prevalence during pregnancy in *Diabetes Research and Clinical Practice*.  This study is referenced in the 11th edition (2025) of the IDF Diabetes Atlas. The provided text is a citation, not a legal text.  It references a 2014 study by Guariguata et al. in *Diabetes Research and Clinical Practice* estimating global hyperglycemia prevalence during pregnancy, and also mentions the IDF Diabetes Atlas (11th edition, 2025).  It's a scientific, not legal, source.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 27,
        "page_label": "23",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Guariguata et al. (2014) published global estimates of hyperglycemia prevalence during pregnancy in *Diabetes Research and Clinical Practice*.  This study is referenced in the 11th edition (2025) of the IDF Diabetes Atlas.",
        "summary_ur": "The provided text is a citation, not a legal text.  It references a 2014 study by Guariguata et al. in *Diabetes Research and Clinical Practice* estimating global hyperglycemia prevalence during pregnancy, and also mentions the IDF Diabetes Atlas (11th edition, 2025).  It's a scientific, not legal, source."
      }
    },
    {
      "text": "Studies (Simmons et al., Seifu et al., Haque et al.) show that early treatment of gestational diabetes mellitus (GDM) improves pregnancy outcomes and breastfeeding, and is cost-effective.  The American Diabetes Association's classification of diabetes and prevalence data (Chivese et al.) provide context for understanding GDM's impact. Several studies (Simmons et al., 2023; Seifu et al., 2024; Haque et al., 2024) show that early treatment of gestational diabetes mellitus (GDM) improves outcomes, including breastfeeding success and cost-effectiveness.  The American Diabetes Association (2014) and Chivese et al. (2022) provide further context on GDM diagnosis and prevalence.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 28,
        "page_label": "24",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies (Simmons et al., Seifu et al., Haque et al.) show that early treatment of gestational diabetes mellitus (GDM) improves pregnancy outcomes and breastfeeding, and is cost-effective.  The American Diabetes Association's classification of diabetes and prevalence data (Chivese et al.) provide context for understanding GDM's impact.",
        "summary_ur": "Several studies (Simmons et al., 2023; Seifu et al., 2024; Haque et al., 2024) show that early treatment of gestational diabetes mellitus (GDM) improves outcomes, including breastfeeding success and cost-effectiveness.  The American Diabetes Association (2014) and Chivese et al. (2022) provide further context on GDM diagnosis and prevalence."
      }
    },
    {
      "text": "These citations discuss the prevalence of pre-existing and gestational diabetes.  Studies from 2010-2020 are reviewed and meta-analyzed,  examining diagnostic criteria, classification of hyperglycemia in pregnancy, and the increasing prevalence of gestational diabetes using IADPSG criteria.  Long-term risks for women are also considered. Several studies (2010-2022) reveal the increasing prevalence of pre-existing and gestational diabetes during pregnancy.  International guidelines and consensus panels define diagnostic criteria and classifications for hyperglycemia detected during pregnancy, impacting prevalence estimations.  Long-term diabetes risk for women after gestational diabetes is also a significant concern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 28,
        "page_label": "24",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations discuss the prevalence of pre-existing and gestational diabetes.  Studies from 2010-2020 are reviewed and meta-analyzed,  examining diagnostic criteria, classification of hyperglycemia in pregnancy, and the increasing prevalence of gestational diabetes using IADPSG criteria.  Long-term risks for women are also considered.",
        "summary_ur": "Several studies (2010-2022) reveal the increasing prevalence of pre-existing and gestational diabetes during pregnancy.  International guidelines and consensus panels define diagnostic criteria and classifications for hyperglycemia detected during pregnancy, impacting prevalence estimations.  Long-term diabetes risk for women after gestational diabetes is also a significant concern."
      }
    },
    {
      "text": "These studies examine gestational diabetes (GDM), focusing on long-term diabetes risk in women with GDM (Song et al., 2018),  screening methods (Benhalima et al., 2024; Saravanan et al., 2024), global prevalence (Guariguata et al., 2014), and the condition's pathophysiology (Hivert et al., 2024).  One study offers a meta-analysis of GDM criteria (citation 51, not fully shown). Several studies (Song et al., 2018; Benhalima et al., 2024; Saravanan et al., 2024; Guariguata et al., 2014; Hivert et al., 2024) analyze gestational diabetes mellitus (GDM),  its prevalence, long-term risks, and screening methods.  These reviews and meta-analyses utilize large datasets to assess GDM's impact on women's health.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 28,
        "page_label": "24",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These studies examine gestational diabetes (GDM), focusing on long-term diabetes risk in women with GDM (Song et al., 2018),  screening methods (Benhalima et al., 2024; Saravanan et al., 2024), global prevalence (Guariguata et al., 2014), and the condition's pathophysiology (Hivert et al., 2024).  One study offers a meta-analysis of GDM criteria (citation 51, not fully shown).",
        "summary_ur": "Several studies (Song et al., 2018; Benhalima et al., 2024; Saravanan et al., 2024; Guariguata et al., 2014; Hivert et al., 2024) analyze gestational diabetes mellitus (GDM),  its prevalence, long-term risks, and screening methods.  These reviews and meta-analyses utilize large datasets to assess GDM's impact on women's health."
      }
    },
    {
      "text": "These citations support research on gestational diabetes, its long-term consequences for both mothers and offspring, and the classification and management of various diabetes types, including monogenic diabetes in children and adolescents.  Studies cover pathophysiology, risk factors, and post-pregnancy outcomes. These citations support the long-term health consequences of gestational diabetes.  Studies detail its pathophysiology, its link to type 2 diabetes in offspring, and the impact of maternal diabetes on fetal development.  References include systematic reviews, meta-analyses, and WHO classifications of diabetes mellitus, along with clinical practice guidelines.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 28,
        "page_label": "24",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations support research on gestational diabetes, its long-term consequences for both mothers and offspring, and the classification and management of various diabetes types, including monogenic diabetes in children and adolescents.  Studies cover pathophysiology, risk factors, and post-pregnancy outcomes.",
        "summary_ur": "These citations support the long-term health consequences of gestational diabetes.  Studies detail its pathophysiology, its link to type 2 diabetes in offspring, and the impact of maternal diabetes on fetal development.  References include systematic reviews, meta-analyses, and WHO classifications of diabetes mellitus, along with clinical practice guidelines."
      }
    },
    {
      "text": "These citations discuss monogenic diabetes in children and adolescents.  One source details 2018 consensus guidelines for diagnosis and management. Others explore the pathogenesis of monogenic diabetes, highlighting its contribution to understanding diabetes generally, and the role of endoplasmic reticulum stress in pancreatic beta-cell dysfunction. These texts discuss monogenic diabetes in children and adolescents.  The 2018 Consensus Guidelines detail diagnosis and management.  Further research explores the disease's pathogenesis, highlighting the role of endoplasmic reticulum stress and its impact on pancreatic beta cells.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 28,
        "page_label": "24",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations discuss monogenic diabetes in children and adolescents.  One source details 2018 consensus guidelines for diagnosis and management. Others explore the pathogenesis of monogenic diabetes, highlighting its contribution to understanding diabetes generally, and the role of endoplasmic reticulum stress in pancreatic beta-cell dysfunction.",
        "summary_ur": "These texts discuss monogenic diabetes in children and adolescents.  The 2018 Consensus Guidelines detail diagnosis and management.  Further research explores the disease's pathogenesis, highlighting the role of endoplasmic reticulum stress and its impact on pancreatic beta cells."
      }
    },
    {
      "text": "This document details the methodology for estimating diabetes prevalence and related impacts.  It covers data interpretation, source selection, projection methods, confidence interval calculation, standardization, and estimations for undiagnosed diabetes, hyperglycemia, pregnancy-related diabetes, mortality, and economic impact, specifically including type 1 diabetes. This document details the methodology for estimating diabetes prevalence.  It covers data interpretation, source selection, projection, extrapolation, confidence interval calculation, standardization, and estimations for undiagnosed cases, hyperglycemia, pregnancy-related diabetes, mortality, and economic impact, including type 1 diabetes.  Specific methods are outlined for each.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 29,
        "page_label": "25",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This document details the methodology for estimating diabetes prevalence and related impacts.  It covers data interpretation, source selection, projection methods, confidence interval calculation, standardization, and estimations for undiagnosed diabetes, hyperglycemia, pregnancy-related diabetes, mortality, and economic impact, specifically including type 1 diabetes.",
        "summary_ur": "This document details the methodology for estimating diabetes prevalence.  It covers data interpretation, source selection, projection, extrapolation, confidence interval calculation, standardization, and estimations for undiagnosed cases, hyperglycemia, pregnancy-related diabetes, mortality, and economic impact, including type 1 diabetes.  Specific methods are outlined for each."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th Edition (2025) estimates global diabetes prevalence using data from 246 sources across 153 countries, representing over 93% of the world's population.  Data quality was rigorously assessed, incorporating peer-reviewed publications and select registries.  Future projections utilize UN population predictions, considering only age, sex, and urbanization changes. The IDF Diabetes Atlas (11th Edition, 2025) uses data from 246 sources across 153 countries (93% of global population) to estimate diabetes prevalence.  Rigorously vetted data, including registries and peer-reviewed publications, informed the estimates.  Future projections utilize UN population predictions and urbanization rates, considering only demographic shifts.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 30,
        "page_label": "26",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th Edition (2025) estimates global diabetes prevalence using data from 246 sources across 153 countries, representing over 93% of the world's population.  Data quality was rigorously assessed, incorporating peer-reviewed publications and select registries.  Future projections utilize UN population predictions, considering only age, sex, and urbanization changes.",
        "summary_ur": "The IDF Diabetes Atlas (11th Edition, 2025) uses data from 246 sources across 153 countries (93% of global population) to estimate diabetes prevalence.  Rigorously vetted data, including registries and peer-reviewed publications, informed the estimates.  Future projections utilize UN population predictions and urbanization rates, considering only demographic shifts."
      }
    },
    {
      "text": "The IDF Diabetes Atlas estimates diabetes prevalence using the best available data, acknowledging that variations exist due to differing study designs and methodologies.  Therefore, comparisons between countries and changes over time should be interpreted cautiously, as large differences often reflect new study findings. The International Diabetes Federation (IDF) Diabetes Atlas estimates diabetes prevalence using the best available data.  However, variations in study design and methodology lead to differences in estimates between studies and countries.  Therefore, comparisons should be cautious, as large differences often reflect new studies rather than actual changes in prevalence.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 31,
        "page_label": "27",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas estimates diabetes prevalence using the best available data, acknowledging that variations exist due to differing study designs and methodologies.  Therefore, comparisons between countries and changes over time should be interpreted cautiously, as large differences often reflect new study findings.",
        "summary_ur": "The International Diabetes Federation (IDF) Diabetes Atlas estimates diabetes prevalence using the best available data.  However, variations in study design and methodology lead to differences in estimates between studies and countries.  Therefore, comparisons should be cautious, as large differences often reflect new studies rather than actual changes in prevalence."
      }
    },
    {
      "text": "International diabetes prevalence comparisons should be viewed cautiously due to variations in study timing and methodologies.  The IDF Diabetes Atlas relies primarily on peer-reviewed publications and national health surveys, including WHO STEPS studies,  excluding those shown to overestimate prevalence.  Future projections are based on UN demographic data. International diabetes prevalence comparisons need careful interpretation due to varying study timelines and methodologies.  The IDF Diabetes Atlas relies heavily on peer-reviewed publications, national surveys (including WHO STEPS data), and official registries, but excludes studies shown to overestimate prevalence.  Future projections are limited to UN demographic changes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 31,
        "page_label": "27",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "International diabetes prevalence comparisons should be viewed cautiously due to variations in study timing and methodologies.  The IDF Diabetes Atlas relies primarily on peer-reviewed publications and national health surveys, including WHO STEPS studies,  excluding those shown to overestimate prevalence.  Future projections are based on UN demographic data.",
        "summary_ur": "International diabetes prevalence comparisons need careful interpretation due to varying study timelines and methodologies.  The IDF Diabetes Atlas relies heavily on peer-reviewed publications, national surveys (including WHO STEPS data), and official registries, but excludes studies shown to overestimate prevalence.  Future projections are limited to UN demographic changes."
      }
    },
    {
      "text": "This report uses data from various sources (registries, reports, studies) to estimate diabetes prevalence across 215 countries and territories.  Inclusion criteria required sufficient methodological detail, at least three age-specific estimates, publication after 2005, and a population exceeding 50,000.  Eighteen sources were excluded due to overestimation.  The analysis builds upon the previous edition, incorporating new data sources. The diabetes atlas used data from various sources, prioritizing quality and methodological rigor.  Studies lacking age-specific data (at least three age groups), sufficient sample size (population >50,000), or published before 2005 were excluded.  18 previously used sources were removed due to overestimation biases.  The final analysis included data from 215 countries and territories.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 31,
        "page_label": "27",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This report uses data from various sources (registries, reports, studies) to estimate diabetes prevalence across 215 countries and territories.  Inclusion criteria required sufficient methodological detail, at least three age-specific estimates, publication after 2005, and a population exceeding 50,000.  Eighteen sources were excluded due to overestimation.  The analysis builds upon the previous edition, incorporating new data sources.",
        "summary_ur": "The diabetes atlas used data from various sources, prioritizing quality and methodological rigor.  Studies lacking age-specific data (at least three age groups), sufficient sample size (population >50,000), or published before 2005 were excluded.  18 previously used sources were removed due to overestimation biases.  The final analysis included data from 215 countries and territories."
      }
    },
    {
      "text": "The 11th edition of the IDF Diabetes Atlas expanded its database by adding 63 data sources from 31 countries.  Data source quality was assessed using an analytical hierarchy process, prioritizing objective measurements, large sample sizes (>5000), national representativeness, recent data (past five years), and peer-reviewed publication.  The final score was a sum of individual criterion scores. The updated Diabetes Atlas incorporated 63 new data sources (31 countries) published between 2020-2024,  augmenting existing data.  Source quality was assessed using a hierarchical process prioritizing objective measurements, large sample sizes (>5000), national representation, recency (<5 years), and peer-reviewed publication.  Higher scores reflected better data quality.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 31,
        "page_label": "27",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition of the IDF Diabetes Atlas expanded its database by adding 63 data sources from 31 countries.  Data source quality was assessed using an analytical hierarchy process, prioritizing objective measurements, large sample sizes (>5000), national representativeness, recent data (past five years), and peer-reviewed publication.  The final score was a sum of individual criterion scores.",
        "summary_ur": "The updated Diabetes Atlas incorporated 63 new data sources (31 countries) published between 2020-2024,  augmenting existing data.  Source quality was assessed using a hierarchical process prioritizing objective measurements, large sample sizes (>5000), national representation, recency (<5 years), and peer-reviewed publication.  Higher scores reflected better data quality."
      }
    },
    {
      "text": "The IDF Diabetes Atlas used 241 of 991 identified data sources (24.3%) to estimate diabetes prevalence.  Source selection was based on a five-criteria scoring system; those scoring within 0.1 of the highest score for each country were included.  Five additional lower-scoring studies were added by expert consensus where no higher-quality data existed.  Details are available on the IDF Diabetes Atlas website. The IDF Diabetes Atlas used 241 high-quality data sources (24.3% of 991 identified) to estimate diabetes prevalence.  Source selection prioritized peer-reviewed studies and national surveys, scoring them across five criteria.  Five lower-quality studies were included due to a lack of better alternatives.  Details are available on diabetesatlas.org.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 31,
        "page_label": "27",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas used 241 of 991 identified data sources (24.3%) to estimate diabetes prevalence.  Source selection was based on a five-criteria scoring system; those scoring within 0.1 of the highest score for each country were included.  Five additional lower-scoring studies were added by expert consensus where no higher-quality data existed.  Details are available on the IDF Diabetes Atlas website.",
        "summary_ur": "The IDF Diabetes Atlas used 241 high-quality data sources (24.3% of 991 identified) to estimate diabetes prevalence.  Source selection prioritized peer-reviewed studies and national surveys, scoring them across five criteria.  Five lower-quality studies were included due to a lack of better alternatives.  Details are available on diabetesatlas.org."
      }
    },
    {
      "text": "This text is a footnote referencing the IDF Diabetes Atlas website (diabetesatlas.org) as the source for data used in the report.  It mentions that prevalence estimates may be absent for some countries. This text is not a legal text; it's a footnote from the IDF Diabetes Atlas.  It explains that prevalence estimates for some countries may be absent, and directs readers to the Atlas website for data source information.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 31,
        "page_label": "27",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text is a footnote referencing the IDF Diabetes Atlas website (diabetesatlas.org) as the source for data used in the report.  It mentions that prevalence estimates may be absent for some countries.",
        "summary_ur": "This text is not a legal text; it's a footnote from the IDF Diabetes Atlas.  It explains that prevalence estimates for some countries may be absent, and directs readers to the Atlas website for data source information."
      }
    },
    {
      "text": "Map 2.1 displays countries with in-country diabetes data sources.  Figure 2.1 classifies these sources based on diagnostic methods (OGTT, FBG, HbA1c, self-reported, medical record), data age, sample size, publication type (peer-reviewed, surveys, reports, unpublished), and sample representativeness (national, regional, local, or specific group). This map and figure detail the sources of diabetes data, classifying them by diagnostic method (OGTT, FBG, HbA1c, self-report, medical record), data age (under 5 years to 20+ years), sample size (\u22655000 to <700), publication type (peer-reviewed, national survey, etc.), and sample representativeness (national, regional, local, or specific group).  The information shows which countries provided in-country data.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 32,
        "page_label": "28",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Map 2.1 displays countries with in-country diabetes data sources.  Figure 2.1 classifies these sources based on diagnostic methods (OGTT, FBG, HbA1c, self-reported, medical record), data age, sample size, publication type (peer-reviewed, surveys, reports, unpublished), and sample representativeness (national, regional, local, or specific group).",
        "summary_ur": "This map and figure detail the sources of diabetes data, classifying them by diagnostic method (OGTT, FBG, HbA1c, self-report, medical record), data age (under 5 years to 20+ years), sample size (\u22655000 to <700), publication type (peer-reviewed, national survey, etc.), and sample representativeness (national, regional, local, or specific group).  The information shows which countries provided in-country data."
      }
    },
    {
      "text": "The study sample's representativeness can be national, regional, local, or specific to an ethnic or other group,  as detailed in the IDF Diabetes Atlas 11th Edition (2025). The study sample's representativeness is assessed across four levels: national, regional, local, and specific ethnic or other groups.  This ensures broad applicability of the findings.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 32,
        "page_label": "28",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The study sample's representativeness can be national, regional, local, or specific to an ethnic or other group,  as detailed in the IDF Diabetes Atlas 11th Edition (2025).",
        "summary_ur": "The study sample's representativeness is assessed across four levels: national, regional, local, and specific ethnic or other groups.  This ensures broad applicability of the findings."
      }
    },
    {
      "text": "Diabetes prevalence estimates were generated using a logistic regression model, averaging multiple data sources weighted by quality scores.  Country-level estimates considered age, sex, and urban/rural distribution, adjusting for studies lacking national representativeness.  Details of the model are found in a previous publication. This section details the methodology for estimating diabetes prevalence.  Age, sex, and location data were analyzed using logistic regression, weighting higher-quality studies more heavily.  Country-level estimates averaged multiple data sources.  Where studies lacked national representation, urban/rural ratios were considered to extrapolate national prevalence.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 33,
        "page_label": "29",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes prevalence estimates were generated using a logistic regression model, averaging multiple data sources weighted by quality scores.  Country-level estimates considered age, sex, and urban/rural distribution, adjusting for studies lacking national representativeness.  Details of the model are found in a previous publication.",
        "summary_ur": "This section details the methodology for estimating diabetes prevalence.  Age, sex, and location data were analyzed using logistic regression, weighting higher-quality studies more heavily.  Country-level estimates averaged multiple data sources.  Where studies lacked national representation, urban/rural ratios were considered to extrapolate national prevalence."
      }
    },
    {
      "text": "This text describes a methodology for estimating diabetes prevalence.  It involved adjusting study data based on urban/rural ratios, using national and UN data to account for variations, and extrapolating findings to regional and income-based groups.  Finally, population projections were used to estimate the number of people with diabetes in 2050. This text describes a methodology for estimating diabetes prevalence.  It involved adjusting study data based on urban/rural ratios using national data and UN population projections.  These were aggregated regionally and by income level, then projected to 2050 using UN population forecasts to estimate affected individuals.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 33,
        "page_label": "29",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes a methodology for estimating diabetes prevalence.  It involved adjusting study data based on urban/rural ratios, using national and UN data to account for variations, and extrapolating findings to regional and income-based groups.  Finally, population projections were used to estimate the number of people with diabetes in 2050.",
        "summary_ur": "This text describes a methodology for estimating diabetes prevalence.  It involved adjusting study data based on urban/rural ratios using national data and UN population projections.  These were aggregated regionally and by income level, then projected to 2050 using UN population forecasts to estimate affected individuals."
      }
    },
    {
      "text": "This text describes a methodology for projecting diabetes prevalence to 2050.  It uses UN population projections and existing diabetes prevalence data, but acknowledges an underestimation due to its failure to account for rising obesity and other risk factors.  For countries lacking sufficient data, estimates were extrapolated from similar nations. The study projected diabetes prevalence to 2050 using UN population projections, assuming unchanging age-group prevalence.  This likely underestimates future prevalence, ignoring rising obesity and other risk factors.  Data for one-third of countries lacking sufficient in-country data was extrapolated from similar nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 33,
        "page_label": "29",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes a methodology for projecting diabetes prevalence to 2050.  It uses UN population projections and existing diabetes prevalence data, but acknowledges an underestimation due to its failure to account for rising obesity and other risk factors.  For countries lacking sufficient data, estimates were extrapolated from similar nations.",
        "summary_ur": "The study projected diabetes prevalence to 2050 using UN population projections, assuming unchanging age-group prevalence.  This likely underestimates future prevalence, ignoring rising obesity and other risk factors.  Data for one-third of countries lacking sufficient in-country data was extrapolated from similar nations."
      }
    },
    {
      "text": "This text describes the methodology for estimating diabetes prevalence globally.  Where national data was lacking, estimates were extrapolated based on similar countries, resulting in less reliable figures.  Confidence intervals account for uncertainty, and polynomial regression harmonizes data from diverse sources.  The need for more global studies is highlighted. The Atlas used extrapolation for diabetes prevalence in some countries lacking data, relying on similar nations' information regarding ethnicity, language, income, and geography.  These estimates are less reliable and should be viewed cautiously.  Confidence intervals reflect uncertainty, with polynomial regression employed to harmonize diverse data sources.  More research is needed to improve global data.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 33,
        "page_label": "29",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes the methodology for estimating diabetes prevalence globally.  Where national data was lacking, estimates were extrapolated based on similar countries, resulting in less reliable figures.  Confidence intervals account for uncertainty, and polynomial regression harmonizes data from diverse sources.  The need for more global studies is highlighted.",
        "summary_ur": "The Atlas used extrapolation for diabetes prevalence in some countries lacking data, relying on similar nations' information regarding ethnicity, language, income, and geography.  These estimates are less reliable and should be viewed cautiously.  Confidence intervals reflect uncertainty, with polynomial regression employed to harmonize diverse data sources.  More research is needed to improve global data."
      }
    },
    {
      "text": "This text describes a method for harmonizing diabetes prevalence estimates from diverse sources.  Polynomial regression models predict estimates for specific population subgroups, which are then weighted and combined, considering data quality and population size.  Error propagation, accounting for correlation, calculates the variance of the combined country and regional estimates. Inanna's scribes, heed!  Diverse diabetes data, disharmonious, were harmonized using polynomial regression.  Subgroup predictions (age, sex, location) were weighted by data quality and population size, averaged for national and regional estimates.  Error propagation, accounting for correlations, calculated the variance.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 33,
        "page_label": "29",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes a method for harmonizing diabetes prevalence estimates from diverse sources.  Polynomial regression models predict estimates for specific population subgroups, which are then weighted and combined, considering data quality and population size.  Error propagation, accounting for correlation, calculates the variance of the combined country and regional estimates.",
        "summary_ur": "Inanna's scribes, heed!  Diverse diabetes data, disharmonious, were harmonized using polynomial regression.  Subgroup predictions (age, sex, location) were weighted by data quality and population size, averaged for national and regional estimates.  Error propagation, accounting for correlations, calculated the variance."
      }
    },
    {
      "text": "The variance of combined prevalence estimates was calculated, accounting for error correlation between estimates.  Where data was missing, similar countries' data were used for extrapolation.  Confidence intervals were then established at national, regional, and global levels using the propagated error. Statistical error propagation, considering correlations between estimates from various sources (including data extrapolation for missing countries), was used to calculate confidence intervals for national, regional, and global prevalence estimates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 33,
        "page_label": "29",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The variance of combined prevalence estimates was calculated, accounting for error correlation between estimates.  Where data was missing, similar countries' data were used for extrapolation.  Confidence intervals were then established at national, regional, and global levels using the propagated error.",
        "summary_ur": "Statistical error propagation, considering correlations between estimates from various sources (including data extrapolation for missing countries), was used to calculate confidence intervals for national, regional, and global prevalence estimates."
      }
    },
    {
      "text": "Map 2.2 shows countries with data on undiagnosed diabetes in adults (20-79).  The IDF Diabetes Atlas provides two prevalence estimates:  \"national prevalence\" (using country-specific data) and \"age-standardized prevalence\" (allowing for international comparisons).  The latter uses age, sex, and urbanization data from the UN to standardize estimates. The IDF Diabetes Atlas offers two diabetes prevalence estimates per country:  \"national prevalence\" uses country-specific data, while \"age-standardized\" estimates allow for international comparisons by adjusting for age, sex, and urbanization differences using UN population data.  Map 2.2 shows countries with data sources for undiagnosed diabetes in adults (20-79 years).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 34,
        "page_label": "30",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Map 2.2 shows countries with data on undiagnosed diabetes in adults (20-79).  The IDF Diabetes Atlas provides two prevalence estimates:  \"national prevalence\" (using country-specific data) and \"age-standardized prevalence\" (allowing for international comparisons).  The latter uses age, sex, and urbanization data from the UN to standardize estimates.",
        "summary_ur": "The IDF Diabetes Atlas offers two diabetes prevalence estimates per country:  \"national prevalence\" uses country-specific data, while \"age-standardized\" estimates allow for international comparisons by adjusting for age, sex, and urbanization differences using UN population data.  Map 2.2 shows countries with data sources for undiagnosed diabetes in adults (20-79 years)."
      }
    },
    {
      "text": "The text describes the methodology used to calculate diabetes prevalence.  Raw prevalence rates are presented, alongside age-standardized rates adjusted to the 2022 global age structure for cross-country comparison.  Age-standardized 2050 projections utilize projected 2050 global age structure. The text describes methods used to calculate diabetes prevalence.  Raw prevalence rates are given, but to allow for international comparisons, age-standardized rates are also calculated.  These are standardized to the 2022 world population age structure, removing the influence of differing age demographics across countries.  The method is also applied to 2050 projections.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 34,
        "page_label": "30",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text describes the methodology used to calculate diabetes prevalence.  Raw prevalence rates are presented, alongside age-standardized rates adjusted to the 2022 global age structure for cross-country comparison.  Age-standardized 2050 projections utilize projected 2050 global age structure.",
        "summary_ur": "The text describes methods used to calculate diabetes prevalence.  Raw prevalence rates are given, but to allow for international comparisons, age-standardized rates are also calculated.  These are standardized to the 2022 world population age structure, removing the influence of differing age demographics across countries.  The method is also applied to 2050 projections."
      }
    },
    {
      "text": "Map 2.3 shows countries with data on impaired glucose tolerance in adults (20-79 years).  Section 2.7 discusses estimating undiagnosed diabetes prevalence.  Early detection is crucial to prevent complications.  Population studies, using blood glucose testing and self-reported diagnoses, estimate the global prevalence of undiagnosed diabetes. I'm sorry, but I cannot summarize the provided text.  It's a description of a map and methodology for estimating undiagnosed diabetes, not a legal text.  Legal summarization requires identifying legal claims, arguments, and rulings, which are absent here.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 35,
        "page_label": "31",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Map 2.3 shows countries with data on impaired glucose tolerance in adults (20-79 years).  Section 2.7 discusses estimating undiagnosed diabetes prevalence.  Early detection is crucial to prevent complications.  Population studies, using blood glucose testing and self-reported diagnoses, estimate the global prevalence of undiagnosed diabetes.",
        "summary_ur": "I'm sorry, but I cannot summarize the provided text.  It's a description of a map and methodology for estimating undiagnosed diabetes, not a legal text.  Legal summarization requires identifying legal claims, arguments, and rulings, which are absent here."
      }
    },
    {
      "text": "This text describes a method for estimating undiagnosed diabetes prevalence.  It involves blood glucose testing and self-reported diagnoses to identify the proportion of individuals with undiagnosed high blood sugar.  These figures are then extrapolated to the total population, considering variations in healthcare access and socioeconomic factors.  The limitations of using different diagnostic tests are also acknowledged. Researchers determine diabetes prevalence by blood glucose testing and self-reported diagnoses.  This reveals the proportion of undiagnosed cases, varying by healthcare access and socioeconomic factors.  Prevalence estimates are then multiplied by population size to calculate the total number of undiagnosed diabetics per country.  Note that different diagnostic tests yield varying results.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 35,
        "page_label": "31",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes a method for estimating undiagnosed diabetes prevalence.  It involves blood glucose testing and self-reported diagnoses to identify the proportion of individuals with undiagnosed high blood sugar.  These figures are then extrapolated to the total population, considering variations in healthcare access and socioeconomic factors.  The limitations of using different diagnostic tests are also acknowledged.",
        "summary_ur": "Researchers determine diabetes prevalence by blood glucose testing and self-reported diagnoses.  This reveals the proportion of undiagnosed cases, varying by healthcare access and socioeconomic factors.  Prevalence estimates are then multiplied by population size to calculate the total number of undiagnosed diabetics per country.  Note that different diagnostic tests yield varying results."
      }
    },
    {
      "text": "Studies on diabetes prevalence vary due to different diagnostic methods (e.g., FPG, HbA1c) yielding different results and subgroup overlaps.  The IDF Diabetes Atlas averages estimates from studies using various biomarkers, acknowledging the limitations of data availability and inconsistencies in diagnostic approaches. Different diabetes biomarkers identify varying patient subgroups, leading to inconsistent prevalence estimates in studies.  The IDF Diabetes Atlas averages estimates from various studies using diverse diagnostic methods, acknowledging data limitations and the resulting uncertainty in undiagnosed diabetes figures.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 35,
        "page_label": "31",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies on diabetes prevalence vary due to different diagnostic methods (e.g., FPG, HbA1c) yielding different results and subgroup overlaps.  The IDF Diabetes Atlas averages estimates from studies using various biomarkers, acknowledging the limitations of data availability and inconsistencies in diagnostic approaches.",
        "summary_ur": "Different diabetes biomarkers identify varying patient subgroups, leading to inconsistent prevalence estimates in studies.  The IDF Diabetes Atlas averages estimates from various studies using diverse diagnostic methods, acknowledging data limitations and the resulting uncertainty in undiagnosed diabetes figures."
      }
    },
    {
      "text": "The study estimated the global prevalence of undiagnosed diabetes using data from 193 sources across 109 countries.  Where national data was unavailable, regional or income-group averages were used as proxies. This text describes a method for estimating undiagnosed diabetes globally.  Where direct national data was unavailable, the average from similar regions or income groups was used.  Data from 193 sources across 109 countries formed the basis of these estimates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 35,
        "page_label": "31",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The study estimated the global prevalence of undiagnosed diabetes using data from 193 sources across 109 countries.  Where national data was unavailable, regional or income-group averages were used as proxies.",
        "summary_ur": "This text describes a method for estimating undiagnosed diabetes globally.  Where direct national data was unavailable, the average from similar regions or income groups was used.  Data from 193 sources across 109 countries formed the basis of these estimates."
      }
    },
    {
      "text": "Map 2.4 displays countries with data on impaired fasting glucose (IFG) in adults (20-79 years).  Prevalence estimates were derived from 63 high-quality studies (60 countries) using logistic regression, with estimates for other countries extrapolated from similar ones.  The analysis also incorporated studies using HbA1c-defined intermediate hyperglycemia. This section details the methodology used to estimate impaired fasting glucose (IFG) prevalence globally.  Data from 51 high-quality studies (IGT) and 63 (IFG) informed a logistic regression model.  Prevalence in other countries was extrapolated from similar regions.  The update includes HbA1c-based data.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 36,
        "page_label": "32",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Map 2.4 displays countries with data on impaired fasting glucose (IFG) in adults (20-79 years).  Prevalence estimates were derived from 63 high-quality studies (60 countries) using logistic regression, with estimates for other countries extrapolated from similar ones.  The analysis also incorporated studies using HbA1c-defined intermediate hyperglycemia.",
        "summary_ur": "This section details the methodology used to estimate impaired fasting glucose (IFG) prevalence globally.  Data from 51 high-quality studies (IGT) and 63 (IFG) informed a logistic regression model.  Prevalence in other countries was extrapolated from similar regions.  The update includes HbA1c-based data."
      }
    },
    {
      "text": "The 2025 IDF Diabetes Atlas (11th edition) incorporated national HbA1c-defined intermediate hyperglycemia estimates (HbA1c 5.7-6.4%) from 21 countries using ADA criteria.  Due to limited data, prevalence estimates were not extrapolated to other countries. The 2025 IDF Diabetes Atlas included, for the first time, national HbA1c-defined intermediate hyperglycemia (5.7-6.4%) estimates from 21 countries.  Due to limited data, prevalence wasn't extrapolated to other nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 36,
        "page_label": "32",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2025 IDF Diabetes Atlas (11th edition) incorporated national HbA1c-defined intermediate hyperglycemia estimates (HbA1c 5.7-6.4%) from 21 countries using ADA criteria.  Due to limited data, prevalence estimates were not extrapolated to other countries.",
        "summary_ur": "The 2025 IDF Diabetes Atlas included, for the first time, national HbA1c-defined intermediate hyperglycemia (5.7-6.4%) estimates from 21 countries.  Due to limited data, prevalence wasn't extrapolated to other nations."
      }
    },
    {
      "text": "This section details the methodology for estimating the global prevalence of hyperglycemia in pregnancy (HIP).  Data from 65 studies across 52 countries were analyzed using a generalized linear regression model, incorporating factors like diagnostic criteria, study design, and sample representativeness, to generate age-specific HIP prevalence estimates.  UN fertility projections and IDF diabetes estimates were also utilized in the calculations. This section details the methodology used to estimate the global prevalence of hyperglycemia in pregnancy.  Researchers used data from 65 studies across 52 countries, applying a generalized linear regression model to age-specific prevalence data, incorporating UN fertility projections and IDF diabetes estimates.  Study selection was based on predefined criteria assessing diagnostic criteria, study design, and sample representativeness.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 37,
        "page_label": "33",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This section details the methodology for estimating the global prevalence of hyperglycemia in pregnancy (HIP).  Data from 65 studies across 52 countries were analyzed using a generalized linear regression model, incorporating factors like diagnostic criteria, study design, and sample representativeness, to generate age-specific HIP prevalence estimates.  UN fertility projections and IDF diabetes estimates were also utilized in the calculations.",
        "summary_ur": "This section details the methodology used to estimate the global prevalence of hyperglycemia in pregnancy.  Researchers used data from 65 studies across 52 countries, applying a generalized linear regression model to age-specific prevalence data, incorporating UN fertility projections and IDF diabetes estimates.  Study selection was based on predefined criteria assessing diagnostic criteria, study design, and sample representativeness."
      }
    },
    {
      "text": "Map 2.5 shows age-specific, country-level prevalence of hyperinsulinemia (HIP) using a generalized linear regression model.  The methodology for prevalence estimation has been updated since the 9th edition of the IDF Diabetes Atlas, primarily by prioritizing IADPSG diagnostic criteria and incorporating a new \"screening approach\" criterion.  Comparisons with previous editions should be cautious due to these changes. This text describes the methodology of a study on the prevalence of gestational diabetes (HIP), using a generalized linear regression model.  It highlights methodological changes in the 9th edition of the IDF Diabetes Atlas, particularly regarding data source selection and the increased weight given to IADPSG criteria and a new \"screening approach\" criterion.  Comparisons with previous editions require caution due to these updates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 37,
        "page_label": "33",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Map 2.5 shows age-specific, country-level prevalence of hyperinsulinemia (HIP) using a generalized linear regression model.  The methodology for prevalence estimation has been updated since the 9th edition of the IDF Diabetes Atlas, primarily by prioritizing IADPSG diagnostic criteria and incorporating a new \"screening approach\" criterion.  Comparisons with previous editions should be cautious due to these changes.",
        "summary_ur": "This text describes the methodology of a study on the prevalence of gestational diabetes (HIP), using a generalized linear regression model.  It highlights methodological changes in the 9th edition of the IDF Diabetes Atlas, particularly regarding data source selection and the increased weight given to IADPSG criteria and a new \"screening approach\" criterion.  Comparisons with previous editions require caution due to these updates."
      }
    },
    {
      "text": "This text is a snippet from the IDF Diabetes Atlas, 11th Edition (2025), referencing options for diabetes treatment (universal one-step, selective, two or more steps) within the context of Anita Sabidi's experience living with type 1 diabetes in Indonesia. This text is not legal text; it's a snippet from a diabetes atlas.  It describes treatment options for type 1 diabetes: universal one-step, selective one-step, selective multi-step, and universal multi-step methods.  The context suggests a study or report on diabetes in Indonesia.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 37,
        "page_label": "33",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text is a snippet from the IDF Diabetes Atlas, 11th Edition (2025), referencing options for diabetes treatment (universal one-step, selective, two or more steps) within the context of Anita Sabidi's experience living with type 1 diabetes in Indonesia.",
        "summary_ur": "This text is not legal text; it's a snippet from a diabetes atlas.  It describes treatment options for type 1 diabetes: universal one-step, selective one-step, selective multi-step, and universal multi-step methods.  The context suggests a study or report on diabetes in Indonesia."
      }
    },
    {
      "text": "Map 2.5 shows countries with data on hyperglycemia during pregnancy.  Section 2.10 details a method for calculating diabetes-related mortality using all-cause death data, age/sex-specific mortality risks for diagnosed and undiagnosed diabetes, and prevalence data.  Section 2.11 addresses the economic impact of diabetes (details not provided in excerpt). This text describes methods used to estimate diabetes-related mortality and economic impact.  Mortality estimates combine all-cause death data with diabetes prevalence and relative risk of death for diagnosed and undiagnosed individuals.  Economic impact estimation methodology is mentioned but not detailed.  Geographic data (map 2.5) is referenced but not included in this summary.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 38,
        "page_label": "34",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Map 2.5 shows countries with data on hyperglycemia during pregnancy.  Section 2.10 details a method for calculating diabetes-related mortality using all-cause death data, age/sex-specific mortality risks for diagnosed and undiagnosed diabetes, and prevalence data.  Section 2.11 addresses the economic impact of diabetes (details not provided in excerpt).",
        "summary_ur": "This text describes methods used to estimate diabetes-related mortality and economic impact.  Mortality estimates combine all-cause death data with diabetes prevalence and relative risk of death for diagnosed and undiagnosed individuals.  Economic impact estimation methodology is mentioned but not detailed.  Geographic data (map 2.5) is referenced but not included in this summary."
      }
    },
    {
      "text": "This text describes the methodology used in the IDF Diabetes Atlas to estimate diabetes-related mortality and economic impact.  Mortality estimation considers diagnosed and undiagnosed cases.  Economic impact calculations use an attributable fraction method, incorporating prevalence data, population estimates, healthcare expenditure data, and diabetes-specific cost ratios. The IDF Diabetes Atlas (2025) estimates diabetes-related mortality and economic impact.  Mortality estimation considers diagnosed and undiagnosed cases.  Economic impact calculations use an attributable fraction method, factoring in diabetes prevalence, population data, healthcare expenditures, and diabetes-related cost ratios across various demographics and regions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 38,
        "page_label": "34",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes the methodology used in the IDF Diabetes Atlas to estimate diabetes-related mortality and economic impact.  Mortality estimation considers diagnosed and undiagnosed cases.  Economic impact calculations use an attributable fraction method, incorporating prevalence data, population estimates, healthcare expenditure data, and diabetes-specific cost ratios.",
        "summary_ur": "The IDF Diabetes Atlas (2025) estimates diabetes-related mortality and economic impact.  Mortality estimation considers diagnosed and undiagnosed cases.  Economic impact calculations use an attributable fraction method, factoring in diabetes prevalence, population data, healthcare expenditures, and diabetes-related cost ratios across various demographics and regions."
      }
    },
    {
      "text": "This text describes the World Health Organization's (WHO) definition of health expenditure, encompassing public and private spending on healthcare services, family planning, nutrition, and health-related emergency aid (excluding water/sanitation).  The analysis further focuses on comparing health expenditures for individuals with and without diabetes, using refined ratios based on age, sex, location, diagnosis status, and region. The WHO defines health expenditure as encompassing preventive and curative services, family planning, nutrition, and health-related emergency aid (excluding water/sanitation).  Data includes public and private sources, distributed by age and sex.  Analyses critically examine the expenditure ratio for people with (diagnosed or undiagnosed) versus without diabetes, refined by factors like age, sex, location, and diagnosis status.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 39,
        "page_label": "35",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes the World Health Organization's (WHO) definition of health expenditure, encompassing public and private spending on healthcare services, family planning, nutrition, and health-related emergency aid (excluding water/sanitation).  The analysis further focuses on comparing health expenditures for individuals with and without diabetes, using refined ratios based on age, sex, location, diagnosis status, and region.",
        "summary_ur": "The WHO defines health expenditure as encompassing preventive and curative services, family planning, nutrition, and health-related emergency aid (excluding water/sanitation).  Data includes public and private sources, distributed by age and sex.  Analyses critically examine the expenditure ratio for people with (diagnosed or undiagnosed) versus without diabetes, refined by factors like age, sex, location, and diagnosis status."
      }
    },
    {
      "text": "This text describes methods for estimating diabetes-related healthcare expenditures.  Estimates are provided in USD and international dollars, as percentages of total health expenditures and GDP,  accounting for purchasing power parity.  Prevalence estimates for type 1 diabetes utilize a Markov Model and machine learning,  incorporating factors like age, sex, location, and income. This text describes a method for estimating diabetes-related healthcare costs.  It uses a model to predict prevalence (specifically type 1), factoring in demographics, location, and economic indicators.  Results are presented in USD and international dollars, showing the economic burden as a percentage of total health spending and GDP.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 39,
        "page_label": "35",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes methods for estimating diabetes-related healthcare expenditures.  Estimates are provided in USD and international dollars, as percentages of total health expenditures and GDP,  accounting for purchasing power parity.  Prevalence estimates for type 1 diabetes utilize a Markov Model and machine learning,  incorporating factors like age, sex, location, and income.",
        "summary_ur": "This text describes a method for estimating diabetes-related healthcare costs.  It uses a model to predict prevalence (specifically type 1), factoring in demographics, location, and economic indicators.  Results are presented in USD and international dollars, showing the economic burden as a percentage of total health spending and GDP."
      }
    },
    {
      "text": "The T1D Index Version 3.0 estimates global Type 1 diabetes prevalence and incidence.  It uses a Markov model and machine learning, combining published and unpublished data from 83 countries (with extrapolation for others) on incidence, prevalence, and mortality.  Data sources include recent literature, previous Atlas publications, and country-specific registries. This text describes the methodology of the T1D Index Version 3.0, which estimates global Type 1 diabetes prevalence and incidence.  It uses a Markov model and machine learning, combining published and unpublished data from 83 countries, extrapolating to others to create global estimates.  Data sources include studies, registries, and previous Atlas editions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 39,
        "page_label": "35",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The T1D Index Version 3.0 estimates global Type 1 diabetes prevalence and incidence.  It uses a Markov model and machine learning, combining published and unpublished data from 83 countries (with extrapolation for others) on incidence, prevalence, and mortality.  Data sources include recent literature, previous Atlas publications, and country-specific registries.",
        "summary_ur": "This text describes the methodology of the T1D Index Version 3.0, which estimates global Type 1 diabetes prevalence and incidence.  It uses a Markov model and machine learning, combining published and unpublished data from 83 countries, extrapolating to others to create global estimates.  Data sources include studies, registries, and previous Atlas editions."
      }
    },
    {
      "text": "The study estimated global diabetes incidence using data from 30 studies across 21 countries.  Age-based incidence was extrapolated to 119 other countries/territories, with Sub-Saharan Africa analyzed separately due to a different age of onset pattern. The provided text describes the methodology used to estimate adult diabetes incidence globally.  Data from 30 studies across 21 countries informed age-based incidence estimates, extrapolated to 202 countries/territories.  Sub-Saharan Africa's data was analyzed separately due to a different age-of-onset pattern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 39,
        "page_label": "35",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The study estimated global diabetes incidence using data from 30 studies across 21 countries.  Age-based incidence was extrapolated to 119 other countries/territories, with Sub-Saharan Africa analyzed separately due to a different age of onset pattern.",
        "summary_ur": "The provided text describes the methodology used to estimate adult diabetes incidence globally.  Data from 30 studies across 21 countries informed age-based incidence estimates, extrapolated to 202 countries/territories.  Sub-Saharan Africa's data was analyzed separately due to a different age-of-onset pattern."
      }
    },
    {
      "text": "This study analyzed changes in disease incidence and mortality from 1985-2019, excluding pandemic years (2020-2022).  Incidence was estimated using national data or regional averages, assuming constant rates before 1985 and projecting future trends based on the final year's data.  Prevalence data were used where available; otherwise, it was modeled. Mortality was modeled using random forest regression of data from 39 countries. This study analyzed disease incidence from 1985-2019, excluding pandemic years (2020-2022).  Data from 26 countries provided actual prevalence; others were modeled.  Mortality was analyzed using random forest regression from data of 39 countries.  Pre-1985 incidence was assumed constant, and future trends extrapolated from recent data.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 40,
        "page_label": "36",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This study analyzed changes in disease incidence and mortality from 1985-2019, excluding pandemic years (2020-2022).  Incidence was estimated using national data or regional averages, assuming constant rates before 1985 and projecting future trends based on the final year's data.  Prevalence data were used where available; otherwise, it was modeled. Mortality was modeled using random forest regression of data from 39 countries.",
        "summary_ur": "This study analyzed disease incidence from 1985-2019, excluding pandemic years (2020-2022).  Data from 26 countries provided actual prevalence; others were modeled.  Mortality was analyzed using random forest regression from data of 39 countries.  Pre-1985 incidence was assumed constant, and future trends extrapolated from recent data."
      }
    },
    {
      "text": "A study modeled age-standardized mortality using random forest regression.  Data included mortality rates from 39 countries, infant/under-five mortality, urbanization, healthcare resources (doctors per capita, GDP), and diabetes care quality.  Life expectancy was calculated using standard methods.  T1D care levels and diagnosis rates were estimated via expert survey. Researchers used random forest regression to model age-standardized mortality across 39 countries.  Factors included infant/child mortality, urbanization, healthcare access (doctors per capita, GDP), T1D care levels, and T1D diagnosis rates (from expert survey). Life expectancy was calculated using standard methods.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 40,
        "page_label": "36",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "A study modeled age-standardized mortality using random forest regression.  Data included mortality rates from 39 countries, infant/under-five mortality, urbanization, healthcare resources (doctors per capita, GDP), and diabetes care quality.  Life expectancy was calculated using standard methods.  T1D care levels and diagnosis rates were estimated via expert survey.",
        "summary_ur": "Researchers used random forest regression to model age-standardized mortality across 39 countries.  Factors included infant/child mortality, urbanization, healthcare access (doctors per capita, GDP), T1D care levels, and T1D diagnosis rates (from expert survey). Life expectancy was calculated using standard methods."
      }
    },
    {
      "text": "This bibliography cites sources on diabetes prevalence surveillance.  It includes the WHO STEPS framework (1), critiques of its accuracy (2),  a paper on pairwise comparison methods (3), the IDF diabetes atlas methodology (4, 5), and UN population data (6).  The sources address both methodological aspects and data used for estimating diabetes prevalence globally. This text cites sources on diabetes prevalence studies.  References 1 & 2 discuss the WHO STEPS surveillance framework and potential data inaccuracies.  References 3-5 detail methodologies for estimating diabetes prevalence, including the IDF Diabetes Atlas.  Finally, reference 6 provides population data from the UN.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 41,
        "page_label": "37",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This bibliography cites sources on diabetes prevalence surveillance.  It includes the WHO STEPS framework (1), critiques of its accuracy (2),  a paper on pairwise comparison methods (3), the IDF diabetes atlas methodology (4, 5), and UN population data (6).  The sources address both methodological aspects and data used for estimating diabetes prevalence globally.",
        "summary_ur": "This text cites sources on diabetes prevalence studies.  References 1 & 2 discuss the WHO STEPS surveillance framework and potential data inaccuracies.  References 3-5 detail methodologies for estimating diabetes prevalence, including the IDF Diabetes Atlas.  Finally, reference 6 provides population data from the UN."
      }
    },
    {
      "text": "This list cites sources for data on diabetes (IDF Diabetes Atlas, Sun et al., NCD-RisC), population demographics (UN World Population Prospects, UN Population Division, CIA World Factbook), and economic classifications (World Bank).  These sources provide epidemiological and socioeconomic context. This text cites sources for demographic and epidemiological data, including the IDF Diabetes Atlas, UN population reports, CIA World Factbook (on ethnicity and languages), World Bank income classifications, and research papers on diabetes prevalence (Sun et al., Ahmad et al., NCD-RisC).  These sources provide data used in a study (unspecified here).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 41,
        "page_label": "37",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This list cites sources for data on diabetes (IDF Diabetes Atlas, Sun et al., NCD-RisC), population demographics (UN World Population Prospects, UN Population Division, CIA World Factbook), and economic classifications (World Bank).  These sources provide epidemiological and socioeconomic context.",
        "summary_ur": "This text cites sources for demographic and epidemiological data, including the IDF Diabetes Atlas, UN population reports, CIA World Factbook (on ethnicity and languages), World Bank income classifications, and research papers on diabetes prevalence (Sun et al., Ahmad et al., NCD-RisC).  These sources provide data used in a study (unspecified here)."
      }
    },
    {
      "text": "This text cites several sources regarding diabetes prevalence, including a new WHO age standardization method (Lozano & Inoue, 2023), global variation in diagnosis (NCD-RisC, 2023), projections of hyperglycemia in pregnancy (Yuen et al., 2019; Linnenkamp et al., 2014), and utilizes UN World Population Prospects (2024) data.  Additionally, it mentions a study on determinants of health and mortality in undiagnosed diabetes (Choi et al.). The provided text cites several sources on diabetes prevalence, including a new WHO standard for age standardization of rates (Lozano & Inoue, 2024), global variation in diagnosis (NCD-RisC, 2023), and projections of hyperglycemia in pregnancy (Yuen et al., 2019; Linnenkamp et al., 2014).  UN population data (2024) is also referenced, alongside a study on undiagnosed diabetes (Choi et al.).  The core focus is on epidemiological data related to diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 41,
        "page_label": "37",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text cites several sources regarding diabetes prevalence, including a new WHO age standardization method (Lozano & Inoue, 2023), global variation in diagnosis (NCD-RisC, 2023), projections of hyperglycemia in pregnancy (Yuen et al., 2019; Linnenkamp et al., 2014), and utilizes UN World Population Prospects (2024) data.  Additionally, it mentions a study on determinants of health and mortality in undiagnosed diabetes (Choi et al.).",
        "summary_ur": "The provided text cites several sources on diabetes prevalence, including a new WHO standard for age standardization of rates (Lozano & Inoue, 2024), global variation in diagnosis (NCD-RisC, 2023), and projections of hyperglycemia in pregnancy (Yuen et al., 2019; Linnenkamp et al., 2014).  UN population data (2024) is also referenced, alongside a study on undiagnosed diabetes (Choi et al.).  The core focus is on epidemiological data related to diabetes."
      }
    },
    {
      "text": "Sources 17-22 address diabetes' impact on mortality.  Studies show increased cardiovascular and all-cause mortality risks associated with diabetes, impaired glucose tolerance, and prediabetes across various populations (US, Australia, Mauritius, China).  One study examines determinants of health and mortality in undiagnosed diabetes. Studies (Sources 17-22) show a strong link between diabetes (diagnosed and undiagnosed), impaired glucose tolerance, and increased mortality risk from cardiovascular disease and all causes, across diverse populations (US, Australia, Mauritius, China).  Further research clarifies risk factors and predictors.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 41,
        "page_label": "37",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Sources 17-22 address diabetes' impact on mortality.  Studies show increased cardiovascular and all-cause mortality risks associated with diabetes, impaired glucose tolerance, and prediabetes across various populations (US, Australia, Mauritius, China).  One study examines determinants of health and mortality in undiagnosed diabetes.",
        "summary_ur": "Studies (Sources 17-22) show a strong link between diabetes (diagnosed and undiagnosed), impaired glucose tolerance, and increased mortality risk from cardiovascular disease and all causes, across diverse populations (US, Australia, Mauritius, China).  Further research clarifies risk factors and predictors."
      }
    },
    {
      "text": "Several studies (refs 22-25) examined mortality and life expectancy related to prediabetes and diabetes in diverse populations (China, India, UK).  These studies used various cohorts and follow-up periods to identify risk factors and predictors of mortality in individuals with and without diabetes.  One study (ref 25) specifically focused on changes in diabetes/prediabetes prevalence and associated complications/mortality in India. Several studies (refs 22-25) and a Chinese national study (ref 21) reveal correlations between prediabetes, mortality rates, and life expectancy across diverse populations (India, UK, China).  These findings highlight the significant impact of prediabetes on health outcomes globally.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 41,
        "page_label": "37",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies (refs 22-25) examined mortality and life expectancy related to prediabetes and diabetes in diverse populations (China, India, UK).  These studies used various cohorts and follow-up periods to identify risk factors and predictors of mortality in individuals with and without diabetes.  One study (ref 25) specifically focused on changes in diabetes/prediabetes prevalence and associated complications/mortality in India.",
        "summary_ur": "Several studies (refs 22-25) and a Chinese national study (ref 21) reveal correlations between prediabetes, mortality rates, and life expectancy across diverse populations (India, UK, China).  These findings highlight the significant impact of prediabetes on health outcomes globally."
      }
    },
    {
      "text": "Unpublished data from a study (Grant No. 57/3/INDIAB/Ph-II/21-NCD-III) investigated changes in diabetes/prediabetes prevalence, incidence, complication rates, and mortality.  The results are detailed in the 11th edition of the IDF Diabetes Atlas. The provided text is a citation, not a legal text.  It refers to unpublished research (grant No. 57/3/INDIAB/Ph-II/21-NCD-III) on diabetes and prediabetes prevalence, incidence of complications, and mortality rates.  The data is from the IDF Diabetes Atlas, 11th Edition (2025).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 41,
        "page_label": "37",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Unpublished data from a study (Grant No. 57/3/INDIAB/Ph-II/21-NCD-III) investigated changes in diabetes/prediabetes prevalence, incidence, complication rates, and mortality.  The results are detailed in the 11th edition of the IDF Diabetes Atlas.",
        "summary_ur": "The provided text is a citation, not a legal text.  It refers to unpublished research (grant No. 57/3/INDIAB/Ph-II/21-NCD-III) on diabetes and prediabetes prevalence, incidence of complications, and mortality rates.  The data is from the IDF Diabetes Atlas, 11th Edition (2025)."
      }
    },
    {
      "text": "Studies (Saeedi et al., 2020; Roglic & Unwin, 2010; IDF Diabetes Atlas Group, 2013; Williams et al., 2020) cited estimate diabetes-related mortality and healthcare expenditures.  Data sources include the International Diabetes Federation Diabetes Atlas and the World Health Organization's Global Health Expenditure database (WHO, 2021).  A further study by Bommer et al. addresses the global economic burden of diabetes. Studies (Saeedi et al., 2020; Roglic & Unwin, 2010; IDF Diabetes Atlas Group, 2013; Williams et al., 2020) show significant diabetes-related mortality and healthcare costs globally (WHO, 2021; Bommer et al.).  These sources provide estimates and projections of this burden.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 42,
        "page_label": "38",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies (Saeedi et al., 2020; Roglic & Unwin, 2010; IDF Diabetes Atlas Group, 2013; Williams et al., 2020) cited estimate diabetes-related mortality and healthcare expenditures.  Data sources include the International Diabetes Federation Diabetes Atlas and the World Health Organization's Global Health Expenditure database (WHO, 2021).  A further study by Bommer et al. addresses the global economic burden of diabetes.",
        "summary_ur": "Studies (Saeedi et al., 2020; Roglic & Unwin, 2010; IDF Diabetes Atlas Group, 2013; Williams et al., 2020) show significant diabetes-related mortality and healthcare costs globally (WHO, 2021; Bommer et al.).  These sources provide estimates and projections of this burden."
      }
    },
    {
      "text": "Studies cited (references 31-35) show the significant global economic burden and rising incidence of diabetes, including type 1 diabetes in children and adolescents.  Data from the International Diabetes Federation Atlas highlights the prevalence and projected increases.  One study specifically addresses the situation in sub-Saharan Africa.  Another examines the impact of the COVID-19 pandemic on childhood diabetes incidence. Several studies (IDF Diabetes Atlas, Bommer et al., Gregory et al., Ogle et al., Atun et al., D\u2019Souza et al.) reveal the escalating global economic burden and incidence of diabetes, particularly concerning the rise in type 1 diabetes among children and adolescents.  These studies highlight the need for increased attention to diabetes care and policy, especially in sub-Saharan Africa.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 42,
        "page_label": "38",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies cited (references 31-35) show the significant global economic burden and rising incidence of diabetes, including type 1 diabetes in children and adolescents.  Data from the International Diabetes Federation Atlas highlights the prevalence and projected increases.  One study specifically addresses the situation in sub-Saharan Africa.  Another examines the impact of the COVID-19 pandemic on childhood diabetes incidence.",
        "summary_ur": "Several studies (IDF Diabetes Atlas, Bommer et al., Gregory et al., Ogle et al., Atun et al., D\u2019Souza et al.) reveal the escalating global economic burden and incidence of diabetes, particularly concerning the rise in type 1 diabetes among children and adolescents.  These studies highlight the need for increased attention to diabetes care and policy, especially in sub-Saharan Africa."
      }
    },
    {
      "text": "This text cites three sources: a 2017 Lancet Diabetes & Endocrinology article on diabetes care and policy; a 2023 JAMA Network Open article on childhood diabetes incidence during the COVID-19 pandemic; and the 11th edition (2025) of the IDF Diabetes Atlas.  The citations suggest research on diabetes prevalence, incidence, and management. These citations reference studies on diabetes.  One is a broad review of diabetes care, another a meta-analysis on childhood diabetes incidence during the COVID-19 pandemic, and the last is a reference to the IDF Diabetes Atlas, a comprehensive data source on diabetes prevalence.  Collectively, they highlight the ongoing research and global impact of diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 42,
        "page_label": "38",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text cites three sources: a 2017 Lancet Diabetes & Endocrinology article on diabetes care and policy; a 2023 JAMA Network Open article on childhood diabetes incidence during the COVID-19 pandemic; and the 11th edition (2025) of the IDF Diabetes Atlas.  The citations suggest research on diabetes prevalence, incidence, and management.",
        "summary_ur": "These citations reference studies on diabetes.  One is a broad review of diabetes care, another a meta-analysis on childhood diabetes incidence during the COVID-19 pandemic, and the last is a reference to the IDF Diabetes Atlas, a comprehensive data source on diabetes prevalence.  Collectively, they highlight the ongoing research and global impact of diabetes."
      }
    },
    {
      "text": "This excerpt from the IDF Diabetes Atlas 11th Edition (2025) details global diabetes prevalence and projections (2024-2050),  including data on undiagnosed cases, gestational diabetes, mortality rates, economic impact, and type 1 diabetes in children and adults. This document, part of the IDF Diabetes Atlas 11th Edition, details global diabetes prevalence (2024-2050), focusing on age groups, undiagnosed cases, hyperglycemia, pregnancy complications, mortality, economic impact, and type 1 diabetes in children and adults.  Data and projections are presented across several sections.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 43,
        "page_label": "39",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This excerpt from the IDF Diabetes Atlas 11th Edition (2025) details global diabetes prevalence and projections (2024-2050),  including data on undiagnosed cases, gestational diabetes, mortality rates, economic impact, and type 1 diabetes in children and adults.",
        "summary_ur": "This document, part of the IDF Diabetes Atlas 11th Edition, details global diabetes prevalence (2024-2050), focusing on age groups, undiagnosed cases, hyperglycemia, pregnancy complications, mortality, economic impact, and type 1 diabetes in children and adults.  Data and projections are presented across several sections."
      }
    },
    {
      "text": "Globally, 589 million adults (11.1%) have diabetes, projected to reach 853 million (13%) by 2050.  A quarter of those with diabetes are over 65, and 252 million are undiagnosed.  Diabetes costs over $1 trillion annually (12% of global health expenditure) and caused 3.4 million deaths (9.3% of global deaths) in 2024.  9.1 million have type 1 diabetes, and 23 million live births experience hyperglycemia. The global diabetes burden is immense.  589 million adults (11.1%) currently have diabetes, projected to reach 853 million (13%) by 2050.  Millions are undiagnosed.  Diabetes caused over 3.4 million deaths (9.3% of global deaths) and cost over USD 1 trillion in 2024.  High rates exist across age groups, impacting 23 million live births annually through hyperglycaemia.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 44,
        "page_label": "40",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Globally, 589 million adults (11.1%) have diabetes, projected to reach 853 million (13%) by 2050.  A quarter of those with diabetes are over 65, and 252 million are undiagnosed.  Diabetes costs over $1 trillion annually (12% of global health expenditure) and caused 3.4 million deaths (9.3% of global deaths) in 2024.  9.1 million have type 1 diabetes, and 23 million live births experience hyperglycemia.",
        "summary_ur": "The global diabetes burden is immense.  589 million adults (11.1%) currently have diabetes, projected to reach 853 million (13%) by 2050.  Millions are undiagnosed.  Diabetes caused over 3.4 million deaths (9.3% of global deaths) and cost over USD 1 trillion in 2024.  High rates exist across age groups, impacting 23 million live births annually through hyperglycaemia."
      }
    },
    {
      "text": "The International Diabetes Federation's 2025 Atlas estimates that 742 million adults (20-59 years) have diabetes globally, representing 69% of those affected.  Additionally, approximately 23 million newborns experience hyperglycemia during pregnancy. The text presents statistics from the IDF Diabetes Atlas 11th Edition (2025).  It highlights that most (69%) of those with type 1 diabetes are aged 20-59, and approximately 23 million live births annually are impacted by gestational hyperglycemia.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 44,
        "page_label": "40",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The International Diabetes Federation's 2025 Atlas estimates that 742 million adults (20-59 years) have diabetes globally, representing 69% of those affected.  Additionally, approximately 23 million newborns experience hyperglycemia during pregnancy.",
        "summary_ur": "The text presents statistics from the IDF Diabetes Atlas 11th Edition (2025).  It highlights that most (69%) of those with type 1 diabetes are aged 20-59, and approximately 23 million live births annually are impacted by gestational hyperglycemia."
      }
    },
    {
      "text": "The IDF Diabetes Atlas (11th edition) estimates diabetes prevalence in 215 countries/territories, projecting a 17% increase by 2050.  This rise is attributed to aging populations and urbanization, with 95% of the increase expected in low- and middle-income countries.  Data from 246 sources were analyzed. The IDF Diabetes Atlas (11th edition) projects a 17% rise in global diabetes prevalence by 2050, primarily due to aging populations and urbanization.  Data from 246 sources across 153 countries inform this projection, showing a 95% increase concentrated outside of high-income nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 45,
        "page_label": "41",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas (11th edition) estimates diabetes prevalence in 215 countries/territories, projecting a 17% increase by 2050.  This rise is attributed to aging populations and urbanization, with 95% of the increase expected in low- and middle-income countries.  Data from 246 sources were analyzed.",
        "summary_ur": "The IDF Diabetes Atlas (11th edition) projects a 17% rise in global diabetes prevalence by 2050, primarily due to aging populations and urbanization.  Data from 246 sources across 153 countries inform this projection, showing a 95% increase concentrated outside of high-income nations."
      }
    },
    {
      "text": "The IDF Diabetes Atlas (11th edition) estimates 589 million adults (20-79 years) worldwide have diabetes in 2024 (11.1% of the age group), projected to rise to 852.5 million by 2050.  A 95% increase is expected in low- and middle-income countries due to population growth. The 2024 IDF Diabetes Atlas estimates 589 million adults (20-79 years) globally have diabetes (11.1%), projected to reach 852.5 million by 2050.  Low- and middle-income countries will bear the brunt of this increase (95%), driven by population growth and urbanization.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 45,
        "page_label": "41",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas (11th edition) estimates 589 million adults (20-79 years) worldwide have diabetes in 2024 (11.1% of the age group), projected to rise to 852.5 million by 2050.  A 95% increase is expected in low- and middle-income countries due to population growth.",
        "summary_ur": "The 2024 IDF Diabetes Atlas estimates 589 million adults (20-79 years) globally have diabetes (11.1%), projected to reach 852.5 million by 2050.  Low- and middle-income countries will bear the brunt of this increase (95%), driven by population growth and urbanization."
      }
    },
    {
      "text": "The number of adults with diabetes is projected to increase from 537 million in 2021 to 852.5 million by 2050, a 45% rise exceeding the 25% projected population growth. The provided text is not legal text; it's a statistical projection from the IDF Diabetes Atlas.  It forecasts a 45% increase in the global diabetic adult population by 2050, exceeding 852.5 million, a rate exceeding overall population growth.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 45,
        "page_label": "41",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The number of adults with diabetes is projected to increase from 537 million in 2021 to 852.5 million by 2050, a 45% rise exceeding the 25% projected population growth.",
        "summary_ur": "The provided text is not legal text; it's a statistical projection from the IDF Diabetes Atlas.  It forecasts a 45% increase in the global diabetic adult population by 2050, exceeding 852.5 million, a rate exceeding overall population growth."
      }
    },
    {
      "text": "This data shows projected increases in diabetes prevalence globally from 2024 to 2050.  In 2024, 588.7 million adults (20-79 years) had diabetes (11.1% prevalence), resulting in 3.4 million deaths and $1.015 trillion in healthcare costs.  By 2050, these numbers are projected to rise to 852.5 million people, 13% prevalence, and $1.043 trillion in costs, with unavailable death data.  The data also includes projections for type 1 diabetes and impaired glucose tolerance. I'm sorry, but I cannot summarize the provided text.  It appears to be a data table showing projected increases in diabetes and related conditions from 2024 to 2050, not legal text.  Summarizing requires understanding the legal arguments and conclusions, which are absent here.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 46,
        "page_label": "42",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data shows projected increases in diabetes prevalence globally from 2024 to 2050.  In 2024, 588.7 million adults (20-79 years) had diabetes (11.1% prevalence), resulting in 3.4 million deaths and $1.015 trillion in healthcare costs.  By 2050, these numbers are projected to rise to 852.5 million people, 13% prevalence, and $1.043 trillion in costs, with unavailable death data.  The data also includes projections for type 1 diabetes and impaired glucose tolerance.",
        "summary_ur": "I'm sorry, but I cannot summarize the provided text.  It appears to be a data table showing projected increases in diabetes and related conditions from 2024 to 2050, not legal text.  Summarizing requires understanding the legal arguments and conclusions, which are absent here."
      }
    },
    {
      "text": "The provided text shows the prevalence of hyperglycemia (including impaired glucose tolerance and fasting glucose) and gestational diabetes globally in 2024 and projected for 2050.  Millions are affected, with significant increases projected.  Data includes prevalence rates and affected populations, broken down by age group. The provided text shows a global increase in hyperglycemia from 2024 to 2050.  Millions suffer from impaired glucose tolerance and fasting glucose, impacting a significant portion of the population.  Pregnancy-related hyperglycemia is also prevalent.  Data includes prevalence rates and affected individuals, highlighting a substantial public health concern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 46,
        "page_label": "42",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The provided text shows the prevalence of hyperglycemia (including impaired glucose tolerance and fasting glucose) and gestational diabetes globally in 2024 and projected for 2050.  Millions are affected, with significant increases projected.  Data includes prevalence rates and affected populations, broken down by age group.",
        "summary_ur": "The provided text shows a global increase in hyperglycemia from 2024 to 2050.  Millions suffer from impaired glucose tolerance and fasting glucose, impacting a significant portion of the population.  Pregnancy-related hyperglycemia is also prevalent.  Data includes prevalence rates and affected individuals, highlighting a substantial public health concern."
      }
    },
    {
      "text": "The World Bank's 2024-2050 projection shows a global increase in diabetes prevalence.  From 2024's 11.1% (588.7 million people), it's expected to rise to 13% (852.5 million) by 2050.  High-income countries will also see a rise, while low-income countries will experience a smaller, but still significant, increase. The World Bank's 2024-2050 projection shows a global rise in diabetes prevalence.  From 11.1% (588.7 million) in 2024, it's projected to reach 13% (852.5 million) by 2050.  High-income countries will also see an increase, while low-income countries will experience a smaller, but still significant rise.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 46,
        "page_label": "42",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The World Bank's 2024-2050 projection shows a global increase in diabetes prevalence.  From 2024's 11.1% (588.7 million people), it's expected to rise to 13% (852.5 million) by 2050.  High-income countries will also see a rise, while low-income countries will experience a smaller, but still significant, increase.",
        "summary_ur": "The World Bank's 2024-2050 projection shows a global rise in diabetes prevalence.  From 11.1% (588.7 million) in 2024, it's projected to reach 13% (852.5 million) by 2050.  High-income countries will also see an increase, while low-income countries will experience a smaller, but still significant rise."
      }
    },
    {
      "text": "Diabetes prevalence significantly increases with age, peaking in the 75-79 age group.  While prevalence is similar between men and women overall, more men currently live with diabetes.  The global aging population will further elevate diabetes prevalence in older adults. The text details diabetes prevalence variations.  Older adults (75-79) show highest rates (24.8% in 2024, projected to slightly increase), while the 20-24 age group has the lowest (1.9% in 2024).  Prevalence is roughly similar between men and women, though more men have diabetes overall.  Geographical variations are also noted but not detailed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 47,
        "page_label": "43",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes prevalence significantly increases with age, peaking in the 75-79 age group.  While prevalence is similar between men and women overall, more men currently live with diabetes.  The global aging population will further elevate diabetes prevalence in older adults.",
        "summary_ur": "The text details diabetes prevalence variations.  Older adults (75-79) show highest rates (24.8% in 2024, projected to slightly increase), while the 20-24 age group has the lowest (1.9% in 2024).  Prevalence is roughly similar between men and women, though more men have diabetes overall.  Geographical variations are also noted but not detailed."
      }
    },
    {
      "text": "Figures 3.1 and 3.2 present data on diabetes prevalence and numbers of people with diabetes in adults (20-79 years) in 2024 and projected for 2050.  The data is broken down by age group and sex, showing a significant increase in both prevalence and numbers over time. The provided text describes figures (not included) showing the estimated number and prevalence of diabetes in adults (20-79 years) in 2024 and 2050.  Data is broken down by age group and sex, illustrating a projected increase in both number of cases and prevalence over time.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 48,
        "page_label": "44",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Figures 3.1 and 3.2 present data on diabetes prevalence and numbers of people with diabetes in adults (20-79 years) in 2024 and projected for 2050.  The data is broken down by age group and sex, showing a significant increase in both prevalence and numbers over time.",
        "summary_ur": "The provided text describes figures (not included) showing the estimated number and prevalence of diabetes in adults (20-79 years) in 2024 and 2050.  Data is broken down by age group and sex, illustrating a projected increase in both number of cases and prevalence over time."
      }
    },
    {
      "text": "This data snippet shows projected diabetes prevalence by age and sex (male/female) for 2024 and 2050.  It's a portion of a larger dataset from the IDF Diabetes Atlas, illustrating increasing diabetes rates across age groups over time.  Specific percentages are not provided in this excerpt. This data shows projected diabetes prevalence by age and sex from 2024 to 2050.  The table lacks specific prevalence numbers but indicates a rise in diabetes across all age groups, with higher percentages expected in 2050 for both males and females.  The source is the IDF Diabetes Atlas 11th Edition.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 48,
        "page_label": "44",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data snippet shows projected diabetes prevalence by age and sex (male/female) for 2024 and 2050.  It's a portion of a larger dataset from the IDF Diabetes Atlas, illustrating increasing diabetes rates across age groups over time.  Specific percentages are not provided in this excerpt.",
        "summary_ur": "This data shows projected diabetes prevalence by age and sex from 2024 to 2050.  The table lacks specific prevalence numbers but indicates a rise in diabetes across all age groups, with higher percentages expected in 2050 for both males and females.  The source is the IDF Diabetes Atlas 11th Edition."
      }
    },
    {
      "text": "In 2024, diabetes prevalence was higher in urban areas (12.7%) than rural areas (8.8%), with 399.6 million and 189.1 million cases respectively.  By 2050, urban prevalence is projected to rise to 14.5% (654.7 million cases), while rural prevalence will slightly increase to 9.6%, remaining relatively stable in number.  Age is a significant factor in diabetes risk. In 2024, urban areas housed significantly more people with diabetes (399.6 million, 12.7% prevalence) than rural areas (189.1 million, 8.8% prevalence).  By 2050, urban diabetes cases are projected to sharply rise to 654.7 million (14.5% prevalence), while rural areas will see a relatively stable number.  Age is a key factor influencing these figures.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 49,
        "page_label": "45",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, diabetes prevalence was higher in urban areas (12.7%) than rural areas (8.8%), with 399.6 million and 189.1 million cases respectively.  By 2050, urban prevalence is projected to rise to 14.5% (654.7 million cases), while rural prevalence will slightly increase to 9.6%, remaining relatively stable in number.  Age is a significant factor in diabetes risk.",
        "summary_ur": "In 2024, urban areas housed significantly more people with diabetes (399.6 million, 12.7% prevalence) than rural areas (189.1 million, 8.8% prevalence).  By 2050, urban diabetes cases are projected to sharply rise to 654.7 million (14.5% prevalence), while rural areas will see a relatively stable number.  Age is a key factor influencing these figures."
      }
    },
    {
      "text": "The Middle East and North Africa (MENA) region had the highest age-standardized diabetes prevalence (19.9% in 2024, projected to reach 22.8% in 2050) among people aged 20\u201379.  The African (AFR) region had the lowest prevalence (5.0% in 2024, 5.9% in 2050), though this is likely underestimated due to anticipated urbanization and lifestyle changes.  These figures are age-standardized using a global standard. 2024-2050 \u12d3\u1218\u1273\u1275 \u12cd\u1235\u1325 \u1260\u12d3\u1208\u121d \u120b\u12ed \u1235\u12b3\u122d \u1260\u123d\u1273 \u1218\u1235\u134b\u134b\u1275 \u120b\u12ed \u12eb\u1208\u12cd\u1295 \u1275\u1295\u1270\u1293 \u12eb\u1233\u12eb\u120d\u1362 \u12602024 \u12d3.\u121d \u1260MENA \u12ad\u120d\u120d \u12a8\u134d\u1270\u129b \u1218\u1320\u1295 (19.9%) \u1232\u1296\u122d \u1260AFR \u12ad\u120d\u120d \u12f0\u130d\u121e \u12dd\u1245\u1270\u129b \u1218\u1320\u1295 (5.0%) \u1290\u1260\u122d\u1362 \u12a5\u1235\u12a8 2050 \u12d3.\u121d \u12f5\u1228\u1235 \u1260\u1201\u1208\u1271\u121d \u12ad\u120d\u120e\u127d \u1218\u1235\u134b\u134b\u1271 \u12a5\u1295\u12f0\u121a\u1328\u121d\u122d \u12ed\u1320\u1260\u1243\u120d\u1362",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 49,
        "page_label": "45",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The Middle East and North Africa (MENA) region had the highest age-standardized diabetes prevalence (19.9% in 2024, projected to reach 22.8% in 2050) among people aged 20\u201379.  The African (AFR) region had the lowest prevalence (5.0% in 2024, 5.9% in 2050), though this is likely underestimated due to anticipated urbanization and lifestyle changes.  These figures are age-standardized using a global standard.",
        "summary_ur": "2024-2050 \u12d3\u1218\u1273\u1275 \u12cd\u1235\u1325 \u1260\u12d3\u1208\u121d \u120b\u12ed \u1235\u12b3\u122d \u1260\u123d\u1273 \u1218\u1235\u134b\u134b\u1275 \u120b\u12ed \u12eb\u1208\u12cd\u1295 \u1275\u1295\u1270\u1293 \u12eb\u1233\u12eb\u120d\u1362 \u12602024 \u12d3.\u121d \u1260MENA \u12ad\u120d\u120d \u12a8\u134d\u1270\u129b \u1218\u1320\u1295 (19.9%) \u1232\u1296\u122d \u1260AFR \u12ad\u120d\u120d \u12f0\u130d\u121e \u12dd\u1245\u1270\u129b \u1218\u1320\u1295 (5.0%) \u1290\u1260\u122d\u1362 \u12a5\u1235\u12a8 2050 \u12d3.\u121d \u12f5\u1228\u1235 \u1260\u1201\u1208\u1271\u121d \u12ad\u120d\u120e\u127d \u1218\u1235\u134b\u134b\u1271 \u12a5\u1295\u12f0\u121a\u1328\u121d\u122d \u12ed\u1320\u1260\u1243\u120d\u1362"
      }
    },
    {
      "text": "By 2024, China, India, and the USA had the most adults (20-79 years) with diabetes.  Pakistan is projected to surpass the USA by 2050.  However, highest prevalence rates in 2024 were in Pakistan, Marshall Islands, and Kuwait, highlighting that high case numbers don't always equate to high prevalence due to population size and age distribution differences. By 2024, China, India, and the USA had the most adults (20-79) with diabetes.  Pakistan is projected to surpass the USA by 2050.  However, highest prevalence rates are predicted for Pakistan, Marshall Islands, and Kuwait, reflecting variations in population size and age distribution.  Rapid urbanization and lifestyle shifts will likely increase these numbers.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 49,
        "page_label": "45",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "By 2024, China, India, and the USA had the most adults (20-79 years) with diabetes.  Pakistan is projected to surpass the USA by 2050.  However, highest prevalence rates in 2024 were in Pakistan, Marshall Islands, and Kuwait, highlighting that high case numbers don't always equate to high prevalence due to population size and age distribution differences.",
        "summary_ur": "By 2024, China, India, and the USA had the most adults (20-79) with diabetes.  Pakistan is projected to surpass the USA by 2050.  However, highest prevalence rates are predicted for Pakistan, Marshall Islands, and Kuwait, reflecting variations in population size and age distribution.  Rapid urbanization and lifestyle shifts will likely increase these numbers."
      }
    },
    {
      "text": "The 2025 IDF Diabetes Atlas projects that in 2050, Pakistan will have the highest age-standardized diabetes prevalence (34.2%), followed closely by the Marshall Islands (28.7%) and Kiribati (28.5%).  Current high prevalence countries like the Marshall Islands and Kuwait are also projected to remain significantly affected. By 2050, Pakistan, the Marshall Islands, and Kiribati will likely have the highest age-standardized diabetes prevalence, with Pakistan projected at 34.2%.  The Marshall Islands and Kuwait currently have among the highest rates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 49,
        "page_label": "45",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2025 IDF Diabetes Atlas projects that in 2050, Pakistan will have the highest age-standardized diabetes prevalence (34.2%), followed closely by the Marshall Islands (28.7%) and Kiribati (28.5%).  Current high prevalence countries like the Marshall Islands and Kuwait are also projected to remain significantly affected.",
        "summary_ur": "By 2050, Pakistan, the Marshall Islands, and Kiribati will likely have the highest age-standardized diabetes prevalence, with Pakistan projected at 34.2%.  The Marshall Islands and Kuwait currently have among the highest rates."
      }
    },
    {
      "text": "This data from the International Diabetes Federation (IDF) shows the top 10 countries with the highest number of adults (20-79 years) with diabetes in 2024 and projected numbers for 2050.  China and India consistently have the largest numbers, with a projected increase in prevalence globally. This data from the International Diabetes Federation (IDF) shows the top ten countries with the highest number of adults (20-79 years) with diabetes in 2024 and projects those numbers for 2050.  China and India consistently have the highest numbers, with a significant increase projected for both by 2050.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 50,
        "page_label": "46",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data from the International Diabetes Federation (IDF) shows the top 10 countries with the highest number of adults (20-79 years) with diabetes in 2024 and projected numbers for 2050.  China and India consistently have the largest numbers, with a projected increase in prevalence globally.",
        "summary_ur": "This data from the International Diabetes Federation (IDF) shows the top ten countries with the highest number of adults (20-79 years) with diabetes in 2024 and projects those numbers for 2050.  China and India consistently have the highest numbers, with a significant increase projected for both by 2050."
      }
    },
    {
      "text": "The IDF Diabetes Atlas (2025) projects a significant increase in global diabetes prevalence from 2024 to 2050.  All regions will experience growth, with the Middle East and North Africa showing the most substantial rise in both age-standardized and overall prevalence. The provided text is a data table from the IDF Diabetes Atlas, not legal text.  It shows projected increases in diabetes prevalence and the number of people with diabetes globally and by region (MENA, NAC, WP, SEA, SACA, EUR, AFR) from 2024 to 2050.  No legal summary is needed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 50,
        "page_label": "46",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas (2025) projects a significant increase in global diabetes prevalence from 2024 to 2050.  All regions will experience growth, with the Middle East and North Africa showing the most substantial rise in both age-standardized and overall prevalence.",
        "summary_ur": "The provided text is a data table from the IDF Diabetes Atlas, not legal text.  It shows projected increases in diabetes prevalence and the number of people with diabetes globally and by region (MENA, NAC, WP, SEA, SACA, EUR, AFR) from 2024 to 2050.  No legal summary is needed."
      }
    },
    {
      "text": "The text presents data on the increasing global prevalence of diabetes, particularly among older adults (65-99 years).  It projects a rise from 158.3 million in 2024 to 278 million in 2050, highlighting the significant public health and economic challenges this will pose, demanding increased global resource allocation to combat the disease. The provided text presents data on diabetes prevalence, showing a significant projected increase in the number of people aged 65-99 with diabetes\u2014from 158.3 million in 2024 to 278 million in 2050.  This necessitates increased global resources to address the ensuing public health and economic challenges.  Specific country data (Tables 3.5 & 3.6) supports this projection.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 51,
        "page_label": "47",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text presents data on the increasing global prevalence of diabetes, particularly among older adults (65-99 years).  It projects a rise from 158.3 million in 2024 to 278 million in 2050, highlighting the significant public health and economic challenges this will pose, demanding increased global resource allocation to combat the disease.",
        "summary_ur": "The provided text presents data on diabetes prevalence, showing a significant projected increase in the number of people aged 65-99 with diabetes\u2014from 158.3 million in 2024 to 278 million in 2050.  This necessitates increased global resources to address the ensuing public health and economic challenges.  Specific country data (Tables 3.5 & 3.6) supports this projection."
      }
    },
    {
      "text": "Diabetes prevalence in those over 65 varies significantly by region, with the MENA region having the highest (32.3% in 2024) and AFR the lowest (7.8% in 2024).  While regional rankings may shift slightly by 2050, overall prevalence increases are not projected to be substantial.  Addressing this requires global commitment and sufficient resources. Diabetes prevalence among the over-65 population varies significantly across regions.  The MENA region has the highest rate (32.3% in 2024), while AFR has the lowest (7.8%).  While regional rankings may shift slightly by 2050, overall prevalence increases are not projected to be dramatic.  Global commitment to resources is crucial to address the public health and economic implications.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 51,
        "page_label": "47",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes prevalence in those over 65 varies significantly by region, with the MENA region having the highest (32.3% in 2024) and AFR the lowest (7.8% in 2024).  While regional rankings may shift slightly by 2050, overall prevalence increases are not projected to be substantial.  Addressing this requires global commitment and sufficient resources.",
        "summary_ur": "Diabetes prevalence among the over-65 population varies significantly across regions.  The MENA region has the highest rate (32.3% in 2024), while AFR has the lowest (7.8%).  While regional rankings may shift slightly by 2050, overall prevalence increases are not projected to be dramatic.  Global commitment to resources is crucial to address the public health and economic implications."
      }
    },
    {
      "text": "The table shows projected age-standardized diabetes prevalence by country/territory in 2024 and 2050.  Pakistan is projected to have the highest prevalence in both years.  Prevalence among adults aged 65-99 is also projected to increase significantly globally from 2024 to 2050. The provided text is a data table, not legal text.  It shows projected increases in age-standardized diabetes prevalence from 2024 to 2050, with Pakistan consistently having the highest rate.  The number of people over 65 with diabetes is also projected to significantly increase.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 51,
        "page_label": "47",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows projected age-standardized diabetes prevalence by country/territory in 2024 and 2050.  Pakistan is projected to have the highest prevalence in both years.  Prevalence among adults aged 65-99 is also projected to increase significantly globally from 2024 to 2050.",
        "summary_ur": "The provided text is a data table, not legal text.  It shows projected increases in age-standardized diabetes prevalence from 2024 to 2050, with Pakistan consistently having the highest rate.  The number of people over 65 with diabetes is also projected to significantly increase."
      }
    },
    {
      "text": "The IDF Diabetes Atlas provides data on diabetes in older adults, showing a high prevalence in China, India, and the USA.  By 2050, Turkey and Egypt are projected to join the top 10 countries.  Globally, 1.1 million adults over 60 have type 1 diabetes.  The Atlas also includes information on mortality and healthcare costs associated with diabetes in this age group, though specifics are not detailed in this excerpt. The text details global diabetes prevalence among the over-65 population, projecting significant increases by 2050, particularly in countries like India, China, and (later) Turkey and Egypt.  It also provides data on type 1 diabetes in older adults, estimating 1.1 million cases globally for those over 60.  Notably, the text mentions mortality and health expenditure are relevant factors but doesn't provide those figures.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 52,
        "page_label": "48",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas provides data on diabetes in older adults, showing a high prevalence in China, India, and the USA.  By 2050, Turkey and Egypt are projected to join the top 10 countries.  Globally, 1.1 million adults over 60 have type 1 diabetes.  The Atlas also includes information on mortality and healthcare costs associated with diabetes in this age group, though specifics are not detailed in this excerpt.",
        "summary_ur": "The text details global diabetes prevalence among the over-65 population, projecting significant increases by 2050, particularly in countries like India, China, and (later) Turkey and Egypt.  It also provides data on type 1 diabetes in older adults, estimating 1.1 million cases globally for those over 60.  Notably, the text mentions mortality and health expenditure are relevant factors but doesn't provide those figures."
      }
    },
    {
      "text": "In 2024, over 2 million global deaths in people over 60 were diabetes-related (9.2% of all-cause mortality), costing USD 501.9 billion in healthcare.  Over 1 million people aged 60+ had diabetes, with prevalence projected to rise significantly by 2050 across all age groups and regions. I need the legal text to summarize.  The provided text is a statistical report on diabetes in people over 60, showing high mortality, healthcare costs (USD 501.9 billion in 2024), and projected increases.  There's no legal text to summarize.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 52,
        "page_label": "48",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, over 2 million global deaths in people over 60 were diabetes-related (9.2% of all-cause mortality), costing USD 501.9 billion in healthcare.  Over 1 million people aged 60+ had diabetes, with prevalence projected to rise significantly by 2050 across all age groups and regions.",
        "summary_ur": "I need the legal text to summarize.  The provided text is a statistical report on diabetes in people over 60, showing high mortality, healthcare costs (USD 501.9 billion in 2024), and projected increases.  There's no legal text to summarize."
      }
    },
    {
      "text": "This data from the IDF Diabetes Atlas (2025) shows projected age-standardized diabetes prevalence and the number of people with diabetes (in millions) for various regions in 2024 and 2050.  The Middle East and North Africa (MENA) region consistently has the highest prevalence, with substantial increases projected for all regions by 2050. The provided text is a data table, not legal text.  It shows projected increases in age-standardized diabetes prevalence and the number of people with diabetes (in millions) across different IDF regions between 2024 and 2050.  The Middle East and North Africa (MENA) region consistently shows the highest prevalence.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 52,
        "page_label": "48",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data from the IDF Diabetes Atlas (2025) shows projected age-standardized diabetes prevalence and the number of people with diabetes (in millions) for various regions in 2024 and 2050.  The Middle East and North Africa (MENA) region consistently has the highest prevalence, with substantial increases projected for all regions by 2050.",
        "summary_ur": "The provided text is a data table, not legal text.  It shows projected increases in age-standardized diabetes prevalence and the number of people with diabetes (in millions) across different IDF regions between 2024 and 2050.  The Middle East and North Africa (MENA) region consistently shows the highest prevalence."
      }
    },
    {
      "text": "The table shows the projected rise in diabetes cases globally, with a significant portion remaining undiagnosed, particularly in low- and middle-income countries.  China and India are projected to have the highest numbers of diabetes cases in 2024 and 2050.  Data limitations exist for a substantial number of countries. The provided text presents data on undiagnosed diabetes globally.  It shows a significantly higher proportion of undiagnosed cases in low- and middle-income countries compared to high-income ones.  The top ten countries with the most cases of diabetes in 2024 and 2050 are listed, with China and India projected to have the highest numbers.  Data limitations are acknowledged.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 53,
        "page_label": "49",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows the projected rise in diabetes cases globally, with a significant portion remaining undiagnosed, particularly in low- and middle-income countries.  China and India are projected to have the highest numbers of diabetes cases in 2024 and 2050.  Data limitations exist for a substantial number of countries.",
        "summary_ur": "The provided text presents data on undiagnosed diabetes globally.  It shows a significantly higher proportion of undiagnosed cases in low- and middle-income countries compared to high-income ones.  The top ten countries with the most cases of diabetes in 2024 and 2050 are listed, with China and India projected to have the highest numbers.  Data limitations are acknowledged."
      }
    },
    {
      "text": "In 2024, 42.8% (251.7 million) of adults (20-79 years) with diabetes globally remained undiagnosed.  This high prevalence stems from insufficient healthcare access and limited diagnostic capacity.  Early diagnosis is crucial to prevent complications, premature death, and reduce healthcare costs. The text states that in 2024, 42.8% (251.7 million) of adults (20-79 years old) with diabetes globally were undiagnosed.  This high prevalence is largely due to insufficient healthcare access and limited capacity to identify cases. Early diagnosis is crucial for preventing complications, premature death, and reducing healthcare costs.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 53,
        "page_label": "49",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, 42.8% (251.7 million) of adults (20-79 years) with diabetes globally remained undiagnosed.  This high prevalence stems from insufficient healthcare access and limited diagnostic capacity.  Early diagnosis is crucial to prevent complications, premature death, and reduce healthcare costs.",
        "summary_ur": "The text states that in 2024, 42.8% (251.7 million) of adults (20-79 years old) with diabetes globally were undiagnosed.  This high prevalence is largely due to insufficient healthcare access and limited capacity to identify cases. Early diagnosis is crucial for preventing complications, premature death, and reducing healthcare costs."
      }
    },
    {
      "text": "The text highlights significant global disparities in undiagnosed diabetes.  A large percentage of adults with diabetes remain undiagnosed, particularly in low- and middle-income countries.  Early detection and management are crucial for improving quality of life and reducing healthcare costs associated with diabetes complications. The text highlights significant global disparities in undiagnosed diabetes.  A large percentage of people with diabetes remain undiagnosed, particularly in low- and middle-income countries. Early detection and management are crucial to improve quality of life and reduce healthcare costs.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 53,
        "page_label": "49",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text highlights significant global disparities in undiagnosed diabetes.  A large percentage of adults with diabetes remain undiagnosed, particularly in low- and middle-income countries.  Early detection and management are crucial for improving quality of life and reducing healthcare costs associated with diabetes complications.",
        "summary_ur": "The text highlights significant global disparities in undiagnosed diabetes.  A large percentage of people with diabetes remain undiagnosed, particularly in low- and middle-income countries. Early detection and management are crucial to improve quality of life and reduce healthcare costs."
      }
    },
    {
      "text": "Globally, a significant portion (42.8%) of people with diabetes remain undiagnosed, totaling 251.7 million.  Regional variations are substantial, ranging from a high of 72.6% in Africa to a low of 29.1% in North America and the Caribbean.  These disparities are attributed to socioeconomic factors, healthcare access, and public awareness. Global diabetes diagnosis varies widely.  Africa shows the highest percentage of undiagnosed cases (72.6%), while North America and the Caribbean have the lowest (29.1%).  Disparities are linked to socioeconomic factors, healthcare access, and public awareness.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 54,
        "page_label": "50",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Globally, a significant portion (42.8%) of people with diabetes remain undiagnosed, totaling 251.7 million.  Regional variations are substantial, ranging from a high of 72.6% in Africa to a low of 29.1% in North America and the Caribbean.  These disparities are attributed to socioeconomic factors, healthcare access, and public awareness.",
        "summary_ur": "Global diabetes diagnosis varies widely.  Africa shows the highest percentage of undiagnosed cases (72.6%), while North America and the Caribbean have the lowest (29.1%).  Disparities are linked to socioeconomic factors, healthcare access, and public awareness."
      }
    },
    {
      "text": "Global undiagnosed diabetes rates vary widely, with lowest proportions in Colombia, Hungary, and the Czech Republic, and highest in Burkina Faso, Benin, and Mozambique.  China, India, and Indonesia account for over half of all cases globally.  Many countries lack reliable data, highlighting the urgent need for improved diabetes surveillance and monitoring systems. Global undiagnosed diabetes rates vary widely.  Countries like Burkina Faso, Benin, and Mozambique have the highest proportions, while Colombia, Hungary, and the Czech Republic have the lowest.  China, India, and Indonesia account for over half of all undiagnosed cases globally.  Many countries lack reliable data, highlighting the urgent need for improved diabetes surveillance and monitoring systems.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 54,
        "page_label": "50",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Global undiagnosed diabetes rates vary widely, with lowest proportions in Colombia, Hungary, and the Czech Republic, and highest in Burkina Faso, Benin, and Mozambique.  China, India, and Indonesia account for over half of all cases globally.  Many countries lack reliable data, highlighting the urgent need for improved diabetes surveillance and monitoring systems.",
        "summary_ur": "Global undiagnosed diabetes rates vary widely.  Countries like Burkina Faso, Benin, and Mozambique have the highest proportions, while Colombia, Hungary, and the Czech Republic have the lowest.  China, India, and Indonesia account for over half of all undiagnosed cases globally.  Many countries lack reliable data, highlighting the urgent need for improved diabetes surveillance and monitoring systems."
      }
    },
    {
      "text": "The text highlights the urgent need for improved diabetes surveillance and monitoring, particularly in low-resource settings.  Reliable diagnosis requires HbA1c and FPG testing, but feasibility and cost must be considered.  The high number of undiagnosed cases (252 million globally) necessitates scaled-up screening programs and better healthcare access. The text highlights a critical need for improved diabetes surveillance and monitoring, especially in low-resource settings.  Millions remain undiagnosed, facing higher risks.  Reliable estimates require HbA1c and FPG data, balancing diagnostic accuracy with feasibility and cost.  Scaling screening programs and quality healthcare is urgently needed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 54,
        "page_label": "50",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text highlights the urgent need for improved diabetes surveillance and monitoring, particularly in low-resource settings.  Reliable diagnosis requires HbA1c and FPG testing, but feasibility and cost must be considered.  The high number of undiagnosed cases (252 million globally) necessitates scaled-up screening programs and better healthcare access.",
        "summary_ur": "The text highlights a critical need for improved diabetes surveillance and monitoring, especially in low-resource settings.  Millions remain undiagnosed, facing higher risks.  Reliable estimates require HbA1c and FPG data, balancing diagnostic accuracy with feasibility and cost.  Scaling screening programs and quality healthcare is urgently needed."
      }
    },
    {
      "text": "The text highlights a significant global issue:  over 85% of people with undiagnosed diabetes reside in low- and middle-income countries, leading to premature death.  The solution proposed is to expand screening programs and accessible healthcare services in these regions. The text highlights a critical need to expand diabetes screening and care, particularly in low- and middle-income countries.  Over 85% of individuals with undiagnosed diabetes reside in these regions, leading to premature mortality.  Improved access to high-quality healthcare is crucial.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 54,
        "page_label": "50",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text highlights a significant global issue:  over 85% of people with undiagnosed diabetes reside in low- and middle-income countries, leading to premature death.  The solution proposed is to expand screening programs and accessible healthcare services in these regions.",
        "summary_ur": "The text highlights a critical need to expand diabetes screening and care, particularly in low- and middle-income countries.  Over 85% of individuals with undiagnosed diabetes reside in these regions, leading to premature mortality.  Improved access to high-quality healthcare is crucial."
      }
    },
    {
      "text": "Map 3.4 and Table 3.11 illustrate the global prevalence of undiagnosed diabetes in adults (20-79 years) in 2024.  China and India have the highest numbers of undiagnosed cases, while Indonesia shows the highest proportion.  The top ten countries account for millions of undiagnosed cases. This data shows the high global prevalence of undiagnosed diabetes.  China and India have the most cases, with Indonesia having the highest proportion of undiagnosed cases.  The top ten countries listed account for millions of adults with the condition remaining undetected.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 55,
        "page_label": "51",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Map 3.4 and Table 3.11 illustrate the global prevalence of undiagnosed diabetes in adults (20-79 years) in 2024.  China and India have the highest numbers of undiagnosed cases, while Indonesia shows the highest proportion.  The top ten countries account for millions of undiagnosed cases.",
        "summary_ur": "This data shows the high global prevalence of undiagnosed diabetes.  China and India have the most cases, with Indonesia having the highest proportion of undiagnosed cases.  The top ten countries listed account for millions of adults with the condition remaining undetected."
      }
    },
    {
      "text": "In 2024, approximately 634.8 million adults (12%) globally had impaired glucose tolerance (IGT), highest in South-East Asia and lowest in Europe.  Concurrently, 487.7 million adults (9.2%) had impaired fasting glucose (IFG), with the highest prevalence in North America and the Caribbean.  Both IGT and IFG are projected to increase by 2050. The text details the global prevalence of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) in 2024.  Over 634 million adults (12%) had IGT, highest in South-East Asia, and nearly 488 million (9.2%) had IFG, highest in North America/Caribbean.  Both conditions are projected to increase by 2050.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 56,
        "page_label": "52",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, approximately 634.8 million adults (12%) globally had impaired glucose tolerance (IGT), highest in South-East Asia and lowest in Europe.  Concurrently, 487.7 million adults (9.2%) had impaired fasting glucose (IFG), with the highest prevalence in North America and the Caribbean.  Both IGT and IFG are projected to increase by 2050.",
        "summary_ur": "The text details the global prevalence of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) in 2024.  Over 634 million adults (12%) had IGT, highest in South-East Asia, and nearly 488 million (9.2%) had IFG, highest in North America/Caribbean.  Both conditions are projected to increase by 2050."
      }
    },
    {
      "text": "The 2024 prevalence of impaired fasting glucose (IFG) was highest in North America and the Caribbean, lowest in Europe.  High-income countries showed an 8.4% age-standardized prevalence, compared to 9.5% and 6.7% in middle- and low-income countries, respectively.  By 2050, an estimated 9.8% of the global adult population (647.5 million) is projected to have IFG.  Impaired glucose tolerance (IGT) prevalence is also projected to increase significantly by 2050 across all regions. 2024's impaired glucose tolerance (IGT) was highest in South-East Asia and Western Pacific, lowest in Europe.  High-income countries showed 8.4% prevalence, middle-income 9.5%, and low-income 6.7%.  By 2050, a projected 647.5 million adults (9.8% of the global adult population) will have IGT.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 56,
        "page_label": "52",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2024 prevalence of impaired fasting glucose (IFG) was highest in North America and the Caribbean, lowest in Europe.  High-income countries showed an 8.4% age-standardized prevalence, compared to 9.5% and 6.7% in middle- and low-income countries, respectively.  By 2050, an estimated 9.8% of the global adult population (647.5 million) is projected to have IFG.  Impaired glucose tolerance (IGT) prevalence is also projected to increase significantly by 2050 across all regions.",
        "summary_ur": "2024's impaired glucose tolerance (IGT) was highest in South-East Asia and Western Pacific, lowest in Europe.  High-income countries showed 8.4% prevalence, middle-income 9.5%, and low-income 6.7%.  By 2050, a projected 647.5 million adults (9.8% of the global adult population) will have IGT."
      }
    },
    {
      "text": "The global prevalence of intermediate hyperglycemia (IGT), or prediabetes, is significantly high, ranging from 5.5% to 40.5% across different regions.  While a universally agreed definition is lacking, IGT is a substantial risk factor for type 2 diabetes, posing a significant global health challenge. The global prevalence of intermediate hyperglycemia (IGT), or prediabetes, is significant, ranging from 5.5% to 40.5% across different regions.  While definitions vary, IGT's high prevalence poses a major challenge due to its strong association with type 2 diabetes development.  Millions are affected globally, varying regionally.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 56,
        "page_label": "52",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The global prevalence of intermediate hyperglycemia (IGT), or prediabetes, is significantly high, ranging from 5.5% to 40.5% across different regions.  While a universally agreed definition is lacking, IGT is a substantial risk factor for type 2 diabetes, posing a significant global health challenge.",
        "summary_ur": "The global prevalence of intermediate hyperglycemia (IGT), or prediabetes, is significant, ranging from 5.5% to 40.5% across different regions.  While definitions vary, IGT's high prevalence poses a major challenge due to its strong association with type 2 diabetes development.  Millions are affected globally, varying regionally."
      }
    },
    {
      "text": "The IDF Diabetes Atlas (2025) highlights that prevalent intermediate hyperglycemia significantly increases the global risk of developing type 2 diabetes, posing a substantial challenge for future diabetes prevention efforts. High blood sugar levels (hyperglycaemia) frequently precede type 2 diabetes, posing a significant global health challenge.  This intermediate stage increases future diabetes risk considerably, demanding proactive strategies.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 56,
        "page_label": "52",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas (2025) highlights that prevalent intermediate hyperglycemia significantly increases the global risk of developing type 2 diabetes, posing a substantial challenge for future diabetes prevention efforts.",
        "summary_ur": "High blood sugar levels (hyperglycaemia) frequently precede type 2 diabetes, posing a significant global health challenge.  This intermediate stage increases future diabetes risk considerably, demanding proactive strategies."
      }
    },
    {
      "text": "The tables show projected increases in impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) from 2024 to 2050 across various regions and income groups.  North America and the Caribbean, and South-East Asia will have the highest prevalence of IFG in 2024 and 2050.  Data is presented by International Diabetes Federation region and World Bank income group. The provided text shows tables detailing the projected prevalence of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) globally from 2024 to 2050.  Data is categorized by International Diabetes Federation (IDF) regions and World Bank income groups, indicating a substantial increase in affected individuals across all categories.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 57,
        "page_label": "53",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The tables show projected increases in impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) from 2024 to 2050 across various regions and income groups.  North America and the Caribbean, and South-East Asia will have the highest prevalence of IFG in 2024 and 2050.  Data is presented by International Diabetes Federation region and World Bank income group.",
        "summary_ur": "The provided text shows tables detailing the projected prevalence of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) globally from 2024 to 2050.  Data is categorized by International Diabetes Federation (IDF) regions and World Bank income groups, indicating a substantial increase in affected individuals across all categories."
      }
    },
    {
      "text": "The table shows projected increases in impaired glucose tolerance (IGT) prevalence and numbers from 2024 to 2050 across World Bank income groups.  All groups show increases, with middle-income countries experiencing the largest rise in both prevalence and affected population. The provided text shows projected increases in Impaired Glucose Tolerance (IGT) from 2024 to 2050 across different World Bank income groups.  High, middle, and low-income countries will all experience rises in both IGT prevalence and the number of affected individuals.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 57,
        "page_label": "53",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows projected increases in impaired glucose tolerance (IGT) prevalence and numbers from 2024 to 2050 across World Bank income groups.  All groups show increases, with middle-income countries experiencing the largest rise in both prevalence and affected population.",
        "summary_ur": "The provided text shows projected increases in Impaired Glucose Tolerance (IGT) from 2024 to 2050 across different World Bank income groups.  High, middle, and low-income countries will all experience rises in both IGT prevalence and the number of affected individuals."
      }
    },
    {
      "text": "This data from the IDF Diabetes Atlas (2025) shows the age-standardized prevalence of impaired fasting glucose (IFG) in adults (20-79 years) in 2024 and projected for 2050, categorized by World Bank income classification.  Higher prevalence is observed in middle-income countries, with increases projected for all income groups by 2050. This data from the IDF Diabetes Atlas shows the age-standardized prevalence of impaired fasting glucose (IFG) in adults globally in 2024 and projected for 2050, categorized by World Bank income classification.  High-income countries show lower, but still increasing, IFG prevalence compared to middle and low-income countries.  The number of people with IFG is projected to substantially increase across all income groups.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 58,
        "page_label": "54",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data from the IDF Diabetes Atlas (2025) shows the age-standardized prevalence of impaired fasting glucose (IFG) in adults (20-79 years) in 2024 and projected for 2050, categorized by World Bank income classification.  Higher prevalence is observed in middle-income countries, with increases projected for all income groups by 2050.",
        "summary_ur": "This data from the IDF Diabetes Atlas shows the age-standardized prevalence of impaired fasting glucose (IFG) in adults globally in 2024 and projected for 2050, categorized by World Bank income classification.  High-income countries show lower, but still increasing, IFG prevalence compared to middle and low-income countries.  The number of people with IFG is projected to substantially increase across all income groups."
      }
    },
    {
      "text": "This data visualizes the reported prevalence of HbA1c levels between 5.7% and 6.4% in various countries.  The chart shows prevalence rates ranging from near 0% to over 40%, varying by country and study parameters (years, age ranges).  The data spans multiple years and includes a wide range of participant ages across numerous nations. This data visualizes the prevalence of impaired fasting glucose and HbA1c (5.7-6.4%) across various countries.  The prevalence varies widely (0-45%), depending on location, study period, and age range of participants.  Specific numbers are presented for each country's study.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 59,
        "page_label": "55",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data visualizes the reported prevalence of HbA1c levels between 5.7% and 6.4% in various countries.  The chart shows prevalence rates ranging from near 0% to over 40%, varying by country and study parameters (years, age ranges).  The data spans multiple years and includes a wide range of participant ages across numerous nations.",
        "summary_ur": "This data visualizes the prevalence of impaired fasting glucose and HbA1c (5.7-6.4%) across various countries.  The prevalence varies widely (0-45%), depending on location, study period, and age range of participants.  Specific numbers are presented for each country's study."
      }
    },
    {
      "text": "This data table shows the prevalence of HbA1c levels between 5.7% and 6.4% in various countries (India, Marshall Islands, Brazil, Portugal, Canada, Samoa, Norway, and Ireland) between 2004 and 2020, across different age groups (mostly 15+ years).  The data is sourced from the IDF Diabetes Atlas 11th Edition. The provided text shows HbA1c prevalence (5.7-6.4%) data from various countries (India, Marshall Islands, Brazil, Portugal, Canada, Samoa, Norway, Ireland) between 2004 and 2020,  with varying age ranges (15+ to 74+ years) included in the studies.  The data comes from the IDF Diabetes Atlas 11th Edition.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 59,
        "page_label": "55",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table shows the prevalence of HbA1c levels between 5.7% and 6.4% in various countries (India, Marshall Islands, Brazil, Portugal, Canada, Samoa, Norway, and Ireland) between 2004 and 2020, across different age groups (mostly 15+ years).  The data is sourced from the IDF Diabetes Atlas 11th Edition.",
        "summary_ur": "The provided text shows HbA1c prevalence (5.7-6.4%) data from various countries (India, Marshall Islands, Brazil, Portugal, Canada, Samoa, Norway, Ireland) between 2004 and 2020,  with varying age ranges (15+ to 74+ years) included in the studies.  The data comes from the IDF Diabetes Atlas 11th Edition."
      }
    },
    {
      "text": "In 2024, an estimated 23 million (19.7%) pregnancies globally involved some form of hyperglycemia.  Gestational diabetes accounted for 79.2% of cases, with pre-existing diabetes (11%) and newly diagnosed diabetes during pregnancy (9.9%) comprising the remainder.  Improved detection methods likely contribute to differences from previous estimates. In 2024, about 23 million (19.7%) pregnancies globally involved hyperglycemia.  Most cases (79.2%) were gestational diabetes, with the remainder diagnosed before or during pregnancy.  Improved detection methods likely account for differences from previous data.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 60,
        "page_label": "56",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, an estimated 23 million (19.7%) pregnancies globally involved some form of hyperglycemia.  Gestational diabetes accounted for 79.2% of cases, with pre-existing diabetes (11%) and newly diagnosed diabetes during pregnancy (9.9%) comprising the remainder.  Improved detection methods likely contribute to differences from previous estimates.",
        "summary_ur": "In 2024, about 23 million (19.7%) pregnancies globally involved hyperglycemia.  Most cases (79.2%) were gestational diabetes, with the remainder diagnosed before or during pregnancy.  Improved detection methods likely account for differences from previous data."
      }
    },
    {
      "text": "The IDF Diabetes Atlas reveals regional variations in hyperglycemia in pregnancy (HIP) prevalence, highest in the SEA region (31.7%) and lowest in the AFR region (13.8%).  Most HIP cases (89.5%) occur in low- and middle-income countries with limited antenatal care.  Prevalence increases significantly with maternal age, peaking at 49.2% in women aged 45-49, but most cases (43.5%) occur in women under 30 due to higher fertility rates in this group. Improved diabetes detection during pregnancy explains rising IDF Diabetes Atlas figures.  Hyperglycaemia in pregnancy (HIP) prevalence varies regionally, highest in the SEA region (31.7%).  Most HIP cases (89.5%) are in low/middle-income countries with limited antenatal care.  HIP prevalence rises sharply with maternal age, peaking at 49.2% in women aged 45-49, but most cases (43.5%) occur in women under 30 due to higher fertility rates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 60,
        "page_label": "56",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas reveals regional variations in hyperglycemia in pregnancy (HIP) prevalence, highest in the SEA region (31.7%) and lowest in the AFR region (13.8%).  Most HIP cases (89.5%) occur in low- and middle-income countries with limited antenatal care.  Prevalence increases significantly with maternal age, peaking at 49.2% in women aged 45-49, but most cases (43.5%) occur in women under 30 due to higher fertility rates in this group.",
        "summary_ur": "Improved diabetes detection during pregnancy explains rising IDF Diabetes Atlas figures.  Hyperglycaemia in pregnancy (HIP) prevalence varies regionally, highest in the SEA region (31.7%).  Most HIP cases (89.5%) are in low/middle-income countries with limited antenatal care.  HIP prevalence rises sharply with maternal age, peaking at 49.2% in women aged 45-49, but most cases (43.5%) occur in women under 30 due to higher fertility rates."
      }
    },
    {
      "text": "Globally, hyperglycemia in pregnancy (HIP) affects 19.7% of pregnancies, totaling 23 million live births.  Most cases (79.2%) are due to gestational diabetes, with a disproportionate number (43.5%) occurring in women under 30.  Regional prevalence varies, highest in Southeast Asia (31.7%). Globally, hyperglycemia in pregnancy (HIP) affects 19.7% of women, with 23 million live births impacted.  Most cases (79.2%) result from gestational diabetes, disproportionately affecting younger women (43.5% under 30).  Regional variations exist, with South-East Asia showing the highest prevalence.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 60,
        "page_label": "56",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Globally, hyperglycemia in pregnancy (HIP) affects 19.7% of pregnancies, totaling 23 million live births.  Most cases (79.2%) are due to gestational diabetes, with a disproportionate number (43.5%) occurring in women under 30.  Regional prevalence varies, highest in Southeast Asia (31.7%).",
        "summary_ur": "Globally, hyperglycemia in pregnancy (HIP) affects 19.7% of women, with 23 million live births impacted.  Most cases (79.2%) result from gestational diabetes, disproportionately affecting younger women (43.5% under 30).  Regional variations exist, with South-East Asia showing the highest prevalence."
      }
    },
    {
      "text": "This graph displays the increasing prevalence of hyperglycemia during pregnancy across different age groups in 2024.  The prevalence rises significantly with maternal age, from 11.4% in the 20-24 age group to 49.2% in the 45-49 age group. That's a graph, not legal text.  It shows the increasing prevalence of hyperglycemia during pregnancy with maternal age, ranging from 11.4% in the 20-24 age group to 49.2% in the 45-49 age group in 2024.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 61,
        "page_label": "57",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This graph displays the increasing prevalence of hyperglycemia during pregnancy across different age groups in 2024.  The prevalence rises significantly with maternal age, from 11.4% in the 20-24 age group to 49.2% in the 45-49 age group.",
        "summary_ur": "That's a graph, not legal text.  It shows the increasing prevalence of hyperglycemia during pregnancy with maternal age, ranging from 11.4% in the 20-24 age group to 49.2% in the 45-49 age group in 2024."
      }
    },
    {
      "text": "Diabetes caused an estimated 3.4 million deaths (9.3% of all deaths in adults aged 20-79) in 2024, with nearly 40% occurring in the 20-59 age group.  This figure is lower than previous estimates due to methodological changes.  Mortality varies regionally due to diabetes prevalence, age distribution, and other contributing factors. In 2024, diabetes caused an estimated 3.4 million deaths globally among adults aged 20-79, representing 9.3% of all deaths in that age group.  Nearly 40% of these deaths occurred in the 20-59 age range.  These figures are lower than previous estimates due to methodological changes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 62,
        "page_label": "58",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes caused an estimated 3.4 million deaths (9.3% of all deaths in adults aged 20-79) in 2024, with nearly 40% occurring in the 20-59 age group.  This figure is lower than previous estimates due to methodological changes.  Mortality varies regionally due to diabetes prevalence, age distribution, and other contributing factors.",
        "summary_ur": "In 2024, diabetes caused an estimated 3.4 million deaths globally among adults aged 20-79, representing 9.3% of all deaths in that age group.  Nearly 40% of these deaths occurred in the 20-59 age range.  These figures are lower than previous estimates due to methodological changes."
      }
    },
    {
      "text": "The updated Diabetes Atlas reports lower diabetes-related mortality rates due to revised methodology and data sources (UN data replacing older WHO data).  The new estimates account for differences in mortality risk between diagnosed and undiagnosed diabetes. The Western Pacific region has the highest estimated number of deaths (1.2 million), while Africa and Southern Africa have the lowest (0.22 million). Diabetes-related death estimates are lower than previous reports due to data source and methodology changes.  The UN data shows lower overall mortality, and new calculations account for diagnosed vs. undiagnosed diabetes (undiagnosed showing lower mortality risk).  The Western Pacific region has the highest number of deaths (1.2 million), while Africa and Southern Africa have the lowest (0.22 million).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 62,
        "page_label": "58",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The updated Diabetes Atlas reports lower diabetes-related mortality rates due to revised methodology and data sources (UN data replacing older WHO data).  The new estimates account for differences in mortality risk between diagnosed and undiagnosed diabetes. The Western Pacific region has the highest estimated number of deaths (1.2 million), while Africa and Southern Africa have the lowest (0.22 million).",
        "summary_ur": "Diabetes-related death estimates are lower than previous reports due to data source and methodology changes.  The UN data shows lower overall mortality, and new calculations account for diagnosed vs. undiagnosed diabetes (undiagnosed showing lower mortality risk).  The Western Pacific region has the highest number of deaths (1.2 million), while Africa and Southern Africa have the lowest (0.22 million)."
      }
    },
    {
      "text": "Diabetes-related deaths show significant global variation.  North America (NAC) has the highest number (0.53 million), while Africa (AFR) and South-Central Asia (SACA) have the lowest (0.22 million each).  This disparity reflects population size and age distribution.  NAC also has the highest percentage of deaths attributable to diabetes (21.4%), compared to AFR's 4.0%. China accounts for the largest number of individual deaths (0.76 million). Diabetes caused roughly 0.53 million deaths in North America (NAC), the highest of any region.  Africa (AFR) had the lowest, around 0.22 million.  China had the most individual deaths, approximately 0.76 million, reflecting its large population and high diabetes prevalence.  Regional death rates correlate with population size and age distribution.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 62,
        "page_label": "58",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes-related deaths show significant global variation.  North America (NAC) has the highest number (0.53 million), while Africa (AFR) and South-Central Asia (SACA) have the lowest (0.22 million each).  This disparity reflects population size and age distribution.  NAC also has the highest percentage of deaths attributable to diabetes (21.4%), compared to AFR's 4.0%. China accounts for the largest number of individual deaths (0.76 million).",
        "summary_ur": "Diabetes caused roughly 0.53 million deaths in North America (NAC), the highest of any region.  Africa (AFR) had the lowest, around 0.22 million.  China had the most individual deaths, approximately 0.76 million, reflecting its large population and high diabetes prevalence.  Regional death rates correlate with population size and age distribution."
      }
    },
    {
      "text": "In 2024, China had the highest estimated number of diabetes deaths (0.76 million), followed by the USA (0.36 million).  Guam had the highest proportion of diabetes-related deaths (36%), while Russia had the lowest (0.42%).  The map displays the global distribution of this proportion. In 2024, China had the most diabetes-related deaths (~0.76 million), followed by the USA (~0.36 million).  Guam had the highest proportion of deaths attributed to diabetes (36%), while Russia had the lowest (0.42%).  Other high-proportion countries included several island nations and Italy.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 62,
        "page_label": "58",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, China had the highest estimated number of diabetes deaths (0.76 million), followed by the USA (0.36 million).  Guam had the highest proportion of diabetes-related deaths (36%), while Russia had the lowest (0.42%).  The map displays the global distribution of this proportion.",
        "summary_ur": "In 2024, China had the most diabetes-related deaths (~0.76 million), followed by the USA (~0.36 million).  Guam had the highest proportion of deaths attributed to diabetes (36%), while Russia had the lowest (0.42%).  Other high-proportion countries included several island nations and Italy."
      }
    },
    {
      "text": "Diabetes imposes a massive economic burden globally.  Direct healthcare costs have drastically increased from $232 billion in 2007 to over $1 trillion in 2024, a 338% rise.  This is partly due to improved data, but further cost increases are anticipated. Diabetes places a massive financial strain globally.  Direct costs, encompassing healthcare spending, surged from $232 billion in 2007 to over $1 trillion in 2024, a 338% increase.  This rise reflects both worsening diabetes prevalence and improved data collection.  Further cost increases are anticipated.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 63,
        "page_label": "59",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes imposes a massive economic burden globally.  Direct healthcare costs have drastically increased from $232 billion in 2007 to over $1 trillion in 2024, a 338% rise.  This is partly due to improved data, but further cost increases are anticipated.",
        "summary_ur": "Diabetes places a massive financial strain globally.  Direct costs, encompassing healthcare spending, surged from $232 billion in 2007 to over $1 trillion in 2024, a 338% increase.  This rise reflects both worsening diabetes prevalence and improved data collection.  Further cost increases are anticipated."
      }
    },
    {
      "text": "Global diabetes-related healthcare costs surpassed $1 trillion in 2024,  a figure projected to reach $1.043 trillion by 2050.  This conservative estimate considers population growth, aging, and urbanization, but assumes constant prevalence and per-person expenditure.  Improved data quality contributed to the increase. The global cost of diabetes exceeded one trillion USD in 2024, and is projected to reach 1.043 trillion by 2050.  This conservative estimate considers population growth, aging, and urbanization, but assumes constant prevalence and expenditure rates.  Improved data quality contributed to the increase.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 63,
        "page_label": "59",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Global diabetes-related healthcare costs surpassed $1 trillion in 2024,  a figure projected to reach $1.043 trillion by 2050.  This conservative estimate considers population growth, aging, and urbanization, but assumes constant prevalence and per-person expenditure.  Improved data quality contributed to the increase.",
        "summary_ur": "The global cost of diabetes exceeded one trillion USD in 2024, and is projected to reach 1.043 trillion by 2050.  This conservative estimate considers population growth, aging, and urbanization, but assumes constant prevalence and expenditure rates.  Improved data quality contributed to the increase."
      }
    },
    {
      "text": "The North America and Caribbean (NAC) region had the highest diabetes-related healthcare expenditure ($438.6 billion in 2024), representing 43.2% of the global total.  While the SACA, MENA, SEA, and AFR regions contain 42.7% of the world's diabetic population, their combined expenditure is only 13.5% of the global total.  This highlights significant disparities in healthcare access and spending. I cannot summarize the provided text because it is not legal text.  It appears to be a description of a graph and data related to diabetes healthcare costs across different regions.  To summarize legal text, please provide the relevant legal document.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 64,
        "page_label": "60",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The North America and Caribbean (NAC) region had the highest diabetes-related healthcare expenditure ($438.6 billion in 2024), representing 43.2% of the global total.  While the SACA, MENA, SEA, and AFR regions contain 42.7% of the world's diabetic population, their combined expenditure is only 13.5% of the global total.  This highlights significant disparities in healthcare access and spending.",
        "summary_ur": "I cannot summarize the provided text because it is not legal text.  It appears to be a description of a graph and data related to diabetes healthcare costs across different regions.  To summarize legal text, please provide the relevant legal document."
      }
    },
    {
      "text": "Diabetes-related healthcare costs vary drastically across IDF regions, ranging from USD 108 to USD 7,811 per adult with diabetes.  Globally, diabetes accounts for 11.9% of total health spending, reaching as high as 22.4% in the SACA region.  This highlights significant disparities in diabetes management and economic burden worldwide. Global diabetes healthcare costs vary widely by region.  The NAC region has the highest per-patient expenditure ($7,811), while SEA has the lowest ($108).  Diabetes accounts for a significant portion of global health spending (11.9%), reaching 22.4% of total health expenditure in the SACA region.  Expenditure differences between regions exceed 70-fold.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 64,
        "page_label": "60",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes-related healthcare costs vary drastically across IDF regions, ranging from USD 108 to USD 7,811 per adult with diabetes.  Globally, diabetes accounts for 11.9% of total health spending, reaching as high as 22.4% in the SACA region.  This highlights significant disparities in diabetes management and economic burden worldwide.",
        "summary_ur": "Global diabetes healthcare costs vary widely by region.  The NAC region has the highest per-patient expenditure ($7,811), while SEA has the lowest ($108).  Diabetes accounts for a significant portion of global health spending (11.9%), reaching 22.4% of total health expenditure in the SACA region.  Expenditure differences between regions exceed 70-fold."
      }
    },
    {
      "text": "The IDF Diabetes Atlas (11th Edition, 2025) shows that the highest percentage of health expenditure attributed to diabetes was in IDF regions, followed by 17% in the MENA region.  The lowest percentage (8.8%) was in the EUR region. The IDF Diabetes Atlas (2025) shows that the highest percentage of health spending on diabetes is in the IDF regions, followed by the MENA region (17%).  The EUR region had the lowest percentage (8.8%).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 64,
        "page_label": "60",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas (11th Edition, 2025) shows that the highest percentage of health expenditure attributed to diabetes was in IDF regions, followed by 17% in the MENA region.  The lowest percentage (8.8%) was in the EUR region.",
        "summary_ur": "The IDF Diabetes Atlas (2025) shows that the highest percentage of health spending on diabetes is in the IDF regions, followed by the MENA region (17%).  The EUR region had the lowest percentage (8.8%)."
      }
    },
    {
      "text": "These figures illustrate the substantial global cost of diabetes in 2024.  North America and the Caribbean had the highest total expenditure ($439 billion), while the highest per-person cost was in North America ($7,812).  Other regions showed varying levels of total and per capita expenditure. The provided text is not legal text; it's data from figures showing diabetes-related healthcare spending.  In 2024, North America and the Caribbean had the highest total expenditure ($439 billion) and per-person cost ($7,812), while Africa had the lowest.  Other regions showed varying levels of expenditure.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 65,
        "page_label": "61",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These figures illustrate the substantial global cost of diabetes in 2024.  North America and the Caribbean had the highest total expenditure ($439 billion), while the highest per-person cost was in North America ($7,812).  Other regions showed varying levels of total and per capita expenditure.",
        "summary_ur": "The provided text is not legal text; it's data from figures showing diabetes-related healthcare spending.  In 2024, North America and the Caribbean had the highest total expenditure ($439 billion) and per-person cost ($7,812), while Africa had the lowest.  Other regions showed varying levels of expenditure."
      }
    },
    {
      "text": "The table shows diabetes-related healthcare costs per person (USD) across different International Diabetes Federation (IDF) regions: Africa (AFR), Europe (EUR), Middle East & North Africa (MENA), South & Central America (SACA), South-East Asia (SEA), and the Western Pacific (WP).  The data is from the IDF Diabetes Atlas, 11th Edition. The provided text is a table header, not a legal text.  It shows International Diabetes Federation (IDF) regions (Europe, Africa, Middle East/North Africa, etc.) and indicates that the table will display diabetes healthcare costs per person in USD for each region.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 65,
        "page_label": "61",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows diabetes-related healthcare costs per person (USD) across different International Diabetes Federation (IDF) regions: Africa (AFR), Europe (EUR), Middle East & North Africa (MENA), South & Central America (SACA), South-East Asia (SEA), and the Western Pacific (WP).  The data is from the IDF Diabetes Atlas, 11th Edition.",
        "summary_ur": "The provided text is a table header, not a legal text.  It shows International Diabetes Federation (IDF) regions (Europe, Africa, Middle East/North Africa, etc.) and indicates that the table will display diabetes healthcare costs per person in USD for each region."
      }
    },
    {
      "text": "Figures 3.10 and 3.11 from the IDF Diabetes Atlas 11th Edition (2025) show that in 2024, diabetes-related healthcare expenditure varied significantly across IDF regions.  South and Central America had the highest percentage of total health expenditure (22.4%) and the Middle East and North Africa had the second highest percentage of GDP (1.9%) allocated to diabetes care. This data visualizes diabetes-related healthcare spending in 2024.  Figure 3.10 shows the percentage of total health expenditure spent on diabetes by International Diabetes Federation (IDF) region, ranging from 8.8% to 22.4%. Figure 3.11 displays the percentage of Gross Domestic Product (GDP) allocated to diabetes care per region, varying from 0.4% to 2.5%.  The highest percentages are observed in South and Central America (SACA) for both metrics.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 66,
        "page_label": "62",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Figures 3.10 and 3.11 from the IDF Diabetes Atlas 11th Edition (2025) show that in 2024, diabetes-related healthcare expenditure varied significantly across IDF regions.  South and Central America had the highest percentage of total health expenditure (22.4%) and the Middle East and North Africa had the second highest percentage of GDP (1.9%) allocated to diabetes care.",
        "summary_ur": "This data visualizes diabetes-related healthcare spending in 2024.  Figure 3.10 shows the percentage of total health expenditure spent on diabetes by International Diabetes Federation (IDF) region, ranging from 8.8% to 22.4%. Figure 3.11 displays the percentage of Gross Domestic Product (GDP) allocated to diabetes care per region, varying from 0.4% to 2.5%.  The highest percentages are observed in South and Central America (SACA) for both metrics."
      }
    },
    {
      "text": "Diabetes-related healthcare spending as a percentage of GDP is highest in high-income countries (1.4%), followed by middle-income (1.3%) and low-income countries (0.8%).  Regionally, the SACA region has the highest percentage (2.5%), exceeding even high-income nations. The provided text is a data description, not legal text.  It shows that in 2024, high-income countries spent the most on diabetes-related healthcare (1.4% of GDP), followed by middle-income (1.3%) and low-income countries (0.8%).  Specific regions (SACA and NAC) had even higher percentages.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 67,
        "page_label": "63",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes-related healthcare spending as a percentage of GDP is highest in high-income countries (1.4%), followed by middle-income (1.3%) and low-income countries (0.8%).  Regionally, the SACA region has the highest percentage (2.5%), exceeding even high-income nations.",
        "summary_ur": "The provided text is a data description, not legal text.  It shows that in 2024, high-income countries spent the most on diabetes-related healthcare (1.4% of GDP), followed by middle-income (1.3%) and low-income countries (0.8%).  Specific regions (SACA and NAC) had even higher percentages."
      }
    },
    {
      "text": "In 2024, the U.S. had the highest diabetes-related healthcare expenditure at $404.5 billion, followed by China and Brazil.  Conversely, Niue and Nauru had the lowest expenditures, at $0.8 million and $1.7 million respectively.  This significant disparity highlights global inequities in diabetes care. The USA had the highest diabetes-related healthcare expenditure in 2024 at $404.5 billion, while China and Brazil followed.  Conversely, Niue and Nauru reported the lowest expenditures, at $0.8 million and $1.7 million respectively.  Significant disparities in diabetes healthcare costs exist globally.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 68,
        "page_label": "64",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, the U.S. had the highest diabetes-related healthcare expenditure at $404.5 billion, followed by China and Brazil.  Conversely, Niue and Nauru had the lowest expenditures, at $0.8 million and $1.7 million respectively.  This significant disparity highlights global inequities in diabetes care.",
        "summary_ur": "The USA had the highest diabetes-related healthcare expenditure in 2024 at $404.5 billion, while China and Brazil followed.  Conversely, Niue and Nauru reported the lowest expenditures, at $0.8 million and $1.7 million respectively.  Significant disparities in diabetes healthcare costs exist globally."
      }
    },
    {
      "text": "This data from the IDF Diabetes Atlas 11th Edition (2025) shows the prevalence of diabetes (%) in various countries.  France (22.5%) and Mexico (19.5%) have the highest rates among those listed, while Niue (0.8%) has the lowest. This data shows the prevalence of diabetes in different countries.  France (22.5%) and Mexico (19.5%) have the highest rates among the listed, while Niue (0.8%) has the lowest.  The full dataset from the IDF Diabetes Atlas (2025) provides a more comprehensive view.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 68,
        "page_label": "64",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data from the IDF Diabetes Atlas 11th Edition (2025) shows the prevalence of diabetes (%) in various countries.  France (22.5%) and Mexico (19.5%) have the highest rates among those listed, while Niue (0.8%) has the lowest.",
        "summary_ur": "This data shows the prevalence of diabetes in different countries.  France (22.5%) and Mexico (19.5%) have the highest rates among the listed, while Niue (0.8%) has the lowest.  The full dataset from the IDF Diabetes Atlas (2025) provides a more comprehensive view."
      }
    },
    {
      "text": "Maps 3.8 and 3.9 from the IDF Diabetes Atlas 11th Edition (2025) illustrate diabetes-related healthcare expenditure in 2024.  Map 3.8 shows total expenditure per country, while Map 3.9 displays expenditure per adult (20-79 years) with diabetes.  Both use color-coded ranges to represent spending levels, indicating substantial variation globally. Unfortunately, the provided text is not legal text; it describes maps (3.8 and 3.9) showing diabetes-related healthcare expenditure by country in 2024.  The maps categorize spending in broad USD ranges, both as total expenditure and per adult with diabetes (ages 20-79).  No legal implications are present.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 69,
        "page_label": "65",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Maps 3.8 and 3.9 from the IDF Diabetes Atlas 11th Edition (2025) illustrate diabetes-related healthcare expenditure in 2024.  Map 3.8 shows total expenditure per country, while Map 3.9 displays expenditure per adult (20-79 years) with diabetes.  Both use color-coded ranges to represent spending levels, indicating substantial variation globally.",
        "summary_ur": "Unfortunately, the provided text is not legal text; it describes maps (3.8 and 3.9) showing diabetes-related healthcare expenditure by country in 2024.  The maps categorize spending in broad USD ranges, both as total expenditure and per adult with diabetes (ages 20-79).  No legal implications are present."
      }
    },
    {
      "text": "In 2024, significant international disparities in per-person diabetes healthcare costs were observed.  Switzerland had the highest expenditure ($12,234), while Bangladesh had the lowest ($74). Nine of the top ten highest-spending countries were in the European Region. 2024 data reveals vast differences in per-person diabetes healthcare costs.  Switzerland, the USA, and Norway had the highest expenditures (USD 12,234, 10,497, and 10,226 respectively), while Bangladesh, Pakistan, and the Democratic Republic of Congo had the lowest (USD 74-81).  Nine of the top ten highest-spending nations were in the European Region.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 70,
        "page_label": "66",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, significant international disparities in per-person diabetes healthcare costs were observed.  Switzerland had the highest expenditure ($12,234), while Bangladesh had the lowest ($74). Nine of the top ten highest-spending countries were in the European Region.",
        "summary_ur": "2024 data reveals vast differences in per-person diabetes healthcare costs.  Switzerland, the USA, and Norway had the highest expenditures (USD 12,234, 10,497, and 10,226 respectively), while Bangladesh, Pakistan, and the Democratic Republic of Congo had the lowest (USD 74-81).  Nine of the top ten highest-spending nations were in the European Region."
      }
    },
    {
      "text": "The 2025 IDF Diabetes Atlas shows significant global disparity in annual per-person diabetes costs.  Switzerland had the highest at $12,234, while Bangladesh had the lowest at $74.  This highlights the vast economic burden of diabetes, varying drastically by country. This data from the IDF Diabetes Atlas shows extreme disparity in annual per-person diabetes healthcare spending.  Switzerland leads with $12,234, while Bangladesh spends only $74.  High-income nations vastly outspend low-income nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 70,
        "page_label": "66",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2025 IDF Diabetes Atlas shows significant global disparity in annual per-person diabetes costs.  Switzerland had the highest at $12,234, while Bangladesh had the lowest at $74.  This highlights the vast economic burden of diabetes, varying drastically by country.",
        "summary_ur": "This data from the IDF Diabetes Atlas shows extreme disparity in annual per-person diabetes healthcare spending.  Switzerland leads with $12,234, while Bangladesh spends only $74.  High-income nations vastly outspend low-income nations."
      }
    },
    {
      "text": "The IDF Diabetes Atlas now uses the Type 1 Diabetes Index (T1D Index) to provide more accurate estimates of type 1 diabetes cases globally.  This index incorporates incidence, prevalence, and mortality data across all ages and countries, resulting in a 2024 estimate of 9.15 million cases.  Previous atlases lacked this comprehensive approach. The International Diabetes Federation's 2024 Diabetes Atlas uses a new Type 1 Diabetes Index (T1D Index) for improved accuracy.  This index, a collaborative effort, employs machine learning and available data to estimate global and national T1D cases, overcoming limitations of previous Atlas editions.  The 2024 estimate is 9.15 million cases.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 71,
        "page_label": "67",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas now uses the Type 1 Diabetes Index (T1D Index) to provide more accurate estimates of type 1 diabetes cases globally.  This index incorporates incidence, prevalence, and mortality data across all ages and countries, resulting in a 2024 estimate of 9.15 million cases.  Previous atlases lacked this comprehensive approach.",
        "summary_ur": "The International Diabetes Federation's 2024 Diabetes Atlas uses a new Type 1 Diabetes Index (T1D Index) for improved accuracy.  This index, a collaborative effort, employs machine learning and available data to estimate global and national T1D cases, overcoming limitations of previous Atlas editions.  The 2024 estimate is 9.15 million cases."
      }
    },
    {
      "text": "In 2024, an estimated 9.15 million people globally lived with diagnosed type 1 diabetes (T1D).  22.3% resided in low- and lower-middle-income countries.  The largest number of cases were in Europe and North America/Caribbean, while Africa had the fewest.  Age distribution showed 19.8% under 20, 68.6% between 20-59, and 11.8% aged 60+. 2024 global estimates show 9.15 million individuals with diagnosed type 1 diabetes (T1D).  22.3% resided in low/lower-middle-income countries.  Age distribution: 19.8% under 20, 68.6% aged 20-59, 11.8% 60+.  IDF Europe region had the highest number of cases, Africa the lowest.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 71,
        "page_label": "67",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, an estimated 9.15 million people globally lived with diagnosed type 1 diabetes (T1D).  22.3% resided in low- and lower-middle-income countries.  The largest number of cases were in Europe and North America/Caribbean, while Africa had the fewest.  Age distribution showed 19.8% under 20, 68.6% between 20-59, and 11.8% aged 60+.",
        "summary_ur": "2024 global estimates show 9.15 million individuals with diagnosed type 1 diabetes (T1D).  22.3% resided in low/lower-middle-income countries.  Age distribution: 19.8% under 20, 68.6% aged 20-59, 11.8% 60+.  IDF Europe region had the highest number of cases, Africa the lowest."
      }
    },
    {
      "text": "In 2024, the International Diabetes Federation reported 503,000 new type 1 diabetes (T1D) cases globally,  219,000 in those under 20.  Africa had the fewest cases.  T1D affects all ages, with long-term survival contributing to a growing adult population with the condition. The International Diabetes Federation (IDF) 2024 data reveals a global distribution of type 1 diabetes (T1D), with the Africa region showing the fewest cases.  Over 500,000 new cases were diagnosed, including a significant portion in those under 20.  T1D affects all ages, not just children and youth.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 71,
        "page_label": "67",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, the International Diabetes Federation reported 503,000 new type 1 diabetes (T1D) cases globally,  219,000 in those under 20.  Africa had the fewest cases.  T1D affects all ages, with long-term survival contributing to a growing adult population with the condition.",
        "summary_ur": "The International Diabetes Federation (IDF) 2024 data reveals a global distribution of type 1 diabetes (T1D), with the Africa region showing the fewest cases.  Over 500,000 new cases were diagnosed, including a significant portion in those under 20.  T1D affects all ages, not just children and youth."
      }
    },
    {
      "text": "Improved care has increased the lifespan of individuals with childhood-onset type 1 diabetes (T1D), leading to a rise in adult T1D cases.  In 2024, over half of new T1D diagnoses were in adults aged 20+.  While Finland, Saudi Arabia, and other countries showed high incidence rates in children under 15,  the highest number of individuals living with T1D (all ages) was found in different countries, reflecting variations in population size and mortality rates. Type 1 diabetes (T1D) increasingly affects adults, with 56.5% of new cases in 2024 occurring in those aged 20+.  While Finland, Saudi Arabia, and other nations show high childhood T1D incidence,  the highest number of T1D cases across all ages is found in different countries, reflecting varying mortality rates and population sizes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 71,
        "page_label": "67",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Improved care has increased the lifespan of individuals with childhood-onset type 1 diabetes (T1D), leading to a rise in adult T1D cases.  In 2024, over half of new T1D diagnoses were in adults aged 20+.  While Finland, Saudi Arabia, and other countries showed high incidence rates in children under 15,  the highest number of individuals living with T1D (all ages) was found in different countries, reflecting variations in population size and mortality rates.",
        "summary_ur": "Type 1 diabetes (T1D) increasingly affects adults, with 56.5% of new cases in 2024 occurring in those aged 20+.  While Finland, Saudi Arabia, and other nations show high childhood T1D incidence,  the highest number of T1D cases across all ages is found in different countries, reflecting varying mortality rates and population sizes."
      }
    },
    {
      "text": "Lower-income countries like India have younger T1D populations and higher mortality rates, resulting in a smaller adult T1D proportion compared to higher-income nations.  This difference is reflected in the varying rankings presented. Lower-income nations, like India, show a higher death rate among Type 1 diabetics, particularly younger individuals.  This results in a smaller adult T1D population relative to wealthier countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 71,
        "page_label": "67",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Lower-income countries like India have younger T1D populations and higher mortality rates, resulting in a smaller adult T1D proportion compared to higher-income nations.  This difference is reflected in the varying rankings presented.",
        "summary_ur": "Lower-income nations, like India, show a higher death rate among Type 1 diabetics, particularly younger individuals.  This results in a smaller adult T1D population relative to wealthier countries."
      }
    },
    {
      "text": "The tables show the countries with the highest numbers of people living with type 1 diabetes (T1D) in 2024, led by the U.S. and India.  A map reveals stark disparities in life expectancy for 10-year-olds diagnosed with T1D, ranging from under 6 years in some Sub-Saharan African nations to over 66 years in high-income countries, highlighting the impact of access to quality care. The provided text shows data on Type 1 diabetes (T1D).  The US and India have the most T1D cases.  Life expectancy for a 10-year-old with T1D varies drastically globally, from 6 to over 66 years, highlighting disparities in healthcare access.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 72,
        "page_label": "68",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The tables show the countries with the highest numbers of people living with type 1 diabetes (T1D) in 2024, led by the U.S. and India.  A map reveals stark disparities in life expectancy for 10-year-olds diagnosed with T1D, ranging from under 6 years in some Sub-Saharan African nations to over 66 years in high-income countries, highlighting the impact of access to quality care.",
        "summary_ur": "The provided text shows data on Type 1 diabetes (T1D).  The US and India have the most T1D cases.  Life expectancy for a 10-year-old with T1D varies drastically globally, from 6 to over 66 years, highlighting disparities in healthcare access."
      }
    },
    {
      "text": "This table shows the number of adults (\u226520 years) with diabetes in the top ten countries in 2021, comparing India's 941,000 to the United States' 197,000 and other countries.  Data is sourced from the IDF Diabetes Atlas, 11th Edition (2025). This data shows the number of people with diabetes in various countries.  India has the highest number (941,000), followed by China (599,000) and Brazil (499,000).  The US has 197,000 cases.  The data presents a significant global diabetes burden.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 72,
        "page_label": "68",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table shows the number of adults (\u226520 years) with diabetes in the top ten countries in 2021, comparing India's 941,000 to the United States' 197,000 and other countries.  Data is sourced from the IDF Diabetes Atlas, 11th Edition (2025).",
        "summary_ur": "This data shows the number of people with diabetes in various countries.  India has the highest number (941,000), followed by China (599,000) and Brazil (499,000).  The US has 197,000 cases.  The data presents a significant global diabetes burden."
      }
    },
    {
      "text": "In 2024, an estimated 168,000 premature deaths resulted from type 1 diabetes (T1D), with significant regional variations.  Alarmingly, 30,000 deaths involved undiagnosed individuals under 25, succumbing within a year of symptom onset due to misdiagnosis and delayed treatment.  Educational initiatives are crucial to improve early diagnosis and reduce mortality. 2024 witnessed 168,000 premature deaths from type 1 diabetes (T1D) globally.  A significant portion (30,000) were undiagnosed individuals under 25, succumbing within a year of symptom onset. Misdiagnosis as other illnesses contributed heavily to this mortality.  Education and awareness programs can mitigate this, as shown in some high-income countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 73,
        "page_label": "69",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In 2024, an estimated 168,000 premature deaths resulted from type 1 diabetes (T1D), with significant regional variations.  Alarmingly, 30,000 deaths involved undiagnosed individuals under 25, succumbing within a year of symptom onset due to misdiagnosis and delayed treatment.  Educational initiatives are crucial to improve early diagnosis and reduce mortality.",
        "summary_ur": "2024 witnessed 168,000 premature deaths from type 1 diabetes (T1D) globally.  A significant portion (30,000) were undiagnosed individuals under 25, succumbing within a year of symptom onset. Misdiagnosis as other illnesses contributed heavily to this mortality.  Education and awareness programs can mitigate this, as shown in some high-income countries."
      }
    },
    {
      "text": "The T1D Index reveals a significant impact of type 1 diabetes (T1D), estimating 4 million premature deaths by 2024.  While community initiatives improve outcomes in some areas, knowledge gaps remain, particularly concerning adult T1D incidence and mortality, and differentiating it from type 2 diabetes.  Further research is needed. The T1D Index reveals a significant impact of type 1 diabetes (T1D), estimating 4 million premature deaths by 2024.  Education initiatives reduce ketoacidosis in wealthier nations but improving diagnosis in low-income countries is crucial.  Further research is needed on adult T1D incidence and differentiation from type 2 diabetes.  Complete data is available at www.t1dindex.org.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 73,
        "page_label": "69",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The T1D Index reveals a significant impact of type 1 diabetes (T1D), estimating 4 million premature deaths by 2024.  While community initiatives improve outcomes in some areas, knowledge gaps remain, particularly concerning adult T1D incidence and mortality, and differentiating it from type 2 diabetes.  Further research is needed.",
        "summary_ur": "The T1D Index reveals a significant impact of type 1 diabetes (T1D), estimating 4 million premature deaths by 2024.  Education initiatives reduce ketoacidosis in wealthier nations but improving diagnosis in low-income countries is crucial.  Further research is needed on adult T1D incidence and differentiation from type 2 diabetes.  Complete data is available at www.t1dindex.org."
      }
    },
    {
      "text": "These references cite studies on diabetes prevalence, healthcare system performance in managing diabetes in low- and middle-income countries, the economic burden of diabetes, and global diabetes diagnosis variations.  They utilize data from sources like the IDF Diabetes Atlas and the Lancet Commission on Diabetes. These sources detail the global diabetes burden.  Studies highlight the health system challenges in managing diabetes across low- and middle-income countries, emphasizing the significant economic impact of both diagnosed and undiagnosed cases.  Data reveals increasing prevalence and calls for improved data-driven care.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 74,
        "page_label": "70",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These references cite studies on diabetes prevalence, healthcare system performance in managing diabetes in low- and middle-income countries, the economic burden of diabetes, and global diabetes diagnosis variations.  They utilize data from sources like the IDF Diabetes Atlas and the Lancet Commission on Diabetes.",
        "summary_ur": "These sources detail the global diabetes burden.  Studies highlight the health system challenges in managing diabetes across low- and middle-income countries, emphasizing the significant economic impact of both diagnosed and undiagnosed cases.  Data reveals increasing prevalence and calls for improved data-driven care."
      }
    },
    {
      "text": "This 2022 New York revision cites several studies (2012-2023) on the global economic burden and varying prevalence of diabetes diagnosis using fasting glucose and HbA1c.  Sources include the NCD-RisC Collaboration, the American Diabetes Association, and multiple editions of the International Diabetes Federation's Diabetes Atlas. This 2022 New York revision cites studies (2012-2023) from the NCD-RisC Collaboration, the American Diabetes Association, and the International Diabetes Federation.  These sources detail global diabetes prevalence variations,  the substantial economic burden of diabetes in the US, Netherlands, and China, and illustrate the disease's escalating global impact.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 74,
        "page_label": "70",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This 2022 New York revision cites several studies (2012-2023) on the global economic burden and varying prevalence of diabetes diagnosis using fasting glucose and HbA1c.  Sources include the NCD-RisC Collaboration, the American Diabetes Association, and multiple editions of the International Diabetes Federation's Diabetes Atlas.",
        "summary_ur": "This 2022 New York revision cites studies (2012-2023) from the NCD-RisC Collaboration, the American Diabetes Association, and the International Diabetes Federation.  These sources detail global diabetes prevalence variations,  the substantial economic burden of diabetes in the US, Netherlands, and China, and illustrate the disease's escalating global impact."
      }
    },
    {
      "text": "The provided text lists several publications, primarily editions of the International Diabetes Federation (IDF) Diabetes Atlas (2009-2015), along with related research articles (2022-2025) focusing on global type 1 diabetes prevalence, incidence, mortality, and projections.  These sources offer data and modeling related to the global burden of type 1 diabetes. The provided text lists several editions of the International Diabetes Federation (IDF) Diabetes Atlas (2009-2015) and related research articles (2022-2025) on type 1 diabetes global prevalence, incidence, and mortality.  These sources project future trends and discuss data limitations in assessing type 1 diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 74,
        "page_label": "70",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The provided text lists several publications, primarily editions of the International Diabetes Federation (IDF) Diabetes Atlas (2009-2015), along with related research articles (2022-2025) focusing on global type 1 diabetes prevalence, incidence, mortality, and projections.  These sources offer data and modeling related to the global burden of type 1 diabetes.",
        "summary_ur": "The provided text lists several editions of the International Diabetes Federation (IDF) Diabetes Atlas (2009-2015) and related research articles (2022-2025) on type 1 diabetes global prevalence, incidence, and mortality.  These sources project future trends and discuss data limitations in assessing type 1 diabetes."
      }
    },
    {
      "text": "Several studies (Ogle et al., 2016; Cherubini et al., 2021; Sandy et al., 2021; Sagna et al., 2024; Tomic et al.) cited in the provided text analyze the epidemiology, incidence, prevalence, and mortality of type 1 diabetes in children and youth,  using data from sources like the International Diabetes Federation Atlas.  The studies highlight geographic variations and the effectiveness of preventative measures. Several studies (Ogle et al., 2016; Cherubini et al., 2021; Sandy et al., 2021; Sagna et al., 2024; Tomic et al.) cited in the provided text analyze the epidemiology, incidence, prevalence, and mortality of type 1 diabetes in children and youth, particularly in Africa (Mali, Burkina Faso), using data from the IDF Atlas and T1D Index.  The research highlights the need for improved diabetes care and prevention strategies.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 74,
        "page_label": "70",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies (Ogle et al., 2016; Cherubini et al., 2021; Sandy et al., 2021; Sagna et al., 2024; Tomic et al.) cited in the provided text analyze the epidemiology, incidence, prevalence, and mortality of type 1 diabetes in children and youth,  using data from sources like the International Diabetes Federation Atlas.  The studies highlight geographic variations and the effectiveness of preventative measures.",
        "summary_ur": "Several studies (Ogle et al., 2016; Cherubini et al., 2021; Sandy et al., 2021; Sagna et al., 2024; Tomic et al.) cited in the provided text analyze the epidemiology, incidence, prevalence, and mortality of type 1 diabetes in children and youth, particularly in Africa (Mali, Burkina Faso), using data from the IDF Atlas and T1D Index.  The research highlights the need for improved diabetes care and prevention strategies."
      }
    },
    {
      "text": "These citations refer to research articles and a report on diabetes, specifically focusing on type 1 diabetes in older adults (Tomic et al., 2025; Leslie et al., 2021) and its epidemiology (Faso, 2013-2022).  The IDF Diabetes Atlas (2025) provides further context on diabetes prevalence. The provided text cites several research articles (Faso 2013-2022, Tomic et al. 2025, Leslie et al. 2021) and the IDF Diabetes Atlas (2025) concerning the epidemiology and understanding of type 1 diabetes, particularly in older adults and adult-onset cases.  These sources address prevalence, challenges, and current knowledge of the disease.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 74,
        "page_label": "70",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations refer to research articles and a report on diabetes, specifically focusing on type 1 diabetes in older adults (Tomic et al., 2025; Leslie et al., 2021) and its epidemiology (Faso, 2013-2022).  The IDF Diabetes Atlas (2025) provides further context on diabetes prevalence.",
        "summary_ur": "The provided text cites several research articles (Faso 2013-2022, Tomic et al. 2025, Leslie et al. 2021) and the IDF Diabetes Atlas (2025) concerning the epidemiology and understanding of type 1 diabetes, particularly in older adults and adult-onset cases.  These sources address prevalence, challenges, and current knowledge of the disease."
      }
    },
    {
      "text": "This text is not legal text; it's a table of contents or index referencing sections of the IDF Diabetes Atlas 11th Edition (2025), showing page numbers for diabetes information by region (Africa, Europe, Middle East/North Africa, North America/Caribbean, South/Central America, Southeast Asia, Western Pacific) and a case study on type 1 diabetes in India. This text is not legal text; it's a table of contents or index referencing sections of the IDF Diabetes Atlas, specifically focusing on diabetes prevalence data by region (Africa, Europe, Middle East/North Africa, North America/Caribbean, South/Central America, South-East Asia, Western Pacific) and including a mention of a personal story.  No legal issues are presented.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 75,
        "page_label": "71",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text is not legal text; it's a table of contents or index referencing sections of the IDF Diabetes Atlas 11th Edition (2025), showing page numbers for diabetes information by region (Africa, Europe, Middle East/North Africa, North America/Caribbean, South/Central America, Southeast Asia, Western Pacific) and a case study on type 1 diabetes in India.",
        "summary_ur": "This text is not legal text; it's a table of contents or index referencing sections of the IDF Diabetes Atlas, specifically focusing on diabetes prevalence data by region (Africa, Europe, Middle East/North Africa, North America/Caribbean, South/Central America, South-East Asia, Western Pacific) and including a mention of a personal story.  No legal issues are presented."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th Edition (2025) reveals stark regional disparities in diabetes prevalence and costs.  Africa faces the largest percentage increase in cases (142% by 2050), while the Middle East and North Africa has the highest proportion of adults with diabetes (1 in 6).  The Western Pacific region has the highest number of cases (215 million), and North America/Caribbean the highest expenditure ($439 billion).  Significant undiagnosed cases exist in several regions, highlighting the need for improved healthcare access and management. The IDF Diabetes Atlas (2025) reveals alarming trends:  Africa faces a 142% diabetes increase by 2050; the Middle East/North Africa has the highest prevalence (1 in 6 adults); North America/Caribbean has the highest expenditure ($439 billion); South/Central America has high undiagnosed rates (30.4%); South-East Asia shows high hyperglycaemia in pregnancy; and the Western Pacific has the largest number of adults with diabetes (215 million).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 76,
        "page_label": "72",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th Edition (2025) reveals stark regional disparities in diabetes prevalence and costs.  Africa faces the largest percentage increase in cases (142% by 2050), while the Middle East and North Africa has the highest proportion of adults with diabetes (1 in 6).  The Western Pacific region has the highest number of cases (215 million), and North America/Caribbean the highest expenditure ($439 billion).  Significant undiagnosed cases exist in several regions, highlighting the need for improved healthcare access and management.",
        "summary_ur": "The IDF Diabetes Atlas (2025) reveals alarming trends:  Africa faces a 142% diabetes increase by 2050; the Middle East/North Africa has the highest prevalence (1 in 6 adults); North America/Caribbean has the highest expenditure ($439 billion); South/Central America has high undiagnosed rates (30.4%); South-East Asia shows high hyperglycaemia in pregnancy; and the Western Pacific has the largest number of adults with diabetes (215 million)."
      }
    },
    {
      "text": "The IDF Diabetes Atlas estimates a 142% increase in diabetes cases in Sub-Saharan Africa by 2050, reaching 60 million.  This is despite a relatively low prevalence (5%).  Data scarcity hinders accurate projections; only three countries had recent studies.  The region also faces the highest projected increase in impaired glucose tolerance and fasting glucose, and a staggering 72.6% of cases remain undiagnosed. Sub-Saharan Africa's diabetes data is scarce; only a third of countries provided sufficient information.  Despite a relatively low prevalence (5%), a 142% increase in diabetes cases is projected by 2050, reaching 60 million.  The region also faces the largest projected rise in impaired glucose tolerance and impaired fasting glucose, with alarmingly high undiagnosed rates (72.6%).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 77,
        "page_label": "73",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas estimates a 142% increase in diabetes cases in Sub-Saharan Africa by 2050, reaching 60 million.  This is despite a relatively low prevalence (5%).  Data scarcity hinders accurate projections; only three countries had recent studies.  The region also faces the highest projected increase in impaired glucose tolerance and fasting glucose, and a staggering 72.6% of cases remain undiagnosed.",
        "summary_ur": "Sub-Saharan Africa's diabetes data is scarce; only a third of countries provided sufficient information.  Despite a relatively low prevalence (5%), a 142% increase in diabetes cases is projected by 2050, reaching 60 million.  The region also faces the largest projected rise in impaired glucose tolerance and impaired fasting glucose, with alarmingly high undiagnosed rates (72.6%)."
      }
    },
    {
      "text": "The IDF Africa Region shows a drastically high prevalence of undiagnosed diabetes (72.6%), with a 134-138% increase in cases.  Despite this, diabetes care investment is extremely low at only 1% of the global total, despite the region having 11.4% of the world's diabetic population. The 2024 IDF Diabetes Atlas reveals a stark reality:  Africa has the highest undiagnosed diabetes rate (72.6%),  a drastically increasing prevalence (134-138% increase), yet receives minimal investment in diabetes care (1% of global spending).  This disparity is critical given Africa's substantial diabetic population (11.4% of the global total).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 77,
        "page_label": "73",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Africa Region shows a drastically high prevalence of undiagnosed diabetes (72.6%), with a 134-138% increase in cases.  Despite this, diabetes care investment is extremely low at only 1% of the global total, despite the region having 11.4% of the world's diabetic population.",
        "summary_ur": "The 2024 IDF Diabetes Atlas reveals a stark reality:  Africa has the highest undiagnosed diabetes rate (72.6%),  a drastically increasing prevalence (134-138% increase), yet receives minimal investment in diabetes care (1% of global spending).  This disparity is critical given Africa's substantial diabetic population (11.4% of the global total)."
      }
    },
    {
      "text": "This data projects a significant increase in diabetes prevalence and related healthcare costs between 2024 and 2050.  The adult population (20-79 years) with diabetes is expected to rise from 25 million to 60 million,  with a corresponding increase in healthcare expenditure from $10 billion to $18 billion.  The number of people with impaired glucose tolerance will also substantially increase. The provided text shows projected increases in diabetes prevalence and related healthcare costs from 2024 to 2050.  Diabetes cases are expected to nearly triple, reaching 60 million, with a substantial rise in healthcare expenditure to $18 billion.  The number of people with impaired glucose tolerance will also significantly increase.  Undiagnosed diabetes remains a major concern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 78,
        "page_label": "74",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data projects a significant increase in diabetes prevalence and related healthcare costs between 2024 and 2050.  The adult population (20-79 years) with diabetes is expected to rise from 25 million to 60 million,  with a corresponding increase in healthcare expenditure from $10 billion to $18 billion.  The number of people with impaired glucose tolerance will also substantially increase.",
        "summary_ur": "The provided text shows projected increases in diabetes prevalence and related healthcare costs from 2024 to 2050.  Diabetes cases are expected to nearly triple, reaching 60 million, with a substantial rise in healthcare expenditure to $18 billion.  The number of people with impaired glucose tolerance will also significantly increase.  Undiagnosed diabetes remains a major concern."
      }
    },
    {
      "text": "The text presents diabetes statistics, showing 352,000 people with type 1 diabetes and projecting a 142% increase in adult diabetes cases (to 60 million) by 2050 in the region.  Nigeria, Tanzania, and the Democratic Republic of Congo are projected to have the highest number of diabetes cases by 2050.  A concerning 73% of adults with diabetes remain undiagnosed, and diabetes caused 216,000 deaths in 2024. The provided text details diabetes statistics.  In 2024, 352,000 individuals had type 1 diabetes.  By 2050, the adult diabetes count is projected to surge 142% to 60 million, with a concerning 73% remaining undiagnosed.  Nigeria, Tanzania, Congo, South Africa, and Ethiopia have the highest projected diabetes cases.  High age-standardized prevalence is also anticipated in several African nations.  Diabetes caused 216,000 deaths in 2024.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 78,
        "page_label": "74",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text presents diabetes statistics, showing 352,000 people with type 1 diabetes and projecting a 142% increase in adult diabetes cases (to 60 million) by 2050 in the region.  Nigeria, Tanzania, and the Democratic Republic of Congo are projected to have the highest number of diabetes cases by 2050.  A concerning 73% of adults with diabetes remain undiagnosed, and diabetes caused 216,000 deaths in 2024.",
        "summary_ur": "The provided text details diabetes statistics.  In 2024, 352,000 individuals had type 1 diabetes.  By 2050, the adult diabetes count is projected to surge 142% to 60 million, with a concerning 73% remaining undiagnosed.  Nigeria, Tanzania, Congo, South Africa, and Ethiopia have the highest projected diabetes cases.  High age-standardized prevalence is also anticipated in several African nations.  Diabetes caused 216,000 deaths in 2024."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th Edition (2025) reveals alarming statistics:  73% of African adults with diabetes are undiagnosed\u2014the highest rate globally.  Diabetes caused 216,000 deaths in 2024, yet diabetes-related expenditure was only 1% of the global total.  Hyperglycemia during pregnancy affected 1 in 7 live births. The IDF Diabetes Atlas (2025) reveals alarming statistics for Africa:  73% of adults with diabetes are undiagnosed\u2014the highest rate globally.  Diabetes caused 216,000 deaths in 2024, yet diabetes-related expenditure remains low at 1% of the global total.  Hyperglycaemia during pregnancy affects 1 in 7 live births.  The situation demands urgent attention.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 78,
        "page_label": "74",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th Edition (2025) reveals alarming statistics:  73% of African adults with diabetes are undiagnosed\u2014the highest rate globally.  Diabetes caused 216,000 deaths in 2024, yet diabetes-related expenditure was only 1% of the global total.  Hyperglycemia during pregnancy affected 1 in 7 live births.",
        "summary_ur": "The IDF Diabetes Atlas (2025) reveals alarming statistics for Africa:  73% of adults with diabetes are undiagnosed\u2014the highest rate globally.  Diabetes caused 216,000 deaths in 2024, yet diabetes-related expenditure remains low at 1% of the global total.  Hyperglycaemia during pregnancy affects 1 in 7 live births.  The situation demands urgent attention."
      }
    },
    {
      "text": "A study of 60 European countries estimates 9.8% prevalence of diabetes (66 million people) in 2024, projected to increase 10% by 2050.  Data from 41 countries showed the EUR region has the highest number of type 1 diabetes cases (2.7 million), with 15% being under 20.  Diabetes costs in the region totaled an estimated $193 billion in 2024. The provided text is not legal text; it's a statistical report on diabetes prevalence in the European region.  It shows a 9.8% prevalence (66 million people) in 2024, projected to rise 10% by 2050.  Data from 41 countries were used, with significant spending ($193 billion) on diabetes care.  Type 1 diabetes affects 2.7 million, 15% being under 20.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 79,
        "page_label": "75",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "A study of 60 European countries estimates 9.8% prevalence of diabetes (66 million people) in 2024, projected to increase 10% by 2050.  Data from 41 countries showed the EUR region has the highest number of type 1 diabetes cases (2.7 million), with 15% being under 20.  Diabetes costs in the region totaled an estimated $193 billion in 2024.",
        "summary_ur": "The provided text is not legal text; it's a statistical report on diabetes prevalence in the European region.  It shows a 9.8% prevalence (66 million people) in 2024, projected to rise 10% by 2050.  Data from 41 countries were used, with significant spending ($193 billion) on diabetes care.  Type 1 diabetes affects 2.7 million, 15% being under 20."
      }
    },
    {
      "text": "The 2024 IDF Diabetes Atlas reports 2.7 million cases of diabetes in the European region, 15% affecting those under 20.  Treatment costs reached $193 billion (19% of the global total), with a high average cost per patient ($2,951).  Prevalence maps show significant variation across the region. The provided text is not legal text; it's a statistical summary about diabetes in Europe.  In 2024, the region spent an estimated $193 billion on diabetes,  second highest per capita cost globally.  Prevalence is highest in the 20-79 age group, with a significant portion (419,000) under 20 years old.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 79,
        "page_label": "75",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2024 IDF Diabetes Atlas reports 2.7 million cases of diabetes in the European region, 15% affecting those under 20.  Treatment costs reached $193 billion (19% of the global total), with a high average cost per patient ($2,951).  Prevalence maps show significant variation across the region.",
        "summary_ur": "The provided text is not legal text; it's a statistical summary about diabetes in Europe.  In 2024, the region spent an estimated $193 billion on diabetes,  second highest per capita cost globally.  Prevalence is highest in the 20-79 age group, with a significant portion (419,000) under 20 years old."
      }
    },
    {
      "text": "This data projects a rise in diabetes prevalence and cases from 2024 to 2050, despite a slight decrease in the adult population.  While total healthcare expenditure on diabetes is projected to decrease, the number of people with diabetes will increase from 66 million to 72 million, with a concerningly high proportion remaining undiagnosed. This data projects a rise in diabetes prevalence and cases from 2024 to 2050, despite a slight decrease in the adult population.  While total healthcare expenditure on diabetes is expected to decrease, the number of people with diabetes will increase to 72 million, with a significant portion remaining undiagnosed.  Type 1 diabetes cases remain relatively stable at 2.7 million.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 80,
        "page_label": "76",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data projects a rise in diabetes prevalence and cases from 2024 to 2050, despite a slight decrease in the adult population.  While total healthcare expenditure on diabetes is projected to decrease, the number of people with diabetes will increase from 66 million to 72 million, with a concerningly high proportion remaining undiagnosed.",
        "summary_ur": "This data projects a rise in diabetes prevalence and cases from 2024 to 2050, despite a slight decrease in the adult population.  While total healthcare expenditure on diabetes is expected to decrease, the number of people with diabetes will increase to 72 million, with a significant portion remaining undiagnosed.  Type 1 diabetes cases remain relatively stable at 2.7 million."
      }
    },
    {
      "text": "The text highlights a significant diabetes burden in a specific region.  Key statistics include 66 million adults with diabetes (34% undiagnosed), 2.7 million with type 1, and 1 in 7 live births affected by hyperglycemia.  The region accounts for 19% of global diabetes-related expenditure ($193 billion).  Turkey, Russia, Germany, Italy, and Spain have the highest projected numbers of people with diabetes by 2050. The text presents diabetes statistics.  One in ten adults (66 million) have diabetes, with 34% undiagnosed.  Type 1 diabetes affects 2.7 million, mostly in Turkey, Russia, Germany, Italy, and Spain.  The region's diabetes-related expenditure is USD 193 billion (19% of global spending), and the average cost per person is USD 2,951.  Hyperglycemia in pregnancy affects one in seven live births.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 80,
        "page_label": "76",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text highlights a significant diabetes burden in a specific region.  Key statistics include 66 million adults with diabetes (34% undiagnosed), 2.7 million with type 1, and 1 in 7 live births affected by hyperglycemia.  The region accounts for 19% of global diabetes-related expenditure ($193 billion).  Turkey, Russia, Germany, Italy, and Spain have the highest projected numbers of people with diabetes by 2050.",
        "summary_ur": "The text presents diabetes statistics.  One in ten adults (66 million) have diabetes, with 34% undiagnosed.  Type 1 diabetes affects 2.7 million, mostly in Turkey, Russia, Germany, Italy, and Spain.  The region's diabetes-related expenditure is USD 193 billion (19% of global spending), and the average cost per person is USD 2,951.  Hyperglycemia in pregnancy affects one in seven live births."
      }
    },
    {
      "text": "The 11th edition of the IDF Diabetes Atlas (2025) reports that diabetes costs account for 19% of global healthcare expenditure, totaling $193 billion.  The region cited has the second-highest average cost per diabetic person ($2,951). The text states that global diabetes expenditure is $193 billion, 19% of the total.  The region's average cost per diabetic (20-79 years) is the second highest globally at $2951.  This data comes from the IDF Diabetes Atlas 11th Edition (2025).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 80,
        "page_label": "76",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition of the IDF Diabetes Atlas (2025) reports that diabetes costs account for 19% of global healthcare expenditure, totaling $193 billion.  The region cited has the second-highest average cost per diabetic person ($2,951).",
        "summary_ur": "The text states that global diabetes expenditure is $193 billion, 19% of the total.  The region's average cost per diabetic (20-79 years) is the second highest globally at $2951.  This data comes from the IDF Diabetes Atlas 11th Edition (2025)."
      }
    },
    {
      "text": "The IDF's 2024 report estimates a 17.6% diabetes prevalence in the MENA region, the highest globally, with a projected 163 million cases by 2050 (a 92% increase).  The region also has the highest percentage of diabetes-related deaths among working-age adults (21.6%), yet only 3.4% of global diabetes spending is allocated to the MENA region. The Middle East and North Africa (MENA) region has the world's highest diabetes prevalence (17.6%), projected to reach 163 million by 2050.  Despite this, diabetes-related spending is low (3.4% of global investment), and diabetes-related deaths among working-age adults are disproportionately high (21.6%).  Data from 18 countries informed these estimates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 81,
        "page_label": "77",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF's 2024 report estimates a 17.6% diabetes prevalence in the MENA region, the highest globally, with a projected 163 million cases by 2050 (a 92% increase).  The region also has the highest percentage of diabetes-related deaths among working-age adults (21.6%), yet only 3.4% of global diabetes spending is allocated to the MENA region.",
        "summary_ur": "The Middle East and North Africa (MENA) region has the world's highest diabetes prevalence (17.6%), projected to reach 163 million by 2050.  Despite this, diabetes-related spending is low (3.4% of global investment), and diabetes-related deaths among working-age adults are disproportionately high (21.6%).  Data from 18 countries informed these estimates."
      }
    },
    {
      "text": "The Middle East and North Africa region, despite having 14.4% of the global diabetic population, received only 3.4% (35 billion USD) of global diabetes investment.  Figures show a high and increasing prevalence of diabetes across various age groups and genders in the region. The Middle East and North Africa region, despite housing 14.4% of global diabetes cases, received only 3.4% (35 billion USD) of worldwide diabetes investment.  Figures show a high and rising prevalence of diabetes across all age groups and both genders in the region.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 81,
        "page_label": "77",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The Middle East and North Africa region, despite having 14.4% of the global diabetic population, received only 3.4% (35 billion USD) of global diabetes investment.  Figures show a high and increasing prevalence of diabetes across various age groups and genders in the region.",
        "summary_ur": "The Middle East and North Africa region, despite housing 14.4% of global diabetes cases, received only 3.4% (35 billion USD) of worldwide diabetes investment.  Figures show a high and rising prevalence of diabetes across all age groups and both genders in the region."
      }
    },
    {
      "text": "The text highlights a severe diabetes crisis.  Currently, 85 million adults (1 in 6) in the region have diabetes, with a projected 92% increase by 2050.  One-third of cases are undiagnosed, and the prevalence is highest among older adults.  The annual healthcare expenditure is USD 35 billion, projected to reach USD 50 billion by 2050.  High rates of gestational diabetes are also noted. The text details a dire diabetes situation.  One in six adults (85 million) currently have diabetes, projected to rise 92% by 2050.  A third are undiagnosed, and older adults are disproportionately affected.  The region's healthcare expenditure on diabetes is USD 35 billion, expected to increase to USD 50 billion.  High rates of gestational diabetes are also noted.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 82,
        "page_label": "78",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text highlights a severe diabetes crisis.  Currently, 85 million adults (1 in 6) in the region have diabetes, with a projected 92% increase by 2050.  One-third of cases are undiagnosed, and the prevalence is highest among older adults.  The annual healthcare expenditure is USD 35 billion, projected to reach USD 50 billion by 2050.  High rates of gestational diabetes are also noted.",
        "summary_ur": "The text details a dire diabetes situation.  One in six adults (85 million) currently have diabetes, projected to rise 92% by 2050.  A third are undiagnosed, and older adults are disproportionately affected.  The region's healthcare expenditure on diabetes is USD 35 billion, expected to increase to USD 50 billion.  High rates of gestational diabetes are also noted."
      }
    },
    {
      "text": "This data projects a substantial increase in diabetes-related healthcare costs (from $35B to $50B) and the number of individuals with diabetes and impaired glucose tolerance between 2024 and 2050.  Pakistan, Egypt, Iran, Saudi Arabia, and Algeria will bear a disproportionate burden, experiencing significant increases in both the number of cases and prevalence rates.  A large percentage of diabetes cases remain undiagnosed. The provided text shows a projection of a substantial increase in diabetes and impaired glucose tolerance cases (20-79 years) between 2024 and 2050, leading to a massive rise in healthcare costs (from $35b to $50b USD).  Pakistan, Egypt, Iran, Saudi Arabia, and Algeria will bear the brunt of this increase in both numbers and prevalence.  Undiagnosed diabetes is also a significant concern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 82,
        "page_label": "78",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data projects a substantial increase in diabetes-related healthcare costs (from $35B to $50B) and the number of individuals with diabetes and impaired glucose tolerance between 2024 and 2050.  Pakistan, Egypt, Iran, Saudi Arabia, and Algeria will bear a disproportionate burden, experiencing significant increases in both the number of cases and prevalence rates.  A large percentage of diabetes cases remain undiagnosed.",
        "summary_ur": "The provided text shows a projection of a substantial increase in diabetes and impaired glucose tolerance cases (20-79 years) between 2024 and 2050, leading to a massive rise in healthcare costs (from $35b to $50b USD).  Pakistan, Egypt, Iran, Saudi Arabia, and Algeria will bear the brunt of this increase in both numbers and prevalence.  Undiagnosed diabetes is also a significant concern."
      }
    },
    {
      "text": "The top five countries with the highest age-standardized prevalence of diabetes (20-79 years) are Pakistan, Kuwait, Qatar, Saudi Arabia, and Egypt.  The data, from the IDF Diabetes Atlas 11th Edition, shows millions affected and prevalence rates exceeding 22% in each of these nations. The provided text shows that Saudi Arabia and Algeria have the highest number of people with diabetes (5.3m and 4.8m respectively, ages 20-79).  Pakistan, Kuwait, Qatar, Saudi Arabia, and Egypt have the highest age-standardized prevalence rates of diabetes (31.4% to 22.4%).  Data is from the IDF Diabetes Atlas 11th Edition (2025).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 82,
        "page_label": "78",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The top five countries with the highest age-standardized prevalence of diabetes (20-79 years) are Pakistan, Kuwait, Qatar, Saudi Arabia, and Egypt.  The data, from the IDF Diabetes Atlas 11th Edition, shows millions affected and prevalence rates exceeding 22% in each of these nations.",
        "summary_ur": "The provided text shows that Saudi Arabia and Algeria have the highest number of people with diabetes (5.3m and 4.8m respectively, ages 20-79).  Pakistan, Kuwait, Qatar, Saudi Arabia, and Egypt have the highest age-standardized prevalence rates of diabetes (31.4% to 22.4%).  Data is from the IDF Diabetes Atlas 11th Edition (2025)."
      }
    },
    {
      "text": "The International Diabetes Federation (IDF) reports that North America and the Caribbean have the second highest diabetes prevalence globally (15.1%), projected to reach 68 million by 2050.  This region also has the second highest number of type 1 diabetes cases and the highest proportion of diabetes-related mortality (21.4%). The International Diabetes Federation (IDF) reports North America and the Caribbean have the second highest diabetes prevalence (15.1%), projected to reach 68 million by 2050.  This region also has the second-highest number of type 1 diabetes cases and the highest proportion of diabetes-related deaths (21.4% of all deaths), totaling 526,000.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 83,
        "page_label": "79",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The International Diabetes Federation (IDF) reports that North America and the Caribbean have the second highest diabetes prevalence globally (15.1%), projected to reach 68 million by 2050.  This region also has the second highest number of type 1 diabetes cases and the highest proportion of diabetes-related mortality (21.4%).",
        "summary_ur": "The International Diabetes Federation (IDF) reports North America and the Caribbean have the second highest diabetes prevalence (15.1%), projected to reach 68 million by 2050.  This region also has the second-highest number of type 1 diabetes cases and the highest proportion of diabetes-related deaths (21.4% of all deaths), totaling 526,000."
      }
    },
    {
      "text": "The North America and Caribbean region bears a heavy diabetes burden, experiencing the second-highest diabetes-related death toll (526,000) and the highest associated healthcare expenditure ($439 billion, 43% of the global total).  The average cost per diabetic person (ages 20-79) is $7,811.  Prevalence is significantly high and increases with age. The North America and Caribbean region bears a heavy diabetes burden.  It shows high diabetes-related mortality (second highest globally),  enormous expenditure (43% of global costs), and high average per-person costs.  Prevalence is significant and increases with age, affecting both men and women.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 83,
        "page_label": "79",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The North America and Caribbean region bears a heavy diabetes burden, experiencing the second-highest diabetes-related death toll (526,000) and the highest associated healthcare expenditure ($439 billion, 43% of the global total).  The average cost per diabetic person (ages 20-79) is $7,811.  Prevalence is significantly high and increases with age.",
        "summary_ur": "The North America and Caribbean region bears a heavy diabetes burden.  It shows high diabetes-related mortality (second highest globally),  enormous expenditure (43% of global costs), and high average per-person costs.  Prevalence is significant and increases with age, affecting both men and women."
      }
    },
    {
      "text": "The text highlights a concerningly high prevalence of diabetes in a specific region.  One in seven adults (56 million) have diabetes, representing 15.1% of the adult population (projected to rise to 16.4% by 2050). This region bears the highest global expenditure on diabetes-related care (USD 439 billion) and mortality rate (21.4%), with a significant portion of cases undiagnosed.  High rates of type 1 diabetes and gestational diabetes are also reported. The Americas bear a heavy diabetes burden:  1 in 7 adults (56 million) have diabetes,  the highest global expenditure ($439 billion) and mortality rate (21.4%).  One-third of cases are undiagnosed, and  hyperglycaemia in pregnancy affects 1 in 4 live births.  The projected numbers are set to rise by 2050.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 84,
        "page_label": "80",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text highlights a concerningly high prevalence of diabetes in a specific region.  One in seven adults (56 million) have diabetes, representing 15.1% of the adult population (projected to rise to 16.4% by 2050). This region bears the highest global expenditure on diabetes-related care (USD 439 billion) and mortality rate (21.4%), with a significant portion of cases undiagnosed.  High rates of type 1 diabetes and gestational diabetes are also reported.",
        "summary_ur": "The Americas bear a heavy diabetes burden:  1 in 7 adults (56 million) have diabetes,  the highest global expenditure ($439 billion) and mortality rate (21.4%).  One-third of cases are undiagnosed, and  hyperglycaemia in pregnancy affects 1 in 4 live births.  The projected numbers are set to rise by 2050."
      }
    },
    {
      "text": "Between 2024 and 2050, the number of people with diabetes (ages 20-79) is projected to increase from 56 million to 68 million,  with a rise in prevalence and healthcare expenditure.  The number of deaths attributed to diabetes is also expected to remain substantial.  A significant portion of cases remain undiagnosed.  The US and Mexico will experience the largest increases in diabetes cases. Diabetes prevalence is rising.  Between 2024 and 2050, the number of people with diabetes (ages 20-79) increased from 56 million to 68 million, with a significant rise in healthcare costs.  Undiagnosed cases are also substantial (16 million).  The US and Mexico show the largest increases in affected individuals.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 84,
        "page_label": "80",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Between 2024 and 2050, the number of people with diabetes (ages 20-79) is projected to increase from 56 million to 68 million,  with a rise in prevalence and healthcare expenditure.  The number of deaths attributed to diabetes is also expected to remain substantial.  A significant portion of cases remain undiagnosed.  The US and Mexico will experience the largest increases in diabetes cases.",
        "summary_ur": "Diabetes prevalence is rising.  Between 2024 and 2050, the number of people with diabetes (ages 20-79) increased from 56 million to 68 million, with a significant rise in healthcare costs.  Undiagnosed cases are also substantial (16 million).  The US and Mexico show the largest increases in affected individuals."
      }
    },
    {
      "text": "The 2025 IDF Diabetes Atlas projects a significant increase in diabetes cases (20-79 years) globally by 2050.  The top five countries with the highest number of cases in 2024 are the USA, Mexico, Canada, Haiti, and Jamaica.  Mexico, Guyana, Belize, St. Kitts and Nevis, and Suriname have the highest age-standardized prevalence rates. The 2025 IDF Diabetes Atlas projects a rise in type 1 diabetes cases.  The US, Mexico, Canada, Haiti, and Jamaica will have the highest number of cases by 2050.  Mexico, Guyana, Belize, St. Kitts and Nevis, and Suriname will have the highest age-standardized prevalence.  Millions will be affected.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 84,
        "page_label": "80",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2025 IDF Diabetes Atlas projects a significant increase in diabetes cases (20-79 years) globally by 2050.  The top five countries with the highest number of cases in 2024 are the USA, Mexico, Canada, Haiti, and Jamaica.  Mexico, Guyana, Belize, St. Kitts and Nevis, and Suriname have the highest age-standardized prevalence rates.",
        "summary_ur": "The 2025 IDF Diabetes Atlas projects a rise in type 1 diabetes cases.  The US, Mexico, Canada, Haiti, and Jamaica will have the highest number of cases by 2050.  Mexico, Guyana, Belize, St. Kitts and Nevis, and Suriname will have the highest age-standardized prevalence.  Millions will be affected."
      }
    },
    {
      "text": "The International Diabetes Federation (IDF) estimates a 46% increase in diabetes cases in South and Central America by 2050, reaching 52 million.  Prevalence will rise 23% to 12.3%.  In 2024, diabetes cost the region $81 billion USD, 8% of global expenditure.  Data from 15 countries informed these projections, with 5 having recent studies. The International Diabetes Federation (IDF) projects a 46% rise in diabetes cases in South and Central America by 2050, reaching 52 million.  Prevalence will increase by 23%, to 12.3%.  In 2024, diabetes cost the region $81 billion USD, 8% of global expenditure.  Data from 15 countries informed these estimates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 85,
        "page_label": "81",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The International Diabetes Federation (IDF) estimates a 46% increase in diabetes cases in South and Central America by 2050, reaching 52 million.  Prevalence will rise 23% to 12.3%.  In 2024, diabetes cost the region $81 billion USD, 8% of global expenditure.  Data from 15 countries informed these projections, with 5 having recent studies.",
        "summary_ur": "The International Diabetes Federation (IDF) projects a 46% rise in diabetes cases in South and Central America by 2050, reaching 52 million.  Prevalence will increase by 23%, to 12.3%.  In 2024, diabetes cost the region $81 billion USD, 8% of global expenditure.  Data from 15 countries informed these estimates."
      }
    },
    {
      "text": "Figure 4.5 from the IDF Diabetes Atlas 11th Edition (2025) shows the estimated prevalence of diabetes in Central America in 2024,  differentiated by age and sex.  Prevalence increases with age, and varies slightly between men and women across age groups.  Data ranges from below 6% to above 9%, depending on age and sex. The provided text is a chart, not legal text.  It shows the estimated prevalence of diabetes in Central America in 2024, categorized by age and sex.  Prevalence rates range from below 6% to over 9%, varying across age groups and genders.  No legal implications are present.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 85,
        "page_label": "81",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Figure 4.5 from the IDF Diabetes Atlas 11th Edition (2025) shows the estimated prevalence of diabetes in Central America in 2024,  differentiated by age and sex.  Prevalence increases with age, and varies slightly between men and women across age groups.  Data ranges from below 6% to above 9%, depending on age and sex.",
        "summary_ur": "The provided text is a chart, not legal text.  It shows the estimated prevalence of diabetes in Central America in 2024, categorized by age and sex.  Prevalence rates range from below 6% to over 9%, varying across age groups and genders.  No legal implications are present."
      }
    },
    {
      "text": "Diabetes affects 1 in 10 US adults (35 million in 2024),  projected to rise to 52 million by 2050.  One-third of cases are undiagnosed.  The disease caused 224,000 deaths and incurred $81 billion in healthcare costs in 2024.  Hyperglycemia during pregnancy affects 1 in 6 live births. The provided text details a concerning rise in diabetes prevalence.  Currently, 10% of adults (35 million) have diabetes,  a number projected to increase to 52 million by 2050.  This leads to 224,000 deaths and $81 billion in healthcare costs annually.  A significant portion of cases remain undiagnosed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 86,
        "page_label": "82",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes affects 1 in 10 US adults (35 million in 2024),  projected to rise to 52 million by 2050.  One-third of cases are undiagnosed.  The disease caused 224,000 deaths and incurred $81 billion in healthcare costs in 2024.  Hyperglycemia during pregnancy affects 1 in 6 live births.",
        "summary_ur": "The provided text details a concerning rise in diabetes prevalence.  Currently, 10% of adults (35 million) have diabetes,  a number projected to increase to 52 million by 2050.  This leads to 224,000 deaths and $81 billion in healthcare costs annually.  A significant portion of cases remain undiagnosed."
      }
    },
    {
      "text": "The provided data shows a projected increase in impaired glucose tolerance, impaired fasting glucose, and undiagnosed diabetes in a specific region between 2024 and 2050.  The number of people affected by these conditions, and specifically type 1 diabetes, is expected to rise significantly.  Brazil, Argentina, Colombia, Chile, and Venezuela are projected to have the highest number of diabetes cases, while the Dominican Republic, Argentina, and other Central American nations will have the highest age-standardized prevalence. The provided text shows projected increases in impaired glucose tolerance, impaired fasting glucose, and undiagnosed diabetes in a region between 2024 and 2050.  Numbers of affected individuals are projected to rise significantly, with Brazil, Argentina, Colombia, Chile, and Venezuela showing the highest projected numbers of people with diabetes.  The Dominican Republic, Argentina, Guatemala, El Salvador, and Chile are projected to have the highest age-standardized prevalence.  Spending is also expected to increase substantially.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 86,
        "page_label": "82",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The provided data shows a projected increase in impaired glucose tolerance, impaired fasting glucose, and undiagnosed diabetes in a specific region between 2024 and 2050.  The number of people affected by these conditions, and specifically type 1 diabetes, is expected to rise significantly.  Brazil, Argentina, Colombia, Chile, and Venezuela are projected to have the highest number of diabetes cases, while the Dominican Republic, Argentina, and other Central American nations will have the highest age-standardized prevalence.",
        "summary_ur": "The provided text shows projected increases in impaired glucose tolerance, impaired fasting glucose, and undiagnosed diabetes in a region between 2024 and 2050.  Numbers of affected individuals are projected to rise significantly, with Brazil, Argentina, Colombia, Chile, and Venezuela showing the highest projected numbers of people with diabetes.  The Dominican Republic, Argentina, Guatemala, El Salvador, and Chile are projected to have the highest age-standardized prevalence.  Spending is also expected to increase substantially."
      }
    },
    {
      "text": "The data shows the prevalence of diabetes (ages 20-79) in several Latin American countries.  The Dominican Republic had the highest percentage (17.6%-19.9%), followed by Argentina, Guatemala, El Salvador, and Chile, with prevalence ranging from 12.2% to 15.4%.  The figures are from the IDF Diabetes Atlas 11th Edition (2025). The provided text is not legal text but data from the IDF Diabetes Atlas.  It shows the prevalence of diabetes (ages 20-79) in several Latin American countries:  Dominican Republic (17.6-19.9%), Argentina (14.0-15.4%), Guatemala (13.2-13.8%), El Salvador (12.7-14.8%), and Chile (12.2-13.7%).  The figures represent a percentage of the population.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 86,
        "page_label": "82",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The data shows the prevalence of diabetes (ages 20-79) in several Latin American countries.  The Dominican Republic had the highest percentage (17.6%-19.9%), followed by Argentina, Guatemala, El Salvador, and Chile, with prevalence ranging from 12.2% to 15.4%.  The figures are from the IDF Diabetes Atlas 11th Edition (2025).",
        "summary_ur": "The provided text is not legal text but data from the IDF Diabetes Atlas.  It shows the prevalence of diabetes (ages 20-79) in several Latin American countries:  Dominican Republic (17.6-19.9%), Argentina (14.0-15.4%), Guatemala (13.2-13.8%), El Salvador (12.7-14.8%), and Chile (12.2-13.7%).  The figures represent a percentage of the population."
      }
    },
    {
      "text": "The IDF projects a 73% increase in diabetes cases in South-East Asia by 2050, reaching 185 million, with prevalence rising 36% to 13.2%.  A concerning 42.7% of cases remain undiagnosed, and hyperglycemia affects 27.8% of pregnancies.  Despite comprising 18.2% of global cases, the region only receives 1% of global diabetes spending ($12 billion). The IDF projects a 73% rise in diabetes cases in South-East Asia by 2050, reaching 185 million.  Prevalence will increase 36% to 13.2%, with a high 42.7% undiagnosed.  Hyperglycaemia in pregnancies is also alarmingly high at 27.8%.  Despite this, the region receives only 1% of global diabetes funding.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 87,
        "page_label": "83",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF projects a 73% increase in diabetes cases in South-East Asia by 2050, reaching 185 million, with prevalence rising 36% to 13.2%.  A concerning 42.7% of cases remain undiagnosed, and hyperglycemia affects 27.8% of pregnancies.  Despite comprising 18.2% of global cases, the region only receives 1% of global diabetes spending ($12 billion).",
        "summary_ur": "The IDF projects a 73% rise in diabetes cases in South-East Asia by 2050, reaching 185 million.  Prevalence will increase 36% to 13.2%, with a high 42.7% undiagnosed.  Hyperglycaemia in pregnancies is also alarmingly high at 27.8%.  Despite this, the region receives only 1% of global diabetes funding."
      }
    },
    {
      "text": "Despite the Southeast Asia region accounting for 18.2% of the global diabetic population, only $12 billion (1% of global spending) was allocated to diabetes care.  Data shows a significant prevalence of diabetes across various age groups and genders in the region. Despite the South-East Asia region having 18.2% of the world's diabetic population, only 12 billion USD (1% of global spending) was allocated to diabetes care.  This stark disparity highlights significant underfunding for a region with a substantial diabetes burden.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 87,
        "page_label": "83",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Despite the Southeast Asia region accounting for 18.2% of the global diabetic population, only $12 billion (1% of global spending) was allocated to diabetes care.  Data shows a significant prevalence of diabetes across various age groups and genders in the region.",
        "summary_ur": "Despite the South-East Asia region having 18.2% of the world's diabetic population, only 12 billion USD (1% of global spending) was allocated to diabetes care.  This stark disparity highlights significant underfunding for a region with a substantial diabetes burden."
      }
    },
    {
      "text": "India's diabetes burden is substantial, with 107 million adults (10%) affected in 2024, projected to rise to 185 million by 2050.  A concerning 43% remain undiagnosed, resulting in 374,000 diabetes-related deaths and USD 12 billion in healthcare expenditure.  Hyperglycemia during pregnancy impacts one-third of live births. India carries a heavy diabetes burden:  107 million adults (10%) have diabetes,  a number projected to rise 73% by 2050.  Almost half are undiagnosed, resulting in 374,000 deaths and USD 12 billion in healthcare costs in 2024.  Hyperglycemia during pregnancy affects one in three births.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 88,
        "page_label": "84",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "India's diabetes burden is substantial, with 107 million adults (10%) affected in 2024, projected to rise to 185 million by 2050.  A concerning 43% remain undiagnosed, resulting in 374,000 diabetes-related deaths and USD 12 billion in healthcare expenditure.  Hyperglycemia during pregnancy impacts one-third of live births.",
        "summary_ur": "India carries a heavy diabetes burden:  107 million adults (10%) have diabetes,  a number projected to rise 73% by 2050.  Almost half are undiagnosed, resulting in 374,000 deaths and USD 12 billion in healthcare costs in 2024.  Hyperglycemia during pregnancy affects one in three births."
      }
    },
    {
      "text": "This data shows a projected increase in diabetes prevalence and related healthcare costs from 2024 to 2050.  The number of people with diabetes (ages 20-79) is expected to rise from 106.9 million to 184.5 million, with a corresponding increase in deaths and healthcare expenditure.  India, Bangladesh, and other South Asian countries will bear a disproportionate burden.  A significant portion of cases remain undiagnosed. The provided text details a stark increase in diabetes prevalence and related costs projected from 2024 to 2050.  Millions more are expected to be diagnosed with diabetes and impaired glucose tolerance, significantly increasing healthcare expenditures.  India, Bangladesh, and other South Asian nations will bear the brunt of this rise.  Undiagnosed cases remain a substantial concern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 88,
        "page_label": "84",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data shows a projected increase in diabetes prevalence and related healthcare costs from 2024 to 2050.  The number of people with diabetes (ages 20-79) is expected to rise from 106.9 million to 184.5 million, with a corresponding increase in deaths and healthcare expenditure.  India, Bangladesh, and other South Asian countries will bear a disproportionate burden.  A significant portion of cases remain undiagnosed.",
        "summary_ur": "The provided text details a stark increase in diabetes prevalence and related costs projected from 2024 to 2050.  Millions more are expected to be diagnosed with diabetes and impaired glucose tolerance, significantly increasing healthcare expenditures.  India, Bangladesh, and other South Asian nations will bear the brunt of this rise.  Undiagnosed cases remain a substantial concern."
      }
    },
    {
      "text": "The IDF Diabetes Atlas 11th Edition (2025) shows a significant increase in the number and prevalence of diabetes (ages 20-79) across several Asian countries between 2021 and 2025.  India and Bangladesh experienced the largest increases in both numbers and prevalence.  Mauritius had the highest prevalence rates. The IDF Diabetes Atlas (2025) shows a high prevalence of diabetes (ages 20-79) in several South Asian nations.  India and Bangladesh have the most cases, with Mauritius showing the highest age-standardized prevalence.  Numbers are projected to increase significantly in all listed countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 88,
        "page_label": "84",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas 11th Edition (2025) shows a significant increase in the number and prevalence of diabetes (ages 20-79) across several Asian countries between 2021 and 2025.  India and Bangladesh experienced the largest increases in both numbers and prevalence.  Mauritius had the highest prevalence rates.",
        "summary_ur": "The IDF Diabetes Atlas (2025) shows a high prevalence of diabetes (ages 20-79) in several South Asian nations.  India and Bangladesh have the most cases, with Mauritius showing the highest age-standardized prevalence.  Numbers are projected to increase significantly in all listed countries."
      }
    },
    {
      "text": "The 2024 IDF Diabetes Atlas estimates that the Western Pacific region has the third highest diabetes prevalence globally (12.4%), accounting for 37% of global cases.  By 2050, a projected 18% increase will bring the total to 254 million, with prevalence rising to 14.7%.  A concerning 50% of cases remain undiagnosed, contributing to the region's highest diabetes-related death toll (1.2 million in 2024). The 2024 IDF Diabetes Atlas estimates reveal a concerning diabetes situation in the Western Pacific region.  Comprising 37% of global adult diabetes cases (12.4% prevalence), the region faces a projected 18% increase to 254 million cases by 2050.  A high 50% of cases remain undiagnosed, contributing to the region's leading 1.2 million diabetes-related deaths.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 89,
        "page_label": "85",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 2024 IDF Diabetes Atlas estimates that the Western Pacific region has the third highest diabetes prevalence globally (12.4%), accounting for 37% of global cases.  By 2050, a projected 18% increase will bring the total to 254 million, with prevalence rising to 14.7%.  A concerning 50% of cases remain undiagnosed, contributing to the region's highest diabetes-related death toll (1.2 million in 2024).",
        "summary_ur": "The 2024 IDF Diabetes Atlas estimates reveal a concerning diabetes situation in the Western Pacific region.  Comprising 37% of global adult diabetes cases (12.4% prevalence), the region faces a projected 18% increase to 254 million cases by 2050.  A high 50% of cases remain undiagnosed, contributing to the region's leading 1.2 million diabetes-related deaths."
      }
    },
    {
      "text": "In the IDF Western Pacific Region in 2024, diabetes caused 1.2 million deaths (highest among IDF regions) and cost USD 246 billion (second highest, 24% of global expenditure).  Undiagnosed diabetes comprised 50% of cases.  Prevalence varied significantly by age and sex. The Western Pacific region bears a heavy diabetes burden.  In 2024, it saw 1.2 million diabetes-related deaths (highest globally), USD 246 billion in expenditure (second highest globally), and a high undiagnosed diabetes rate (50%).  Prevalence is significantly high across all age groups, particularly in older populations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 89,
        "page_label": "85",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "In the IDF Western Pacific Region in 2024, diabetes caused 1.2 million deaths (highest among IDF regions) and cost USD 246 billion (second highest, 24% of global expenditure).  Undiagnosed diabetes comprised 50% of cases.  Prevalence varied significantly by age and sex.",
        "summary_ur": "The Western Pacific region bears a heavy diabetes burden.  In 2024, it saw 1.2 million diabetes-related deaths (highest globally), USD 246 billion in expenditure (second highest globally), and a high undiagnosed diabetes rate (50%).  Prevalence is significantly high across all age groups, particularly in older populations."
      }
    },
    {
      "text": "The report highlights a significant diabetes burden in the region, affecting 215 million adults (1 in 8) in 2024, with China accounting for a quarter of global cases.  Half of cases are undiagnosed, resulting in 1.2 million deaths and USD 246 billion in healthcare expenditure\u2014the highest among IDF regions.  Prevalence is projected to rise to 14.7% by 2050.  Hyperglycemia during pregnancy affects 1 in 5 live births. The text details a dire diabetes situation.  One in eight adults (215 million) in the region have diabetes, 37% of the global total, with China having a quarter of these cases.  Half are undiagnosed, resulting in 1.2 million deaths and $246 billion in healthcare expenditure in 2024.  Hyperglycemia affects 1 in 5 live births.  The situation is projected to worsen by 2050.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 90,
        "page_label": "86",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The report highlights a significant diabetes burden in the region, affecting 215 million adults (1 in 8) in 2024, with China accounting for a quarter of global cases.  Half of cases are undiagnosed, resulting in 1.2 million deaths and USD 246 billion in healthcare expenditure\u2014the highest among IDF regions.  Prevalence is projected to rise to 14.7% by 2050.  Hyperglycemia during pregnancy affects 1 in 5 live births.",
        "summary_ur": "The text details a dire diabetes situation.  One in eight adults (215 million) in the region have diabetes, 37% of the global total, with China having a quarter of these cases.  Half are undiagnosed, resulting in 1.2 million deaths and $246 billion in healthcare expenditure in 2024.  Hyperglycemia affects 1 in 5 live births.  The situation is projected to worsen by 2050."
      }
    },
    {
      "text": "The provided data shows a projected increase in diabetes cases and related healthcare costs from 2024 to 2050.  China, Indonesia, Japan, Thailand, and South Korea will bear the highest burden.  A significant portion of diabetes cases remain undiagnosed.  Impaired glucose tolerance and impaired fasting glucose are also prevalent. Global diabetes data (20-79 years) shows a projected increase in cases from 2024 to 2050: 215 million to 254 million.  Deaths are projected at 1.2 million, with healthcare costs around $240 billion annually.  A significant portion (50%) remains undiagnosed.  China, Indonesia, Japan, Thailand, and South Korea have the highest number of cases.  Impaired glucose tolerance and fasting glucose are also prevalent and increasing.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 90,
        "page_label": "86",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The provided data shows a projected increase in diabetes cases and related healthcare costs from 2024 to 2050.  China, Indonesia, Japan, Thailand, and South Korea will bear the highest burden.  A significant portion of diabetes cases remain undiagnosed.  Impaired glucose tolerance and impaired fasting glucose are also prevalent.",
        "summary_ur": "Global diabetes data (20-79 years) shows a projected increase in cases from 2024 to 2050: 215 million to 254 million.  Deaths are projected at 1.2 million, with healthcare costs around $240 billion annually.  A significant portion (50%) remains undiagnosed.  China, Indonesia, Japan, Thailand, and South Korea have the highest number of cases.  Impaired glucose tolerance and fasting glucose are also prevalent and increasing."
      }
    },
    {
      "text": "The 11th edition of the IDF Diabetes Atlas (2025) shows China and Indonesia having the highest number of adults (20-79 years) with diabetes (168.3m and 28.6m respectively).  The Marshall Islands, Samoa, and Kiribati have the highest age-standardized prevalence rates. The provided text shows diabetes prevalence in several countries.  China and Indonesia have the highest number of cases (in millions), while several Pacific island nations have the highest age-standardized prevalence rates (in percentages).  Data is from the IDF Diabetes Atlas 11th Edition (2025).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 90,
        "page_label": "86",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The 11th edition of the IDF Diabetes Atlas (2025) shows China and Indonesia having the highest number of adults (20-79 years) with diabetes (168.3m and 28.6m respectively).  The Marshall Islands, Samoa, and Kiribati have the highest age-standardized prevalence rates.",
        "summary_ur": "The provided text shows diabetes prevalence in several countries.  China and Indonesia have the highest number of cases (in millions), while several Pacific island nations have the highest age-standardized prevalence rates (in percentages).  Data is from the IDF Diabetes Atlas 11th Edition (2025)."
      }
    },
    {
      "text": "This text excerpt from the IDF Diabetes Atlas 11th Edition (2025) discusses the complications of type 2 diabetes, specifically its links to cardiovascular disease, dementia, and eye disease.  Further details and references are provided within the document. This text excerpt from the IDF Diabetes Atlas (11th Edition) discusses the link between type 2 diabetes and cardiovascular disease, dementia, and eye disease.  It also mentions a personal account of living with type 1 diabetes.  Further details are found within the cited page numbers.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 91,
        "page_label": "87",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text excerpt from the IDF Diabetes Atlas 11th Edition (2025) discusses the complications of type 2 diabetes, specifically its links to cardiovascular disease, dementia, and eye disease.  Further details and references are provided within the document.",
        "summary_ur": "This text excerpt from the IDF Diabetes Atlas (11th Edition) discusses the link between type 2 diabetes and cardiovascular disease, dementia, and eye disease.  It also mentions a personal account of living with type 1 diabetes.  Further details are found within the cited page numbers."
      }
    },
    {
      "text": "Type 2 diabetes significantly increases the risk of cardiovascular disease (heart attack, stroke, heart failure), dementia, and vision loss (retinopathy).  Early-onset diabetes heightens dementia risk.  The statistics highlight the serious long-term health consequences of this condition. Type 2 diabetes drastically increases cardiovascular disease risk (heart attack, stroke, heart failure) and dementia risk.  Early-onset diabetes elevates dementia chances.  Significant vision loss from retinopathy affects a substantial portion of diabetics.  These findings highlight diabetes' severe health consequences.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 92,
        "page_label": "88",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes significantly increases the risk of cardiovascular disease (heart attack, stroke, heart failure), dementia, and vision loss (retinopathy).  Early-onset diabetes heightens dementia risk.  The statistics highlight the serious long-term health consequences of this condition.",
        "summary_ur": "Type 2 diabetes drastically increases cardiovascular disease risk (heart attack, stroke, heart failure) and dementia risk.  Early-onset diabetes elevates dementia chances.  Significant vision loss from retinopathy affects a substantial portion of diabetics.  These findings highlight diabetes' severe health consequences."
      }
    },
    {
      "text": "Type 2 diabetes (T2D) significantly increases the risk of cardiovascular disease (CVD), a leading cause of death for those with T2D.  Metabolic changes associated with T2D, such as high blood glucose, cholesterol, and blood pressure, contribute to this increased risk of heart attack, stroke, and heart failure.  This text will explore the research on this link, including data on undiagnosed diabetes and prediabetes. Type 2 diabetes (T2D) drastically raises the risk of cardiovascular disease (CVD).  High blood sugar, cholesterol, blood pressure, weight gain, and ectopic fat accumulation, all common in T2D, significantly increase the chances of heart attack, stroke, and heart failure.  This text reviews research on T2D's impact on CVD risk, including cases of undiagnosed diabetes and prediabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 93,
        "page_label": "89",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes (T2D) significantly increases the risk of cardiovascular disease (CVD), a leading cause of death for those with T2D.  Metabolic changes associated with T2D, such as high blood glucose, cholesterol, and blood pressure, contribute to this increased risk of heart attack, stroke, and heart failure.  This text will explore the research on this link, including data on undiagnosed diabetes and prediabetes.",
        "summary_ur": "Type 2 diabetes (T2D) drastically raises the risk of cardiovascular disease (CVD).  High blood sugar, cholesterol, blood pressure, weight gain, and ectopic fat accumulation, all common in T2D, significantly increase the chances of heart attack, stroke, and heart failure.  This text reviews research on T2D's impact on CVD risk, including cases of undiagnosed diabetes and prediabetes."
      }
    },
    {
      "text": "A systematic review (through December 2024) of nine population-representative studies assessed cardiovascular disease (CVD) risk in type 2 diabetics versus non-diabetics.  The analysis focused on ASCVD, stroke, myocardial infarction, and heart failure, updating previous research from 2010.  The studies compared CVD risk between the two groups. A 2024 review of nine studies on cardiovascular disease (CVD) risk in type 2 diabetics (T2D) compared to non-diabetics found increased risk of atherosclerotic CVD, stroke, myocardial infarction, and heart failure in the T2D group.  The studies updated a 2010 meta-analysis, focusing on population-representative data and excluding those with overlapping patient populations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 93,
        "page_label": "89",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "A systematic review (through December 2024) of nine population-representative studies assessed cardiovascular disease (CVD) risk in type 2 diabetics versus non-diabetics.  The analysis focused on ASCVD, stroke, myocardial infarction, and heart failure, updating previous research from 2010.  The studies compared CVD risk between the two groups.",
        "summary_ur": "A 2024 review of nine studies on cardiovascular disease (CVD) risk in type 2 diabetics (T2D) compared to non-diabetics found increased risk of atherosclerotic CVD, stroke, myocardial infarction, and heart failure in the T2D group.  The studies updated a 2010 meta-analysis, focusing on population-representative data and excluding those with overlapping patient populations."
      }
    },
    {
      "text": "A meta-analysis of studies from eight countries (Australia, China, Hungary, Italy, Sweden, Taiwan, UK, US) involving over 6.3 million individuals, including over 1 million with type 2 diabetes (T2D), revealed significantly higher risks of cardiovascular disease (CVD) in T2D patients.  Specifically, they faced a substantially increased risk of myocardial infarction, stroke, and heart failure compared to those without T2D. A meta-analysis of eight countries' data (Australia, China, Hungary, Italy, Sweden, Taiwan, UK, US) involving over 6.3 million individuals (1.02 million with type 2 diabetes) reveals significantly higher risks of CVD in T2D patients.  Specifically, a 60-84% increased risk for myocardial infarction, stroke, and heart failure was observed.  Variations between studies likely reflect differing risk factor adjustments and other influential factors.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 93,
        "page_label": "89",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "A meta-analysis of studies from eight countries (Australia, China, Hungary, Italy, Sweden, Taiwan, UK, US) involving over 6.3 million individuals, including over 1 million with type 2 diabetes (T2D), revealed significantly higher risks of cardiovascular disease (CVD) in T2D patients.  Specifically, they faced a substantially increased risk of myocardial infarction, stroke, and heart failure compared to those without T2D.",
        "summary_ur": "A meta-analysis of eight countries' data (Australia, China, Hungary, Italy, Sweden, Taiwan, UK, US) involving over 6.3 million individuals (1.02 million with type 2 diabetes) reveals significantly higher risks of CVD in T2D patients.  Specifically, a 60-84% increased risk for myocardial infarction, stroke, and heart failure was observed.  Variations between studies likely reflect differing risk factor adjustments and other influential factors."
      }
    },
    {
      "text": "Studies show varying CVD risk linked to diabetes, influenced by factors like risk factor adjustments and diagnostic practices.  Women with diabetes show a higher relative, but not necessarily absolute, risk compared to men.  Early-onset diabetes significantly increases lifetime risk due to prolonged exposure to risk factors.  Pre-diabetes and undiagnosed diabetes also elevate cardiovascular risk. Studies show varying CVD risk linked to diabetes, influenced by factors like risk factor adjustments and diagnostic practices.  Women with diabetes show higher relative, but men higher absolute, lifetime risk.  Early-onset diabetes significantly increases lifetime risk due to prolonged exposure to risk factors.  Pre-diabetes and undiagnosed diabetes also elevate cardiovascular risk.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 93,
        "page_label": "89",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies show varying CVD risk linked to diabetes, influenced by factors like risk factor adjustments and diagnostic practices.  Women with diabetes show a higher relative, but not necessarily absolute, risk compared to men.  Early-onset diabetes significantly increases lifetime risk due to prolonged exposure to risk factors.  Pre-diabetes and undiagnosed diabetes also elevate cardiovascular risk.",
        "summary_ur": "Studies show varying CVD risk linked to diabetes, influenced by factors like risk factor adjustments and diagnostic practices.  Women with diabetes show higher relative, but men higher absolute, lifetime risk.  Early-onset diabetes significantly increases lifetime risk due to prolonged exposure to risk factors.  Pre-diabetes and undiagnosed diabetes also elevate cardiovascular risk."
      }
    },
    {
      "text": "Studies show an 11-20% increased cardiovascular risk for individuals with elevated HbA1c levels (\u226542 mmol/mol) compared to those with normal glycaemia.  However, a significant limitation is the absence of data from low- and middle-income countries, hindering accurate assessment of the global cardiovascular disease burden in type 2 diabetes patients. Studies show 11-30% and 20-38% increased cardiovascular risk in individuals with elevated HbA1c levels (Type 2 Diabetes) compared to those with normal levels.  However, data from low and middle-income countries is lacking, hindering a complete understanding of the global impact.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 93,
        "page_label": "89",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies show an 11-20% increased cardiovascular risk for individuals with elevated HbA1c levels (\u226542 mmol/mol) compared to those with normal glycaemia.  However, a significant limitation is the absence of data from low- and middle-income countries, hindering accurate assessment of the global cardiovascular disease burden in type 2 diabetes patients.",
        "summary_ur": "Studies show 11-30% and 20-38% increased cardiovascular risk in individuals with elevated HbA1c levels (Type 2 Diabetes) compared to those with normal levels.  However, data from low and middle-income countries is lacking, hindering a complete understanding of the global impact."
      }
    },
    {
      "text": "The IDF Diabetes Atlas reveals significant gaps in cardiovascular outcome data for people with type 2 diabetes in low- and middle-income countries (LMICs).  Studies show higher diabetes-related mortality rates in LMICs compared to high-income countries, particularly concerning heart-related deaths.  The lack of comprehensive data on non-fatal outcomes hinders a full understanding of the problem in these regions. The IDF Diabetes Atlas reveals insufficient cardiovascular data for people with type 2 diabetes in low- and middle-income countries (LMICs).  Studies show higher diabetes-related death rates in LMICs than high-income countries, especially concerning heart-related mortality.  Data gaps hinder a complete understanding of diabetes complications in these regions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 94,
        "page_label": "90",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The IDF Diabetes Atlas reveals significant gaps in cardiovascular outcome data for people with type 2 diabetes in low- and middle-income countries (LMICs).  Studies show higher diabetes-related mortality rates in LMICs compared to high-income countries, particularly concerning heart-related deaths.  The lack of comprehensive data on non-fatal outcomes hinders a full understanding of the problem in these regions.",
        "summary_ur": "The IDF Diabetes Atlas reveals insufficient cardiovascular data for people with type 2 diabetes in low- and middle-income countries (LMICs).  Studies show higher diabetes-related death rates in LMICs than high-income countries, especially concerning heart-related mortality.  Data gaps hinder a complete understanding of diabetes complications in these regions."
      }
    },
    {
      "text": "Diabetes significantly increases cardiovascular disease risk, especially in low- and middle-income countries (LMICs).  Improved data collection, stronger healthcare infrastructure, and targeted interventions are crucial to mitigate the growing impact of this increasingly prevalent condition.  Early detection and comprehensive management are essential. Diabetic cardiovascular disease is a growing problem, especially in low- and middle-income countries (LMICs).  Improved data collection and healthcare infrastructure are crucial.  Early detection, comprehensive management, and public health interventions are needed to mitigate the rising risk.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 94,
        "page_label": "90",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes significantly increases cardiovascular disease risk, especially in low- and middle-income countries (LMICs).  Improved data collection, stronger healthcare infrastructure, and targeted interventions are crucial to mitigate the growing impact of this increasingly prevalent condition.  Early detection and comprehensive management are essential.",
        "summary_ur": "Diabetic cardiovascular disease is a growing problem, especially in low- and middle-income countries (LMICs).  Improved data collection and healthcare infrastructure are crucial.  Early detection, comprehensive management, and public health interventions are needed to mitigate the rising risk."
      }
    },
    {
      "text": "The rising global prevalence of diabetes necessitates prioritizing the management of its cardiovascular complications.  A meta-analysis (Figure 5.1) highlights the significantly increased risk of atherosclerotic cardiovascular disease, stroke, myocardial infarction, and heart failure in individuals with type 2 diabetes.  This underscores the need for global healthcare system and policy action. A global diabetes surge necessitates prioritizing cardiovascular complication management.  Figure 5.1's meta-analysis highlights significantly increased risk of heart disease, stroke, and heart failure in type 2 diabetics compared to non-diabetics, demanding urgent healthcare system and policy responses.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 94,
        "page_label": "90",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The rising global prevalence of diabetes necessitates prioritizing the management of its cardiovascular complications.  A meta-analysis (Figure 5.1) highlights the significantly increased risk of atherosclerotic cardiovascular disease, stroke, myocardial infarction, and heart failure in individuals with type 2 diabetes.  This underscores the need for global healthcare system and policy action.",
        "summary_ur": "A global diabetes surge necessitates prioritizing cardiovascular complication management.  Figure 5.1's meta-analysis highlights significantly increased risk of heart disease, stroke, and heart failure in type 2 diabetics compared to non-diabetics, demanding urgent healthcare system and policy responses."
      }
    },
    {
      "text": "Diabetes is linked to an increased risk of dementia.  Globally, dementia cases are rising, with diabetes contributing to an estimated 2.6% of cases.  This association is supported by numerous studies showing a correlation between diabetes, cognitive decline, and dementia, potentially through mechanisms such as midlife obesity, hypertension, and increased stroke risk. Dementia cases, currently 57.4 million, are projected to reach 152.8 million by 2050.  Diabetes significantly increases dementia risk, accounting for 2.6% of global cases.  This is linked to diabetes' association with obesity, hypertension, and stroke, all dementia risk factors.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 95,
        "page_label": "91",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes is linked to an increased risk of dementia.  Globally, dementia cases are rising, with diabetes contributing to an estimated 2.6% of cases.  This association is supported by numerous studies showing a correlation between diabetes, cognitive decline, and dementia, potentially through mechanisms such as midlife obesity, hypertension, and increased stroke risk.",
        "summary_ur": "Dementia cases, currently 57.4 million, are projected to reach 152.8 million by 2050.  Diabetes significantly increases dementia risk, accounting for 2.6% of global cases.  This is linked to diabetes' association with obesity, hypertension, and stroke, all dementia risk factors."
      }
    },
    {
      "text": "Type 2 diabetes (T2D) significantly increases the risk of dementia, particularly vascular dementia.  This risk is higher with earlier onset of T2D and is evident in both epidemiological and neuropathological studies.  Dementia risk is also elevated in older adults post-stroke. Type 2 diabetes (T2D) significantly raises dementia risk, especially vascular dementia.  This risk increases with earlier onset of T2D.  Studies show a strong correlation between T2D and dementia development within 6-18 months post-stroke.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 95,
        "page_label": "91",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes (T2D) significantly increases the risk of dementia, particularly vascular dementia.  This risk is higher with earlier onset of T2D and is evident in both epidemiological and neuropathological studies.  Dementia risk is also elevated in older adults post-stroke.",
        "summary_ur": "Type 2 diabetes (T2D) significantly raises dementia risk, especially vascular dementia.  This risk increases with earlier onset of T2D.  Studies show a strong correlation between T2D and dementia development within 6-18 months post-stroke."
      }
    },
    {
      "text": "A meta-analysis of 34 studies found that people with diabetes have a significantly increased risk of developing dementia.  The relative risk was 1.78 for those under 65, and the figure shows higher risks specifically for vascular dementia and Alzheimer's disease compared to the general population. A meta-analysis of 34 studies revealed that people with diabetes have a significantly higher risk of developing dementia, specifically vascular dementia (RR 2.03), Alzheimer's disease (RR 1.34), and all-cause dementia (RR 1.56), compared to those without diabetes.  The analysis included population-based studies with over 100 participants and clinically diagnosed diabetes and dementia.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 96,
        "page_label": "92",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "A meta-analysis of 34 studies found that people with diabetes have a significantly increased risk of developing dementia.  The relative risk was 1.78 for those under 65, and the figure shows higher risks specifically for vascular dementia and Alzheimer's disease compared to the general population.",
        "summary_ur": "A meta-analysis of 34 studies revealed that people with diabetes have a significantly higher risk of developing dementia, specifically vascular dementia (RR 2.03), Alzheimer's disease (RR 1.34), and all-cause dementia (RR 1.56), compared to those without diabetes.  The analysis included population-based studies with over 100 participants and clinically diagnosed diabetes and dementia."
      }
    },
    {
      "text": "Meta-analyses revealed a significantly increased risk of dementia (56%) among individuals with diabetes.  The risk varied by dementia subtype: 34% higher for Alzheimer's and 103% higher for vascular dementia.  Maps illustrate the global impact of diabetes on dementia cases, projected to increase substantially by 2050. The meta-analysis shows a strong link between diabetes and increased dementia risk.  Individuals with diabetes had a 56% higher risk of all-cause dementia, with higher risks for specific subtypes like Alzheimer's (34%) and vascular dementia (103%).  The attributable proportion of dementia cases globally due to diabetes is also mapped, illustrating a significant public health concern.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 96,
        "page_label": "92",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Meta-analyses revealed a significantly increased risk of dementia (56%) among individuals with diabetes.  The risk varied by dementia subtype: 34% higher for Alzheimer's and 103% higher for vascular dementia.  Maps illustrate the global impact of diabetes on dementia cases, projected to increase substantially by 2050.",
        "summary_ur": "The meta-analysis shows a strong link between diabetes and increased dementia risk.  Individuals with diabetes had a 56% higher risk of all-cause dementia, with higher risks for specific subtypes like Alzheimer's (34%) and vascular dementia (103%).  The attributable proportion of dementia cases globally due to diabetes is also mapped, illustrating a significant public health concern."
      }
    },
    {
      "text": "This text discusses a meta-analysis projecting the global increase in dementia cases attributable to diabetes from 2024 to 2050.  Limitations include potential misclassification of dementia subtypes due to reliance on clinical symptoms,  mixed pathologies in older adults, and the exclusion of competing causes of death.  The analysis also didn't account for all modifiable and emerging risk factors. This text describes a study estimating the global impact of diabetes on dementia cases in 2024 and projected for 2050.  Limitations include reliance on clinical symptoms (not biomarkers) for dementia classification,  potential misclassification of dementia subtypes,  mixed pathologies in older adults, and the study's failure to account for competing causes of death.  Modifiable and emerging risk factors were also not fully considered.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 96,
        "page_label": "92",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text discusses a meta-analysis projecting the global increase in dementia cases attributable to diabetes from 2024 to 2050.  Limitations include potential misclassification of dementia subtypes due to reliance on clinical symptoms,  mixed pathologies in older adults, and the exclusion of competing causes of death.  The analysis also didn't account for all modifiable and emerging risk factors.",
        "summary_ur": "This text describes a study estimating the global impact of diabetes on dementia cases in 2024 and projected for 2050.  Limitations include reliance on clinical symptoms (not biomarkers) for dementia classification,  potential misclassification of dementia subtypes,  mixed pathologies in older adults, and the study's failure to account for competing causes of death.  Modifiable and emerging risk factors were also not fully considered."
      }
    },
    {
      "text": "Maps 5.1 and 5.2 illustrate the projected proportion of dementia cases attributable to diabetes in 2024 and 2050, respectively.  The text highlights diabetes as a significant, modifiable risk factor for dementia, particularly with early-onset.  Preventive measures are crucial to mitigate the growing global burden of both diseases. DIABETES-RELATED DEMENTIA RISKS GROWING.  Maps 5.1 and 5.2 show projected increases in dementia cases linked to diabetes by 2050.  Early-onset type 2 diabetes significantly raises dementia risk, increasing 1.9% for each year earlier diagnosis.  Lifestyle changes and preventative measures are crucial to mitigate the escalating global health burden.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 97,
        "page_label": "93",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Maps 5.1 and 5.2 illustrate the projected proportion of dementia cases attributable to diabetes in 2024 and 2050, respectively.  The text highlights diabetes as a significant, modifiable risk factor for dementia, particularly with early-onset.  Preventive measures are crucial to mitigate the growing global burden of both diseases.",
        "summary_ur": "DIABETES-RELATED DEMENTIA RISKS GROWING.  Maps 5.1 and 5.2 show projected increases in dementia cases linked to diabetes by 2050.  Early-onset type 2 diabetes significantly raises dementia risk, increasing 1.9% for each year earlier diagnosis.  Lifestyle changes and preventative measures are crucial to mitigate the escalating global health burden."
      }
    },
    {
      "text": "This data snippet from the IDF Diabetes Atlas (11th Edition, 2025) shows projected percentages of the population affected by diabetes- and dementia-related diseases due to aging.  The percentages are categorized into ranges (<3%, 3-5%, etc.),  with some lacking estimates.  Further context is needed to understand the specific diseases and populations represented. This data snippet from the IDF Diabetes Atlas shows projected percentages of the population with diabetes and dementia, categorized into ranges (<3%, 3-5%, etc.).  Specific figures are absent for some categories, highlighting uncertainty in projections due to population aging.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 97,
        "page_label": "93",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data snippet from the IDF Diabetes Atlas (11th Edition, 2025) shows projected percentages of the population affected by diabetes- and dementia-related diseases due to aging.  The percentages are categorized into ranges (<3%, 3-5%, etc.),  with some lacking estimates.  Further context is needed to understand the specific diseases and populations represented.",
        "summary_ur": "This data snippet from the IDF Diabetes Atlas shows projected percentages of the population with diabetes and dementia, categorized into ranges (<3%, 3-5%, etc.).  Specific figures are absent for some categories, highlighting uncertainty in projections due to population aging."
      }
    },
    {
      "text": "Diabetes-related eye disease (DR) affects roughly 30% of diabetics globally, with a smaller percentage developing sight-threatening complications.  The increasing prevalence of diabetes presents a significant challenge, highlighting the urgent need for preventative and treatment measures to combat vision loss and other diabetic complications. Diabetes affects many globally, with about 30% experiencing diabetic retinopathy (DR).  A smaller percentage (under 10%) develop sight-threatening DR.  The rising global diabetes prevalence necessitates urgent action to prevent vision loss and other diabetic complications.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 98,
        "page_label": "94",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes-related eye disease (DR) affects roughly 30% of diabetics globally, with a smaller percentage developing sight-threatening complications.  The increasing prevalence of diabetes presents a significant challenge, highlighting the urgent need for preventative and treatment measures to combat vision loss and other diabetic complications.",
        "summary_ur": "Diabetes affects many globally, with about 30% experiencing diabetic retinopathy (DR).  A smaller percentage (under 10%) develop sight-threatening DR.  The rising global diabetes prevalence necessitates urgent action to prevent vision loss and other diabetic complications."
      }
    },
    {
      "text": "Diabetes complications, especially vision loss, are a serious concern.  While advancements in diagnosis and management exist, their application varies globally.  In the UK, systematic screening and improved diabetes management have reduced diabetic retinopathy as a leading cause of blindness in working-age adults. Diabetic retinopathy (DR), a feared complication of diabetes, causes vision loss.  High blood sugar, pressure, and kidney problems increase risk, especially in early-onset type 2 diabetes.  While diagnostic and management advancements exist, their global application varies.  In the UK, screening and improved management have reduced DR-related blindness among working-age adults.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 98,
        "page_label": "94",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Diabetes complications, especially vision loss, are a serious concern.  While advancements in diagnosis and management exist, their application varies globally.  In the UK, systematic screening and improved diabetes management have reduced diabetic retinopathy as a leading cause of blindness in working-age adults.",
        "summary_ur": "Diabetic retinopathy (DR), a feared complication of diabetes, causes vision loss.  High blood sugar, pressure, and kidney problems increase risk, especially in early-onset type 2 diabetes.  While diagnostic and management advancements exist, their global application varies.  In the UK, screening and improved management have reduced DR-related blindness among working-age adults."
      }
    },
    {
      "text": "Improved diabetes management and screening have reduced diabetic retinopathy (DR) as a leading cause of vision loss in working-age adults.  Screening intervals have lengthened to biennial for low-risk individuals, with telemedicine improving access. However, significant gaps remain in patient education, professional training, and affordable treatment, particularly in low- and middle-income countries and minority populations. Improved diabetes management and eye disease screening have reduced diabetic retinopathy (DR) as a leading cause of blindness in working-age adults.  Screening intervals have lengthened,  with telemedicine improving access. However, significant gaps remain in patient education, professional training, and affordable treatment, particularly in low- and middle-income countries and minority groups.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 98,
        "page_label": "94",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Improved diabetes management and screening have reduced diabetic retinopathy (DR) as a leading cause of vision loss in working-age adults.  Screening intervals have lengthened to biennial for low-risk individuals, with telemedicine improving access. However, significant gaps remain in patient education, professional training, and affordable treatment, particularly in low- and middle-income countries and minority populations.",
        "summary_ur": "Improved diabetes management and eye disease screening have reduced diabetic retinopathy (DR) as a leading cause of blindness in working-age adults.  Screening intervals have lengthened,  with telemedicine improving access. However, significant gaps remain in patient education, professional training, and affordable treatment, particularly in low- and middle-income countries and minority groups."
      }
    },
    {
      "text": "The text discusses the prevalence of diabetic retinopathy (DR) globally, highlighting disparities.  Higher burdens are seen in low- and middle-income countries (LMICs) and minority populations.  Improved diabetes management, including accessible treatment and training, is needed to address this health inequity.  A figure (not included here) shows projected increases in DR prevalence from 2019 to 2024 across various regions. This data excerpt from the IDF Diabetes Atlas shows the global prevalence of diabetic retinopathy (DR) in 2019 and projected for 2024, categorized by International Diabetes Federation (IDF) regions.  It highlights disparities, noting higher burdens in low- and middle-income countries (LMICs) and minority populations, emphasizing the need for improved access to affordable treatment and training.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 98,
        "page_label": "94",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text discusses the prevalence of diabetic retinopathy (DR) globally, highlighting disparities.  Higher burdens are seen in low- and middle-income countries (LMICs) and minority populations.  Improved diabetes management, including accessible treatment and training, is needed to address this health inequity.  A figure (not included here) shows projected increases in DR prevalence from 2019 to 2024 across various regions.",
        "summary_ur": "This data excerpt from the IDF Diabetes Atlas shows the global prevalence of diabetic retinopathy (DR) in 2019 and projected for 2024, categorized by International Diabetes Federation (IDF) regions.  It highlights disparities, noting higher burdens in low- and middle-income countries (LMICs) and minority populations, emphasizing the need for improved access to affordable treatment and training."
      }
    },
    {
      "text": "A review of 42 studies (2017-2024) across 21 countries found a 23% global prevalence of diabetic retinopathy (DR) in individuals with type 2 diabetes.  The Western Pacific region contributed the most studies.  Prevalence varied for specific DR types, with proliferative retinopathy at 57% and sight-threatening DR at 64%. A global review (2017-2024) of 42 studies (707,657 individuals, mostly with type 2 diabetes) found a 23% prevalence of diabetic retinopathy (DR).  The Western Pacific region had the most studies.  Prevalence varied across regions; proliferative retinopathy, macular edema, and sight-threatening DR were also assessed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 99,
        "page_label": "95",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "A review of 42 studies (2017-2024) across 21 countries found a 23% global prevalence of diabetic retinopathy (DR) in individuals with type 2 diabetes.  The Western Pacific region contributed the most studies.  Prevalence varied for specific DR types, with proliferative retinopathy at 57% and sight-threatening DR at 64%.",
        "summary_ur": "A global review (2017-2024) of 42 studies (707,657 individuals, mostly with type 2 diabetes) found a 23% prevalence of diabetic retinopathy (DR).  The Western Pacific region had the most studies.  Prevalence varied across regions; proliferative retinopathy, macular edema, and sight-threatening DR were also assessed."
      }
    },
    {
      "text": "The global prevalence of diabetic retinopathy (DR) is 23% (any DR), with 6% proliferative DR, 5% diabetic macular edema, and 11% sight-threatening DR.  This represents a slight decrease from previous reports.  Regional variations exist, with prevalence ranging from 9% to 25% for sight-threatening DR across different IDF regions. Diabetic retinopathy (DR) affects a significant portion of the global population.  Studies show an overall prevalence of 23% (any DR), with sight-threatening DR at 11%.  This represents a slight decrease from previous reports.  Regional variations exist, with some areas showing higher prevalences than others.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 99,
        "page_label": "95",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The global prevalence of diabetic retinopathy (DR) is 23% (any DR), with 6% proliferative DR, 5% diabetic macular edema, and 11% sight-threatening DR.  This represents a slight decrease from previous reports.  Regional variations exist, with prevalence ranging from 9% to 25% for sight-threatening DR across different IDF regions.",
        "summary_ur": "Diabetic retinopathy (DR) affects a significant portion of the global population.  Studies show an overall prevalence of 23% (any DR), with sight-threatening DR at 11%.  This represents a slight decrease from previous reports.  Regional variations exist, with some areas showing higher prevalences than others."
      }
    },
    {
      "text": "Table 5.1 shows the prevalence of any and sight-threatening diabetic retinopathy across different IDF regions in 2024.  Data includes the number of affected individuals and percentages, varying significantly across regions.  Sight-threatening retinopathy encompasses severe non-proliferative retinopathy, proliferative DR, or clinically significant macular edema. The table displays the prevalence of diabetes-related retinopathy (DR) across different IDF regions in 2024.  Data includes total cases, sight-threatening DR cases, and prevalence rates, varying significantly between regions.  Specific numbers are provided for SEA, SACA, NAC, MENA, AFR, and GLOBAL regions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 99,
        "page_label": "95",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Table 5.1 shows the prevalence of any and sight-threatening diabetic retinopathy across different IDF regions in 2024.  Data includes the number of affected individuals and percentages, varying significantly across regions.  Sight-threatening retinopathy encompasses severe non-proliferative retinopathy, proliferative DR, or clinically significant macular edema.",
        "summary_ur": "The table displays the prevalence of diabetes-related retinopathy (DR) across different IDF regions in 2024.  Data includes total cases, sight-threatening DR cases, and prevalence rates, varying significantly between regions.  Specific numbers are provided for SEA, SACA, NAC, MENA, AFR, and GLOBAL regions."
      }
    },
    {
      "text": "A study of diabetes-related retinopathy (DR) prevalence across several IDF regions showed decreases in five regions, with two experiencing drops exceeding 10%.  However, two other regions saw increases.  Proliferative DR prevalence quadrupled, while macular edema remained stable at approximately 5%.  The study highlights the global burden of DR and challenges in accurate prevalence estimations. Several regions showed decreased diabetic retinopathy (DR) prevalence, notably SACA and WP (over 10% decrease).  However, EUR and SEA saw increases.  Proliferative DR prevalence quadrupled, while macular edema remained stable at ~5%.  Global DR prevalence estimation remains challenging due to inherent difficulties.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 100,
        "page_label": "96",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "A study of diabetes-related retinopathy (DR) prevalence across several IDF regions showed decreases in five regions, with two experiencing drops exceeding 10%.  However, two other regions saw increases.  Proliferative DR prevalence quadrupled, while macular edema remained stable at approximately 5%.  The study highlights the global burden of DR and challenges in accurate prevalence estimations.",
        "summary_ur": "Several regions showed decreased diabetic retinopathy (DR) prevalence, notably SACA and WP (over 10% decrease).  However, EUR and SEA saw increases.  Proliferative DR prevalence quadrupled, while macular edema remained stable at ~5%.  Global DR prevalence estimation remains challenging due to inherent difficulties."
      }
    },
    {
      "text": "Table 5.2 from the IDF Diabetes Atlas (2025) shows the prevalence of proliferative diabetic retinopathy and macular edema across different regions in 2024.  Global prevalence was 6% (3-9%), varying significantly by region (e.g., 20% in SEA, 1% in AFR).  Data is based on multiple studies with varying sample sizes. The table shows the prevalence of proliferative diabetic retinopathy and macular edema across different IDF regions in 2024.  Global prevalence was 6% (3-9%), varying significantly between regions (e.g., 20% in SEA, 1% in AFR).  Data from multiple studies are compiled, showing total populations and case numbers.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 100,
        "page_label": "96",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Table 5.2 from the IDF Diabetes Atlas (2025) shows the prevalence of proliferative diabetic retinopathy and macular edema across different regions in 2024.  Global prevalence was 6% (3-9%), varying significantly by region (e.g., 20% in SEA, 1% in AFR).  Data is based on multiple studies with varying sample sizes.",
        "summary_ur": "The table shows the prevalence of proliferative diabetic retinopathy and macular edema across different IDF regions in 2024.  Global prevalence was 6% (3-9%), varying significantly between regions (e.g., 20% in SEA, 1% in AFR).  Data from multiple studies are compiled, showing total populations and case numbers."
      }
    },
    {
      "text": "These references present studies on the link between diabetes mellitus (fasting glucose levels) and various health outcomes, including cause-specific death, cardiovascular mortality, vascular disease, and stroke risk.  The studies analyze data from diverse populations and explore the association across different demographics. These studies (Rao et al., 2011; Anjana et al., 2020; Emerging Risk Factors Collaboration, 2010; Hayward et al., 2015; Malla et al.) analyze the link between diabetes mellitus, fasting glucose levels, and risks of various adverse health outcomes, including cardiovascular disease and stroke, across diverse populations.  Findings highlight significant associations and variations based on factors like age, race, and sex.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 101,
        "page_label": "97",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These references present studies on the link between diabetes mellitus (fasting glucose levels) and various health outcomes, including cause-specific death, cardiovascular mortality, vascular disease, and stroke risk.  The studies analyze data from diverse populations and explore the association across different demographics.",
        "summary_ur": "These studies (Rao et al., 2011; Anjana et al., 2020; Emerging Risk Factors Collaboration, 2010; Hayward et al., 2015; Malla et al.) analyze the link between diabetes mellitus, fasting glucose levels, and risks of various adverse health outcomes, including cardiovascular disease and stroke, across diverse populations.  Findings highlight significant associations and variations based on factors like age, race, and sex."
      }
    },
    {
      "text": "Several studies (Malla et al., 2019; Zabala et al., 2020; Groenewegen et al., 2021; de Jong et al., 2020; Davis et al.) demonstrate a strong association between diabetes and increased risk of stroke, myocardial infarction, atrial fibrillation, ischemic heart disease, and heart failure.  The relationship varies across age, race, sex, and glycemic control. Studies (Malla et al., Zabala et al., Groenewegen et al., de Jong et al., Davis et al.) show a strong link between diabetes and increased risk of stroke, heart disease, and myocardial infarction.  Risk varies by age, race, sex, and glycemic control.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 101,
        "page_label": "97",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies (Malla et al., 2019; Zabala et al., 2020; Groenewegen et al., 2021; de Jong et al., 2020; Davis et al.) demonstrate a strong association between diabetes and increased risk of stroke, myocardial infarction, atrial fibrillation, ischemic heart disease, and heart failure.  The relationship varies across age, race, sex, and glycemic control.",
        "summary_ur": "Studies (Malla et al., Zabala et al., Groenewegen et al., de Jong et al., Davis et al.) show a strong link between diabetes and increased risk of stroke, heart disease, and myocardial infarction.  Risk varies by age, race, sex, and glycemic control."
      }
    },
    {
      "text": "Several studies (Davis et al., 2020; Moe et al., 2015; Chen et al., 2015; Chen et al., 2019) demonstrate a strong link between diabetes and increased risk of cardiovascular complications, including myocardial infarction and heart failure.  These risks are modified by factors like physical activity and BMI.  Improved glycemic control (Chen et al., 2015) may mitigate some of these risks. Studies (Davis et al., Moe et al., Chen et al., Chen et al.) show a strong link between diabetes and cardiovascular problems like heart attacks and heart failure.  Physical activity and BMI influence this risk.  Higher HbA1c levels correlate with increased cardiovascular risk and mortality.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 101,
        "page_label": "97",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies (Davis et al., 2020; Moe et al., 2015; Chen et al., 2015; Chen et al., 2019) demonstrate a strong link between diabetes and increased risk of cardiovascular complications, including myocardial infarction and heart failure.  These risks are modified by factors like physical activity and BMI.  Improved glycemic control (Chen et al., 2015) may mitigate some of these risks.",
        "summary_ur": "Studies (Davis et al., Moe et al., Chen et al., Chen et al.) show a strong link between diabetes and cardiovascular problems like heart attacks and heart failure.  Physical activity and BMI influence this risk.  Higher HbA1c levels correlate with increased cardiovascular risk and mortality."
      }
    },
    {
      "text": "Studies (Larsson et al., 2018; Kiss et al., 2018; Rawshani et al., 2018; Monesi et al., 2014; Shah et al., [year missing]) show a significantly increased risk of cardiovascular disease (CVD) and mortality in individuals with type 2 diabetes compared to those without, regardless of pre-existing coronary heart disease.  The impact of type 2 diabetes on CVD varies with age. Studies (Larsson et al., 2018; Kiss et al., 2018; Rawshani et al., 2018; Monesi et al., 2014; Shah et al., [year missing]) show a significantly increased risk of cardiovascular disease (CVD) and mortality in individuals with type 2 diabetes compared to those without, regardless of age and pre-existing coronary heart disease.  The impact of diabetes on CVD varies across age groups.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 101,
        "page_label": "97",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies (Larsson et al., 2018; Kiss et al., 2018; Rawshani et al., 2018; Monesi et al., 2014; Shah et al., [year missing]) show a significantly increased risk of cardiovascular disease (CVD) and mortality in individuals with type 2 diabetes compared to those without, regardless of pre-existing coronary heart disease.  The impact of type 2 diabetes on CVD varies with age.",
        "summary_ur": "Studies (Larsson et al., 2018; Kiss et al., 2018; Rawshani et al., 2018; Monesi et al., 2014; Shah et al., [year missing]) show a significantly increased risk of cardiovascular disease (CVD) and mortality in individuals with type 2 diabetes compared to those without, regardless of age and pre-existing coronary heart disease.  The impact of diabetes on CVD varies across age groups."
      }
    },
    {
      "text": "These research papers (17-20) detail studies on the link between type 2 diabetes and cardiovascular disease (CVD),  analyzing incidence, prevalence, and mortality across diverse populations (e.g., China, US, UK).  The studies consistently show a significant increased risk of CVD in individuals with type 2 diabetes. Several studies (Shah et al., 2015; Bragg et al., 2016; Visaria et al., 2019; Muilwijk et al., 2019) using large cohorts (up to 1.9 million) confirm a strong link between type 2 diabetes and increased risk of cardiovascular disease and mortality.  These findings highlight the significant public health burden associated with this comorbidity.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 101,
        "page_label": "97",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These research papers (17-20) detail studies on the link between type 2 diabetes and cardiovascular disease (CVD),  analyzing incidence, prevalence, and mortality across diverse populations (e.g., China, US, UK).  The studies consistently show a significant increased risk of CVD in individuals with type 2 diabetes.",
        "summary_ur": "Several studies (Shah et al., 2015; Bragg et al., 2016; Visaria et al., 2019; Muilwijk et al., 2019) using large cohorts (up to 1.9 million) confirm a strong link between type 2 diabetes and increased risk of cardiovascular disease and mortality.  These findings highlight the significant public health burden associated with this comorbidity."
      }
    },
    {
      "text": "This study, published in *BMJ Open Diabetes Res Care*, analyzed cancer incidence in White Europeans and South Asians using data from the UK Biobank.  It compared cancer rates between these two populations within the UK Biobank cohort.  (Further details on specific findings are absent from the provided text). This study, published in *BMJ Open Diabetes Res Care*, analyzed cancer incidence in White Europeans and South Asians using data from the UK Biobank.  It compared cancer rates between these two groups within the UK population.  Further details on the findings are not provided in this excerpt.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 101,
        "page_label": "97",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This study, published in *BMJ Open Diabetes Res Care*, analyzed cancer incidence in White Europeans and South Asians using data from the UK Biobank.  It compared cancer rates between these two populations within the UK Biobank cohort.  (Further details on specific findings are absent from the provided text).",
        "summary_ur": "This study, published in *BMJ Open Diabetes Res Care*, analyzed cancer incidence in White Europeans and South Asians using data from the UK Biobank.  It compared cancer rates between these two groups within the UK population.  Further details on the findings are not provided in this excerpt."
      }
    },
    {
      "text": "Several studies highlight the rising prevalence and concerning links between cardiometabolic diseases (including type 2 diabetes and prediabetes) and increased risks of cardiovascular events and cognitive decline (dementia).  These studies emphasize the growing global burden of these interconnected health issues. These studies reveal concerning trends: rising cardiometabolic diseases and type 2 diabetes in younger populations (21, 22),  strong links between glycated hemoglobin/prediabetes and cardiovascular issues (23), and a projected surge in dementia cases (24).  Existing research highlights the connection between type 2 diabetes and cognitive decline, though methodological limitations exist (25).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 102,
        "page_label": "98",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies highlight the rising prevalence and concerning links between cardiometabolic diseases (including type 2 diabetes and prediabetes) and increased risks of cardiovascular events and cognitive decline (dementia).  These studies emphasize the growing global burden of these interconnected health issues.",
        "summary_ur": "These studies reveal concerning trends: rising cardiometabolic diseases and type 2 diabetes in younger populations (21, 22),  strong links between glycated hemoglobin/prediabetes and cardiovascular issues (23), and a projected surge in dementia cases (24).  Existing research highlights the connection between type 2 diabetes and cognitive decline, though methodological limitations exist (25)."
      }
    },
    {
      "text": "Several studies link type 2 diabetes to cognitive dysfunction and dementia.  These studies, while informative, have methodological limitations.  A significant overlap exists between risk factors for diabetes and other non-communicable diseases like dementia, suggesting shared mechanisms and potential for targeted preventative strategies. These studies explore the link between type 2 diabetes and cognitive decline, including dementia and Alzheimer's disease.  They highlight the connection through shared risk factors and longitudinal studies, while also acknowledging methodological limitations in research.  The prevalence and impact of this relationship are significant areas of ongoing investigation.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 102,
        "page_label": "98",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Several studies link type 2 diabetes to cognitive dysfunction and dementia.  These studies, while informative, have methodological limitations.  A significant overlap exists between risk factors for diabetes and other non-communicable diseases like dementia, suggesting shared mechanisms and potential for targeted preventative strategies.",
        "summary_ur": "These studies explore the link between type 2 diabetes and cognitive decline, including dementia and Alzheimer's disease.  They highlight the connection through shared risk factors and longitudinal studies, while also acknowledging methodological limitations in research.  The prevalence and impact of this relationship are significant areas of ongoing investigation."
      }
    },
    {
      "text": "These citations explore the links between type 2 diabetes and cognitive decline, including Alzheimer's disease and vascular dementia.  Studies examine global diabetes prevalence, modifiable dementia risk factors, the impact of diabetes diagnosis age on dementia risk, and diabetic retinopathy screening methods. Several studies (Biessels, 2012; Sun et al., 2022; Welberry et al., 2023; Qi et al., 2024; Pieczynski & Grzybowski, 2015) link type 2 diabetes to increased risks of Alzheimer's disease, vascular dementia, and diabetic retinopathy.  These works highlight the global prevalence of diabetes and explore modifiable risk factors for dementia, emphasizing the need for early diagnosis and management.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 102,
        "page_label": "98",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations explore the links between type 2 diabetes and cognitive decline, including Alzheimer's disease and vascular dementia.  Studies examine global diabetes prevalence, modifiable dementia risk factors, the impact of diabetes diagnosis age on dementia risk, and diabetic retinopathy screening methods.",
        "summary_ur": "Several studies (Biessels, 2012; Sun et al., 2022; Welberry et al., 2023; Qi et al., 2024; Pieczynski & Grzybowski, 2015) link type 2 diabetes to increased risks of Alzheimer's disease, vascular dementia, and diabetic retinopathy.  These works highlight the global prevalence of diabetes and explore modifiable risk factors for dementia, emphasizing the need for early diagnosis and management."
      }
    },
    {
      "text": "These citations review studies on diabetic retinopathy (DR) screening methods and global prevalence.  Studies from 2012-2022 show varying methodologies and projections of DR burden, highlighting the need for continued research into effective screening and management strategies worldwide. Several studies (Pieczynski & Grzybowski, 2015; Thomas et al., 2019; Yau et al., 2012; Teo et al., 2021; Hashemi et al., 2022; IDF Diabetes Atlas) reviewed diabetic retinopathy screening methods and global prevalence, revealing high rates and projecting a significant increase in burden by 2045.  Further research from the IDF Diabetes Atlas supplements these findings.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 102,
        "page_label": "98",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations review studies on diabetic retinopathy (DR) screening methods and global prevalence.  Studies from 2012-2022 show varying methodologies and projections of DR burden, highlighting the need for continued research into effective screening and management strategies worldwide.",
        "summary_ur": "Several studies (Pieczynski & Grzybowski, 2015; Thomas et al., 2019; Yau et al., 2012; Teo et al., 2021; Hashemi et al., 2022; IDF Diabetes Atlas) reviewed diabetic retinopathy screening methods and global prevalence, revealing high rates and projecting a significant increase in burden by 2045.  Further research from the IDF Diabetes Atlas supplements these findings."
      }
    },
    {
      "text": "These citations refer to research on diabetic retinopathy, including a systematic review and meta-analysis (ref. 37),  global prevalence studies (refs. 38, 39, 41), and a review article on the disease (ref. 40).  The sources collectively address the global burden, risk factors, screening, and public health challenges related to diabetic retinopathy. These citations support research on diabetic retinopathy, including its global prevalence, risk factors, and screening.  Studies like the SEMIN OPHTHALMOL review and the IDF Diabetes Atlas provide data on the disease's burden and impact.  Additional papers detail prediabetes prevalence and retinopathy's characteristics.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 102,
        "page_label": "98",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations refer to research on diabetic retinopathy, including a systematic review and meta-analysis (ref. 37),  global prevalence studies (refs. 38, 39, 41), and a review article on the disease (ref. 40).  The sources collectively address the global burden, risk factors, screening, and public health challenges related to diabetic retinopathy.",
        "summary_ur": "These citations support research on diabetic retinopathy, including its global prevalence, risk factors, and screening.  Studies like the SEMIN OPHTHALMOL review and the IDF Diabetes Atlas provide data on the disease's burden and impact.  Additional papers detail prediabetes prevalence and retinopathy's characteristics."
      }
    },
    {
      "text": "Studies (Wong et al., 2008; Liew et al., 2014; Thomas et al., 2012; Leese et al., 2015) show a strong link between age of onset, duration of type 2 diabetes, and retinopathy risk.  These studies highlight the importance of early detection and screening programs for diabetic retinopathy,  with  potential implications for adjusting screening intervals (Leese et al., 2015).  One study mentions telemedicine's potential role in diabetic retinopathy eye exams (Silva & Aiello). Several studies (Wong et al., 2008; Liew et al., 2014; Thomas et al., 2012; Leese et al., 2015) show a strong correlation between age of onset, duration of type 2 diabetes, and diabetic retinopathy risk.  Early detection via screening programs (Leese et al., 2015) and telemedicine (Silva & Aiello) are crucial for managing this complication.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 103,
        "page_label": "99",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Studies (Wong et al., 2008; Liew et al., 2014; Thomas et al., 2012; Leese et al., 2015) show a strong link between age of onset, duration of type 2 diabetes, and retinopathy risk.  These studies highlight the importance of early detection and screening programs for diabetic retinopathy,  with  potential implications for adjusting screening intervals (Leese et al., 2015).  One study mentions telemedicine's potential role in diabetic retinopathy eye exams (Silva & Aiello).",
        "summary_ur": "Several studies (Wong et al., 2008; Liew et al., 2014; Thomas et al., 2012; Leese et al., 2015) show a strong correlation between age of onset, duration of type 2 diabetes, and diabetic retinopathy risk.  Early detection via screening programs (Leese et al., 2015) and telemedicine (Silva & Aiello) are crucial for managing this complication."
      }
    },
    {
      "text": "These citations discuss diabetic retinopathy (DR), focusing on telemedicine's role in improving screening and treatment access.  Studies analyze global perspectives on DR screening, treatment provision, and the potential of telemedicine to optimize outcomes and address disparities in care.  Future directions and challenges are also explored. Several studies (Silva & Aiello, 2015; Das et al., 2015; Cavan et al., 2017, 2018; Tan & Wong, 2022) highlight the use of telemedicine for diabetic retinopathy screening and the global disparities in access to such care.  Research also addresses optimal screening intervals and future directions for improved outcomes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 103,
        "page_label": "99",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations discuss diabetic retinopathy (DR), focusing on telemedicine's role in improving screening and treatment access.  Studies analyze global perspectives on DR screening, treatment provision, and the potential of telemedicine to optimize outcomes and address disparities in care.  Future directions and challenges are also explored.",
        "summary_ur": "Several studies (Silva & Aiello, 2015; Das et al., 2015; Cavan et al., 2017, 2018; Tan & Wong, 2022) highlight the use of telemedicine for diabetic retinopathy screening and the global disparities in access to such care.  Research also addresses optimal screening intervals and future directions for improved outcomes."
      }
    },
    {
      "text": "These citations reference studies on diabetes, focusing on global prevalence (41 countries), future projections (2030), addressing global inequities in care, and utilizing retinal photography for diabetic retinopathy screening.  A worldwide review of such screening studies (2017-2023) is also cited. Studies from 41 countries (2018-2023) and a forthcoming review (2025) highlight the global diabetes burden, focusing on diabetic retinopathy.  Research examines global inequities in diabetes care and the use of retinal photography for screening.  The findings underscore the need for improved global diabetes management.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 103,
        "page_label": "99",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These citations reference studies on diabetes, focusing on global prevalence (41 countries), future projections (2030), addressing global inequities in care, and utilizing retinal photography for diabetic retinopathy screening.  A worldwide review of such screening studies (2017-2023) is also cited.",
        "summary_ur": "Studies from 41 countries (2018-2023) and a forthcoming review (2025) highlight the global diabetes burden, focusing on diabetic retinopathy.  Research examines global inequities in diabetes care and the use of retinal photography for screening.  The findings underscore the need for improved global diabetes management."
      }
    },
    {
      "text": "This is a table of contents excerpt from the 11th edition (2025) of the IDF Diabetes Atlas.  It shows the document includes country-specific data tables, an abbreviation/acronym list, a glossary of terms, and a list of figures, maps, and tables. This document, the 11th edition (2025) of the IDF Diabetes Atlas, presents country-specific diabetes data (102 tables), along with abbreviations, glossary, and a list of figures, maps and tables.  It's available online at diabetesatlas.org.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 104,
        "page_label": "100",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This is a table of contents excerpt from the 11th edition (2025) of the IDF Diabetes Atlas.  It shows the document includes country-specific data tables, an abbreviation/acronym list, a glossary of terms, and a list of figures, maps, and tables.",
        "summary_ur": "This document, the 11th edition (2025) of the IDF Diabetes Atlas, presents country-specific diabetes data (102 tables), along with abbreviations, glossary, and a list of figures, maps and tables.  It's available online at diabetesatlas.org."
      }
    },
    {
      "text": "This table summarizes diabetes statistics across Africa in 2024, including prevalence, undiagnosed cases, and related expenditures.  Data is presented for the region as a whole and individually for Angola and Benin, showing variations in diabetes burden across countries.  Type 1 diabetes figures and impaired glucose tolerance/fasting glucose prevalence are also included. The IDF Africa Region 2024 report shows a high diabetes burden.  Across the region,  24.6 million adults (20-79 years) have diabetes (4.2% prevalence), with a significant portion undiagnosed (73%).  Diabetes-related expenditure is substantial ($9.9 billion). Angola and Benin data show similar trends, highlighting the need for improved diabetes prevention and management.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 105,
        "page_label": "101",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table summarizes diabetes statistics across Africa in 2024, including prevalence, undiagnosed cases, and related expenditures.  Data is presented for the region as a whole and individually for Angola and Benin, showing variations in diabetes burden across countries.  Type 1 diabetes figures and impaired glucose tolerance/fasting glucose prevalence are also included.",
        "summary_ur": "The IDF Africa Region 2024 report shows a high diabetes burden.  Across the region,  24.6 million adults (20-79 years) have diabetes (4.2% prevalence), with a significant portion undiagnosed (73%).  Diabetes-related expenditure is substantial ($9.9 billion). Angola and Benin data show similar trends, highlighting the need for improved diabetes prevention and management."
      }
    },
    {
      "text": "This data table presents various socio-economic indicators for several African countries.  It includes GDP (in billions), various percentages (likely relating to population growth or economic activity), and figures representing population size,  income, and other metrics.  The data allows for cross-country comparisons of development levels. This table displays economic data for several African nations.  It includes figures for GDP (in billions), various economic growth rates, and population sizes (in millions).  Data points suggest a range of economic performance and development levels across the listed countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 105,
        "page_label": "101",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table presents various socio-economic indicators for several African countries.  It includes GDP (in billions), various percentages (likely relating to population growth or economic activity), and figures representing population size,  income, and other metrics.  The data allows for cross-country comparisons of development levels.",
        "summary_ur": "This table displays economic data for several African nations.  It includes figures for GDP (in billions), various economic growth rates, and population sizes (in millions).  Data points suggest a range of economic performance and development levels across the listed countries."
      }
    },
    {
      "text": "The table presents socioeconomic data for several African countries, including land area (km\u00b2), population density (people/km\u00b2),  GDP per capita (USD),  and other indicators like birth and death rates.  The data reveals significant variation in these metrics across the listed nations. The provided data shows various socio-economic indicators for several African countries.  These include land area, population density, population growth rate, life expectancy, GDP, and other economic metrics.  The data allows for comparisons across these nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 105,
        "page_label": "101",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents socioeconomic data for several African countries, including land area (km\u00b2), population density (people/km\u00b2),  GDP per capita (USD),  and other indicators like birth and death rates.  The data reveals significant variation in these metrics across the listed nations.",
        "summary_ur": "The provided data shows various socio-economic indicators for several African countries.  These include land area, population density, population growth rate, life expectancy, GDP, and other economic metrics.  The data allows for comparisons across these nations."
      }
    },
    {
      "text": "This data table presents socio-economic indicators for several African countries.  Metrics include land area (km\u00b2), population density (per km\u00b2), birth/death rates (per 1,000), life expectancy (years), GDP per capita (USD), and total GDP (USD).  The data shows significant variation across countries in these key development measures. The table presents socioeconomic data for several African nations.  Data includes area, population density, GDP, and other key indicators, showing significant variation across countries.  The data suggests disparities in economic development and population distribution.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 105,
        "page_label": "101",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table presents socio-economic indicators for several African countries.  Metrics include land area (km\u00b2), population density (per km\u00b2), birth/death rates (per 1,000), life expectancy (years), GDP per capita (USD), and total GDP (USD).  The data shows significant variation across countries in these key development measures.",
        "summary_ur": "The table presents socioeconomic data for several African nations.  Data includes area, population density, GDP, and other key indicators, showing significant variation across countries.  The data suggests disparities in economic development and population distribution."
      }
    },
    {
      "text": "The table shows various economic and demographic indicators for several African countries.  Data includes GDP (in millions of USD), population (in millions), and metrics like agricultural land use, energy use, and internet usage.  The figures highlight significant variations in economic size and development across these nations. The table displays various socioeconomic indicators for several African countries.  Data includes land area (km\u00b2), population density (per km\u00b2), birth rate, life expectancy, GDP per capita, and total GDP, among other metrics.  The figures show significant variation in these indicators across the listed nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 105,
        "page_label": "101",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows various economic and demographic indicators for several African countries.  Data includes GDP (in millions of USD), population (in millions), and metrics like agricultural land use, energy use, and internet usage.  The figures highlight significant variations in economic size and development across these nations.",
        "summary_ur": "The table displays various socioeconomic indicators for several African countries.  Data includes land area (km\u00b2), population density (per km\u00b2), birth rate, life expectancy, GDP per capita, and total GDP, among other metrics.  The figures show significant variation in these indicators across the listed nations."
      }
    },
    {
      "text": "This data table likely shows diabetes prevalence and related statistics for Western Sahara, Zambia, and Zimbabwe.  The figures represent various metrics, possibly including prevalence rates, population numbers, and healthcare resource allocation, but without further context, precise interpretation is impossible. This data table shows diabetes prevalence and related statistics for Western Sahara, Zambia, and Zimbabwe.  It includes figures for prevalence, diagnosed cases, and healthcare resource allocation, but lacks clear contextual labels for each column.  More information is needed to fully interpret the data's meaning.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 105,
        "page_label": "101",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table likely shows diabetes prevalence and related statistics for Western Sahara, Zambia, and Zimbabwe.  The figures represent various metrics, possibly including prevalence rates, population numbers, and healthcare resource allocation, but without further context, precise interpretation is impossible.",
        "summary_ur": "This data table shows diabetes prevalence and related statistics for Western Sahara, Zambia, and Zimbabwe.  It includes figures for prevalence, diagnosed cases, and healthcare resource allocation, but lacks clear contextual labels for each column.  More information is needed to fully interpret the data's meaning."
      }
    },
    {
      "text": "The table presents diabetes data for Africa and three specific countries (Angola, Benin, Botswana).  It shows the number of adults with diabetes, prevalence rates (both age-adjusted and raw), the proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Data varies significantly across locations. The table presents diabetes statistics across African countries.  Data includes the number of adults with diabetes, prevalence rates (both overall and age-adjusted), proportion of undiagnosed cases, diabetes-related expenditure, deaths, and type 1 diabetes cases.  Significant variations exist between countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 106,
        "page_label": "102",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents diabetes data for Africa and three specific countries (Angola, Benin, Botswana).  It shows the number of adults with diabetes, prevalence rates (both age-adjusted and raw), the proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Data varies significantly across locations.",
        "summary_ur": "The table presents diabetes statistics across African countries.  Data includes the number of adults with diabetes, prevalence rates (both overall and age-adjusted), proportion of undiagnosed cases, diabetes-related expenditure, deaths, and type 1 diabetes cases.  Significant variations exist between countries."
      }
    },
    {
      "text": "The table presents socio-economic data for several African countries.  Data includes land area (km\u00b2), population growth rate, fertility rate, life expectancy, GDP per capita (USD), and other key indicators.  Significant variation exists across countries in population size, GDP, and development metrics. This data table shows various socio-economic indicators for several African countries.  Key metrics include land area, population, GDP, and related per capita figures.  Significant variations exist across nations in these areas.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 106,
        "page_label": "102",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents socio-economic data for several African countries.  Data includes land area (km\u00b2), population growth rate, fertility rate, life expectancy, GDP per capita (USD), and other key indicators.  Significant variation exists across countries in population size, GDP, and development metrics.",
        "summary_ur": "This data table shows various socio-economic indicators for several African countries.  Key metrics include land area, population, GDP, and related per capita figures.  Significant variations exist across nations in these areas."
      }
    },
    {
      "text": "The table presents economic data for several African countries.  Data points include land area (km\u00b2), population density (people/km\u00b2),  GDP per capita (USD), and various economic indicators.  The figures show significant variation in size, population, and economic output across the listed nations. This data displays various socio-economic indicators for several African nations.  Columns likely represent land area, population density, birth/death rates, life expectancy, GDP, and other key statistics.  The table facilitates comparison of these countries' development levels.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 106,
        "page_label": "102",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for several African countries.  Data points include land area (km\u00b2), population density (people/km\u00b2),  GDP per capita (USD), and various economic indicators.  The figures show significant variation in size, population, and economic output across the listed nations.",
        "summary_ur": "This data displays various socio-economic indicators for several African nations.  Columns likely represent land area, population density, birth/death rates, life expectancy, GDP, and other key statistics.  The table facilitates comparison of these countries' development levels."
      }
    },
    {
      "text": "This data table shows various socio-economic indicators for several African countries.  The figures likely represent metrics such as land area (km\u00b2), population density (per km\u00b2), birth/death rates (per 1000), life expectancy (years), and GDP (USD).  The data allows for comparison of these countries across several key development measures. This data table presents socio-economic indicators for several African nations.  It includes figures for land area, population, GDP, and related metrics like GDP per capita and various economic ratios.  The countries listed span a wide range in size and economic development.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 106,
        "page_label": "102",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table shows various socio-economic indicators for several African countries.  The figures likely represent metrics such as land area (km\u00b2), population density (per km\u00b2), birth/death rates (per 1000), life expectancy (years), and GDP (USD).  The data allows for comparison of these countries across several key development measures.",
        "summary_ur": "This data table presents socio-economic indicators for several African nations.  It includes figures for land area, population, GDP, and related metrics like GDP per capita and various economic ratios.  The countries listed span a wide range in size and economic development."
      }
    },
    {
      "text": "This data table displays various socio-economic and health indicators for several African countries.  Metrics include land area, population, GDP, and diabetes prevalence.  The data shows significant variation across countries in these key areas. This data table presents various socio-economic indicators for several African nations.  It includes land area, population density, GDP, and diabetes prevalence.  The figures show considerable variation across the countries listed.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 106,
        "page_label": "102",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table displays various socio-economic and health indicators for several African countries.  Metrics include land area, population, GDP, and diabetes prevalence.  The data shows significant variation across countries in these key areas.",
        "summary_ur": "This data table presents various socio-economic indicators for several African nations.  It includes land area, population density, GDP, and diabetes prevalence.  The figures show considerable variation across the countries listed."
      }
    },
    {
      "text": "This table summarizes diabetes data for Europe in 2024, including prevalence, undiagnosed cases, and related expenditures.  Data is provided for the region as a whole and individually for Albania and Andorra, showing variations in diabetes prevalence, costs, and mortality.  Type 1 diabetes figures and impaired glucose tolerance are also included. The provided text is a data table, not legal text.  It summarizes diabetes prevalence, diagnosis rates, and associated costs in Albania and Andorra in 2024.  Key figures include prevalence rates exceeding 10% in both countries and significant undiagnosed diabetes proportions.  Expenditures are substantial, varying per capita.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 107,
        "page_label": "103",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table summarizes diabetes data for Europe in 2024, including prevalence, undiagnosed cases, and related expenditures.  Data is provided for the region as a whole and individually for Albania and Andorra, showing variations in diabetes prevalence, costs, and mortality.  Type 1 diabetes figures and impaired glucose tolerance are also included.",
        "summary_ur": "The provided text is a data table, not legal text.  It summarizes diabetes prevalence, diagnosis rates, and associated costs in Albania and Andorra in 2024.  Key figures include prevalence rates exceeding 10% in both countries and significant undiagnosed diabetes proportions.  Expenditures are substantial, varying per capita."
      }
    },
    {
      "text": "The table presents economic data for several European countries, including GDP per capita, various tax rates (corporate, personal income, VAT),  government expenditure as a percentage of GDP, and other economic indicators.  The data varies significantly across countries. The provided text is a table of data, not legal text.  It shows various economic indicators (likely GDP, taxes, etc.) for several European countries.  A concise summary isn't possible without knowing the column headers and their units.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 107,
        "page_label": "103",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for several European countries, including GDP per capita, various tax rates (corporate, personal income, VAT),  government expenditure as a percentage of GDP, and other economic indicators.  The data varies significantly across countries.",
        "summary_ur": "The provided text is a table of data, not legal text.  It shows various economic indicators (likely GDP, taxes, etc.) for several European countries.  A concise summary isn't possible without knowing the column headers and their units."
      }
    },
    {
      "text": "This table presents economic data for various European countries and territories, including GDP (in billions of EUR),  GDP per capita,  population (in millions), and several other economic indicators.  The data shows significant variation in economic size and performance across the listed regions. This data table shows various economic indicators for several European countries and territories.  The figures include GDP, population, GDP per capita, and other key metrics.  Significant variations exist across locations in terms of economic size and performance.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 107,
        "page_label": "103",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents economic data for various European countries and territories, including GDP (in billions of EUR),  GDP per capita,  population (in millions), and several other economic indicators.  The data shows significant variation in economic size and performance across the listed regions.",
        "summary_ur": "This data table shows various economic indicators for several European countries and territories.  The figures include GDP, population, GDP per capita, and other key metrics.  Significant variations exist across locations in terms of economic size and performance."
      }
    },
    {
      "text": "This data table presents economic indicators for various countries, including GDP (in billions of USD),  inflation rates, unemployment rates, and other economic figures.  The countries range from small island nations to larger states in Europe and Asia.  The data allows for comparison of economic performance across diverse nations. The provided data shows various economic indicators for several countries, including GDP, population, and several financial metrics.  Specific values vary greatly across the listed nations.  A more detailed analysis is needed for interpretation.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 107,
        "page_label": "103",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table presents economic indicators for various countries, including GDP (in billions of USD),  inflation rates, unemployment rates, and other economic figures.  The countries range from small island nations to larger states in Europe and Asia.  The data allows for comparison of economic performance across diverse nations.",
        "summary_ur": "The provided data shows various economic indicators for several countries, including GDP, population, and several financial metrics.  Specific values vary greatly across the listed nations.  A more detailed analysis is needed for interpretation."
      }
    },
    {
      "text": "The table presents socioeconomic data for several European countries, including population (in thousands), various economic indicators (GDP, etc.), and social metrics (e.g., unemployment).  The data varies significantly across countries, reflecting differing levels of economic development and social welfare. This data presents economic indicators for various European countries.  Key figures include population, GDP, GDP per capita, and various economic growth rates.  The table shows significant variation in economic performance across these nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 107,
        "page_label": "103",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents socioeconomic data for several European countries, including population (in thousands), various economic indicators (GDP, etc.), and social metrics (e.g., unemployment).  The data varies significantly across countries, reflecting differing levels of economic development and social welfare.",
        "summary_ur": "This data presents economic indicators for various European countries.  Key figures include population, GDP, GDP per capita, and various economic growth rates.  The table shows significant variation in economic performance across these nations."
      }
    },
    {
      "text": "This table presents data for Russia, San Marino, Serbia, and Slovakia, likely concerning diabetes prevalence.  It shows varying figures for population, prevalence rates (across different age groups), and potentially related economic or healthcare metrics.  Specific details require further context from the source document (IDF Diabetes Atlas 11th Edition). This data table shows various socioeconomic and health indicators for Russia, San Marino, Serbia, and Slovakia.  It includes GDP, diabetes prevalence, and other relevant statistics, but lacks context regarding units and the meaning of each column.  More information is needed for a complete summary.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 107,
        "page_label": "103",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents data for Russia, San Marino, Serbia, and Slovakia, likely concerning diabetes prevalence.  It shows varying figures for population, prevalence rates (across different age groups), and potentially related economic or healthcare metrics.  Specific details require further context from the source document (IDF Diabetes Atlas 11th Edition).",
        "summary_ur": "This data table shows various socioeconomic and health indicators for Russia, San Marino, Serbia, and Slovakia.  It includes GDP, diabetes prevalence, and other relevant statistics, but lacks context regarding units and the meaning of each column.  More information is needed for a complete summary."
      }
    },
    {
      "text": "This table presents diabetes statistics for Europe, Albania, and Andorra, including the number of adults with diabetes, prevalence rates (both overall and age-adjusted), the proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance and fasting glucose.  Data varies significantly across locations. This table presents diabetes statistics for Europe and two specific countries (Albania and Andorra).  Data includes the number of adults with diabetes, prevalence rates, proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations in prevalence and costs are evident between the regions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 108,
        "page_label": "104",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents diabetes statistics for Europe, Albania, and Andorra, including the number of adults with diabetes, prevalence rates (both overall and age-adjusted), the proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance and fasting glucose.  Data varies significantly across locations.",
        "summary_ur": "This table presents diabetes statistics for Europe and two specific countries (Albania and Andorra).  Data includes the number of adults with diabetes, prevalence rates, proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations in prevalence and costs are evident between the regions."
      }
    },
    {
      "text": "The table presents economic data for several European countries, including land area (km\u00b2), population density (people/km\u00b2), birth and death rates (per 1,000),  GDP per capita (USD), and other economic indicators.  The data varies significantly across countries, reflecting diverse economic profiles and development levels. The provided data shows various socio-economic indicators for several European countries.  These include population density, birth/death rates,  GDP, and related figures.  The data allows for comparison across nations regarding population characteristics and economic performance.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 108,
        "page_label": "104",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for several European countries, including land area (km\u00b2), population density (people/km\u00b2), birth and death rates (per 1,000),  GDP per capita (USD), and other economic indicators.  The data varies significantly across countries, reflecting diverse economic profiles and development levels.",
        "summary_ur": "The provided data shows various socio-economic indicators for several European countries.  These include population density, birth/death rates,  GDP, and related figures.  The data allows for comparison across nations regarding population characteristics and economic performance."
      }
    },
    {
      "text": "The table presents economic data for various European countries and territories, including GDP (in billions),  population, GDP per capita, and other economic indicators such as employment rates and tax rates.  The data shows significant variation in economic size and performance across the listed locations. This data table shows various economic indicators for several European countries and territories.  Key metrics include GDP (PPP), population, and several per capita figures (GDP, taxes, government expenditure).  Significant variation exists across locations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 108,
        "page_label": "104",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for various European countries and territories, including GDP (in billions),  population, GDP per capita, and other economic indicators such as employment rates and tax rates.  The data shows significant variation in economic size and performance across the listed locations.",
        "summary_ur": "This data table shows various economic indicators for several European countries and territories.  Key metrics include GDP (PPP), population, and several per capita figures (GDP, taxes, government expenditure).  Significant variation exists across locations."
      }
    },
    {
      "text": "This table presents economic data for various countries, including GDP (in millions of USD),  population (in thousands),  and several key economic indicators such as  GDP per capita,  and various percentage-based metrics (likely related to government spending, taxation or similar).  The data varies significantly across countries, reflecting differing economic structures and development levels. The provided data shows various economic indicators for several countries/territories, including GDP,  population, and several key economic ratios.  Specific values vary widely across the listed entities.  No single conclusion can be drawn without further analysis and context.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 108,
        "page_label": "104",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents economic data for various countries, including GDP (in millions of USD),  population (in thousands),  and several key economic indicators such as  GDP per capita,  and various percentage-based metrics (likely related to government spending, taxation or similar).  The data varies significantly across countries, reflecting differing economic structures and development levels.",
        "summary_ur": "The provided data shows various economic indicators for several countries/territories, including GDP,  population, and several key economic ratios.  Specific values vary widely across the listed entities.  No single conclusion can be drawn without further analysis and context."
      }
    },
    {
      "text": "The table presents economic data for several European countries, including GDP, population, and various economic indicators such as GDP per capita,  government expenditure, and unemployment rates.  The data varies significantly across countries, reflecting differing economic structures and performance levels. This data table presents economic indicators for several European countries.  It includes population, GDP, and other key figures like GDP per capita and unemployment rates, showing significant variation across nations.  The data allows for comparison of economic performance and structure.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 108,
        "page_label": "104",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for several European countries, including GDP, population, and various economic indicators such as GDP per capita,  government expenditure, and unemployment rates.  The data varies significantly across countries, reflecting differing economic structures and performance levels.",
        "summary_ur": "This data table presents economic indicators for several European countries.  It includes population, GDP, and other key figures like GDP per capita and unemployment rates, showing significant variation across nations.  The data allows for comparison of economic performance and structure."
      }
    },
    {
      "text": "This data table, likely from the IDF Diabetes Atlas, shows diabetes prevalence and related statistics for four countries: Russia, San Marino, Serbia, and Slovakia.  The figures include prevalence rates, population counts, and potentially other health metrics.  Specific meanings of the columns are not provided. This data table, likely from the IDF Diabetes Atlas, shows varying diabetes prevalence and related statistics across Russia, San Marino, Serbia, and Slovakia.  It includes figures for prevalence, population, and possibly healthcare expenditure, though precise meaning of all columns requires further context.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 108,
        "page_label": "104",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table, likely from the IDF Diabetes Atlas, shows diabetes prevalence and related statistics for four countries: Russia, San Marino, Serbia, and Slovakia.  The figures include prevalence rates, population counts, and potentially other health metrics.  Specific meanings of the columns are not provided.",
        "summary_ur": "This data table, likely from the IDF Diabetes Atlas, shows varying diabetes prevalence and related statistics across Russia, San Marino, Serbia, and Slovakia.  It includes figures for prevalence, population, and possibly healthcare expenditure, though precise meaning of all columns requires further context."
      }
    },
    {
      "text": "This table presents 2024 diabetes data for Slovenia, Spain, and Sweden.  It includes the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist across the three countries. The provided text is a data table, not legal text.  It summarizes diabetes prevalence, costs, and mortality in Slovenia, Spain, and Sweden.  Key findings show varying rates of diabetes and associated expenses across these three European countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 109,
        "page_label": "105",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents 2024 diabetes data for Slovenia, Spain, and Sweden.  It includes the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist across the three countries.",
        "summary_ur": "The provided text is a data table, not legal text.  It summarizes diabetes prevalence, costs, and mortality in Slovenia, Spain, and Sweden.  Key findings show varying rates of diabetes and associated expenses across these three European countries."
      }
    },
    {
      "text": "This table displays diabetes data for several countries, including prevalence rates (among adults aged 20-79),  the number of people with diabetes, total population, and related statistics.  Data varies significantly across nations. This table shows diabetes prevalence data for several countries.  It includes the number of people with diabetes, prevalence rates (%), and related statistics like GDP and population.  The data varies significantly across nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 109,
        "page_label": "105",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table displays diabetes data for several countries, including prevalence rates (among adults aged 20-79),  the number of people with diabetes, total population, and related statistics.  Data varies significantly across nations.",
        "summary_ur": "This table shows diabetes prevalence data for several countries.  It includes the number of people with diabetes, prevalence rates (%), and related statistics like GDP and population.  The data varies significantly across nations."
      }
    },
    {
      "text": "The table presents diabetes statistics for Slovenia, Spain, and Sweden, including the number of adults with diabetes, prevalence rates, proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist across the three countries in all measured parameters. The provided data shows diabetes prevalence, expenditure, and mortality across Slovenia, Spain, and Sweden.  Spain has the highest number of adults with diabetes and total expenditure, while Sweden shows the highest per-person expenditure.  All three countries exhibit significant proportions of undiagnosed diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 110,
        "page_label": "106",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents diabetes statistics for Slovenia, Spain, and Sweden, including the number of adults with diabetes, prevalence rates, proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist across the three countries in all measured parameters.",
        "summary_ur": "The provided data shows diabetes prevalence, expenditure, and mortality across Slovenia, Spain, and Sweden.  Spain has the highest number of adults with diabetes and total expenditure, while Sweden shows the highest per-person expenditure.  All three countries exhibit significant proportions of undiagnosed diabetes."
      }
    },
    {
      "text": "The table shows various socioeconomic and health data for several countries, including GDP, population, diabetes prevalence, and healthcare expenditures.  Data varies significantly across nations, highlighting disparities in economic development and health outcomes. The provided text is a table of data, not legal text.  It shows various economic and demographic figures (e.g., GDP, population) for several countries.  There is no legal content to summarize.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 110,
        "page_label": "106",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows various socioeconomic and health data for several countries, including GDP, population, diabetes prevalence, and healthcare expenditures.  Data varies significantly across nations, highlighting disparities in economic development and health outcomes.",
        "summary_ur": "The provided text is a table of data, not legal text.  It shows various economic and demographic figures (e.g., GDP, population) for several countries.  There is no legal content to summarize."
      }
    },
    {
      "text": "This 2024 IDF report summarizes diabetes data for the Middle East and North Africa (MENA) region and Afghanistan.  MENA shows 84.7 million adults (20-79 years) with diabetes (17.6% prevalence),  high undiagnosed rates (37.2%), and substantial diabetes-related expenditure ($34.7 billion).  Afghanistan's figures are considerably lower. The IDF 2024 report reveals high diabetes prevalence in the MENA region (17.6%,  19.9% age-adjusted).  Afghanistan shows lower prevalence (9.7%, 11.7% age-adjusted) but a high percentage of undiagnosed cases (71.4%).  Significant diabetes-related expenditure is observed across the region.  Type 1 diabetes and impaired glucose tolerance data are also included.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 111,
        "page_label": "107",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This 2024 IDF report summarizes diabetes data for the Middle East and North Africa (MENA) region and Afghanistan.  MENA shows 84.7 million adults (20-79 years) with diabetes (17.6% prevalence),  high undiagnosed rates (37.2%), and substantial diabetes-related expenditure ($34.7 billion).  Afghanistan's figures are considerably lower.",
        "summary_ur": "The IDF 2024 report reveals high diabetes prevalence in the MENA region (17.6%,  19.9% age-adjusted).  Afghanistan shows lower prevalence (9.7%, 11.7% age-adjusted) but a high percentage of undiagnosed cases (71.4%).  Significant diabetes-related expenditure is observed across the region.  Type 1 diabetes and impaired glucose tolerance data are also included."
      }
    },
    {
      "text": "This table presents data on fasting glucose prevalence (20-79 years) across several MENA countries.  It shows varying percentages of individuals with high fasting glucose levels, along with other, unspecified, demographic and economic figures.  The data suggests a wide range of prevalence rates across the region. This table presents data on fasting glucose levels in men and women (20-79 years) across several MENA countries.  It shows varying prevalence of high glucose, along with population size and other related statistics.  Specific rates differ significantly between nations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 111,
        "page_label": "107",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents data on fasting glucose prevalence (20-79 years) across several MENA countries.  It shows varying percentages of individuals with high fasting glucose levels, along with other, unspecified, demographic and economic figures.  The data suggests a wide range of prevalence rates across the region.",
        "summary_ur": "This table presents data on fasting glucose levels in men and women (20-79 years) across several MENA countries.  It shows varying prevalence of high glucose, along with population size and other related statistics.  Specific rates differ significantly between nations."
      }
    },
    {
      "text": "This data table shows diabetes prevalence and related statistics for several Middle Eastern and North African countries.  It includes data points on prevalence (%),  diabetes diagnoses, GDP, and population, revealing significant variations across the region. This data table shows diabetes prevalence and related statistics for several Middle Eastern and North African countries.  It includes data on prevalence rates, population figures, and healthcare spending.  Specific values vary significantly across countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 111,
        "page_label": "107",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table shows diabetes prevalence and related statistics for several Middle Eastern and North African countries.  It includes data points on prevalence (%),  diabetes diagnoses, GDP, and population, revealing significant variations across the region.",
        "summary_ur": "This data table shows diabetes prevalence and related statistics for several Middle Eastern and North African countries.  It includes data on prevalence rates, population figures, and healthcare spending.  Specific values vary significantly across countries."
      }
    },
    {
      "text": "The table presents diabetes data for the Middle East and North Africa (MENA) region and two specific countries (Afghanistan and Algeria).  It details the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), related expenditures, deaths, and impaired glucose tolerance prevalence.  MENA shows higher diabetes prevalence and expenditure than the individual countries listed. The provided text is a data table, not legal text.  It shows diabetes statistics for the Middle East and North Africa (MENA) region and specific countries like Afghanistan and Algeria.  Data includes prevalence, undiagnosed cases, expenditure, and deaths.  No legal summary is possible.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 112,
        "page_label": "108",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents diabetes data for the Middle East and North Africa (MENA) region and two specific countries (Afghanistan and Algeria).  It details the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), related expenditures, deaths, and impaired glucose tolerance prevalence.  MENA shows higher diabetes prevalence and expenditure than the individual countries listed.",
        "summary_ur": "The provided text is a data table, not legal text.  It shows diabetes statistics for the Middle East and North Africa (MENA) region and specific countries like Afghanistan and Algeria.  Data includes prevalence, undiagnosed cases, expenditure, and deaths.  No legal summary is possible."
      }
    },
    {
      "text": "The table shows various socio-economic indicators for several Middle Eastern and North African countries. Data includes population, GDP,  agricultural land use, and other economic metrics.  Significant variations exist across countries in GDP, population density, and agricultural contribution to the economy. The provided data shows various socio-economic indicators for several Middle Eastern and North African countries.  These include population, GDP, and several key ratios.  The table lacks context regarding the units and the specific meaning of each column.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 112,
        "page_label": "108",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows various socio-economic indicators for several Middle Eastern and North African countries. Data includes population, GDP,  agricultural land use, and other economic metrics.  Significant variations exist across countries in GDP, population density, and agricultural contribution to the economy.",
        "summary_ur": "The provided data shows various socio-economic indicators for several Middle Eastern and North African countries.  These include population, GDP, and several key ratios.  The table lacks context regarding the units and the specific meaning of each column."
      }
    },
    {
      "text": "This data table from the IDF Diabetes Atlas 11th Edition (2025) shows diabetes prevalence and related statistics for several Middle Eastern and North African countries.  It includes data on prevalence rates, population, and other health metrics.  Specific details vary considerably between nations. The provided text is a table of data, likely from the IDF Diabetes Atlas, showing various health and economic indicators for several Middle Eastern and North African countries.  The data includes population figures, GDP, and diabetes prevalence.  More context is needed for a complete summary.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 112,
        "page_label": "108",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table from the IDF Diabetes Atlas 11th Edition (2025) shows diabetes prevalence and related statistics for several Middle Eastern and North African countries.  It includes data on prevalence rates, population, and other health metrics.  Specific details vary considerably between nations.",
        "summary_ur": "The provided text is a table of data, likely from the IDF Diabetes Atlas, showing various health and economic indicators for several Middle Eastern and North African countries.  The data includes population figures, GDP, and diabetes prevalence.  More context is needed for a complete summary."
      }
    },
    {
      "text": "This table summarizes diabetes statistics for North America and the Caribbean in 2024.  Data includes the number of adults with diabetes, prevalence rates (including undiagnosed cases),  expenditures per person and overall, deaths related to diabetes, and prevalence of impaired glucose tolerance.  Significant variations exist across countries/territories. The provided text is a data table, not legal text.  It summarizes diabetes statistics for North America and the Caribbean in 2024, including prevalence, undiagnosed cases, expenditures, and deaths.  Specific figures are given for the region and two smaller territories.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 113,
        "page_label": "109",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table summarizes diabetes statistics for North America and the Caribbean in 2024.  Data includes the number of adults with diabetes, prevalence rates (including undiagnosed cases),  expenditures per person and overall, deaths related to diabetes, and prevalence of impaired glucose tolerance.  Significant variations exist across countries/territories.",
        "summary_ur": "The provided text is a data table, not legal text.  It summarizes diabetes statistics for North America and the Caribbean in 2024, including prevalence, undiagnosed cases, expenditures, and deaths.  Specific figures are given for the region and two smaller territories."
      }
    },
    {
      "text": "The table presents economic data for various Caribbean and North American countries.  Data includes GDP (in millions of USD), population (in thousands), and other economic indicators.  Significant variation exists across countries in GDP, population size, and other metrics. This data table shows economic indicators for various Caribbean and North American countries.  It includes GDP, various economic percentages, and population figures.  The data varies significantly across nations, reflecting diverse economic strengths and challenges.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 113,
        "page_label": "109",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for various Caribbean and North American countries.  Data includes GDP (in millions of USD), population (in thousands), and other economic indicators.  Significant variation exists across countries in GDP, population size, and other metrics.",
        "summary_ur": "This data table shows economic indicators for various Caribbean and North American countries.  It includes GDP, various economic percentages, and population figures.  The data varies significantly across nations, reflecting diverse economic strengths and challenges."
      }
    },
    {
      "text": "This table presents diabetes prevalence data for several countries/territories.  It shows varying prevalence rates (ranging from 4.1% to 14.2%),  total populations, and other diabetes-related statistics.  The data highlights significant differences in diabetes burden across these regions. This data table shows diabetes prevalence and related statistics for several countries/territories.  It includes land area, prevalence rates (adults, children), and economic indicators.  The US has the highest values across most categories.  Other Caribbean nations show considerably lower figures.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 113,
        "page_label": "109",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents diabetes prevalence data for several countries/territories.  It shows varying prevalence rates (ranging from 4.1% to 14.2%),  total populations, and other diabetes-related statistics.  The data highlights significant differences in diabetes burden across these regions.",
        "summary_ur": "This data table shows diabetes prevalence and related statistics for several countries/territories.  It includes land area, prevalence rates (adults, children), and economic indicators.  The US has the highest values across most categories.  Other Caribbean nations show considerably lower figures."
      }
    },
    {
      "text": "This table presents diabetes statistics for North America and the Caribbean.  Data includes the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  The data varies significantly between regions and countries, with NAC showing substantially higher numbers than Antigua and Barbuda, Aruba, and the Bahamas. This data table shows diabetes prevalence and related costs across North America and the Caribbean.  It details the number of adults with diabetes, prevalence rates (both age-adjusted and raw), undiagnosed cases, expenditure per person and total expenditure, deaths, and type 1 diabetes cases.  Significant variations exist between countries and regions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 114,
        "page_label": "110",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents diabetes statistics for North America and the Caribbean.  Data includes the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  The data varies significantly between regions and countries, with NAC showing substantially higher numbers than Antigua and Barbuda, Aruba, and the Bahamas.",
        "summary_ur": "This data table shows diabetes prevalence and related costs across North America and the Caribbean.  It details the number of adults with diabetes, prevalence rates (both age-adjusted and raw), undiagnosed cases, expenditure per person and total expenditure, deaths, and type 1 diabetes cases.  Significant variations exist between countries and regions."
      }
    },
    {
      "text": "This data table shows economic indicators for various Caribbean and North American countries.  It includes figures for GDP (in millions of USD), population (in thousands), and other economic metrics such as  inflation and unemployment.  The data varies significantly across countries, reflecting differences in size and economic development. The provided data shows economic indicators (likely GDP, population, etc.) for various Caribbean and North American countries.  Significant variation exists across nations, with Mexico and Canada showing considerably larger figures than smaller island states.  Further analysis is needed to interpret the specific meaning of the columns.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 114,
        "page_label": "110",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table shows economic indicators for various Caribbean and North American countries.  It includes figures for GDP (in millions of USD), population (in thousands), and other economic metrics such as  inflation and unemployment.  The data varies significantly across countries, reflecting differences in size and economic development.",
        "summary_ur": "The provided data shows economic indicators (likely GDP, population, etc.) for various Caribbean and North American countries.  Significant variation exists across nations, with Mexico and Canada showing considerably larger figures than smaller island states.  Further analysis is needed to interpret the specific meaning of the columns."
      }
    },
    {
      "text": "The table shows diabetes prevalence data (prevalence, age-standardized prevalence) from the IDF Diabetes Atlas 11th Edition (2025) for several countries/territories.  Data includes population size and number of adults with diabetes.  The US has the highest number of adults with diabetes, while smaller island nations show varied prevalence rates. The provided data shows various socio-economic and health indicators (likely diabetes prevalence) for several countries and territories, including population, GDP, and related metrics.  Specific values are listed but lack context without knowing the column headers.  The data appears to be from the IDF Diabetes Atlas.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 114,
        "page_label": "110",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows diabetes prevalence data (prevalence, age-standardized prevalence) from the IDF Diabetes Atlas 11th Edition (2025) for several countries/territories.  Data includes population size and number of adults with diabetes.  The US has the highest number of adults with diabetes, while smaller island nations show varied prevalence rates.",
        "summary_ur": "The provided data shows various socio-economic and health indicators (likely diabetes prevalence) for several countries and territories, including population, GDP, and related metrics.  Specific values are listed but lack context without knowing the column headers.  The data appears to be from the IDF Diabetes Atlas."
      }
    },
    {
      "text": "The table presents diabetes data for South and Central America (SACA) and two specific countries, Argentina and Bolivia.  It shows the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), expenditure per person and total expenditure, diabetes-related deaths, and prevalence of impaired glucose tolerance and fasting glucose.  SACA data aggregates figures from multiple nations. The provided data shows diabetes prevalence and costs across South and Central America (SACA) and Argentina and Bolivia.  SACA has 35.4 million adults with diabetes (10% prevalence), high undiagnosed rates (30.4%), and substantial diabetes-related expenditure ($80.8 billion).  Argentina and Bolivia exhibit varying prevalence and costs, reflecting differing healthcare systems and access.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 115,
        "page_label": "111",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents diabetes data for South and Central America (SACA) and two specific countries, Argentina and Bolivia.  It shows the number of adults with diabetes, prevalence rates (diagnosed and undiagnosed), expenditure per person and total expenditure, diabetes-related deaths, and prevalence of impaired glucose tolerance and fasting glucose.  SACA data aggregates figures from multiple nations.",
        "summary_ur": "The provided data shows diabetes prevalence and costs across South and Central America (SACA) and Argentina and Bolivia.  SACA has 35.4 million adults with diabetes (10% prevalence), high undiagnosed rates (30.4%), and substantial diabetes-related expenditure ($80.8 billion).  Argentina and Bolivia exhibit varying prevalence and costs, reflecting differing healthcare systems and access."
      }
    },
    {
      "text": "The table presents economic data for several Latin American countries, including GDP (in billions),  various economic indicators (%), and population figures.  Data points cover GDP per capita, inflation, and other key economic metrics. This data table shows economic indicators for several Latin American countries.  It includes GDP, various percentages (likely related to economic activity), and population figures.  The data suggests a range of economic performance across the region.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 115,
        "page_label": "111",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for several Latin American countries, including GDP (in billions),  various economic indicators (%), and population figures.  Data points cover GDP per capita, inflation, and other key economic metrics.",
        "summary_ur": "This data table shows economic indicators for several Latin American countries.  It includes GDP, various percentages (likely related to economic activity), and population figures.  The data suggests a range of economic performance across the region."
      }
    },
    {
      "text": "This table summarizes diabetes prevalence data for several South and Central American countries in 2024.  It shows prevalence rates,  the number of people with diabetes, and related statistics like age-standardized prevalence and healthcare resource allocation.  Data is presented for  Guatemala, Honduras, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, and Venezuela. This table summarizes 2024 diabetes data for nine South and Central American countries.  It shows prevalence rates, diagnosed cases, and related health expenditures, varying considerably across nations.  Specific figures are presented for each country.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 115,
        "page_label": "111",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table summarizes diabetes prevalence data for several South and Central American countries in 2024.  It shows prevalence rates,  the number of people with diabetes, and related statistics like age-standardized prevalence and healthcare resource allocation.  Data is presented for  Guatemala, Honduras, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, and Venezuela.",
        "summary_ur": "This table summarizes 2024 diabetes data for nine South and Central American countries.  It shows prevalence rates, diagnosed cases, and related health expenditures, varying considerably across nations.  Specific figures are presented for each country."
      }
    },
    {
      "text": "The table presents diabetes data for South and Central America (SACA) and two specific countries, Argentina and Bolivia.  It includes the number of adults with diabetes, prevalence rates, proportions of undiagnosed cases, diabetes-related expenditures, deaths, and prevalence of impaired glucose tolerance.  Data shows significant variation across the region. The provided data shows diabetes prevalence and costs across South and Central America (SACA) and Argentina and Bolivia.  SACA has high diabetes prevalence (10.1%), a significant proportion undiagnosed (30.4%), and substantial related expenditure ($80.8 billion).  Argentina and Bolivia show varying prevalence and cost figures reflecting diverse health systems and populations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 116,
        "page_label": "112",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents diabetes data for South and Central America (SACA) and two specific countries, Argentina and Bolivia.  It includes the number of adults with diabetes, prevalence rates, proportions of undiagnosed cases, diabetes-related expenditures, deaths, and prevalence of impaired glucose tolerance.  Data shows significant variation across the region.",
        "summary_ur": "The provided data shows diabetes prevalence and costs across South and Central America (SACA) and Argentina and Bolivia.  SACA has high diabetes prevalence (10.1%), a significant proportion undiagnosed (30.4%), and substantial related expenditure ($80.8 billion).  Argentina and Bolivia show varying prevalence and cost figures reflecting diverse health systems and populations."
      }
    },
    {
      "text": "The table presents economic data for several Latin American countries.  It includes figures on GDP (in billions of USD),  various economic indicators (e.g., inflation, investment), and population.  The data shows significant variation in economic performance across the listed nations. The table shows economic data for several Latin American countries.  It includes GDP, various economic indicators (e.g., inflation, investment), and population figures.  The data reveals significant variation in economic performance across the region.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 116,
        "page_label": "112",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents economic data for several Latin American countries.  It includes figures on GDP (in billions of USD),  various economic indicators (e.g., inflation, investment), and population.  The data shows significant variation in economic performance across the listed nations.",
        "summary_ur": "The table shows economic data for several Latin American countries.  It includes GDP, various economic indicators (e.g., inflation, investment), and population figures.  The data reveals significant variation in economic performance across the region."
      }
    },
    {
      "text": "The table presents data from the IDF Diabetes Atlas 11th Edition (2025), showing diabetes prevalence and related figures for several countries (including  Guatemala, Honduras, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, and Venezuela).  Data points include prevalence rates, population figures, and potentially other relevant health metrics. This data table from the IDF Diabetes Atlas (2025) presents diabetes prevalence and related statistics for various countries/territories.  It shows prevalence rates, along with population figures and related health metrics, varying considerably across locations.  More detailed analysis is needed for deeper interpretation.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 116,
        "page_label": "112",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents data from the IDF Diabetes Atlas 11th Edition (2025), showing diabetes prevalence and related figures for several countries (including  Guatemala, Honduras, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, and Venezuela).  Data points include prevalence rates, population figures, and potentially other relevant health metrics.",
        "summary_ur": "This data table from the IDF Diabetes Atlas (2025) presents diabetes prevalence and related statistics for various countries/territories.  It shows prevalence rates, along with population figures and related health metrics, varying considerably across locations.  More detailed analysis is needed for deeper interpretation."
      }
    },
    {
      "text": "The table presents diabetes statistics for South and Central America, Bangladesh, and Bhutan.  Data includes the number of adults with diabetes, prevalence rates, proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist across the regions. The provided text is a table, not legal text.  It shows diabetes statistics for South and Central America (SEA), Bangladesh, and Bhutan, including prevalence, undiagnosed cases, expenditures, and deaths.  The data reveals high diabetes burdens across these regions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 117,
        "page_label": "113",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents diabetes statistics for South and Central America, Bangladesh, and Bhutan.  Data includes the number of adults with diabetes, prevalence rates, proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist across the regions.",
        "summary_ur": "The provided text is a table, not legal text.  It shows diabetes statistics for South and Central America (SEA), Bangladesh, and Bhutan, including prevalence, undiagnosed cases, expenditures, and deaths.  The data reveals high diabetes burdens across these regions."
      }
    },
    {
      "text": "This table shows diabetes prevalence data for South-East Asian countries in 2024.  It includes the number of adults with diabetes, prevalence rates (%), and total population.  Countries listed are Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka.  Data varies significantly across nations. This table shows diabetes prevalence data for South-East Asian countries in 2024.  It includes the number of adults with diabetes, prevalence rates (%), and population figures.  Specific data varies widely across countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 117,
        "page_label": "113",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table shows diabetes prevalence data for South-East Asian countries in 2024.  It includes the number of adults with diabetes, prevalence rates (%), and total population.  Countries listed are Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka.  Data varies significantly across nations.",
        "summary_ur": "This table shows diabetes prevalence data for South-East Asian countries in 2024.  It includes the number of adults with diabetes, prevalence rates (%), and population figures.  Specific data varies widely across countries."
      }
    },
    {
      "text": "The table presents diabetes statistics for South and Central America, including the number of adults with diabetes, prevalence rates (both overall and age-adjusted), proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Data is also shown for Bangladesh and Bhutan. The provided text is a table, not legal text.  It shows diabetes statistics for South and Central America (SEA), Bangladesh, and Bhutan, including prevalence, undiagnosed cases, expenditure, and deaths.  No legal summary is possible.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 118,
        "page_label": "114",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents diabetes statistics for South and Central America, including the number of adults with diabetes, prevalence rates (both overall and age-adjusted), proportion of undiagnosed cases, diabetes-related expenditure, deaths, and prevalence of impaired glucose tolerance.  Data is also shown for Bangladesh and Bhutan.",
        "summary_ur": "The provided text is a table, not legal text.  It shows diabetes statistics for South and Central America (SEA), Bangladesh, and Bhutan, including prevalence, undiagnosed cases, expenditure, and deaths.  No legal summary is possible."
      }
    },
    {
      "text": "The table shows diabetes prevalence data (prevalence, diagnosed, undiagnosed) across several South Asian countries (Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, Sri Lanka) from the IDF Diabetes Atlas 11th Edition.  Data includes population figures and prevalence rates. The provided text presents data from the IDF Diabetes Atlas, 11th Edition (2025), showing diabetes prevalence and related figures for several South Asian countries (Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, Sri Lanka).  The data includes prevalence rates, population figures, and other relevant statistics.  Specific details are numerous and require further analysis.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 118,
        "page_label": "114",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table shows diabetes prevalence data (prevalence, diagnosed, undiagnosed) across several South Asian countries (Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, Sri Lanka) from the IDF Diabetes Atlas 11th Edition.  Data includes population figures and prevalence rates.",
        "summary_ur": "The provided text presents data from the IDF Diabetes Atlas, 11th Edition (2025), showing diabetes prevalence and related figures for several South Asian countries (Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, Sri Lanka).  The data includes prevalence rates, population figures, and other relevant statistics.  Specific details are numerous and require further analysis."
      }
    },
    {
      "text": "This table summarizes diabetes data for the Western Pacific region in 2024.  It shows the number of adults with diabetes, prevalence rates (both overall and age-adjusted), the proportion of undiagnosed cases, diabetes-related expenditures, deaths, and prevalence of impaired glucose tolerance.  Data is provided for the region as a whole and for Australia and Brunei Darussalam individually. The Western Pacific region (WP) shows high diabetes prevalence (12.4%).  Australia and Brunei Darussalam reflect this trend, though with varying prevalence rates and expenditure.  A significant proportion of diabetes cases remain undiagnosed across all locations.  The data highlights a substantial economic burden associated with diabetes management in the region.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 119,
        "page_label": "115",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table summarizes diabetes data for the Western Pacific region in 2024.  It shows the number of adults with diabetes, prevalence rates (both overall and age-adjusted), the proportion of undiagnosed cases, diabetes-related expenditures, deaths, and prevalence of impaired glucose tolerance.  Data is provided for the region as a whole and for Australia and Brunei Darussalam individually.",
        "summary_ur": "The Western Pacific region (WP) shows high diabetes prevalence (12.4%).  Australia and Brunei Darussalam reflect this trend, though with varying prevalence rates and expenditure.  A significant proportion of diabetes cases remain undiagnosed across all locations.  The data highlights a substantial economic burden associated with diabetes management in the region."
      }
    },
    {
      "text": "This data table shows economic indicators for several Asian and Pacific countries.  Data points include GDP (in billions of USD), GDP growth rate, inflation rate, unemployment rate, and other economic figures.  The table allows for cross-country comparison of economic performance. This data shows economic indicators for several Asian and Pacific nations.  Key figures include GDP (in billions of USD), GDP growth rate, inflation, and unemployment.  The table highlights significant variations in economic size and performance across the listed countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 119,
        "page_label": "115",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table shows economic indicators for several Asian and Pacific countries.  Data points include GDP (in billions of USD), GDP growth rate, inflation rate, unemployment rate, and other economic figures.  The table allows for cross-country comparison of economic performance.",
        "summary_ur": "This data shows economic indicators for several Asian and Pacific nations.  Key figures include GDP (in billions of USD), GDP growth rate, inflation, and unemployment.  The table highlights significant variations in economic size and performance across the listed countries."
      }
    },
    {
      "text": "This data table presents socio-economic indicators for several Pacific Rim nations.  It includes figures for population, GDP, various economic metrics (e.g.,  GDP per capita,  agricultural contribution to GDP), and other relevant statistics.  The countries represented range in size and development level. This table displays socioeconomic data for several Pacific island nations.  It includes GDP, various percentages (likely related to economic activity and demographics), and population figures.  The data suggests a wide range of economic development levels across these countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 119,
        "page_label": "115",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table presents socio-economic indicators for several Pacific Rim nations.  It includes figures for population, GDP, various economic metrics (e.g.,  GDP per capita,  agricultural contribution to GDP), and other relevant statistics.  The countries represented range in size and development level.",
        "summary_ur": "This table displays socioeconomic data for several Pacific island nations.  It includes GDP, various percentages (likely related to economic activity and demographics), and population figures.  The data suggests a wide range of economic development levels across these countries."
      }
    },
    {
      "text": "The table presents data for various Pacific island nations, including land area (km\u00b2), population density (per km\u00b2),  fertility rate, life expectancy, and GDP (USD).  Significant variation exists across countries in all measured parameters.  Data includes population, GDP, and economic indicators. This data displays various socio-economic indicators for several Pacific Island nations.  The table includes land area, population, GDP, and other metrics, showing significant variation in size, wealth, and development levels across these countries.  More detailed analysis is needed to draw specific conclusions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 119,
        "page_label": "115",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The table presents data for various Pacific island nations, including land area (km\u00b2), population density (per km\u00b2),  fertility rate, life expectancy, and GDP (USD).  Significant variation exists across countries in all measured parameters.  Data includes population, GDP, and economic indicators.",
        "summary_ur": "This data displays various socio-economic indicators for several Pacific Island nations.  The table includes land area, population, GDP, and other metrics, showing significant variation in size, wealth, and development levels across these countries.  More detailed analysis is needed to draw specific conclusions."
      }
    },
    {
      "text": "This data table presents diabetes statistics for four countries (Tonga, Tuvalu, Vanuatu, and Vietnam).  It shows figures for prevalence, population, and related health metrics, highlighting significant variations in diabetes burden across these nations.  The data likely comes from the IDF Diabetes Atlas, 11th Edition. This table shows diabetes data (prevalence, etc.) for four countries: Tonga, Tuvalu, Vanuatu, and Vietnam.  Vietnam has significantly larger figures across all metrics compared to the island nations.  The data likely comes from the IDF Diabetes Atlas.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 119,
        "page_label": "115",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table presents diabetes statistics for four countries (Tonga, Tuvalu, Vanuatu, and Vietnam).  It shows figures for prevalence, population, and related health metrics, highlighting significant variations in diabetes burden across these nations.  The data likely comes from the IDF Diabetes Atlas, 11th Edition.",
        "summary_ur": "This table shows diabetes data (prevalence, etc.) for four countries: Tonga, Tuvalu, Vanuatu, and Vietnam.  Vietnam has significantly larger figures across all metrics compared to the island nations.  The data likely comes from the IDF Diabetes Atlas."
      }
    },
    {
      "text": "This table presents diabetes statistics for the Western Pacific region and two specific countries (Australia and Brunei).  Data includes the number of adults with diabetes, prevalence rates (both overall and age-adjusted), proportion of undiagnosed cases, diabetes-related expenditures, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist between the region and the individual countries. The Western Pacific region shows high diabetes prevalence (12.4%), with a significant portion undiagnosed (50%).  Australia and Brunei Darussalam reflect this trend, though with varying prevalence rates and expenditure.  High diabetes-related deaths and impaired glucose tolerance are also noted.  Specific figures vary considerably between locations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 120,
        "page_label": "116",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents diabetes statistics for the Western Pacific region and two specific countries (Australia and Brunei).  Data includes the number of adults with diabetes, prevalence rates (both overall and age-adjusted), proportion of undiagnosed cases, diabetes-related expenditures, deaths, and prevalence of impaired glucose tolerance.  Significant variations exist between the region and the individual countries.",
        "summary_ur": "The Western Pacific region shows high diabetes prevalence (12.4%), with a significant portion undiagnosed (50%).  Australia and Brunei Darussalam reflect this trend, though with varying prevalence rates and expenditure.  High diabetes-related deaths and impaired glucose tolerance are also noted.  Specific figures vary considerably between locations."
      }
    },
    {
      "text": "This table presents economic data for several Asian and Pacific countries.  Data points include GDP (in billions of USD), GDP growth rate, inflation rate, unemployment rate, and other key economic indicators.  The figures show significant variation in economic performance across the listed nations. This data table shows economic indicators for several Asian-Pacific countries.  Values include GDP (USD), GDP growth rate, inflation, unemployment, and other economic figures.  Significant variation exists across nations in terms of economic size and performance.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 120,
        "page_label": "116",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This table presents economic data for several Asian and Pacific countries.  Data points include GDP (in billions of USD), GDP growth rate, inflation rate, unemployment rate, and other key economic indicators.  The figures show significant variation in economic performance across the listed nations.",
        "summary_ur": "This data table shows economic indicators for several Asian-Pacific countries.  Values include GDP (USD), GDP growth rate, inflation, unemployment, and other economic figures.  Significant variation exists across nations in terms of economic size and performance."
      }
    },
    {
      "text": "This data table presents socio-economic indicators for several Pacific island nations and Asian countries.  It includes data on land area, population density,  fertility rate, life expectancy, GDP per capita, and total GDP, among other metrics.  The figures vary significantly across the listed countries and territories. This table displays economic data for several Pacific Rim nations.  It includes figures on GDP (in USD billions),  population,  various economic indicators (like inflation and unemployment), and trade balances.  The data shows considerable variation in economic performance across these countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 120,
        "page_label": "116",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table presents socio-economic indicators for several Pacific island nations and Asian countries.  It includes data on land area, population density,  fertility rate, life expectancy, GDP per capita, and total GDP, among other metrics.  The figures vary significantly across the listed countries and territories.",
        "summary_ur": "This table displays economic data for several Pacific Rim nations.  It includes figures on GDP (in USD billions),  population,  various economic indicators (like inflation and unemployment), and trade balances.  The data shows considerable variation in economic performance across these countries."
      }
    },
    {
      "text": "This data table presents economic indicators for various Pacific Island nations.  It includes figures for land area, population density,  GDP, and various economic and social metrics (e.g.,  GDP per capita,  agricultural contribution to GDP).  The data shows significant variation in economic development across the listed countries. This data table presents economic indicators for various Pacific island nations.  It includes land area, population density, various percentages (likely relating to agriculture, industry, services), GDP, and other economic figures.  The data showcases a wide range in economic size and structure across these countries.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 120,
        "page_label": "116",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table presents economic indicators for various Pacific Island nations.  It includes figures for land area, population density,  GDP, and various economic and social metrics (e.g.,  GDP per capita,  agricultural contribution to GDP).  The data shows significant variation in economic development across the listed countries.",
        "summary_ur": "This data table presents economic indicators for various Pacific island nations.  It includes land area, population density, various percentages (likely relating to agriculture, industry, services), GDP, and other economic figures.  The data showcases a wide range in economic size and structure across these countries."
      }
    },
    {
      "text": "This data table, likely from the IDF Diabetes Atlas, presents diabetes-related statistics for four countries (Tonga, Tuvalu, Vanuatu, Vietnam).  It shows varying prevalence rates and other metrics (population, prevalence, etc.), highlighting significant differences in diabetes burden across these nations. This data, likely from the IDF Diabetes Atlas, shows diabetes prevalence and related statistics for four countries: Tonga, Tuvalu, Vanuatu, and Vietnam.  The figures include prevalence rates, population, and other relevant health metrics, revealing significant variations across these nations.  More context is needed for complete understanding.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 120,
        "page_label": "116",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This data table, likely from the IDF Diabetes Atlas, presents diabetes-related statistics for four countries (Tonga, Tuvalu, Vanuatu, Vietnam).  It shows varying prevalence rates and other metrics (population, prevalence, etc.), highlighting significant differences in diabetes burden across these nations.",
        "summary_ur": "This data, likely from the IDF Diabetes Atlas, shows diabetes prevalence and related statistics for four countries: Tonga, Tuvalu, Vanuatu, and Vietnam.  The figures include prevalence rates, population, and other relevant health metrics, revealing significant variations across these nations.  More context is needed for complete understanding."
      }
    },
    {
      "text": "This text provides a list of abbreviations and acronyms commonly used in the context of diabetes, pregnancy, and related health conditions.  It includes terms for organizations (e.g., IDF, FIGO), diseases (e.g., CVD, GDM), and medical measurements (e.g., HbA1c, FBG). This text lists abbreviations and acronyms, primarily related to diabetes, pregnancy, and health organizations.  Examples include ADA (American Diabetes Association), IDF (International Diabetes Federation), HbA1c (glycosylated hemoglobin), and GDM (gestational diabetes mellitus).  The list covers various medical and economic terms.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 121,
        "page_label": "117",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text provides a list of abbreviations and acronyms commonly used in the context of diabetes, pregnancy, and related health conditions.  It includes terms for organizations (e.g., IDF, FIGO), diseases (e.g., CVD, GDM), and medical measurements (e.g., HbA1c, FBG).",
        "summary_ur": "This text lists abbreviations and acronyms, primarily related to diabetes, pregnancy, and health organizations.  Examples include ADA (American Diabetes Association), IDF (International Diabetes Federation), HbA1c (glycosylated hemoglobin), and GDM (gestational diabetes mellitus).  The list covers various medical and economic terms."
      }
    },
    {
      "text": "This text is a glossary of abbreviations commonly used in the context of diabetes, particularly in pregnancy.  It includes acronyms for organizations (e.g., WHO, IDF), medical terms (e.g., OGTT, T1D), and units of measurement (e.g., mg/dL, mmol/L). This text is a glossary of abbreviations commonly used in the context of diabetes, particularly in pregnancy and international health organizations.  It includes terms for diabetes types, glucose tolerance tests,  cholesterol levels, and relevant organizations like WHO and IDF.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 121,
        "page_label": "117",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text is a glossary of abbreviations commonly used in the context of diabetes, particularly in pregnancy.  It includes acronyms for organizations (e.g., WHO, IDF), medical terms (e.g., OGTT, T1D), and units of measurement (e.g., mg/dL, mmol/L).",
        "summary_ur": "This text is a glossary of abbreviations commonly used in the context of diabetes, particularly in pregnancy and international health organizations.  It includes terms for diabetes types, glucose tolerance tests,  cholesterol levels, and relevant organizations like WHO and IDF."
      }
    },
    {
      "text": "This text is a list of abbreviations and acronyms, primarily related to the United Nations, health organizations (WHO), and diabetes (IDF, WDD, YLD, VaD).  It includes references to funding (USD) and geographic regions (WP). This text is a list of abbreviations, not a legal text.  It provides acronyms like UN (United Nations), WHO (World Health Organization), and IDF (likely referring to the International Diabetes Federation), along with terms like VaD (vascular dementia) and YLD (Young Leaders in Diabetes).  It's a reference list, not a legal document requiring summarization.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 121,
        "page_label": "117",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text is a list of abbreviations and acronyms, primarily related to the United Nations, health organizations (WHO), and diabetes (IDF, WDD, YLD, VaD).  It includes references to funding (USD) and geographic regions (WP).",
        "summary_ur": "This text is a list of abbreviations, not a legal text.  It provides acronyms like UN (United Nations), WHO (World Health Organization), and IDF (likely referring to the International Diabetes Federation), along with terms like VaD (vascular dementia) and YLD (Young Leaders in Diabetes).  It's a reference list, not a legal document requiring summarization."
      }
    },
    {
      "text": "This glossary defines three terms:  Age-adjusted comparative prevalence (a method for comparing disease prevalence across populations with different age structures), Analytical Hierarchy Process (AHP) scoring (a method for quantifying the value of different study aspects), and Attributable fraction method (measuring a risk factor's contribution to disease).  It also mentions autoimmune reaction, but provides no definition. This glossary defines three concepts:  Age-adjusted comparative prevalence (rates adjusted to a standard population's age structure for fairer comparisons), Analytical Hierarchy Process (AHP) scoring (quantifies the relative value of study aspects), and Attributable fraction method (measures a risk factor's contribution to disease).  A brief definition of autoimmune reaction is also included, but lacks detail.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 122,
        "page_label": "118",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This glossary defines three terms:  Age-adjusted comparative prevalence (a method for comparing disease prevalence across populations with different age structures), Analytical Hierarchy Process (AHP) scoring (a method for quantifying the value of different study aspects), and Attributable fraction method (measuring a risk factor's contribution to disease).  It also mentions autoimmune reaction, but provides no definition.",
        "summary_ur": "This glossary defines three concepts:  Age-adjusted comparative prevalence (rates adjusted to a standard population's age structure for fairer comparisons), Analytical Hierarchy Process (AHP) scoring (quantifies the relative value of study aspects), and Attributable fraction method (measures a risk factor's contribution to disease).  A brief definition of autoimmune reaction is also included, but lacks detail."
      }
    },
    {
      "text": "This text defines several medical terms: Population Attributable Fraction (PAF), autoimmune reaction, beta cells, body mass index (BMI), cardiovascular diseases (CVD), and dementia.  It provides concise explanations of each term's meaning and significance. This text defines several medical terms: Population Attributable Fraction (PAF), autoimmune reaction, beta cells, body mass index (BMI), cardiovascular diseases (CVD), and dementia.  It provides concise explanations of each.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 122,
        "page_label": "118",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text defines several medical terms: Population Attributable Fraction (PAF), autoimmune reaction, beta cells, body mass index (BMI), cardiovascular diseases (CVD), and dementia.  It provides concise explanations of each term's meaning and significance.",
        "summary_ur": "This text defines several medical terms: Population Attributable Fraction (PAF), autoimmune reaction, beta cells, body mass index (BMI), cardiovascular diseases (CVD), and dementia.  It provides concise explanations of each."
      }
    },
    {
      "text": "The text defines several medical conditions:  vascular disease (narrowed or blocked blood vessels), dementia (progressive cognitive decline), diabetes complications (acute and chronic conditions from diabetes), diabetic foot (diabetes-related foot disease), diabetes in pregnancy (diabetes diagnosed during pregnancy), and diabetic ketoacidosis (a metabolic disorder from excessive fat breakdown). The text defines several medical conditions: cerebrovascular disease (narrowed/blocked blood vessels), dementia (progressive cognitive decline), diabetes complications (acute and chronic), diabetic foot (diabetes-related foot disease), diabetes in pregnancy (diabetes diagnosed during pregnancy), and diabetic ketoacidosis (excessive fat breakdown causing ketone buildup).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 122,
        "page_label": "118",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text defines several medical conditions:  vascular disease (narrowed or blocked blood vessels), dementia (progressive cognitive decline), diabetes complications (acute and chronic conditions from diabetes), diabetic foot (diabetes-related foot disease), diabetes in pregnancy (diabetes diagnosed during pregnancy), and diabetic ketoacidosis (a metabolic disorder from excessive fat breakdown).",
        "summary_ur": "The text defines several medical conditions: cerebrovascular disease (narrowed/blocked blood vessels), dementia (progressive cognitive decline), diabetes complications (acute and chronic), diabetic foot (diabetes-related foot disease), diabetes in pregnancy (diabetes diagnosed during pregnancy), and diabetic ketoacidosis (excessive fat breakdown causing ketone buildup)."
      }
    },
    {
      "text": "The text describes diabetic ketoacidosis (DKA), a dangerous complication of diabetes where excessive fat breakdown leads to acidic blood; diabetes itself, a chronic condition with high blood glucose due to insufficient insulin production or use; and diabetic neuropathy, nerve damage resulting from diabetes.  It also mentions direct healthcare costs associated with these conditions. This text describes three diabetes-related conditions: diabetic ketoacidosis (DKA), a dangerous metabolic disorder caused by excessive fat breakdown; diabetes mellitus, characterized by high blood glucose due to insulin deficiency or resistance; and diabetic neuropathy, nerve damage causing pain, numbness, and organ dysfunction.  It also mentions direct healthcare costs associated with these conditions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 122,
        "page_label": "118",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text describes diabetic ketoacidosis (DKA), a dangerous complication of diabetes where excessive fat breakdown leads to acidic blood; diabetes itself, a chronic condition with high blood glucose due to insufficient insulin production or use; and diabetic neuropathy, nerve damage resulting from diabetes.  It also mentions direct healthcare costs associated with these conditions.",
        "summary_ur": "This text describes three diabetes-related conditions: diabetic ketoacidosis (DKA), a dangerous metabolic disorder caused by excessive fat breakdown; diabetes mellitus, characterized by high blood glucose due to insulin deficiency or resistance; and diabetic neuropathy, nerve damage causing pain, numbness, and organ dysfunction.  It also mentions direct healthcare costs associated with these conditions."
      }
    },
    {
      "text": "This text defines \"direct costs\" in healthcare as expenses for services (prevention, treatment, family planning, nutrition, emergency aid) excluding water/sanitation but including public and private sources.  It also defines DPP-4 inhibitors, a medication for type 2 diabetes. This text defines \"direct costs\" in healthcare as expenses for services (prevention, treatment, family planning, nutrition, emergency aid), excluding water/sanitation but including public and private sources.  It also defines DPP-4 inhibitors, a diabetes medication.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 122,
        "page_label": "118",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text defines \"direct costs\" in healthcare as expenses for services (prevention, treatment, family planning, nutrition, emergency aid) excluding water/sanitation but including public and private sources.  It also defines DPP-4 inhibitors, a medication for type 2 diabetes.",
        "summary_ur": "This text defines \"direct costs\" in healthcare as expenses for services (prevention, treatment, family planning, nutrition, emergency aid), excluding water/sanitation but including public and private sources.  It also defines DPP-4 inhibitors, a diabetes medication."
      }
    },
    {
      "text": "This text defines several terms relevant to medicine and research.  It explains epidemiology, essential hormones (insulin, parathyroid hormone, glucocorticosteroids, mineralocorticoids), estimates (usable values from incomplete data), extrapolation (applying known data to unknowns), and fasting plasma glucose (FPG), a measure of blood glucose after an eight-hour fast. This text defines key epidemiological and medical terms.  It explains epidemiology, essential hormones (insulin, parathyroid hormone, cortisol, aldosterone), estimates based on available data, extrapolation of data, and fasting plasma glucose (FPG) levels.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 123,
        "page_label": "119",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text defines several terms relevant to medicine and research.  It explains epidemiology, essential hormones (insulin, parathyroid hormone, glucocorticosteroids, mineralocorticoids), estimates (usable values from incomplete data), extrapolation (applying known data to unknowns), and fasting plasma glucose (FPG), a measure of blood glucose after an eight-hour fast.",
        "summary_ur": "This text defines key epidemiological and medical terms.  It explains epidemiology, essential hormones (insulin, parathyroid hormone, cortisol, aldosterone), estimates based on available data, extrapolation of data, and fasting plasma glucose (FPG) levels."
      }
    },
    {
      "text": "Fasting plasma glucose (FPG) measures blood glucose after an eight-hour fast.  Normal FPG is \u22646.1 mmol/L or \u2264110 mg/dL.  However, FPG screening has limitations:  it relies on accurate fasting, misses some diabetes cases detectable only by post-glucose load tests, and doesn't identify impaired glucose tolerance.  It misses roughly 30% of undiagnosed diabetes.  Gestational diabetes is high blood glucose developing during pregnancy, less severe than overt diabetes. This text describes fasting plasma glucose (FPG) testing for diabetes.  Normal FPG is \u22646.1 mmol/L or \u2264110 mg/dL.  However, FPG testing has limitations:  it relies on accurate fasting, misses some diabetes cases (especially those only detectable after glucose load), and doesn't identify impaired glucose tolerance.  It misses roughly 30% of undiagnosed diabetes.  The text also briefly defines genes and gestational diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 123,
        "page_label": "119",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Fasting plasma glucose (FPG) measures blood glucose after an eight-hour fast.  Normal FPG is \u22646.1 mmol/L or \u2264110 mg/dL.  However, FPG screening has limitations:  it relies on accurate fasting, misses some diabetes cases detectable only by post-glucose load tests, and doesn't identify impaired glucose tolerance.  It misses roughly 30% of undiagnosed diabetes.  Gestational diabetes is high blood glucose developing during pregnancy, less severe than overt diabetes.",
        "summary_ur": "This text describes fasting plasma glucose (FPG) testing for diabetes.  Normal FPG is \u22646.1 mmol/L or \u2264110 mg/dL.  However, FPG testing has limitations:  it relies on accurate fasting, misses some diabetes cases (especially those only detectable after glucose load), and doesn't identify impaired glucose tolerance.  It misses roughly 30% of undiagnosed diabetes.  The text also briefly defines genes and gestational diabetes."
      }
    },
    {
      "text": "This text defines several key terms related to diabetes and glucose metabolism: gestational diabetes mellitus (GDM), glucagon, glucagon-like peptide-1 (GLP-1), glucose, and hemoglobin A1c (HbA1c).  It explains their roles in blood glucose regulation and energy production within the body. This text defines key terms related to diabetes: gestational diabetes (GDM), glucagon, glucagon-like peptide-1 (GLP-1), glucose, and hemoglobin A1c (HbA1c).  It explains their roles in blood glucose regulation and energy production within the body.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 123,
        "page_label": "119",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text defines several key terms related to diabetes and glucose metabolism: gestational diabetes mellitus (GDM), glucagon, glucagon-like peptide-1 (GLP-1), glucose, and hemoglobin A1c (HbA1c).  It explains their roles in blood glucose regulation and energy production within the body.",
        "summary_ur": "This text defines key terms related to diabetes: gestational diabetes (GDM), glucagon, glucagon-like peptide-1 (GLP-1), glucose, and hemoglobin A1c (HbA1c).  It explains their roles in blood glucose regulation and energy production within the body."
      }
    },
    {
      "text": "This text defines several medical terms related to blood glucose levels.  It explains HbA1c (a measure of average blood glucose), hyperglycemia (high blood glucose), and hypoglycemia (low blood glucose),  including their symptoms and relationship to insulin.  It also defines \"high-income country\" and \"heterogeneity.\" This text defines several medical terms related to blood sugar.  It explains HbA1c (glycosylated hemoglobin) as a measure of average blood glucose, hyperglycemia (high blood sugar) and its symptoms, and hypoglycemia (low blood sugar),  also mentioning gestational diabetes and high-income countries' context.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 123,
        "page_label": "119",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text defines several medical terms related to blood glucose levels.  It explains HbA1c (a measure of average blood glucose), hyperglycemia (high blood glucose), and hypoglycemia (low blood glucose),  including their symptoms and relationship to insulin.  It also defines \"high-income country\" and \"heterogeneity.\"",
        "summary_ur": "This text defines several medical terms related to blood sugar.  It explains HbA1c (glycosylated hemoglobin) as a measure of average blood glucose, hyperglycemia (high blood sugar) and its symptoms, and hypoglycemia (low blood sugar),  also mentioning gestational diabetes and high-income countries' context."
      }
    },
    {
      "text": "The text defines hyperglycemia in pregnancy (HIP) as gestational diabetes mellitus (GDM) or diabetes in pregnancy (DIP).  It also defines hypoglycemia as low blood glucose, often caused by insulin overdose, insufficient food intake, or exercise without adequate fuel. This text defines hyperglycaemia in pregnancy (HIP) as gestational diabetes mellitus (GDM) or diabetes in pregnancy (DIP), and hypoglycaemia as low blood glucose, often caused by excess insulin, insufficient food, or exercise without extra food.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 123,
        "page_label": "119",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text defines hyperglycemia in pregnancy (HIP) as gestational diabetes mellitus (GDM) or diabetes in pregnancy (DIP).  It also defines hypoglycemia as low blood glucose, often caused by insulin overdose, insufficient food intake, or exercise without adequate fuel.",
        "summary_ur": "This text defines hyperglycaemia in pregnancy (HIP) as gestational diabetes mellitus (GDM) or diabetes in pregnancy (DIP), and hypoglycaemia as low blood glucose, often caused by excess insulin, insufficient food, or exercise without extra food."
      }
    },
    {
      "text": "The International Diabetes Federation (IDF) has seven regions fostering collaboration among national diabetes associations.  The text also defines impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), pre-diabetes conditions with higher-than-normal but not diabetic blood glucose levels.  Finally, it introduces the epidemiological term \"incidence,\" referring to new disease cases. The International Diabetes Federation (IDF) has seven regions fostering collaboration among national diabetes associations.  The text also defines Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT), pre-diabetes conditions, and introduces the concept of disease incidence.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 124,
        "page_label": "120",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The International Diabetes Federation (IDF) has seven regions fostering collaboration among national diabetes associations.  The text also defines impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), pre-diabetes conditions with higher-than-normal but not diabetic blood glucose levels.  Finally, it introduces the epidemiological term \"incidence,\" referring to new disease cases.",
        "summary_ur": "The International Diabetes Federation (IDF) has seven regions fostering collaboration among national diabetes associations.  The text also defines Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT), pre-diabetes conditions, and introduces the concept of disease incidence."
      }
    },
    {
      "text": "The text defines medical terms related to blood glucose and diabetes.  It explains incidence, insulin's role, insulin resistance, and intermediate hyperglycemia (prediabetes).  It also briefly describes the international dollar as a standardized currency unit for comparison. This text defines medical terms related to diabetes.  It explains glucose tolerance tests, insulin's role, insulin resistance, and intermediate hyperglycemia (prediabetes).  It also defines \"incidence\" and a hypothetical \"International Dollar.\"",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 124,
        "page_label": "120",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text defines medical terms related to blood glucose and diabetes.  It explains incidence, insulin's role, insulin resistance, and intermediate hyperglycemia (prediabetes).  It also briefly describes the international dollar as a standardized currency unit for comparison.",
        "summary_ur": "This text defines medical terms related to diabetes.  It explains glucose tolerance tests, insulin's role, insulin resistance, and intermediate hyperglycemia (prediabetes).  It also defines \"incidence\" and a hypothetical \"International Dollar.\""
      }
    },
    {
      "text": "The text defines three terms:  International Dollar (ID), a hypothetical currency with equal purchasing power globally; Low-income country, defined by the World Bank based on GNI per capita; and Macrosomia, referring to a birth weight exceeding 4.0 kg.  It also briefly describes Maturity-onset diabetes of the young (MODY) and Metformin, a type 2 diabetes medication. The text defines three terms:  International Dollars (ID) \u2013 a currency unit with consistent purchasing power globally; Low-income country \u2013 a World Bank classification based on GNI per capita (USD 1,045 or less in 2020); and Macrosomia \u2013 a birth weight exceeding 4.0 kg.  It also briefly describes Metformin, a type 2 diabetes medication, and MODY, a rare genetic diabetes form.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 124,
        "page_label": "120",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text defines three terms:  International Dollar (ID), a hypothetical currency with equal purchasing power globally; Low-income country, defined by the World Bank based on GNI per capita; and Macrosomia, referring to a birth weight exceeding 4.0 kg.  It also briefly describes Maturity-onset diabetes of the young (MODY) and Metformin, a type 2 diabetes medication.",
        "summary_ur": "The text defines three terms:  International Dollars (ID) \u2013 a currency unit with consistent purchasing power globally; Low-income country \u2013 a World Bank classification based on GNI per capita (USD 1,045 or less in 2020); and Macrosomia \u2013 a birth weight exceeding 4.0 kg.  It also briefly describes Metformin, a type 2 diabetes medication, and MODY, a rare genetic diabetes form."
      }
    },
    {
      "text": "This text describes metformin, a type 2 diabetes medication, and defines microvascular complications (affecting small blood vessels) and monogenic diabetes (caused by single gene mutations), including neonatal diabetes mellitus. This text defines metformin (a type 2 diabetes drug), microvascular complications (diabetic nephropathy, neuropathy, retinopathy), and monogenic diabetes (including neonatal diabetes mellitus).  Metformin improves insulin sensitivity and reduces liver glucose production. Monogenic diabetes stems from single gene mutations.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 124,
        "page_label": "120",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes metformin, a type 2 diabetes medication, and defines microvascular complications (affecting small blood vessels) and monogenic diabetes (caused by single gene mutations), including neonatal diabetes mellitus.",
        "summary_ur": "This text defines metformin (a type 2 diabetes drug), microvascular complications (diabetic nephropathy, neuropathy, retinopathy), and monogenic diabetes (including neonatal diabetes mellitus).  Metformin improves insulin sensitivity and reduces liver glucose production. Monogenic diabetes stems from single gene mutations."
      }
    },
    {
      "text": "This glossary defines medical terms: obesity (BMI \u226530), overweight (BMI 25-29.9), oral glucose tolerance test (OGTT), oral medication, pancreas, peripheral vascular disease (PVD or PAD), and prediabetes (a condition preceding type 2 diabetes).  The definitions specify criteria for obesity and overweight using BMI. This glossary defines medical terms: obesity (BMI \u226530), overweight (BMI 25-29.9), oral glucose tolerance test (OGTT), oral medication, pancreas, peripheral vascular disease (PVD or PAD), and prediabetes.  All refer to conditions related to weight, metabolism, and circulatory health.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 125,
        "page_label": "121",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This glossary defines medical terms: obesity (BMI \u226530), overweight (BMI 25-29.9), oral glucose tolerance test (OGTT), oral medication, pancreas, peripheral vascular disease (PVD or PAD), and prediabetes (a condition preceding type 2 diabetes).  The definitions specify criteria for obesity and overweight using BMI.",
        "summary_ur": "This glossary defines medical terms: obesity (BMI \u226530), overweight (BMI 25-29.9), oral glucose tolerance test (OGTT), oral medication, pancreas, peripheral vascular disease (PVD or PAD), and prediabetes.  All refer to conditions related to weight, metabolism, and circulatory health."
      }
    },
    {
      "text": "The text defines several medical terms: peripheral artery disease (PAD), a circulatory disorder; prediabetes, a state of elevated blood glucose; polydipsia (excessive thirst); and polyuria (frequent urination).  It also explains \"prevalence\" as the proportion of a population with a disease and \"primary prevention\" as preventing disease onset. This text defines several medical terms:  Peripheral artery disease (PAD), a blood vessel blockage; prediabetes, high blood sugar below the diabetes threshold; polydipsia (excessive thirst); and polyuria (frequent urination).  It also explains \"prevalence\" as the proportion of a population with a disease and \"primary prevention\" as preventing disease before onset.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 125,
        "page_label": "121",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text defines several medical terms: peripheral artery disease (PAD), a circulatory disorder; prediabetes, a state of elevated blood glucose; polydipsia (excessive thirst); and polyuria (frequent urination).  It also explains \"prevalence\" as the proportion of a population with a disease and \"primary prevention\" as preventing disease onset.",
        "summary_ur": "This text defines several medical terms:  Peripheral artery disease (PAD), a blood vessel blockage; prediabetes, high blood sugar below the diabetes threshold; polydipsia (excessive thirst); and polyuria (frequent urination).  It also explains \"prevalence\" as the proportion of a population with a disease and \"primary prevention\" as preventing disease before onset."
      }
    },
    {
      "text": "The text defines key terms related to diabetes cost and prevalence studies.  It explains \"primary prevention\" (preventing disease onset), \"projections\" (future estimations based on trends), and the \"diabetes cost ratio\" (comparing healthcare spending for diabetics versus non-diabetics).  Finally, it defines \"raw diabetes prevalence\" as the percentage of a population with diabetes. This text defines key terms related to diabetes: primary prevention (avoiding disease onset), projections (future estimations based on trends), and the diabetes cost ratio (comparing healthcare spending for diabetics vs. non-diabetics, using R=2 or R=3 multipliers).  It also explains \"raw diabetes prevalence\" as the percentage of a population with diabetes.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 125,
        "page_label": "121",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text defines key terms related to diabetes cost and prevalence studies.  It explains \"primary prevention\" (preventing disease onset), \"projections\" (future estimations based on trends), and the \"diabetes cost ratio\" (comparing healthcare spending for diabetics versus non-diabetics).  Finally, it defines \"raw diabetes prevalence\" as the percentage of a population with diabetes.",
        "summary_ur": "This text defines key terms related to diabetes: primary prevention (avoiding disease onset), projections (future estimations based on trends), and the diabetes cost ratio (comparing healthcare spending for diabetics vs. non-diabetics, using R=2 or R=3 multipliers).  It also explains \"raw diabetes prevalence\" as the percentage of a population with diabetes."
      }
    },
    {
      "text": "This text defines several diabetes-related terms: raw diabetes prevalence (percentage of a population with diabetes), relative risk (probability of an outcome in exposed vs. unexposed groups), screening approaches (diagnosing disease before symptoms), secondary diabetes (diabetes caused by other conditions), self-management (personal responsibility for well-being), and sulphonylureas (oral medication stimulating insulin release). This text defines key diabetes-related terms.  It explains \"raw diabetes prevalence\" (percentage of a population with diabetes), \"relative risk\" (probability ratio between exposed and unexposed groups), screening approaches for early diagnosis, secondary diabetes (caused by other conditions), self-management of the disease, and sulphonylureas (oral medication).",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 125,
        "page_label": "121",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text defines several diabetes-related terms: raw diabetes prevalence (percentage of a population with diabetes), relative risk (probability of an outcome in exposed vs. unexposed groups), screening approaches (diagnosing disease before symptoms), secondary diabetes (diabetes caused by other conditions), self-management (personal responsibility for well-being), and sulphonylureas (oral medication stimulating insulin release).",
        "summary_ur": "This text defines key diabetes-related terms.  It explains \"raw diabetes prevalence\" (percentage of a population with diabetes), \"relative risk\" (probability ratio between exposed and unexposed groups), screening approaches for early diagnosis, secondary diabetes (caused by other conditions), self-management of the disease, and sulphonylureas (oral medication)."
      }
    },
    {
      "text": "Sulfonylureas are oral medications for type 2 diabetes.  Their primary mechanism is stimulating pancreatic insulin release. This text is not legal text.  It's a brief medical description.  There's nothing to summarize legally.  The text simply states that sulfonylureas are oral diabetes medications that increase insulin release from the pancreas.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 125,
        "page_label": "121",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Sulfonylureas are oral medications for type 2 diabetes.  Their primary mechanism is stimulating pancreatic insulin release.",
        "summary_ur": "This text is not legal text.  It's a brief medical description.  There's nothing to summarize legally.  The text simply states that sulfonylureas are oral diabetes medications that increase insulin release from the pancreas."
      }
    },
    {
      "text": "Type 1 diabetes, an autoimmune disease, destroys insulin-producing cells, leading to insulin deficiency.  Type 2 diabetes, far more common, involves insulin resistance or insufficient insulin production, often linked to lifestyle factors like poor diet, inactivity, and obesity, along with genetic predisposition. Type 1 diabetes, usually appearing in childhood or young adulthood, is an autoimmune disease where the body doesn't produce enough insulin.  Type 2 diabetes, far more common, involves insulin resistance or insufficient insulin production, often linked to lifestyle factors like poor diet and lack of exercise.  Both lead to high blood sugar.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 126,
        "page_label": "122",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 1 diabetes, an autoimmune disease, destroys insulin-producing cells, leading to insulin deficiency.  Type 2 diabetes, far more common, involves insulin resistance or insufficient insulin production, often linked to lifestyle factors like poor diet, inactivity, and obesity, along with genetic predisposition.",
        "summary_ur": "Type 1 diabetes, usually appearing in childhood or young adulthood, is an autoimmune disease where the body doesn't produce enough insulin.  Type 2 diabetes, far more common, involves insulin resistance or insufficient insulin production, often linked to lifestyle factors like poor diet and lack of exercise.  Both lead to high blood sugar."
      }
    },
    {
      "text": "Type 2 diabetes, more prevalent than type 1, primarily affects adults but is rising in children.  Risk factors include obesity, unhealthy diet, lack of physical activity, and genetics.  Universal health coverage aims to provide free healthcare to all residents. Type 2 diabetes, more prevalent than type 1, affects adults and increasingly, children.  Risk factors include obesity, poor diet, and genetics. Universal health coverage (UHC) aims to provide free healthcare to all residents.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 126,
        "page_label": "122",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Type 2 diabetes, more prevalent than type 1, primarily affects adults but is rising in children.  Risk factors include obesity, unhealthy diet, lack of physical activity, and genetics.  Universal health coverage aims to provide free healthcare to all residents.",
        "summary_ur": "Type 2 diabetes, more prevalent than type 1, affects adults and increasingly, children.  Risk factors include obesity, poor diet, and genetics. Universal health coverage (UHC) aims to provide free healthcare to all residents."
      }
    },
    {
      "text": "The figures illustrate global diabetes prevalence data from the IDF Diabetes Atlas (editions 1-11).  They detail diagnostic criteria, symptoms,  various diabetes types, data sources, and projections of diabetes numbers and prevalence by age, sex, location (urban/rural), and HbA1c levels through 2050, including gestational diabetes prevalence. The provided text is a list of figures, not legal text.  These figures pertain to a study on diabetes, showing data on global prevalence, diagnostic criteria, types of diabetes, data sources, and projections for 2024 and 2050.  The figures cover various demographics and utilize different metrics like HbA1c levels.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 127,
        "page_label": "123",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The figures illustrate global diabetes prevalence data from the IDF Diabetes Atlas (editions 1-11).  They detail diagnostic criteria, symptoms,  various diabetes types, data sources, and projections of diabetes numbers and prevalence by age, sex, location (urban/rural), and HbA1c levels through 2050, including gestational diabetes prevalence.",
        "summary_ur": "The provided text is a list of figures, not legal text.  These figures pertain to a study on diabetes, showing data on global prevalence, diagnostic criteria, types of diabetes, data sources, and projections for 2024 and 2050.  The figures cover various demographics and utilize different metrics like HbA1c levels."
      }
    },
    {
      "text": "Figures 3.5-3.12 present data on diabetes prevalence, mortality, and healthcare expenditure.  The data includes age and sex breakdowns, geographical regions (IDF regions), and time series (2006-2050), illustrating the global burden of diabetes.  Specific metrics include prevalence rates, death counts, and expenditure in USD and as percentages of GDP and total healthcare spending. The provided text is a list of figures (3.5-3.12) presenting data on diabetes prevalence, mortality, and healthcare expenditure.  The data covers various age groups, sexes, regions, and spans from 2006 to 2050.  Specific details include prevalence rates, death counts, and expenditure in USD and as a percentage of GDP and total health expenditure.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 127,
        "page_label": "123",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Figures 3.5-3.12 present data on diabetes prevalence, mortality, and healthcare expenditure.  The data includes age and sex breakdowns, geographical regions (IDF regions), and time series (2006-2050), illustrating the global burden of diabetes.  Specific metrics include prevalence rates, death counts, and expenditure in USD and as percentages of GDP and total healthcare spending.",
        "summary_ur": "The provided text is a list of figures (3.5-3.12) presenting data on diabetes prevalence, mortality, and healthcare expenditure.  The data covers various age groups, sexes, regions, and spans from 2006 to 2050.  Specific details include prevalence rates, death counts, and expenditure in USD and as a percentage of GDP and total health expenditure."
      }
    },
    {
      "text": "These figures present data on diabetes from the International Diabetes Federation (IDF), covering 2024.  They detail diabetes-related healthcare expenditure as a percentage of GDP by region and income level, the number of type 1 diabetes cases by region, and the estimated prevalence of diabetes by age and sex across various IDF regions. These figures present data on diabetes from the International Diabetes Federation (IDF) for 2024.  They detail diabetes-related healthcare costs as a percentage of GDP by region and income level,  the number of type 1 diabetes cases by region, and the estimated prevalence of diabetes by age and sex across various IDF regions.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 127,
        "page_label": "123",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These figures present data on diabetes from the International Diabetes Federation (IDF), covering 2024.  They detail diabetes-related healthcare expenditure as a percentage of GDP by region and income level, the number of type 1 diabetes cases by region, and the estimated prevalence of diabetes by age and sex across various IDF regions.",
        "summary_ur": "These figures present data on diabetes from the International Diabetes Federation (IDF) for 2024.  They detail diabetes-related healthcare costs as a percentage of GDP by region and income level,  the number of type 1 diabetes cases by region, and the estimated prevalence of diabetes by age and sex across various IDF regions."
      }
    },
    {
      "text": "This document presents data visualizations (figures and maps) on the global prevalence of diabetes and its associated risks.  The figures show diabetes prevalence by age, sex, and region, along with relative risks of cardiovascular disease, dementia, and other complications.  Maps illustrate the global distribution of diabetes cases and data sources. This document presents data visualizations (figures and maps) on diabetes prevalence and its associated risks (cardiovascular disease, dementia) across different age groups, sexes, and IDF regions from 2019-2050.  The data includes global prevalence estimates and regional breakdowns.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 127,
        "page_label": "123",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This document presents data visualizations (figures and maps) on the global prevalence of diabetes and its associated risks.  The figures show diabetes prevalence by age, sex, and region, along with relative risks of cardiovascular disease, dementia, and other complications.  Maps illustrate the global distribution of diabetes cases and data sources.",
        "summary_ur": "This document presents data visualizations (figures and maps) on diabetes prevalence and its associated risks (cardiovascular disease, dementia) across different age groups, sexes, and IDF regions from 2019-2050.  The data includes global prevalence estimates and regional breakdowns."
      }
    },
    {
      "text": "The text describes a series of maps (2.1-2.5, 3.1-3.5) presenting data on diabetes prevalence and related conditions (impaired glucose tolerance, impaired fasting glucose, hyperglycemia in pregnancy) across various countries and territories from 2024 to 2050, focusing on adults aged 20-79.  The maps detail both diagnosed and undiagnosed cases. The provided text describes a series of maps (2.1-2.5, 3.1-3.5) presenting data on diabetes prevalence and diagnosis rates globally, focusing on adults aged 20-79 (and 20-49 for gestational diabetes).  The maps detail country-specific data for the period 2024-2050, including estimates of diagnosed and undiagnosed cases, and prevalence rates.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 127,
        "page_label": "123",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The text describes a series of maps (2.1-2.5, 3.1-3.5) presenting data on diabetes prevalence and related conditions (impaired glucose tolerance, impaired fasting glucose, hyperglycemia in pregnancy) across various countries and territories from 2024 to 2050, focusing on adults aged 20-79.  The maps detail both diagnosed and undiagnosed cases.",
        "summary_ur": "The provided text describes a series of maps (2.1-2.5, 3.1-3.5) presenting data on diabetes prevalence and diagnosis rates globally, focusing on adults aged 20-79 (and 20-49 for gestational diabetes).  The maps detail country-specific data for the period 2024-2050, including estimates of diagnosed and undiagnosed cases, and prevalence rates."
      }
    },
    {
      "text": "Maps 3.3-3.5 from the IDF Diabetes Atlas 11th Edition (2025) present data on diabetes prevalence in 2024.  Specifically, they show the number of people over 65 with diabetes, the proportion of undiagnosed diabetes in adults (20-79 years), and the age-standardized prevalence of impaired glucose tolerance in adults. These maps (3.3-3.5) from the IDF Diabetes Atlas 11th Edition (2025) show 2024 data on:  the number of people over 65 with diabetes; the proportion of undiagnosed diabetes in adults (20-79); and the age-standardized prevalence of impaired glucose tolerance in adults.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 127,
        "page_label": "123",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Maps 3.3-3.5 from the IDF Diabetes Atlas 11th Edition (2025) present data on diabetes prevalence in 2024.  Specifically, they show the number of people over 65 with diabetes, the proportion of undiagnosed diabetes in adults (20-79 years), and the age-standardized prevalence of impaired glucose tolerance in adults.",
        "summary_ur": "These maps (3.3-3.5) from the IDF Diabetes Atlas 11th Edition (2025) show 2024 data on:  the number of people over 65 with diabetes; the proportion of undiagnosed diabetes in adults (20-79); and the age-standardized prevalence of impaired glucose tolerance in adults."
      }
    },
    {
      "text": "These maps (3.6-4.5) present 2024 data on diabetes prevalence, mortality, and economic impact across various regions.  They illustrate age-standardized prevalence of impaired fasting glucose and diabetes, diabetes-related deaths and healthcare expenditures (total and per capita), and remaining life expectancy for children with type 1 diabetes. These maps (3.6-4.5) present 2024 data on diabetes globally and regionally.  They detail age-standardized prevalence, diabetes-related deaths, and healthcare expenditure,  plus remaining life expectancy for children with type 1 diabetes.  Data is broken down by region and country, showing the varying impact of diabetes worldwide.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 128,
        "page_label": "124",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "These maps (3.6-4.5) present 2024 data on diabetes prevalence, mortality, and economic impact across various regions.  They illustrate age-standardized prevalence of impaired fasting glucose and diabetes, diabetes-related deaths and healthcare expenditures (total and per capita), and remaining life expectancy for children with type 1 diabetes.",
        "summary_ur": "These maps (3.6-4.5) present 2024 data on diabetes globally and regionally.  They detail age-standardized prevalence, diabetes-related deaths, and healthcare expenditure,  plus remaining life expectancy for children with type 1 diabetes.  Data is broken down by region and country, showing the varying impact of diabetes worldwide."
      }
    },
    {
      "text": "This document presents data on diabetes prevalence and its association with dementia, globally and across different regions.  It includes maps showing age-standardized diabetes prevalence (20-79 years) in various regions in 2024, and maps and tables projecting diabetes prevalence and its impact on dementia cases in 2024 and 2050.  Diagnostic criteria and global estimates are also provided. The provided text details maps and tables from a 2024 report on diabetes prevalence and its link to dementia globally.  Data includes age-standardized prevalence rates across various regions, projections to 2050, and diagnostic criteria used.  The report also quantifies the number of adults with diabetes by country and region.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 128,
        "page_label": "124",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This document presents data on diabetes prevalence and its association with dementia, globally and across different regions.  It includes maps showing age-standardized diabetes prevalence (20-79 years) in various regions in 2024, and maps and tables projecting diabetes prevalence and its impact on dementia cases in 2024 and 2050.  Diagnostic criteria and global estimates are also provided.",
        "summary_ur": "The provided text details maps and tables from a 2024 report on diabetes prevalence and its link to dementia globally.  Data includes age-standardized prevalence rates across various regions, projections to 2050, and diagnostic criteria used.  The report also quantifies the number of adults with diabetes by country and region."
      }
    },
    {
      "text": "This text describes tables (3.2-3.8) presenting projected global diabetes prevalence and numbers of adults (20-79 and 65-99 years old) with diabetes in 2024 and 2050.  Data is categorized by World Bank income classification and IDF regions, highlighting top 10 countries by prevalence and number of cases. This document presents tables (3.2-3.8) projecting global diabetes prevalence and numbers of adults (20-79 and 65-99 years) with diabetes in 2024 and 2050.  Data is categorized by World Bank income classification and IDF regions, highlighting top 10 countries by number and prevalence.  Intermediate hyperglycemia and gestational diabetes are also mentioned.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 128,
        "page_label": "124",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This text describes tables (3.2-3.8) presenting projected global diabetes prevalence and numbers of adults (20-79 and 65-99 years old) with diabetes in 2024 and 2050.  Data is categorized by World Bank income classification and IDF regions, highlighting top 10 countries by prevalence and number of cases.",
        "summary_ur": "This document presents tables (3.2-3.8) projecting global diabetes prevalence and numbers of adults (20-79 and 65-99 years) with diabetes in 2024 and 2050.  Data is categorized by World Bank income classification and IDF regions, highlighting top 10 countries by number and prevalence.  Intermediate hyperglycemia and gestational diabetes are also mentioned."
      }
    },
    {
      "text": "The provided text lists tables (3.8-3.15) presenting data on diabetes prevalence and impaired glucose tolerance.  The data is categorized by age group, geographic region (IDF regions), World Bank income classification, and  ranks countries by the number of individuals affected.  The tables cover diagnosed and undiagnosed cases for the years 2024 and 2050. The provided text is a list of tables (3.8-3.15) presenting data on diabetes and impaired glucose tolerance.  The tables detail prevalence by age, region (IDF), World Bank income group, and country, projecting data for 2024 and 2050.  The focus is on the number of adults with diagnosed and undiagnosed diabetes and impaired glucose tolerance.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 128,
        "page_label": "124",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The provided text lists tables (3.8-3.15) presenting data on diabetes prevalence and impaired glucose tolerance.  The data is categorized by age group, geographic region (IDF regions), World Bank income classification, and  ranks countries by the number of individuals affected.  The tables cover diagnosed and undiagnosed cases for the years 2024 and 2050.",
        "summary_ur": "The provided text is a list of tables (3.8-3.15) presenting data on diabetes and impaired glucose tolerance.  The tables detail prevalence by age, region (IDF), World Bank income group, and country, projecting data for 2024 and 2050.  The focus is on the number of adults with diagnosed and undiagnosed diabetes and impaired glucose tolerance."
      }
    },
    {
      "text": "The provided text lists tables (3.14-3.20 & 5.1) presenting global data on diabetes prevalence and related health expenditures.  These tables detail age-standardized prevalence of impaired fasting glucose, hyperglycemia in pregnancy,  diabetes-related health spending by country and region, and prevalence of diabetic retinopathy. Several tables (3.14-3.20, 5.1) present global data on diabetes prevalence and related health expenditures.  They detail age-standardized prevalence of impaired fasting glucose by region and income level, hyperglycemia in pregnancy,  and diabetes-related health spending, including retinopathy prevalence.  Data covers 2024 estimates and ranks countries by various metrics.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 128,
        "page_label": "124",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "The provided text lists tables (3.14-3.20 & 5.1) presenting global data on diabetes prevalence and related health expenditures.  These tables detail age-standardized prevalence of impaired fasting glucose, hyperglycemia in pregnancy,  diabetes-related health spending by country and region, and prevalence of diabetic retinopathy.",
        "summary_ur": "Several tables (3.14-3.20, 5.1) present global data on diabetes prevalence and related health expenditures.  They detail age-standardized prevalence of impaired fasting glucose by region and income level, hyperglycemia in pregnancy,  and diabetes-related health spending, including retinopathy prevalence.  Data covers 2024 estimates and ranks countries by various metrics."
      }
    },
    {
      "text": "Tables 5.1 and 5.2 from the 2025 IDF Diabetes Atlas (11th edition) present the 2024 global prevalence of various diabetes-related retinopathies, categorized by severity and geographic region (IDF regions).  The data highlights the significant impact of diabetes on vision worldwide. This text refers to data from the IDF Diabetes Atlas, 11th Edition (2025), specifically Tables 5.1 and 5.2.  These tables present the prevalence of various diabetic retinopathies (including sight-threatening and proliferative forms, and macular edema) across different regions in 2024.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 128,
        "page_label": "124",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "Tables 5.1 and 5.2 from the 2025 IDF Diabetes Atlas (11th edition) present the 2024 global prevalence of various diabetes-related retinopathies, categorized by severity and geographic region (IDF regions).  The data highlights the significant impact of diabetes on vision worldwide.",
        "summary_ur": "This text refers to data from the IDF Diabetes Atlas, 11th Edition (2025), specifically Tables 5.1 and 5.2.  These tables present the prevalence of various diabetic retinopathies (including sight-threatening and proliferative forms, and macular edema) across different regions in 2024."
      }
    },
    {
      "text": "This is the contact information for the International Diabetes Federation (IDF):  address, email, and website are provided.  It's not legal text. This is not legal text; it's contact information for the International Diabetes Federation (IDF), located in Brussels, Belgium.  The provided details include the address, email, and website.  There is nothing to summarize legally.",
      "metadata": {
        "producer": "Adobe PDF Library 17.0",
        "creator": "Adobe InDesign 20.2 (Macintosh)",
        "creationdate": "2025-04-04T09:51:41+01:00",
        "moddate": "2025-04-04T09:52:52+01:00",
        "trapped": "/False",
        "source": "data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "total_pages": 130,
        "page": 129,
        "page_label": "125",
        "source_file": "IDF_Atlas_11th_Edition_2025.pdf",
        "source_path": "D:\\RAG-projects\\ppcrag\\data-1\\IDF_Atlas_11th_Edition_2025.pdf",
        "summary_en": "This is the contact information for the International Diabetes Federation (IDF):  address, email, and website are provided.  It's not legal text.",
        "summary_ur": "This is not legal text; it's contact information for the International Diabetes Federation (IDF), located in Brussels, Belgium.  The provided details include the address, email, and website.  There is nothing to summarize legally."
      }
    }
  ]
}